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Abstract 
Numerous	  neurodegenerative	  diseases	  are	  pathologically	  characterized	  by	  idiosyncratic	  
protein	  amyloid	  inclusions.	  Not	  surprisingly	  amyloid	  fibrils	  have	  long	  been	  proposed	  to	  be	  the	  
toxic	   protein	   species	   in	   these	   neurodegenerative	   diseases.	   However,	   more	   recent	   work	   has	  
begun	   to	   suggest	   that	   the	   formation	   of	   ordered	   inclusions	   serves	   a	   protective	   role	   and	   that	  
soluble	   oligomers	   on	   pathway	   to	   amyloid	   formation	   cause	   neuronal	   death.	   In	   that	   regard,	  
ordered	   protein	   inclusions,	   such	   as	   aggresomes,	   have	   also	   been	   shown	   to	   facilitate	   the	  
asymmetric	   inheritance	  of	  protein	  damage	  during	   the	  mitoses	  of	   cells	   ranging	   from	  E.	   coli	   to	  
human	  stem	  cells.	  	  
Yeast	   prion	   proteins	   are	   another	   group	   of	   proteins	   capable	   of	   adapting	   an	   amyloid	  
conformation.	   The	   self-­‐templating	   amyloid	   fold	   allows	   yeast	   prions	   to	   act	   as	   non-­‐Mendelian	  
elements	  of	  inheritance.	  We	  have	  shown	  that	  yeast	  prion	  amyloid	  fibrils,	  especially	  upon	  prion	  
protein	  overexpression,	   localize	   to	   the	   IPOD	   (insoluble	  protein	  deposit),	   an	  ordered	   inclusion	  
proximal	  to	  the	  vacuole,	  and	  that	  the	  majority	  of	  the	  prion	  amyloid	  is	  asymmetrically	  inherited	  
upon	  cell	  division.	  
I	   used	   the	   yeast	   prion	   Rnq1	   to	   investigate	   how	   amyloid	   formation	   contributes	   to	  
proteotoxicity.	  Ectopic	  overexpression	  of	  Rnq1	  was	  extremely	  toxic,	  but	  only	  if	  the	  endogenous	  
Rnq1	  protein	  had	  adopted	  its	  amyloid	  conformation.	  The	  Hsp40	  co-­‐chaperone	  Sis1	  was	  able	  to	  
counteract	  the	  Rnq1-­‐induced	  toxicity	  when	  co-­‐overexpressed.	  In	  collaboration	  with	  Doug	  Cyr’s	  
lab	   I	   showed	   that	   Sis1-­‐mediated	   amyloid	   formation	   was	   cytoprotective	   and	   that	   disordered	  
non-­‐amyloid	  aggregates	  induced	  toxicity.	  These	  results	  provide	  evidence	  that	  the	  formation	  of	  
ordered	  inclusions	  can	  be	  cytoprotective.	  	  
I	  further	  characterized	  Rnq1	  toxicity,	  conducted	  two	  genome-­‐wide	  screens	  for	  modifiers	  
and	   found	   that	   Rnq1	   induced	   a	   G2/M	   cell	   cycle	   arrest.	   Rnq1	   overexpression	   resulted	   in	   the	  
mislocalization	   of	   the	   core	   spindle	   pole	   body	   component	   Spc42	   to	   the	   IPOD	   and	   an	  
unduplicated	  spindle	  pole	  body.	   In	  mammalian	  cells	  aggresomes	   localize	   to	  centrosomes,	   the	  
mammalian	   equivalent	   of	   the	   yeast	   spindle	   pole	   body.	   The	   finding	   that	   a	   yeast	   prion	   can	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interact	  with	  a	  spindle	  pole	  body	  component	  represents	  a	  new	  connection	  between	  the	  IPOD	  
and	  aggresomes.	  
Lastly,	   I	   studied	   a	   yeast	  model	   of	   Aβ	   1-­‐42	   toxicity.	   Accumulation	   of	   the	   amyloid	   beta	  
peptide	   is	   thought	   to	   be	   causal	   in	   both	   sporadic	   and	   familial	   Alzheimer’s	   disease.	   In	  
collaboration	  with	  Kent	  Matlack	  I	  developed	  a	  yeast	  model	  that	  expressed	  Aβ	  1-­‐42	  in	  a	  manner	  
recapitulating	  mammalian	  Aβ	  1-­‐42	   generation	   and	   that	  was	   amenable	   to	   screens	   for	   genetic	  
modifiers	   of	   Aβ	   1-­‐42	   toxicity.	   The	   screen	   identified	   the	   yeast	   homolog	   of	   PICALM,	   a	   known	  
Alzheimer’s	   disease	   risk	   factor.	   I	   showed	   that	   Aβ	   1-­‐42	   expression	   resulted	   in	   a	   defect	   in	  
endocytosis	  that	  could	  be	  reverted	  by	  several	  of	  the	  genetic	  suppressors.	  In	  collaboration	  with	  
the	  Caldwell	   lab,	  we	   showed	   that	   the	   genetic	  modifiers	   also	  modulated	  Aβ	  1-­‐42	   toxicity	   in	   a	  
neuronal	   setting,	   C.	   elegans	   glutamatergic	   neurons.	   Finally,	   we	   showed	   that	   PICALM	   could	  
protect	  primary	  rat	  cortical	  neuron	  cultures	  from	  Aβ	  oligomer	  toxicity.	  	  
	  
Thesis	  Supervisor:	  Susan	  Lindquist	  




First	   of	   all,	   I	  would	   like	   to	   thank	  my	  advisor	   Susan	   Lindquist.	   It	   has	  been	  a	  wonderful	  
opportunity	   and	   great	   honor	   to	   have	   been	   a	   member	   of	   her	   lab.	   I	   learned	   a	   tremendous	  
amount	  from	  her,	  not	  only	  as	  a	  scientist	  and	  writer	  but	  also	  as	  a	  person.	   I	  have	  heard	  that	  at	  
the	  end	  of	  one’s	  graduate	  career	  there	  is	  often	  nothing	  more	  to	  be	  learned	  in	  one’s	  graduate	  
lab.	  That	  certainly	  is	  not	  true	  for	  Sue’s	  lab.	  Not	  only	  is	  Sue	  applying	  her	  vast	  expertise	  of	  protein	  
folding	  to	  an	  extensive	  range	  of	   research	  areas,	  Sue	   is	  always	   looking	  to	  develop	  and	  employ	  
new	  technologies	  and	  methods	  in	  her	  lab.	  Sue	  also	  has	  created	  a	  fantastic	  lab	  environment,	  full	  
of	  amazing,	  as	  well	  as	  supportive,	  people.	  	  
My	  thesis	  committee	  has	  been	  very	  supportive	  and	  has	  provided	  an	  immense	  amount	  of	  
valuable	   feedback	  on	  my	   thesis	  projects.	   Iain	  Cheeseman,	  David	  Housman	  and	   Jonathan	  King	  
have	   been	   on	   my	   committee	   for	   several	   years.	   Li-­‐Huei	   Tsai	   joined	   the	   committee	   for	   my	  
defense	  and	   I	  am	  excited	  to	  get	  her	   feedback,	  especially	  on	  the	  Aβ	  project.	  Being	  able	  to	  get	  
advice	  and	  feedback	  from	  my	  committee	  has	  been	  crucial.	   I	  want	  to	  thank	   Iain	  and	  David	   for	  
their	  advice	  and	  support	  as	  I	  was	  preparing	  to	  interview	  for	  postdoctoral	  positions.	  Iain	  always	  
took	   the	   time	   to	   talk	   and	   share	   his	   insights.	   I	   especially	   want	   to	   thank	   him	   for	   his	  
encouragement	  and	  occasionally	  providing	  me	  with	  much	  needed	  perspective.	  	  
As	  I	  mentioned,	  Sue’s	  lab	  is	  full	  of	  people	  that	  have	  supported	  me	  during	  my	  time	  in	  her	  
lab.	  First	  and	  foremost,	  Brooke	  Bevis	  does	  a	  wonderful	  and	  essential	  job	  managing	  the	  lab	  and	  
gracefully	  prevents	   it	   from	   slowly	  descending	   into	   chaos.	   She	  always	   takes	   the	   time	   to	   listen	  
and	   has	   personally	   helped	   me	   through	   several	   “grad	   school	   moments”	   with	   her	  
encouragements	   and	   practical	   advice.	   Martin	   Duennwald,	   a	   former	   postdoc	   with	   whom	   I	  
rotated	  prior	  to	  joining	  the	  lab,	  helped	  me	  to	  get	  acclimated	  and	  started	  in	  the	  lab.	  He	  taught	  
me	  techniques	  used	  throughout	  my	  thesis	  and	  even	  put	  together	  a	  mini	  yeast	  prion	  journal	  club	  
	   4	  
for	  me	  and	  another	  graduate	  student.	  My	  current	  and	  former	  bay	  mates	  Jens	  Tyedmers,	  Chris	  
Pacheco	  and	  Dan	  Termine	  provided	   formative	   scientific	   discussions	   and	  welcome	  distraction.	  
Although	  I	  am	  somewhat	  glad	  that	  we	  did	  not	  have	  Pandora	  when	  Jens	  and	  I	  shared	  the	  bay.	  I	  
am	  not	  sure	  if	  I	  could	  have	  handled	  the	  amount	  of	  80s	  music.	  I	  also	  want	  to	  thank	  my	  baymates	  
for	   putting	  up	  with	  me	  and	  providing	   support	  when	   things	  were	  not	   going	   so	  well.	   And	   that	  
goes	  for	  numerous	  other	  lab	  members	  as	  well.	  
The	   Aβ	   project	   would	   not	   have	   possible	   with	   out	   the	   help	   of	   Haesun	   Han	   and	   Kent	  
Matlack.	  Haesun	  assisted	  me	  with	  the	  genetic	  screen.	  Kent	  not	  only	  started	  the	  Aβ	  project	  but	  
also	  provided	  a	  lot	  of	  suggestions	  and	  great	  conversations	  along	  the	  way.	  Shu	  Hamamichi	  did	  a	  
marvelous	  job	  with	  the	  Aβ	  C.	  elegans	  experiments.	  He	  even	  spent	  additional	  time	  in	  Alabama	  to	  
complete	  them	  before	  joining	  the	  Lindquist	  lab.	  Simon	  Alberti,	  a	  former	  postdoc,	  generated	  an	  
invaluable	   collection	   of	   expression	   constructs	   that	   facilitated	   several	   yeast	   experiments.	   Bob	  
Burger	  does	  a	  simply	  outstanding	  job	  managing	  the	  financial	  side	  of	  the	  lab.	  Karen	  Allendorfer	  
did	   an	   outstanding	   job	   proofreading	   many	   chapters	   of	   this	   thesis.	   Sven	   Heinrich	   gave	   me	  
invaluable	  comments	  and	  suggestions	  on	  hot	  to	  write	  Chapter	  3.	  I	  also	  would	  like	  to	  thank	  all	  
the	  other	  current	  and	  former	  lab	  members	  for	  making	  the	  Lindquist	  lab	  such	  a	  fantastic	  place	  to	  
do	  science.	  
Andreas	  Hochwagen,	  a	  current	  Whitehead	  Fellow,	  shared	  his	  knowledge	  of	  the	  cell	  cylce	  
with	  me	  and	  gifted	  me	  several	  key	  reagents.	  The	  Whitehead	  simply	  has	  been	  a	  fantastic	  place	  
to	   be	   a	   graduate	   student.	   Facilities,	   dish	  washing,	   and	   IT	   services	   have	   been	   incredible.	   The	  
Whitehead	   microarray	   facility	   has	   been	   outstanding	   and	   George	   Bell	   was	   a	   huge	   help	   in	  
analyzing	  Aβ	  microarray	  data.	  
I	  want	   to	   thank	  my	   parents	   for	   their	   love	   and	   support.	   They	   afforded	  me	  with	  many	  
great	  opportunities,	  most	  importantly	  the	  opportunity	  to	  be	  independent.	  
Finally,	  my	  girl	  friend	  Jen	  is	  the	  best	  thing	  that	  happened	  to	  me	  during	  graduate	  school.	  
She	  provided	  constant	  support,	  propping	  me	  up	  countless	  times,	  but	  also	  pointed	  out	  when	  I	  
was	  being	  stubborn	  and	  needed	  to	  look	  at	  things	  from	  a	  different	  side.	  In	  addition	  she	  picked	  
out	  Milan,	  our	  wirehair	  dachshund,	  who	   in	  his	  own	  way	  has	  been	  a	  huge	  help	   in	  writing	   this	  
thesis;	  there	  is	  something	  very	  relaxing	  about	  chasing	  that	  little	  bugger	  around	  the	  coffee	  table.	  
	  
	  
	   5	  
Table	  of	  Contents	  
Summary	  	   2	  
Acknowledgements	  	   3	  	  
Table	  of	  Contents	  	   5	  
List	  of	  Figures	  	   8	  
List	  of	  Tables	  	   10	  
	  
Chapter	  One:	  Introduction	  	   11	  
o 	  Abstract	  and	  Introduction	  	   12	  	  
o 	  Pathological	  features	  associated	  with	  neurodegenerative	  diseases	  	   16	  
o 	  Protein	  deposition	  as	  a	  cellular	  response	  to	  misfolded	  proteins	  	   19	  
o 	  Asymmetric	  Inheritance	  of	  damaged	  Proteins	  	   21	  
o 	  Protein	  deposition	  as	  a	  protective	  mechanism	  	   22	  
o 	  Lessons	  on	  protective	  aggregation	  from	  a	  yeast	  model	  	   26	  
o 	  Formation	  of	  toxic	  protein	  species	  due	  to	  non-­‐productive	  templating	  	   28	  
o 	  Yeast	  models	  of	  neurodegenerative	  diseases	  	   32	  
o 	  Conclusion	  	   34	  
o References	  	   36	  
	  
Chapter	  Two:	  Chaperone-­‐dependent	  amyloid	  assembly	  protects	  cells	  from	  	  
prion	  toxicity	  	   42	  
o 	  Abstract	  and	  Introduction	  	   43	  
o 	  Results	  	   46	  
Overexpression	  of	  Rnq1	  is	  toxic	  in	  [RNQ+]	  cells	  	   46	  
The	  Hsp40	  Sis1	  can	  suppress	  Rnq1	  toxicity	  	   50	  
Sis1-­‐mediated	  amyloid	  formation	  protects	  from	  Rnq1	  toxicity	  	   51	  
Identification	  of	  the	  Sis1	  binding	  site	  in	  Rnq1	  	   54	  
Mutations	  in	  the	  Sis1	  binding	  site	  of	  Rnq1	  interfere	  with	  [RNQ+]	  amyloid	  
assembly	  	   57	  
Suppression	  of	  Rnq1	  toxicity	  by	  Sis1	  requires	  [RNQ+]	  prion	  assembly	  	   60	  
Rnq1	  L94A	  does	  not	  form	  prion	  amyloids	  in	  [rnq-­‐]	  cells	  	   61	  
o 	  Discussion	  	   65	  
o 	  Author	  contributions	  	   68	  
o 	  References	  	   68	  
o 	  Materials	  and	  Methods	  	   70	  
o 	  Supplemental	  Figures	  	   78	  
	  
Chapter	  Three:	  Dissecting	  the	  detrimental	  effects	  of	  prion	  protein	  overexpression	  	  
and	  the	  diversity	  of	  mechanisms	  than	  can	  alleviate	  them	  	   85	  
o 	  Abstract	   86	  
o 	  Introduction	  	   86	  
o 	  Results	  	   89	  
RNQ1	  and	  HSP104	  are	  the	  only	  non-­‐essential	  genes	  strictly	  
	   6	  
	   required	  for	  Rnq1	  toxicity	  and	  the	  [RNQ+]	  prion	  state	  	   89	  
Overexpression	  of	  a	  diverse	  group	  of	  genes	  can	  suppress	  Rnq1	  toxicity	  	   91	  
Proteins	  with	  prion-­‐like	  domains	  do	  not	  affect	  Rnq1	  amyloid	  formation	  	   93	  
Suppressors	  with	  prion-­‐like	  domains	  co-­‐localize	  with	  Rnq1	  inclusions	  	   96	  
Rnq1	  toxicity	  results	  in	  down-­‐regulation	  of	  cytokinetic	  genes	  	   100	  
Rnq1	  overexpression	  causes	  cell	  cycle	  arrest	  in	  mitosis	   102	  
Rnq1	  toxicity	  results	  in	  arrest	  with	  a	  monopolar	  spindle	  	   105	  
Rnq1	  overexpression	  causes	  mislocalization	  of	  Spc42	  	   108	  
Elevated	  expression	  of	  Spc42	  suppresses	  Rnq1	  toxicity	  	   109	  
o 	  Discussion	  	   114	  
o 	  References	  	   119	  
o 	  Materials	  and	  Methods	  	   124	  
o 	  Supplemental	  Information	  	   131	  
	  
Chapter	  Four:	  A	  yeast	  model	  connects	  Alzheimer’s	  disease	  modifiers	  to	  Aβ	  toxicity	  	   136	  
o 	  Abstract	  and	  Introduction	  	   137	  
o 	  Results	  	   139	  
A	  yeast	  model	  of	  Aβ	  toxicity	  	   140	  
Screen	  for	  genetic	  modifiers	  of	  Aβ	  toxicity	  	   144	  
Modifiers	  of	  Aβ	  toxicity	  are	  associated	  with	  AD	  susceptibility	  	   146	  
C.	  elegans	  models	  of	  Aβ	  toxicity	  	   147	  
PICALM	  suppresses	  the	  toxicity	  of	  soluble	  Aβ	  oligomers	  in	  rat	  cortical	  	  
neurons	   152	  
Effect	  of	  Aβ	  on	  endocytosis	  and	  trafficking	  	   155	  
o 	  Conclusions	  and	  Perspectives	   158	  
o 	  Author	  contributions	  	   160	  
o 	  References	  	   161	  
o 	  Materials	  and	  Methods	  	   166	  
o 	  Supplemental	  Information	  	   183	  
	  
Appendix	  One:	  Prion	  induction	  involves	  an	  ancient	  system	  for	  the	  sequestration	  of	  
aggregated	  proteins	  and	  heritable	  changes	  in	  prion	  fragmentation	  	   203	  
o 	  Abstract	   204	  
o 	  Introduction	  	   205	  
o 	  Results	  	   206	  
Expression	  of	  PrD-­‐GFP	  in	  a	  Sup35	  PrD	  deletion	  strain	  results	  in	  Rings	  	  
and	  Dots	  	   206	  
Propagation	  of	  Rings	  and	  Dots	  is	  independent	  of	  [RNQ+]	  	   209	  
Time-­‐lapse	  microscopy	  establishes	  stable	  asymmetric	  inheritance	  of	  both	  
aggregation	  states	  	   209	  
PrD-­‐GFP	  Dots	  can	  transmit	  the	  [PSI+]	  phenotype	  but	  Rings	  cannot	  	   211	  
In	  Ring	  and	  Dot	  cells	  PrD-­‐GFP	  is	  in	  the	  same	  amyloid	  conformation	  	   212	  
Aggregate	  formation	  occurs	  at	  a	  site	  specific	  to	  the	  deposition	  of	  	   	  
insoluble	  aggregates	  	   216	  
	   7	  
Number	  of	  PrD-­‐GFP	  amyloid	  fibers	  differs	  between	  Ring	  	  
and	  Dot	  aggregates	  	   218	  
o 	  Discussion	  	   222	  
o 	  Author	  contributions	  	   227	  
o 	  References	  	   227	  
o 	  Materials	  and	  Methods	  	   230	  
o 	  Supplemental	  Materials	  	   237	  
	  
Appendix	  Two:	  Identification	  of	  malaria	  Hsp40	  chaperone	  inhibitors	  in	  yeast	  	   248	  
o 	  Abstract	  	   249	  
o 	  Specific	  Aims	  	   249	  
o 	  Significance	  	   253	  
o 	  Preliminary	  Studies	  	   255	  
o 	  Research	  Design	  and	  Methods	   258	  
o 	  References	  	   262	  
o Figures	  	   263	  
	  
Appendix	  Three:	  Future	  Experiments	  	   268	  
o 	  Rnq1	  and	  asymmetric	  inheritance	  of	  damaged	  proteins	  	   269	  
o 	  Yeast	  model	  of	  Aβ	  toxicity	  	   273	  
	   8	  
Figure	  List	  
Chapter:	  Introdution	  
C1.1:	  Aggregation	  of	  misfolded	  protein.	  	   14	  
C1.2:	  Amyloid	  and	  Non-­‐productive	  templating.	  	   31	  
	  
Chapter	  Two:	  Chaperone-­‐dependent	  amyloid	  assembly	  protects	  cells	  from	  prion	  toxicity	  
C2.1:	  	  Overexpression	  of	  Rnq1	  is	  toxic	  to	  [RNQ+]	  cells.	  	   48	  
C2.2:	  Sis1	  overexpression	  protects	  against	  Rnq1	  toxicity.	  	   53	  
C2.3:	  Sis1	  binding	  to	  a	  conserved	  chaperone-­‐binding	  motif	  in	  the	  non-­‐prion	  	  
domain	  of	  Rnq1.	  	   55	  
C2.4:	  Mutations	  in	  the	  chaperone-­‐binding	  motif	  of	  Rnq1	  reduce	  the	  efficiency	  of	  	  
[RNQ+]	  amyloid	  assembly.	  	   58	  
C2.5:	  Rnq1	  L94A	  toxicity	  and	  assembly	  status	  in	  [rnq-­‐]	  yeast.	  	   63	  
Supplemental	  C2.1:	  Factors	  influencing	  Rnq1	  toxicity	  include	  the	  expression	  level	  	  
and	  presence	  of	  a	  carboxy-­‐terminal	  tag.	  	   78	  
Supplemental	  C2.2:	  Mutation	  of	  the	  chaperone-­‐binding	  motif	  slows	  the	  rate	  of	  	  
Rnq1	  assembly	  into	  [RNQ+]	  prions.	  	   80	  
Supplemental	  C2.3:	  Depletion	  of	  Sis1	  hinders	  assembly	  of	  nascent	  Rnq1-­‐GFP	  into	  	  
SDS-­‐resistant	  [RNQ+]	  aggregates.	  	   82	  
Supplemental	  C2.4:	  Analysis	  of	  the	  mobility	  of	  Rnq1	  L94A	  in	  extracts	  from	  [RNQ+]	  	  
and	  [rnq-­‐]	  strains	  by	  gel	  filtration	  chromatography.	  	   84	  
	  
Chapter	  Three:	  Dissecting	  the	  detrimental	  effects	  of	  prion	  protein	  overexpression	  and	  the	  
complex	  routes	  to	  its	  detoxification	  
C3.1:	  Overexpression	  suppressors	  of	  Rnq1	  toxicity.	  	   94	  
C3.2:	  Co-­‐localization	  of	  OE	  screen	  hits	  with	  Rnq1.	  	   97	  
C3.3:	  Rnq1	  overexpression	  induces	  a	  MAD2-­‐dependent	  cell	  cycle	  arrest.	  	   103	  
C3.4:	  Rnq1	  toxicity	  results	  in	  arrest	  with	  a	  monopolar	  spindle.	  	   107	  
C3.5:	  Rnq1	  overexpression	  induces	  mislocalization	  of	  Spc42	  to	  inclusions.	  	   111	  
C3.6:	  Elevated	  expression	  of	  Spc42	  can	  suppress	  Rnq1	  toxicity.	  	   113	  
C3.7:	  Model	  of	  Rnq1	  toxicity.	  	   117	  
Supplemental	  C3.1:	  Deletions	  that	  suppress	  Rnq1	  toxicity.	  	   132	  
Supplemental	  C3.2:	  Effect	  of	  OE	  screen	  hits	  on	  GAL1-­‐mediated	  YFP	  expression.	  	   133	  
	  
Chapter	  Four:	  A	  yeast	  model	  connects	  Alzheimer’s	  disease	  modifiers	  to	  Aβ	  toxicity	  	  
C4.1:	  Expression	  of	  ssAβ	  in	  the	  yeast	  secretory	  compartment.	  	   142	   	  
C4.2:	  Hits	  from	  the	  screen	  modify	  the	  toxicity	  of	  Aβ	  C.	  elegans	  glutamatergic	  neurons	  
in	  the	  same	  direction	  as	  they	  do	  in	  yeast.	  	   150	  
C4.3:	  PICALM	  protects	  cultured	  rat	  cortical	  neurons	  from	  exogenously	  applied	  	  
Aβ	  oligomers.	  	   153	  
C4.4:	  Aβ	  causes	  defects	  in	  endocytosis	  and	  receptor	  protein	  trafficking.	  	   157	  
	   9	  
Supplemental	  C4.1:	  Immunoblot	  analysis	  for	  strains	  expressing	  Aβ	   184	  
Supplemental	  C4.2:	  Localization	  of	  Aβ	  to	  the	  endoplasmic	  reticulum	  and	  vesicular	  	  
compartment.	   185	  
Supplemental	  C4.3:	  Example	  of	  a	  screening	  plate.	   186	  
Supplemental	  C4.4:	  Effect	  of	  suppressors	  on	  YFP	  expression	  levels.	   187	  
Supplemental	  C4.5:	  Analysis	  of	  transgene	  expression	  in	  worm	  strains.	  	   197	  
Supplemental	  C4.6:	  Aβ	  toxicity	  modifiers	  modulate	  the	  Aβ-­‐induced	  change	  in	  	  
Ste3-­‐YFP	  trafficking.	   199	  
Supplemental	  C4.7:	  Aβ	  toxicity	  modifiers	  modulate	  the	  Aβ-­‐induced	  change	  in	  	  
clathrin	  localization.	   201	  
	  
Appendix	  One:	  Prion	  induction	  involves	  an	  ancient	  system	  for	  the	  sequestration	  of	  
aggregated	  proteins	  and	  heritable	  changes	  in	  prion	  fragmentation	  
A1.1:	  Expression	  of	  PrD-­‐GFP	  at	  high	  levels	  produces	  self-­‐propagating	  Ring	  	  
assemblies	  that	  transition	  to	  a	  Dot	  assembly	  only	  after	  many	  generations.	  	   208	  
A1.2:	  Cells	  with	  Rings	  do	  not	  induce	  the	  [PSI+]	  prion	  state	  in	  a	  mating	  partner.	  	   210	  
A1.3:	  Cells	  with	  Rings	  and	  Dots	  contain	  PrD-­‐GFP	  in	  the	  same	  prion	  conformation.	  	   213	  
A1.4:	  Prion	  aggregates	  localize	  to	  the	  IPOD	  compartment	  as	  shown	  using	  markers	  	  
for	  the	  pre-­‐autophagosomal	  structure	  (PAS)	  and	  additional	  IPOD	  substrates.	  	   217	  
A1.5:	  Electron	  microscopy	  of	  Ring	  and	  Dot	  cells	  reveals	  the	  different	  degrees	  of	  	  
PrD-­‐GFP	  fibril	  fragmentation.	  	   220	  
A1.6:	  Schematic	  model	  for	  the	  induction	  and	  maturation	  of	  the	  PrD-­‐GFP	  prion	  via	  	  
a	  long-­‐lived	  poorly	  fragmented	  fibril	  state.	  	   224	  
Supplemental	  A1.1:	  PrD-­‐GFP	  is	  a	  prion	  on	  its	  own	  right.	  	   238	  
Supplemental	  A1.2:	  The	  formation	  of	  Ring	  aggregates	  and	  Dot	  aggregates	  requires	  	  
HSP104	  and	  RNQ1.	  	   239	  
Supplemental	  A1.3:	  Both	  Ring	  and	  Dot	  aggregates	  can	  propagate	  in	  the	  absence	  	  
of	  Rnq1.	  	   240	  
Supplemental	  A1.4:	  Co-­‐purification	  of	  proteins	  with	  PrD-­‐GFP	  from	  cell	  lysates	  with	  	  
Dot	  aggregates.	  	   242	  
Supplemental	  A1.5:	  Characterization	  of	  PrD-­‐GFP	  in	  Ring-­‐	  or	  Dot	  aggregates	  by	  	  
immuno-­‐EM	  and	  determination	  of	  the	  dimensions	  in	  PrD-­‐GFP	  fibrils.	  	   244	  
Supplemental	  A1.6:	  Prion	  fibril	  accumulations	  at	  the	  IPOD	  are	  partially	  surrounded	  	  
by	  electron-­‐dense	  material	  typical	  for	  amorphously	  aggregated	  proteins.	  	   245	  
Supplemental	  A1.7:	  Expression	  of	  the	  dominant	  negative	  HSP104	  mutant	  K620T	  	  
induces	  the	  formation	  of	  PrD-­‐GFP	  Rings	  in	  the	  progeny	  of	  Dot-­‐containing	  cells.	  	   246	  
Supplemental	  A1.8:	  Similar	  levels	  of	  Hsp104	  in	  cells	  with	  diffuse	  PrD-­‐GFP	  	  
fluorescence,	  PrD-­‐GFP	  Rings	  or	  Dots.	  	   247	  
	  
Appendix	  Two:	  Identification	  of	  malaria	  Hsp40	  chaperone	  inhibitors	  in	  yeast	  
A2.1:	  The	  Plasmodium	  falciparum	  genome	  has	  an	  increased	  abundance	  of	  	  
Hsp40	  chaperones.	  	   264	  
A2.2:	  Expression	  of	  codon-­‐optimized	  P.	  falciparum	  Hsp40s	  in	  yeast.	  	   265	  
	   10	  
A2.3:	  Toxicity	  of	  P.	  falciparum	  Hsp40s	  depends	  on	  chaperone	  function.	  	   266	  
A2.4:	  The	  P.	  falciparum	  Hsp40	  PFE055c	  can	  complement	  the	  loss	  of	  the	  	  






Chapter	  Three:	  Dissecting	  the	  detrimental	  effects	  of	  prion	  protein	  overexpression	  and	  the	  
complex	  routes	  to	  its	  detoxification	  
Table	  C3.1:	  Suppressors	  of	  Rnq1	  toxicity	  identified	  in	  screens	  of	  the	  deletion	  and	  	  
overexpression	  libraries.	  	   92	  
Table	  C3.2:	  Co-­‐localization	  of	  screen	  hits	  with	  prion-­‐like	  domains.	  	   99	  
Table	  C3.3:	  Categories	  of	  genes	  changed	  2-­‐fold	  upon	  Rnq1	  overexpression.	  	   101	  
Supplemental	  Table	  C3.1:	  Genes	  up-­‐	  or	  down-­‐regulated	  upon	  Rnq1	  	  
overexpression.	  	   134	  
Supplemental	  Table	  C3.2:	  Quantification	  of	  cell	  cycle	  profiling	  of	  strain	  	  
overexpressing	  Rnq1.	  	   135	  
	  
Chapter	  Four:	  A	  yeast	  model	  connects	  Alzheimer’s	  disease	  modifiers	  to	  Aβ	  toxicity	  	  
Table	  C4.1:	  Modifiers	  of	  Aβ	  toxicity	  with	  clear	  human	  homologs.	  	   145	  
Supplemental	  Table	  C4.1:	  Suppressors	  and	  enhancers	  of	  Aβ	  toxicity	  identified	  in	  	  
the	  yeast	  screen.	  	   188	  
Supplemental	  Table	  C4.2:	  	  Genome-­‐wide	  FBAT-­‐GEE	  association	  results	  from	  	  
NIMH	  cohort.	  	   191	  
Supplemental	  Table	  C4.3:	  	  Cohort	  demographics	  and	  characteristics.	  	   193	  
Supplemental	  Table	  C4.4:	  	  Human	  loci	  tested	  for	  associations	  with	  intermediate	  AD	  	  
cognitive	  and	  neuropathologic	  phenotypes.	  	   194	  
Supplemental	  Table	  C4.5:	  	  Locus	  associations	  with	  episodic	  memory	  decline.	  	   195	  
Supplemental	  Table	  C4.6:	  	  Locus	  associations	  with	  global	  AD	  pathology.	  	   196	  
	  
Appendix	  One:	  Prion	  induction	  involves	  an	  ancient	  system	  for	  the	  sequestration	  of	  
aggregated	  proteins	  and	  heritable	  changes	  in	  prion	  fragmentation	  
Supplemental	  Table	  A1.1:	  Table	  of	  proteins	  present	  only	  in	  protein	  bands	  isolated	  	  


















Much	  of	  this	  chapter	  was	  published	  as	  “Amyloid	  deposits:	  Protection	  against	  toxic	  
protein	  species?”	  Cell	  Cycle	  Sebastian	  Treusch,	  Douglas	  M.	  Cyr	  and	  Susan	  Lindquist.	  
Sections	  on	  asymmetric	  inheritance	  of	  protein	  damage	  and	  yeast	  models	  of	  





Neurodegenerative	   diseases	   ranging	   from	   Alzheimer’s	   disease	   and	  
polyglutamine	   diseases	   to	   transmissible	   spongiform	   encephalopathies	   are	   associated	  
with	   the	   aggregation	   and	   accumulation	   of	   misfolded	   proteins.	   In	   several	   cases	   the	  
intracellular	  and	  extracellular	  protein	  deposits	   contain	  a	   fibrillar	  protein	   species	  called	  
amyloid.	   However,	   while	   amyloid	   deposits	   are	   hallmarks	   of	   numerous	  
neurodegenerative	   diseases,	   their	   actual	   role	   in	   disease	   progression	   remains	   unclear.	  
Especially	  perplexing	   is	  the	  often	  poor	  correlation	  between	  protein	  deposits	  and	  other	  
markers	   of	   neurodegeneration.	   As	   a	   result	   the	   question	   remains	   whether	   amyloid	  
deposits	  are	  the	  disease	  causing	  species,	  the	  consequence	  of	  cellular	  disease	  pathology	  
or	  even	  the	  result	  of	  a	  protective	  cellular	   response	  to	  misfolded	  protein	  species.	  Here	  
we	   highlight	   studies	   that	   suggest	   that	   accumulation	   and	   sequestration	   of	   misfolded	  
protein	   in	   amyloid	   inclusion	   bodies	   and	   plaques	   can	   serve	   a	   protective	   function.	  
Furthermore,	  we	  discuss	  how	  exceeding	  the	  cellular	  capacity	   for	  protective	  deposition	  
of	  misfolded	  proteins	  may	  contribute	  to	  the	  formation	  of	  toxic	  protein	  species.	  We	  also	  
highlight	   how	   yeast	   model	   systems	   can	   be	   employed	   to	   study	   the	   proteotoxicity	   of	  
amyloidogenic	  proteins	  and	  proteins	  implicated	  in	  neurodegeneration.	  
	  
Introduction	  
The	  study	  of	  neurodegenerative	  diseases	  began	  over	  a	  hundred	  years	  ago	  when	  
Alois	  Alzheimer	   identified	   fibrillar	   structures	  within	   the	  postmortem	  brain	  of	  a	  patient	  




1995).	  It	  is	  now	  known	  that	  the	  majority	  of	  neurodegenerative	  diseases	  characterized	  by	  
progressive	   neuronal	   dysfunction	   and	   loss	   are	   associated	   with	   the	   deposition	   of	  
misfolded	   proteins.	   These	   misfolded	   proteins	   are	   frequently	   found	   in	   a	   β-­‐sheet	   rich	  
fibrillar	   protein	   conformation	   known	   as	   amyloid	   (CAUGHEY,	   et	   al.	   2003;	   NELSON,	   et	   al.	  
2005)	   (Figure	   C1.1).	   For	   more	   than	   forty	   years	   amyloid	   deposits	   were	   thought	   to	   be	  
causative	   agents	   in	   the	   degenerative	   process	   (ROTH,	   et	   al.	   1966).	   But	   the	   tables	   have	  
turned.	  Recent	  studies	  suggest	   instead	  that	  a	  group	  of	  still	  poorly	  defined	  pre-­‐amyloid	  
species,	  rather	  than	  the	  amyloid	  deposits	  themselves,	  are	  the	  true	  toxic	  conformations	  	  
(KAYED,	   et	  al.	  2003;	   LESNE,	   et	  al.	  2006;	  SHANKAR,	   et	  al.	  2008;	  WALSH,	   et	  al.	  2002)	   (Figure	  
C1.1).	   These	   soluble	   prefibrillar	   oligomers	   share	   conformational	   characteristics	  
independent	  of	   the	  proteins	  primary	  amino	  acid	  sequences	  and	  may	  share	  a	  common	  
mechanism	  of	  toxicity	  (KAYED,	  et	  al.	  2003).	  Indeed	  even	  proteins	  completely	  unrelated	  to	  
disease,	  such	  as	  PI3	  kinase	  and	  the	  E.	  Coli	  protein	  HypF-­‐N,	  can	  be	  induced	  to	  form	  such	  
prefibrillar	   structures	   in	   vitro	   and,	   when	   they	   do,	   they	   are	   toxic	   when	   applied	  
extracellularly	   to	   cells	   in	   culture	   or	   injected	   into	   rat	   brains	   (BAGLIONI,	   et	   al.	   2006;	  
BUCCIANTINI,	   et	   al.	   2002).	   The	   intra-­‐	   and	   extracellular	   conversion	   of	  misfolded	   proteins	  
into	  highly	   structured	  and	   less	   reactive	  amyloid	   forms	  may	   reduce	   the	   levels	  of	   these	  






Figure	   C1.1	   Aggregation	   of	   misfolded	   protein	   can	   give	   rise	   to	   oligomers,	   amorphous	  
aggregates	   and	   inclusion	   bodies.	   The	   accumulation	   of	  misfolded	   protein	   leads	   to	   the	  
formation	   of	   different	   protein	   assemblies.	   Prefibrillar	   oligomers	   formed	   by	   different	  
proteins	  share	  a	  common	  structure	  and	  are	   thought	   to	  be	  the	  toxic	  protein	  species	   in	  
diseases	   such	   as	   Alzheimer’s	   and	  Huntington’s	   (KAYED,	   et	   al.	   2003;	   LESNE,	   et	   al.	   2006).	  
Oligomers	   are	   conformationaly	   molten	   and	   can	   associate	   to	   form	   amorphous	  
aggregates	  or	  convert	  to	  an	  amyloidogenic	  nucleus	  to	   initiate	  amyloid	  fibril	   formation.	  




insoluble.	  Amyloid	   fibrils	   are	  often	   found	   in	   intra-­‐	   and	  extracellular	   inclusions	   such	   as	  
inclusion	   bodies	   and	   amyloid	   plaques.	   The	   generation	   of	   amyloid	   fibers	   and	   inclusion	  
bodies	  can	  protect	  cells	  by	  reducing	  the	  formation	  of	  highly	  interactive	  toxic	  oligomers	  





We	   focus	   on	   three	   neurodegenerative	   diseases,	   Alzheimer’s,	   Huntington’s	   and	  
prion	  disease.	  We	  will	   first	  present	   studies	   in	  which	   the	   formation	  of	   inclusion	  bodies	  
and	  amyloid	  plaques	  protects	  against	  proteotoxicity	  and	  then	  discuss	  how	  exceeding	  the	  
cellular	   capacity	   for	   deposition	   of	   misfolded	   proteins	   may	   give	   rise	   to	   toxic	   protein	  
species.	  Although	  these	  studies	  do	  not	  preclude	  detrimental	  effects	  of	  amyloid	  deposits	  
in	  particular	  contexts	  (eg.	  obstructive	  vascular	  amyloid),	  they	  clearly	  show	  that	  amyloid	  
formation	  can	  be	  beneficial.	  Furthmore,	  we	  highlight	  how	  yeast	  models	  have	  been	  used	  
to	   garner	   insight	   into	  how	   the	  misfolded	  proteins	   central	   to	   these	  neurodegenerative	  
diseases	  lead	  to	  cellular	  defects	  and	  ultimately	  death.	  	  
	  	  
Pathological	  features	  associated	  with	  neurodegenerative	  diseases	  
The	   protein	   deposits	   found	   in	   Alzheimer’s,	   Huntington’s	   and	   prion	   disease	   are	  
formed	  by	  completely	  unrelated	  proteins.	  They	  accumulate	  in	  distinct	  brain	  regions	  and	  
have	   highly	   characteristic	   morphologies	   that	   form	   the	   basis	   of	   histological	   diagnosis.	  	  
Neurodegeneration	  also	  affects	  distinct	  regions	  of	  the	  brain	  in	  each	  diseases,	  reflecting	  
disease	  specific	  vulnerability	  of	  particular	  neurons	  (ELLISON,	  et	  al.	  2004).	  However,	  in	  all	  
three	   diseases	   the	   correlation	   between	   the	   localization	   of	   neurodegeneration	   and	  
protein	  deposition	  is	  weak.	  
Alzheimer’s	  disease	   (AD),	   the	  most	  common	  cause	  of	  dementia,	  most	  severely	  
affects	   the	   temporal	  pole,	  hippocampus	  and	  amygdala	   (DUYCKAERTS,	   et	  al.	   2003).	  AD	   is	  




distribution.	   Aβ	   (amyloid	   β)	   peptide	   accumulates	   extracellularly	   in	   amyloid	   plaques	  
while	   hyperphosphorylated	   tau,	   a	   microtubule	   binding	   protein,	   accumulates	  
intracellularly	   in	   neurofibrillary	   tangles.	   A	   definitive	   pathological	   diagnosis	   of	   AD	  
requires	   the	   detection	   of	   both	   types	   of	   aggregation.	   Aβ	   may	   accumulate	   in	   different	  
plaque	   forms.	  Neuritic	  plaques,	   also	   referred	   to	  as	   classic	  or	   cored	  plaques,	   contain	  a	  
dense	  amyloid	  core	  surrounded	   in	   turn	  by	  a	  ring	  of	  abnormal	  cellular	  processes	  and	  a	  
rim	   of	   diffuse	   amyloid	   (DUYCKAERTS,	   et	   al.	   2003;	   ELLISON,	   et	   al.	   2004).	   In	   these	   neuritic	  
plaques	   tau	   accumulation	   can	   also	   be	   present	   in	   dystrophic	   neurites	   surrounding	   the	  
amyloid	  core.	  	  
It	   has	   been	   hypothesized	   that	   Aβ	   accumulation	   is	   the	   primary	   cause	   of	  
pathogenesis	  in	  AD,	  yet	  there	  is	  a	  weak	  correlation	  between	  Aβ	  plaque	  density	  and	  the	  
severity	  of	  dementia	  (ELLISON,	  et	  al.	  2004).	  For	  example,	  brain	  samples	  of	  aged	  patients	  
without	   clinical	   dementia	   can	   display	   abundant	   Aβ	   plaques	   (ELLISON,	   et	   al.	   2004).	   To	  
some	  extent	   this	  may	  be	  the	  consequence	  of	  Aβ	  accumulating	   in	  plaques	  without	  any	  
associated	   neuritic	   degeneration	   (such	   as	   “burned-­‐out”	   and	   “diffuse	   plaques”).	   Tau-­‐
containing	   neurofibrillary	   tangles	   correlate	   better	  with	   clinical	   severity	   of	   AD	   than	  Aβ	  
plaques,	  but	  even	  here,	  the	  question	  remains	  whether	  tau	  aggregation	  itself	  is	  toxic	  or	  if	  
it	  is	  the	  result	  of	  a	  protective	  mechanism	  	  (BRETTEVILLE,	  et	  al.	  2008;	  CONGDON,	  et	  al.	  2008;	  
GOTZ,	  et	  al.	  2008;	  HERNANDEZ,	  et	  al.	  2008).	  	  
Huntington’s	   disease	   (HD),	   classified	   as	   a	   hyperkinetic	   movement	   disorder,	  
tends	  to	  affect	  brain	  regions	  distinct	  from	  those	  affected	  by	  Alzheimer’s	  disease.	  HD	  is	  




with	  loss	  of	  medium	  spiny	  neurons	  within	  the	  neostriatum	  (CUMMINGS,	  et	  al.	  2000;	  ROSS	  
2003;	   ZOGHBI,	   et	   al.	   2000).	   HD	   is	   caused	   by	   CAG	   repeat	   expansions	   in	   the	   huntingtin	  
gene,	   which	   lead	   to	   the	   accumulation	   of	   polyglutamine-­‐expanded	   Huntingtin	   protein	  
within	   intranuclear	   inclusion	   bodies	   or	   neurites	   (ELLISON,	   et	   al.	   2004).	   The	   density	   of	  
intranuclear	   inclusions	  correlates	  positively	  with	   the	  CAG	  repeat	   length	  present	   in	   the	  
huntingtin	   gene	   (HEDREEN,	   et	   al.	   2003).	   However	   neuronal	   vulnerability	   does	   not	  
correspond	   to	   the	   cellular	   concentration	   of	   Huntingtin	   protein	   nor	   the	   distribution	   of	  
Huntingtin	   inclusions	   (GUTEKUNST,	   et	  al.	   1999).	   In	   fact	   there	   is	  a	  distinct	  dissociation	  of	  
inclusion	   distribution	   and	   the	   selective	   pattern	   of	   striatal	   neuron	   loss,	   as	   few	   to	   no	  
inclusions	  are	  detected	  in	  the	  vulnerable	  striatal	  neurons	  (KUEMMERLE,	  et	  al.	  1999).	  
Prion	  diseases	  or	  spongiform	  encephalopathies	  can	  present	  in	  numerous	  ways,	  
such	  as	  sporadic	  versus	  variant	  Creutzfeldt-­‐Jakob	  disease	  (CJD).	  While	  the	  prion	  disease	  
subtypes	   all	   involve	   the	   accumulation	   of	   a	   proteinase-­‐K	   resistant	   form	   of	   the	   prion	  
protein	   PrP	   (PrPres),	   they	   each	   affect	   different	   brain	   regions	   and	   involve	   distinct	  
patterns	   of	   PrP	   aggregation	   (ELLISON,	   et	   al.	   2004).	   Sporadic	   CJD	   causes	   spongiform	  
change	   in	   the	   neuropil	   of	   the	   cerebral	   cortex,	   subcortical	   grey	  matter	   and	   cerebellar	  
molecular	   layer	   (BUDKA,	   et	   al.	   2003).	   The	   brainstem	   and	   spinal	   cord	   do	   not	   exhibit	  
spongiform	   change	   although	  PrP	   deposits	   can	   be	   present.	   PrPres	   deposits	   in	   sporadic	  
CJD	  are	  found	  in	  synaptic,	  perivacuolar,	  perineuronal	  and	  plaque-­‐like	  patterns	  (BUDKA,	  et	  
al.	   2003).	   However	   neuronal	   loss	   correlates	   with	   microglial	   activation	   and	   axonal	  
damage,	  but	  not	  with	  local	  deposition	  of	  PrPres.	  In	  contrast,	  variant	  CJD,	  caused	  by	  the	  




presence	   of	   a	   large	   number	   of	   florid	   plaques	   in	   the	   cerbral	   and	   cerebellar	   cortex	  
(IRONSIDE,	  et	  al.	  2003).	  Florid	  plaques	  have	  a	  dense	  amyloid	  core,	  a	  pale	  radiating	  fibrillar	  
periphery	  and	  are	  surrounded	  by	  a	  halo	  of	  spongiform	  change.	  Interestingly,	  spongiform	  
change	  in	  variant	  CJD	  is	  most	  pronounced	  in	  the	  basal	  ganglia,	  which	  contain	  relatively	  
few	  amyloid	  plaques	  (IRONSIDE,	  et	  al.	  2003).	  	  
	   In	  summary,	  while	  the	  particular	  misfolded	  proteins	  vary	  in	  these	  diseases,	  in	  all	  
three	   cases	   protein	   deposits	   are	   a	   poor	   indicator	   of	   neuronal	   loss.	   This	   makes	   it	  
plausible	   that	   structured	   protein	   deposits	   help	   cells	   cope	   with	  misfolded	   proteins.	   In	  
turn,	   the	   failure	  of	  particular	  neurons	  to	  create	  such	  deposits	  may	  cause	  their	  disease	  
specific	  vulnerability.	  	  
	  
Protein	  deposition	  as	  a	  cellular	  response	  to	  misfolded	  proteins	  
One	  of	   the	   first	   indications	   that	  protein	   inclusions	  may	  protect	  cells	   from	  toxic	  
misfolded	  proteins	  came	  from	  a	  study	  investigating	  the	  response	  of	  tissue	  culture	  cells	  
to	   either	   proteasome	   inhibitors	   or	   to	   overexpression	   of	   proteins	   targeted	   to	   the	  
proteasome.	   The	   Kopito	   laboratory	   established	   that	   exceeding	   the	   proteasome’s	  
capacity	   to	   cope	   with	   misfolded	   proteins,	   by	   either	   perturbation,	   leads	   to	   the	  
accumulation	   of	   stable	   aggregates	   at	   a	   distinct	   structure	   adjacent	   to	   the	   centrosome	  
(JOHNSTON,	  et	  al.	  1998).	  This	  structure	  was	  termed	  the	  aggresome	  to	  emphasize	  that	  its	  





The	  aggresome	  is	  highly	  structured	  deposit	  of	  insoluble	  protein	  surrounded	  by	  a	  
cage	  formed	  by	  the	  intermediate	  filament	  protein	  vimentin.	  Most	  strikingly,	  aggresomes	  
are	   actively	   formed	   near	   the	   centrosome	   through	   dynein-­‐dependent	   retrograde	  
transport	  of	  protein	  aggregates	  along	  microtubules	  (GARCIA-­‐MATA,	  et	  al.	  1999;	  JOHNSTON,	  
et	   al.	   2002;	   JOHNSTON,	   et	   al.	   1998).	   Far	   from	  being	   amorphous	   protein	   accumulations,	  
aggresomes	  are	  formed	  through	  an	  active	  and	  conserved	  cellular	  process,	  that	  appears	  
to	  serve	  a	  vital	  purpose:	  sweeping	  the	  cytoplasm	  clear	  of	  potentially	  toxic	  aggregates	  of	  
misfolded	  proteins	  (KOPITO	  2000).	  
In	  yeast,	  misfolded	  proteins	  can	  accumulate	   in	   two	  distinct	   compartments,	   the	  
JUNQ	   (juxta-­‐nuclear	   quality	   control	   compartment)	   and	   the	   IPOD	   (insoluble	   protein	  
deposit)	   	   (KAGANOVICH,	   et	   al.	   2008).	   The	   JUNQ	   forms	   mostly	   upon	   inhibition	   of	   the	  
proteasome	   and	   contains	   poly-­‐ubiquitinated	   proteins	   targeted	   for	   proteasomal	  
degradation.	   The	   IPOD	   co-­‐localizes	   with	   the	   pre-­‐autophagosomal	   structure	   at	   the	  
vacuole	  and	  contains	  amyloidogenic	  proteins,	  such	  as	  yeast	  prions	  as	  well	  as	  ectopically	  
expressed	  mutant	  huntingtin	  exon	  one	  (both	  discussed	  below)	  (KAGANOVICH,	  et	  al.	  2008;	  
TYEDMERS,	  et	  al.	  2010).	  Furthermore,	  a	  variant	  of	  mutant	  huntingtin	  exon	  one	  that	  does	  
not	  localize	  to	  the	  IPOD	  can	  associate	  with	  the	  spindle	  pole	  body,	  the	  yeast	  equivalent	  
of	   the	   centrosome	   (WANG,	   et	   al.	   2009).	   This	   microtubule-­‐dependent	   aggregation	   has	  
been	  taken	  as	  evidence	  for	  aggresome	  formation	  in	  yeast.	  However,	  it	  remains	  unclear	  
how	   the	   yeast	   quality	   control	   compartments,	   JUNQ	   and	   IPOD,	   relate	   to	   mammalian	  




Asymmetric	  Inheritance	  of	  Damaged	  Proteins	  
Further	  support	  for	  the	  notion	  that	  protein	  inclusions	  serve	  a	  protective	  function	  
has	  come	  from	  a	  different	  direction.	  In	  yeast	  oxidatively	  damaged	  proteins	  are	  retained	  
in	   progenitor	   cells	   during	  mitosis	   (AGUILANIU,	   et	   al.	   2003).	  While	   dispersed	   throughout	  
the	   cytosol	   in	   young	   cells,	   oxidatively	   damaged	   proteins	   accumulate	   in	   aggregates	  
during	   replicative	   aging.	   The	   segregation	   of	   these	   aggregates	   partially	   determines	   the	  
life	  span	  and	  fitness	  of	  the	  progeny	  (ERJAVEC,	  et	  al.	  2007).	  In	  Escherichia	  coli	  aggregates	  
consisting	  of	  damaged	  proteins	  also	  are	  retained	  in	  the	  progenitor	  cells	  and	  contribute	  
to	  the	  aging	  of	  those	  cells	  (LINDNER,	  et	  al.	  2008).	  	  
In	   human	   embryonic	   stem	   cells	   polyubiquitinylated	   proteins	   were	   not	   only	  
contained	   in	   aggresome-­‐like	   deposits	   but	   also	   were	   inherited	   asymmetrically	  
(FUENTEALBA,	   et	   al.	   2008).	   Furthermore,	   tissue	   culture	   cells	   containing	   aggresomes	   of	  
mutant	   huntingtin	   underwent	   mitoses	   during	   which	   only	   one	   of	   the	   daughter	   cells	  
inherited	   the	   accumulated	   protein	   damage	   (RUJANO,	   et	   al.	   2006).	  Most	   convincing	   are	  
the	   findings	   from	   the	   examination	   of	   epithelial	   crypts	   of	   the	   small	   intestine	   of	   ataxia	  
type	  3	  patients	  	  (RUJANO,	  et	  al.	  2006).	  Similar	  to	  HD,	  this	  protein	  folding	  disease	  is	  caused	  
by	   a	   polyglutamine	   expansion,	   albeit	   in	   the	   ataxin-­‐3	   protein	   instead	   of	   huntingtin.	   In	  
these	   epithelial	   crypts,	   long-­‐lived	   stem	   cells	   were	   devoid	   of	   ataxin-­‐3	   polyglutamine	  
inclusions.	   On	   the	   contrary,	   short-­‐lived	   terminally	   differentiated	   cells	   did	   contain	  
polyglutamine	  inclusions	  (RUJANO,	  et	  al.	  2006).	  These	  studies	  indicate	  that	  the	  deposition	  
of	   damaged	   and	   misfolded	   proteins	   in	   aggresomes	   enables	   mitotic	   cells	   to	  




expectancy.	  This	  evolutionarily	  conserved	  mechanism	  allows	  one	  of	  the	  mitotic	  cells	  to	  
start	  with	  a	  clean	  slate,	  ensuring	  its	  fitness	  and	  increasing	  its	  life	  expectancy	  (ERJAVEC,	  et	  
al.	   2007;	   RUJANO,	   et	   al.	   2006).	   These	   studies	   show	   that,	   at	   least	   in	   mitotic	   cells,	   the	  
intracellular	   formation	   of	   inclusion	   bodies	   serves	   a	   protective	   function.	   Furthermore,	  
while	  protein	  damage	  has	  consistently	  been	  associated	  with	  neurodegeneration	  in	  aging	  
individuals,	   these	   studies	  also	   suggest	   that,	   to	  an	  extent,	  aging	   is	   the	  accumulation	  of	  
protein	  damage.	  	  
	  
Protein	  deposition	  as	  a	  protective	  mechanism	  
A	   host	   of	   studies	   involving	   proteins	   linked	   to	   neurodegenerative	   diseases	   and	  
other	   amyloidogenic	   proteins	   have	   investigated	   the	   role	   of	   inclusion	   and	   plaque	  
formation	  in	  pathogenicity.	  The	  case	   is	  perhaps	  strongest	  for	  Huntington’s	  disease,	  for	  
which	  it	  has	  been	  postulated	  that	   inclusions	  cause	  toxicity	  due	  to	  the	  sequestration	  of	  
proteins	  critical	  for	  cell	  homeostasis	  (PREISINGER,	  et	  al.	  1999).	  Indeed,	  inclusions	  formed	  
by	   mutant	   Huntingtin	   protein	   have	   been	   shown	   to	   sequester	   glyceraldehydes-­‐3-­‐
phosphate	   dehydrogenase,	   to	   impair	   transcription	   due	   to	   sequestration	   of	   the	  
transcriptional	   coactivator	  CREB	  binding	  protein,	   and	   to	   interfere	  with	   the	   function	  of	  
the	  ubiquitin-­‐proteasome	  system	  (BENCE,	  et	  al.	  2001;	  BURKE,	  et	  al.	  1996;	  NUCIFORA,	  et	  al.	  
2001).	  However	   smaller	   oligomeric	   species	   and	   loosely	   packed	  amorphous	   aggregates	  
may	   be	   more	   prone	   to	   interact	   with	   and	   sequester	   proteins	   than	   densely	   packed	  




Indeed,	   several	   studies	  suggest	   that	   the	   formation	  of	   tightly	  packed	  Huntingtin	  
deposits	  is	  beneficial	  for	  cell	  survival.	  The	  Greenberg	  lab	  demonstrated	  that	  transfection	  
of	  mutant	  huntingtin	   into	  primary	  striatal	  neurons	   induced	  the	  formation	  of	   inclusions	  
(SAUDOU,	   et	   al.	   1998).	   The	   inclusions	   formed	   resembled	   protein	   deposits	   found	   in	   the	  
brains	   of	   Huntington	   patients,	   as	   they	   were	   intranuclear	   and	   ubiquitinylated.	   But	  
inclusions	   were	   not	   sufficient	   to	   induce	   apoptosis.	   On	   the	   contrary,	   inhibiting	   the	  
ubiquitinylation	  of	  mutant	  Huntingtin	  prevented	  the	  formation	  of	  inclusions	  and	  actually	  
increased	  cell	  death	  (SAUDOU,	  et	  al.	  1998).	  	  
In	  a	  complementary	  study,	  the	  Finkbeiner	  group	  used	  time-­‐lapse	  microscopy	  to	  
follow	   the	   fate	   of	   individual	  huntingtin	   transfected	   neurons.	   The	  majority	   of	   neurons	  
died	  without	  the	  formation	  of	   inclusion	  bodies	  and	  the	  formation	  of	  an	  inclusion	  body	  
actually	   increased	   the	   probability	   of	   neuron	   survival	   (ARRASATE,	   et	   al.	   2004).	   The	  
formation	  of	  inclusion	  bodies	  directly	  correlated	  with	  a	  decrease	  in	  soluble	  Huntingtin,	  
suggesting	   that	   inclusion	   bodies	   protect	   neurons	   by	   decreasing	   levels	   of	   soluble	   toxic	  
isoforms	  of	  Huntingtin	  (ARRASATE,	  et	  al.	  2004).	  Inclusion	  body	  formation	  could	  also	  serve	  
a	   protective	   function	   by	   increasing	   the	   autophagic	   degradation	   of	   the	   aggregated	  
protein	   species	   (TAYLOR,	   et	   al.	   2003).	   Inclusions	   of	   mutant	   Huntingtin	   directly	   induce	  
autophagy	   through	   sequestration	   of	   mTOR,	   a	   negative	   regulator	   of	   autophagy,	   and	  
autophagy	  not	  only	  reduces	  the	  levels	  of	  aggregated	  but	  also	  soluble	  mutant	  huntingtin	  
(RAVIKUMAR,	  et	  al.	  2004;	  WILLIAMS,	  et	  al.	  2008).	  	  
Together,	   these	   studies	   suggest	   that	   compounds	   elevating	   the	   formation	   of	  




hand	   compounds	   antagonizing	   the	   toxicity	   of	   mutant	   huntingtin	   by	   reducing	   its	  
aggregation	  have	  been	  identified	  (EHRNHOEFER,	  et	  al.	  2006).	  On	  the	  surface,	  this	  appears	  
to	   conflict	   with	   the	   notion	   that	   promoting	   inclusions	   may	   be	   beneficial,	   but	   both,	  
solubilization	  and	  inclusion	  body	  formation,	  may	  diminish	  the	  levels	  of	  toxic	  oligomers,	  
the	   more	   critical	   species	   in	   pathogenesis.	   In	   fact,	   in	   a	   HD	   model	   a	   compound	   could	  
prevent	  huntingtin-­‐mediated	  proteasome	  dysfunction	  by	  promoting	  inclusion	  formation	  
(BODNER,	  et	  al.	  2006).	  
Although	  the	  characteristic	  protein	  deposits	  are	  found	  extracellularly	   in	  AD	  and	  
prion	   disease,	   not	   intracellularly	   as	   in	   HD,	   here	   too	   studies	   suggest	   that	   structured	  
protein	  deposits	  are	  less	  toxic	  than	  other	  conformers.	  As	  for	  HD,	  amyloid	  assembly	  may	  
serve	  a	  beneficial	  function	  by	  shifting	  the	  equilibrium	  away	  from	  more	  toxic	  conformers,	  
such	  as	  prefibrillar	  oligomers	  (KAYED,	  et	  al.	  2003;	  LESNE,	  et	  al.	  2006;	  WALSH,	  et	  al.	  2002).	  	  
	  In	  a	  collaborative	  effort,	  the	  Kelly	  and	  Dillin	  laboratories	  investigated	  the	  roles	  of	  
the	  aging	  process	  and	  the	  heat	  shock	  response	  in	  the	  formation	  of	  proteotoxic	  species	  in	  
a	  Caenorhabiditis	  elegans	  model	  of	  AD.	  The	  intracellular	  expression	  of	  Aβ	  resulted	  in	  the	  
formation	  of	  Aβ	  aggregates,	  but	  these	  aggregates	  did	  not	  correlate	  with	  toxicity	  (COHEN,	  
et	  al.	  2006).	  RNAi	  mediated	  repression	  of	  the	  insulin/IGF-­‐1	  receptor	  DAF-­‐2,	  resulting	  in	  
increased	   life	  span,	   reduced	  Aβ-­‐mediated	  toxicity	  while	  slightly	   increasing	   the	  amount	  
of	   Aβ	   aggregates.	   This	   protection	   depended	   on	   both	   daf-­‐16	   and	   hsf-­‐1.	   Interestingly,	  
repression	   of	   DAF-­‐16	   reduced	   the	   number	   of	   high	   molecular	   weight	   Aβ	   aggregates,	  
while	  repression	  of	  HSF-­‐1	   increased	   it.	  The	  Kelly	  and	  Dillin	   laboratories	  concluded	  that	  




disaggregation,	  while	  the	  DAF-­‐16	  pathway	  transforms	  toxic	  Aβ	  oligomers	  into	  larger	  Aβ	  
aggregates	  of	  lower	  toxicity	  (COHEN,	  et	  al.	  2006).	  
In	  a	  separate	  study	  by	  the	  Mucke	  group,	  a	  point	  mutation	  within	  Aβ,	  the	  Arctic	  
mutation	  (Aβ	  E22G),	   influenced	  the	  rate	  at	  which	  Aβ	  assembled	  into	  amyloid	  fibers.	   In	  
vitro	  and	  in	  transgenic	  mice,	  the	  Artic	  mutation	  enhanced	  formation	  of	  neuritic	  amyloid	  
plaques	  and	  diminished	  non-­‐amyloid	  Aβ	  assemblies	  (CHENG,	  et	  al.	  2007).	  As	  non-­‐amyloid	  
Aβ	  assemblies	  correlated	  with	  behavioral	  and	  neuronal	  deficits	  in	  these	  transgenic	  mice,	  
the	   promotion	   of	   Aβ	   amyloid	   fibril	   formation,	   without	   a	   coinciding	   increase	   in	  
oligomeric	  Aβ,	  may	  be	  beneficial.	  
Most	   recently,	   in	   a	   follow-­‐up	   study	   of	   a	   clinical	   trial,	   the	   immunization	   of	   AD	  
patients	   with	   the	   full	   length	   Aβ	   peptide	   exhibited	   reduced	   Aβ	   immunostaining	   and	  
amyloid	  plaques	  (HOLMES,	  et	  al.	  2008).	  Unfortunately,	  immunization	  neither	  slowed	  nor	  
stopped	  the	  progression	  of	  neurodegeneration.	  As	   immunization	  with	  Aβ	  peptide	  may	  
not	   have	   reduced	   the	   levels	   of	   toxic	   oligomeric	   Aβ	   species,	   the	   authors	   suggest,	   that	  
immunization	   specifically	   against	   oligomeric	   Aβ	   species	   may	   be	   more	   successful	   at	  
halting	  neurodegeneration.	  	  
Plaque	  formation	  may	  also	  prove	  beneficial	   in	  the	  case	  of	  prion	  disease.	  PrPres	  
isoforms,	  the	  protease	  resistant	  forms	  of	  PrP	  that	  include	  amyloid,	  are	  not	  toxic	  on	  their	  
own.	  Mice	  that	  do	  not	  express	  their	  own	  PrP	  protein	  (Prn-­‐p0/0)	  are	  completely	  resistant	  
to	  the	  intracerebral	  injection	  of	  even	  very	  high	  doses	  PrPres	  (BUELER,	  et	  al.	  1993).	  Equally	  
striking,	   mice	   producing	   a	   secreted	   form	   of	   PrP,	   GPI	   anchor-­‐less	   PrP,	   accumulated	  




(CHESEBRO,	   et	   al.	   2005).	   Some	   brain	   lesions	   were	   present,	   but	   there	   was	   less	  
neurodegeneration	  associated	  with	   these	  amyloid	  plaques	   than	  with	  diffuse	  wild	   type	  
PrPres	  deposits.	  These	  results	  were	  especially	  significant	  as	   transgenic	  mice	  had	  up	  to	  
40%	   more	   PrPres	   in	   comparison	   to	   mice	   with	   WT	   PrP	   (CHESEBRO,	   et	   al.	   2005).	   Using	  
human	  tissue	  samples,	  the	  Barron	  laboratory	  showed	  that	  the	  accumulation	  of	  certain	  
forms	   of	   PrPres	   failed	   to	   result	   in	   spongiform	   degeneration.	   Brain	   extracts	   from	   two	  
cases	   of	   familial	   prion	   disease	   were	   used	   to	   test	   the	   transmission	   of	   disease	   to	  
transgenic	  mice.	  One	  of	  the	  samples	  exhibited	  PrPres	  deposits	  and	  spongiform	  change,	  
while	  the	  other	  presented	  with	  PrPres	  deposits	  and	  no	  spongiform	  change.	  Brain	  extract	  
from	  the	  patient	  without	  spongiform	  degeneration	  did	  not	  result	  in	  disease	  transmission	  
but	   elicited	   PrPres	   deposition	   in	   large	   multicentric	   plaques.	   Therefore,	   PrPres	   would	  
appear	  to	  be	  rendered	  nonpathogenic	  by	  its	  sequestration	  in	  amyloid	  plaques	  (PICCARDO,	  
et	  al.	  2007).	  
	  
Lessons	  on	  protective	  aggregation	  from	  a	  yeast	  model	  
	   Yeast	   prion	   proteins,	   just	   as	   PrP,	   can	   adopt	   self-­‐perpetuating	   conformational	  
states.	   In	   yeast,	   however,	   prions	   do	   not	   cause	   disease,	   but	   rather	   serve	   as	   heritable	  
genetic	   elements,	   perpetuated	   by	   the	   transfer	   of	   the	   prion	   template	   from	  mother	   to	  
daughter	   cell	   (SHORTER,	   et	   al.	   2005).	   The	   heritable	   protein	   conformation	   of	   the	   yeast	  
prions	  is	  amyloid	  in	  nature	  and,	  as	  for	  Aβ,	  Huntingtin	  and	  PrP,	  amyloid	  formation	  by	  the	  
yeast	  prion	  proteins	  proceeds	  through	  intermediate	  oligomeric	  protein	  species	  (CHITI,	  et	  




intermediates	   in	   amyloid	   formation	  was	   first	  made	   for	   the	   yeast	   prion	   protein	   Sup35	  
(SERIO,	   et	  al.	   2000;	   SHORTER,	   et	  al.	   2004).	  Oligomers	   formed	  by	   the	  yeast	  prion	  protein	  
Sup35	   share	   structural	   features	   with	   the	   oligomers	   formed	   by	   disease-­‐related	  
amyloidogenic	   proteins,	   including	   recognition	   by	   anti-­‐oligomeric	   antibodies	   and	  
interaction	  with	  specific	  small	  compounds	  (SHORTER,	  et	  al.	  2004;	  WANG,	  et	  al.	  2008).	  Thus	  
the	   study	   of	   yeast	   prions	   can	   provide	   insight	   into	   amyloid	   formation	   and	   cellular	  
responses	  to	  the	  presence	  of	  amyloid.	  	  
The	   yeast	   prion	   [RNQ+]	   is	   formed	   by	   the	   Rnq1	   protein	   (The	   cytoplasmic	  
inheritance	  of	  yeast	  prions	  is	  designated	  by	  [	  ]).	  Rnq	  is	  nonessential	  and	  has	  no	  known	  
biological	  function,	  except	  when	  it	  is	  in	  prion	  state	  (SONDHEIMER,	  et	  al.	  2000).	  In	  this	  case	  
the	  [RNQ+]	  prion	  interacts	  with	  other	  amyloidogenic	  proteins	  in	  vivo	  and	  enables	  them	  
to	   adopt	   their	   amyloid	   conformation.	   For	   example,	   [RNQ+]	   facilitates	   the	   de	   novo	  
induction	   of	   the	   [PSI+]	   prion	   state	   by	   enhancing	   the	   amyloid	   conversion	   of	   the	   yeast	  
prion	  protein	  Sup35	  (DERKATCH,	  et	  al.	  2001).	  	  
We	   recently	   reported	   that	   moderate	   ectopic	   overexpression	   of	   Rnq1	   is	  
extremely	  toxic	  if	  endogenous	  Rnq1	  is	  in	  the	  [RNQ+]	  prion	  conformation	  (DOUGLAS,	  et	  al.	  
2008).	  While	  overexpression	  of	  Rnq1	  did	  result	   in	  the	  formation	  of	  amyloid	   inclusions,	  
as	  assessed	  by	  Thioflavin-­‐T	  staining,	   semi-­‐denaturing	  agarose	  gels	  and	   in	  vitro	   seeding	  
assays,	   the	   amyloid	   conformation	   did	   not	   represent	   the	   toxic	   species.	   In	   fact,	   co-­‐
expression	  of	  an	  Hsp40	  chaperone,	  Sis1,	  known	  to	  interact	  with	  the	  prion	  form	  of	  Rnq1	  
(SONDHEIMER,	   et	   al.	   2001),	   suppressed	   the	   toxicity	   elicited	   by	   Rnq1	   overexpression	   by	  




with	   the	   chaperone	   and	   their	   ability	   to	   readily	   form	   amyloid,	   exhibited	   enhanced	  
toxicity.	   Chaperones	   have	   been	   shown	   to	   antagonize	   toxicity	   associated	   with	   protein	  
misfolding	   before,	   but	   in	   those	   cases	   overexpressed	   chaperones	   either	   decreased	  
protein	  aggregation	  (CUMMINGS,	  et	  al.	  1998)	  or	  appeared	  to	  have	  no	  observable	  effect	  on	  
protein	  aggregation	  (WARRICK,	  et	  al.	  1999).	  This	  study	  presents	  the	  first	  instance	  in	  which	  
a	  chaperone	  antagonizes	  the	  toxicity	  of	  a	  misfolding	  protein	  by	  facilitating	  its	  deposition	  
into	  an	  amyloid	  inclusion.	  It	  clearly	  demonstrates	  that	  actively	  promoting	  the	  formation	  
of	  inclusion	  bodies	  and	  even	  amyloid	  plaques	  may	  prove	  beneficial	  in	  protein	  misfolding	  
pathologies.	  	  
	  	  
Formation	  of	  toxic	  protein	  species	  due	  to	  non-­‐productive	  templating	  
While	  the	  formation	  of	  aggresomes	  and	  extracellular	  amyloid	  plaques	  appears	  to	  
serve	   a	  protective	   function,	   they	   could	  be	   associated	  with	   toxicity	   if	   their	   assembly	   is	  
overwhelmed	   by	   the	   amount	   of	   protein	   damage	   or	   impeded	   by	   other	  molecular	   and	  
cellular	   factors.	   As	   shown	   by	   the	   Kampinga	   group,	   aggresome	   formation	   by	   mutant	  
huntingtin	  in	  tissue	  culture	  cells	  did	  not	  affect	  the	  cellular	  progression	  through	  mitosis.	  
However,	   when	   the	   mutant	   huntingtin	   formed	   scattered	   secondary	   inclusions,	   the	  
completion	  of	  mitosis	  was	  delayed	  or	  even	  failed	  completely	  (RUJANO,	  et	  al.	  2006).	  The	  
Kampinga	  group	  speculated	  that	  these	  secondary	  inclusions,	  distinct	  from	  aggresomes,	  
form	  when	  the	  process	  of	  aggresome	  formation	  is	  saturated	  (RUJANO,	  et	  al.	  2006).	  	  These	  
results	  are	  reminiscent	  of	  our	  studies	  in	  which	  overexpression	  of	  the	  yeast	  prion	  protein	  




the	  prion	  protein	  into	  amyloid.	  The	  toxicity	  of	  Rnq1	  overexpression	  was	  exacerbated	  by	  
factors	   interfering	   with	   amyloid	   assembly,	   such	   as	   repression	   of	   Sis1,	   the	   chaperone	  
required	   for	   Rnq1	   amyloid	   formation,	   or	   mutations	   within	   Rnq1,	   which	   reduce	   its	  
interaction	  with	  the	  chaperone	  (DOUGLAS,	  et	  al.	  2008).	  	  
Importantly,	   Rnq1	   overexpression	   only	   resulted	   in	   toxicity	   if	   the	   endogenous	  
Rnq1	  protein	  was	  in	  its	  [RNQ+]	  prion	  conformation,	  making	  the	  otherwise	  benign	  prion	  
state	   a	   prerequisite	   for	   Rnq1	  mediated	   toxicity.	   Interestingly,	   the	   Rnq1	   prion	   state	   is	  
also	  required	  for	   toxicity	  of	  mutant	  huntingtin	  exon	  1	   in	  yeast	  models	  of	  Huntington’s	  
disease	   (MERIIN,	   et	   al.	   2002).	   While	   the	   Rnq1	   prion	   conformation	   usually	   acts	   as	   a	  
template	   for	   the	   conversion	   of	   soluble	   Rnq1	   protein	   conformers	   into	   benign	   amyloid	  
conformers,	  we	  hypothesize	   that	   this	  process	  can	  also	   result	   in	   the	   formation	  of	   toxic	  
protein	  species.	  We	  refer	  to	  this	  as	  non-­‐productive	  templating,	  which	  occurs	  when	  the	  
cellular	  capacity	  to	  facilitate	  amyloid	  formation	  is	  exceeded	  or	  impeded	  (Figure	  C1.2).	  	  
The	   notion	   of	   non-­‐productive	   templating	   offers	   a	   unifying	   explanation	   for	   the	  
observation	   that	   amyloid	   formation	   is	   sometimes	   associated	  with	   toxicity	   even	  when	  
the	  amyloid	  form	  itself	   is	  benign.	  We	  discuss	  two	  cases	  in	  point:	  As	  mentioned	  earlier,	  
the	  expression	  of	  GPI-­‐anchorless	  PrP	  resulted	   in	  the	  formation	  of	  amyloid	  plaques	  but	  
was	  not	  overtly	  toxic.	  However,	  when	  GPI-­‐anchorless	  PrP	  was	  expressed	  together	  with	  
WT	   PrP,	   deposits	   of	   both	   amyloid	   and	   non-­‐amyloid	   PrPres	   formed	   and	   the	   clinical	  
manifestations	   of	   scrapie	   disease	   were	   enhanced	   (CHESEBRO,	   et	   al.	   2005).	   It	   has	   been	  
suggested	   that	   PrPres	   subverts	   a	   stress	   protective	   function	   of	   PrP	   into	   an	   apoptotic	  




PrPres	   and	   the	   expression	   of	   GPI-­‐anchored	   PrP	   (RAMBOLD,	   et	   al.	   2008).	   PrPres	   may	  
influence	  the	  folding	  state	  of	  the	  GPI-­‐anchored	  PrP	  through	  incomplete	  templating	  and	  
thus	  cause	  the	  induction	  of	  a	  toxic	  signal.	  	  
The	   second	   case	   in	   point	   involves	   the	   fungal	   prion	   [Het-­‐s].	   Non-­‐productive	  
templating	  can	  explain	  how	  the	  [Het-­‐s]	  prion	  mediates	  heterokaryon	  incompatibility	   in	  
the	   fungus	   Podospora	   anserina	   (COUSTOU-­‐LINARES,	   et	   al.	   2001).	   Heterokaryon	  
incompatability,	   a	   type	   of	   programmed	   cell	   death,	   results	   when	   two	   cells	   with	  
incompatible	   geneotypes,	   het-­‐s	   and	   het-­‐S,	   fuse	   to	   form	   a	   mixed	   cytoplasm.	   The	   two	  
alleles	   encode	   distinct	   sequence	   variants	   of	   the	   Het-­‐s	   protein.	   One,	   HET-­‐s,	   is	   able	   to	  
form	   the	   [Het-­‐s]	   prion,	   where	   as	   the	   other,	   HET-­‐S,	   cannot	   adopt	   an	   amyloid	  
conformation.	   The	   prion	   form	   of	   the	   HET-­‐s	   allele	   by	   itself	   is	   completely	   benign.	  
However,	   if	   the	  HET-­‐S	   allele	   is	   expressed	   in	   the	   presence	   of	   the	   [Het-­‐s]	   prion	   form	   it	  
results	  in	  cell	  death.	  The	  interaction	  of	  HET-­‐s	  protein	  with	  the	  [Het-­‐s]	  prion	  form	  leads	  to	  
the	  templated	  formation	  of	  additional	  non-­‐toxic	  prion	  amyloid.	  On	  the	  other	  hand,	  we	  
speculated	   that	  non-­‐productive	   templating	  of	   the	  HET-­‐S	  protein	  variant,	  which	  cannot	  
form	   amyloid,	   by	   the	   [Het-­‐s]	   prion	   form	   leads	   to	   the	   formation	   of	   a	   toxic	   misfolded	  






Figure	  C1.2	  Amyloid	  and	  Non-­‐productive	  templating.	  	  
Amyloid	  fibrils	  grow	  by	  causing	  protein	  of	  the	  same	  amino-­‐acid	  sequence	  to	  adopt	  the	  
same	  amyloid	  conformation.	  This	  is	  referred	  to	  as	  amyloid	  templating	  and	  involves	  the	  
efficient	  addition	  of	  monomer	  or	  oligomeric	  species	  to	  the	  amyloid	  fiber,	  which	  maybe	  
assisted	  by	   specific	   chaperones	   (e.g.	   Rnq1	   and	   the	  Hsp40	   Sis1,	   Sup35NM	  and	  Hsp104	  
(SHORTER,	   et	   al.	   2004)).	   If	   the	   amount	   of	   substrate	   exceeds	   the	   cellular	   capacity	   for	  
amyloid	   conversion	  or	   if	   amino	   acid	   sequences	   are	   incompatible,	   the	   interaction	  with	  
the	  amyloid	  fibrils	  may	  give	  rise	  to	  other	  abnormal	  conformational	  species,	  which	  may	  
go	  on	  to	  form	  toxic	  oligomers	  and	  amorphous	  aggregates	  (Rnq1,	  PrP	  and	  Het-­‐s/S).	  We	  




Yeast	  models	  of	  neurodegenerative	  diseases	  
Studying	  the	  neurodegenerative	  diseases	  discussed	  is	  encumbered	  by	  their	   late	  
onset	  and	  complex	  etiology.	  Several	  mouse	  models	  of	  neurodegenerative	  diseases	  have	  
been	   developed,	   but	   often	   it	   takes	   several	   combinatorial	   genetic	   alterations,	   such	   as	  
mutations,	  deletions,	  and	  transgene	  insertions,	  to	  produce	  a	  phenotype	  mimicking	  the	  
human	   disease	   (OAKLEY,	   et	   al.	   2006).	  Our	   lab	   has	   developed	  mouse	  models	   of	   human	  
prion	   diseases,	   such	   as	   Fatal	   Familial	   Insomnia,	   that	   more	   precisely	   recapitulate	   the	  
mutations	   thought	   to	   be	   causal	   in	   these	   diseases	   (JACKSON,	   et	   al.	   2009).	   But	   although	  
mouse	  models	  provide	  a	  tremendous	  tool	  for	  studying	  these	  diseases	  it	  can	  take	  up	  to	  a	  
year	  for	  these	  mice	  to	  develop	  disease	  phenotypes	  (JACKSON,	  et	  al.	  2009).	  	  	  
In	   addition	   to	   the	   more	   common	   methods	   of	   studying	   neurodegenerative	  
diseases,	   our	   lab	   has	   taken	   the	   unique	   approach	   of	   studying	   the	   proteotoxicity	   of	  
disease-­‐associated	   proteins	   in	   the	   yeast	   S.	   cerevisiae	   (KHURANA,	   et	   al.	   2010).	   As	   a	  
eukaryotic	  organism,	  yeast	  shares	  a	  wealth	  of	  cell	  biological	   features	  with	  mammalian	  
organisms.	   Cellular	   organelles	   such	   as	   the	   nucleus,	   mitochondria,	   the	   endoplasmic	  
reticulum,	   endocytic	   vesicles	   and	   degradative	   compartments	   are	   present	   in	   yeast.	  
Additionally,	   cellular	   processes	   such	   as	   autophagy,	   the	   cell	   cycle,	   and	   proteasomal	  
protein	   degradation	   are	   conserved	   between	   yeast	   and	   higher	   eukaryotic	   organisms.	  
Most	   importantly,	   the	   protein	   folding	  machinery,	   in	   part	   chaperones	   like	   Hsp40s	   and	  
Hsp70s,	  is	  very	  highly	  conserved	  between	  all	  eukaryotic	  organisms.	  	  	  
	   As	  previously	  mentioned,	  HD	  has	  been	  modeled	  in	  yeast	  through	  the	  expression	  




expansions	   (MERIIN,	   et	   al.	   2002).	   As	   in	   the	   human	   disease,	   yeast	   expressing	   mutant	  
huntingtin	   exon	   one	   displayed	   aggregation	   dependent	   on	   the	   length	   of	   the	  
polyglutamine	   expansion.	   Expression	   of	   mutant	   huntingtin	   exon	   one	   containing	   a	  
stretch	   of	   72	   or	   more	   glutamines	   caused	   a	   growth	   defect	   in	   yeast	   and	   lead	   to	   the	  
sequestration	   of	   multiple	   ERAD	   components	   (DUENNWALD,	   et	   al.	   2008;	   MERIIN,	   et	   al.	  
2002).	   Importantly,	   overexpression	   of	   ERAD	   proteins	   Npl4	   and	   Ufd1	   not	   only	  
ameliorated	  mutant	  huntingtin	  toxicity	  in	  yeast	  but	  also	  in	  mammalian	  neuron-­‐like	  cells	  
(DUENNWALD,	  et	  al.	  2008).	  
	   Several	   aspects	   of	   Parkinson’s	   disease	   and	   related	   synucleinopathies	   have	   also	  
been	   recapitulated	   in	   yeast	   (COOPER,	   et	   al.	   2006;	   OUTEIRO,	   et	   al.	   2003).	   Parkinson’s	  
disease,	  such	  as	  other	  synucleinopathies,	  is	  characterized	  by	  the	  presence	  of	  α-­‐synuclein	  
containing	   Lewy	  Bodies.	  α	   -­‐synuclein	   is	   a	   small	   lipid-­‐binding	  protein	   and	   its	  moderate	  
expression	  in	  yeast	  results	  in	  localization	  to	  the	  plasma	  membrane.	  Increased	  expression	  
of	  α-­‐synuclein	  gave	  rise	  to	  the	  formation	  of	  α-­‐synuclein	  foci	  and	  diminished	  cell	  growth	  
(OUTEIRO,	  et	  al.	  2003).	  Subsequent	  studies	  revealed	  that	  α-­‐synuclein	  impairs	  ER	  to	  Golgi	  
trafficking	  and	  that	  the	  α-­‐synuclein	  foci	  contain	  stalled	  vesicles	  (COOPER,	  et	  al.	  2006).	  A	  
genetic	  screen	  for	  modifiers	  of	  α-­‐synuclein	  toxicity	  identified	  several	  genes	  that	  not	  only	  
modulated	   toxicity	   in	   yeast;	   their	   homologs	   decreased	   α-­‐synuclein	   toxicity	   in	   other	  
model	   systems	   such	   a	   C.	   elegans	   and	   rat	   primary	   neurons	   (COOPER,	   et	   al.	   2006).	  
Furthermore,	   this	   yeast	   model	   was	   used	   to	   conduct	   a	   small	   molecule	   screen	   for	  
compounds	   capable	   of	   counteracting	   α-­‐synuclein	   toxicity.	   Again	   the	   identified	  




organisms	  (SU,	  et	  al.	  2009).	  In	  addition,	  the	  compounds	  could	  counteract	  the	  toxicity	  of	  
rotenone,	  a	  mitochondrial	  poison	  that	  elicits	  Parkinson-­‐like	  defects	  (SU,	  et	  al.	  2009).	  
More	   recently,	   toxicity	   of	   TDP-­‐43	   has	   been	   modeled	   in	   yeast	   (JOHNSON,	   et	   al.	  
2008).	  Aggregation	  of	  TDP-­‐43,	  a	  ubiquitously	  expressed	  nuclear	  DNA	  binding	  protein,	  in	  
cytoplasmic	  inclusions	  is	  associated	  with	  amyotrophic	  lateral	  sclerosis	  (ALS)	  and	  frontal	  
temporal	  lobar	  degeneration	  with	  ubiquitin-­‐positive	  inclusions	  (FTLD-­‐U)	  (NEUMANN,	  et	  al.	  
2006).	   Expression	   of	   TDP-­‐43	   in	   yeast	   resulted	   in	   toxicity	   and	   recapitulated	   the	  
cytoplasmic	   aggregation	   observed	   in	   the	   human	   diseases	   (JOHNSON,	   et	   al.	   2008).	   A	  
subsequent	   yeast	   screen	   for	   modifiers	   of	   TDP-­‐43	   toxicity	   identified	   Pbp1,	   the	   yeast	  
ortholog	  of	   the	  human	  ATAXIN-­‐2	  gene,	  poly-­‐glutamine	  expansions	   in	  which	   cause	   the	  
neurodegenerative	   disease	   spinocerebellar	   ataxia	   type	   2	   (SCA2)	   (ELDEN,	   et	   al.	   2010).	  
Subsequent	   sequencing	   analyses	   of	   human	   patients	   revealed	   that	   intermediate	   poly-­‐
glutamine	  expansions	  in	  ATAXIN-­‐2	  showed	  a	  significant	  association	  with	  ALS,	  suggesting	  
that	  ATAXIN-­‐2	  is	  a	  risk	  factor	  for	  ALS	  (ELDEN,	  et	  al.	  2010).	  	  
	  
Conclusion	  
The	   protein	   deposits	   that	   are	   the	   hallmark	   of	   neurodegenerative	   diseases	   are	  
now	  seen	  in	  a	  different	  light.	  Formerly	  viewed	  as	  the	  cause	  of	  cellular	  dysfunction	  and	  
neuronal	   loss,	   intracellular	  protein	  deposits,	  especially,	  are	   the	  product	  of	  a	   regulated	  
cellular	  process	  enabling	  cells	  to	  cope	  with	  the	  accumulation	  of	  misfolded	  and	  damaged	  
proteins.	   This	   notion	   is	   supported	   by	   studies	   demonstrating	   that	   the	   deposition	   of	  




unicellular	  organism	  Escherichia	  coli	  to	  human	  embryonic	  stem	  cells,	  to	  asymmetrically	  
segregate	  the	  accumulated	  damage	  to	  the	  daughter	  cell	  with	  the	  shorter	  life	  expectancy	  
(AGUILANIU,	  et	  al.	  2003;	  ERJAVEC,	  et	  al.	  2007;	  FUENTEALBA,	  et	  al.	  2008;	  LINDNER,	  et	  al.	  2008;	  
RUJANO,	   et	   al.	   2006).	   Based	   on	   our	   results	   in	   yeast,	   we	   suggest	   that	   inefficiencies	   in	  
inclusion	   body	   and	   plaque	   formation,	   arising	   with	   accumulating	   protein	   damage,	   can	  
result	   in	   the	   inception	   of	   toxic	   protein	   species	   due	   to	   non-­‐productive	   templating.	  
Further	  studies	  are	  needed	  to	  elucidate	  which	  types	  of	  protein	  deposits	  in	  the	  individual	  
diseases	   are	   protective	   and	   how	   their	   formation	   circumvents	   the	   formation	   of	   more	  
toxic	  species,	  such	  as	  prefibrillar	  oligomers.	  	  
	   In	  addition	  to	  studies	  of	  endogenous	  amyloidogenic	  proteins,	  such	  as	  yeast	  prion	  
proteins,	   yeast	   has	   proven	   to	   be	   a	   fertile	   ground	   for	   elucidating	   the	   mechanisms	   of	  
proteotoxicity	  elicited	  by	  neurodegenerative	  disease	  associated	  proteins	  (KHURANA,	  et	  
al.	  2010).	  The	  cellular	  toxicities	  induced	  by	  mutant	  huntingtin,	  α-­‐synuclein	  and	  TDP-­‐43	  
have	  been	  modeled	  in	  yeast.	   In	  each	  case	  these	  studies	  in	  yeast	  have	  helped	  to	  reveal	  
how	   particular	   misfolding	   proteins	   cause	   toxicity	   in	   mammalian	   cells.	   In	   the	   future,	  
yeast-­‐based	  small	  molecule	  screens	  may	  yield	  compounds	  that	  can	  directly	  counteract	  
the	  misfolding	  and	  toxicity	  of	  these	  disease-­‐associated	  proteins	  (SU,	  et	  al.	  2009).	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Abstract	  
Protein	  conformational	  diseases	  are	  associated	  with	  the	  aberrant	  accumulation	  
of	  amyloid	  protein	  aggregates,	  but	  whether	  amyloid	  formation	  is	  cytotoxic	  or	  protective	  
is	  unclear.	  To	  address	  this	   issue	  we	   investigated	  a	  normally	  benign	  amyloid	  formed	  by	  
the	  yeast	  prion	  [RNQ+].	  Surprisingly,	  modest	  overexpression	  of	  Rnq1	  protein	  was	  deadly,	  
but	   only	   when	   preexisting	   Rnq1	   was	   in	   the	   [RNQ+]	   prion	   conformation.	   Molecular	  
chaperones	  protect	  against	  protein	  aggregation	  diseases,	  and	  are	  generally	  believed	  to	  
do	   so	   by	   solubilizing	   their	   substrates.	   The	   Hsp40	   chaperone,	   Sis1,	   suppressed	   Rnq1	  
proteotoxicity,	   but	   instead	   of	   blocking	   Rnq1	   protein	   aggregation,	   it	   stimulated	  
conversion	   of	   soluble	   Rnq1	   to	   [RNQ+]	   amyloid.	   Furthermore,	   interference	   with	   Sis1-­‐
mediated	   [RNQ+]	   amyloid	   formation	   exacerbated	   Rnq1	   toxicity.	   These	   and	   other	   data	  
establish	   that	   even	   subtle	   changes	   in	   the	   folding	   homeostasis	   of	   an	   amyloidogenic	  
protein	  can	  create	  a	  severe	  proteotoxic	  gain-­‐of-­‐function	  phenotype	  and	  that	  chaperone-­‐
mediated	   amyloid	   assembly	   can	   be	   cytoprotective.	   The	   possible	   relevance	   of	   these	  
findings	   to	   other	   phenomena,	   including	   prion-­‐driven	   neurodegenerative	   diseases	   and	  
heterokaryon	  incompatibility	  in	  fungi	  is	  discussed.	  
	  
Introduction	  
Alzheimer’s	   disease,	   transmissible	   spongiform	   encephalopathies	   and	  
polyglutamine	   diseases	   are	   representatives	   of	   a	   large	   group	   of	   neurodegenerative	  
disorders	  that	  are	  associated	  with	  the	  misfolding	  and	  conversion	  of	  particular	  proteins	  
into	  amyloid	  	  (CARRELL,	  et	  al.	  1997).	  Amyloids	  form	  in	  response	  to	  many	  perturbations	  in	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protein	  homeostasis,	  namely	  mutations	  in	  the	  amino	  acid	  sequence	  of	  a	  disease-­‐related	  
protein,	   expansion	   of	   simple	   sequence	   elements	   in	   disease	   genes,	   elevated	   protein	  
levels	  and	  age-­‐associated	  cell	  stress	   	   (CHITI,	  et	  al.	  2006).	  Amyloid	  fibrils	  share	  a	  cross-­‐β	  
structural	   motif,	   in	   which	   β-­‐strands	   run	   perpendicular	   to	   the	   long	   fiber	   axis,	   and	  
accumulate	  in	  intracellular	  and	  extracellular	  inclusions	  	  (CAUGHEY,	  et	  al.	  2003;	  NELSON,	  et	  
al.	  2005).	  Fibril	  formation	  requires	  that	  a	  misfolded	  protein	  expose	  a	  pleated	  β-­‐surface	  
that	  is	  capable	  of	  serving	  as	  a	  template	  and	  hydrogen	  bonding	  partner	  with	  an	  extra	  β-­‐
strand	   	   (CARRELL,	   et	   al.	   1997).	   	   Biochemical	   parameters	   for	   classification	   of	   protein	  
aggregates	  as	  amyloid	  include	  resistance	  to	  solubilization	  by	  the	  detergent	  SDS	  and	  the	  
ability	  to	  bind	  indicator	  dyes	  such	  as	  thioflavin-­‐T	  	  (CHITI,	  et	  al.	  2006).	  
Amyloid	  deposits	  in	  the	  brain	  are	  a	  hallmark	  of	  protein	  conformational	  disease,	  
but	  often	  there	  is	  only	  a	  poor	  correlation	  between	  the	  detection	  of	  amyloid	  fibrils	  and	  
other	  markers	   of	   neurodegeneration	   	   (HAASS,	   et	   al.	   2007).	   Thus,	   there	   is	   still	   intense	  
debate	   about	   whether	   amyloids	   are	   the	   causative	   toxic	   protein	   species	   in	  
neurodegenerative	   diseases.	   In	   fact,	   recent,	   still	   controversial,	   work	   suggests	   that	  
amyloids	   might	   be	   benign	   or	   cytoprotective	   and	   that	   difficult-­‐to-­‐characterize	   soluble	  
oligomeric	   conformers	  are	   the	   toxic	   species	  of	  disease	  causing	  proteins	   	   (CHENG,	   et	  al.	  
2007;	  KAYED,	  et	  al.	  2003;	  SHORTER,	  et	  al.	  2005).	  
Cells	   buffer	   proteotoxic	   events	   related	   to	   intracellular	   protein	   misfolding	   via	  
chaperone-­‐mediated	   partitioning	   of	   non-­‐native	   conformers	   between	   pathways	   for	  
proper	  folding,	  inclusion	  body	  formation,	  and	  degradation	  (ROSS,	  et	  al.	  2005).	  Molecular	  
chaperones	   also	   play	   a	   critical	   role	   in	   the	   propagation	   of	   yeast	   prions,	   which	   are	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examples	   of	   intracellular	   amyloids	   that	   in	   general	   are	   not	   inherently	   toxic	   	   (LINDQUIST	  
1997;	  WICKNER	   1994).	  However,	   the	   conversion	   of	   active	   soluble	   Sup35	   and	  Ure2	   into	  
their	  prion	  states	   [PSI+]	  and	   [URE3],	   respectively,	   inactivates	   these	  proteins	   	   (LINDQUIST	  
1997;	  WICKNER	  1994).	  Yeast	  prion	  formation	  occurs	  spontaneously,	  at	  a	   low	  frequency,	  
and	   the	  prion	   state	   is	   then	  perpetuated	   through	   the	   templating	   of	   newly	   synthesized	  
prion	  proteins	  by	  preexisting	  amyloid-­‐like	  prions	   	   (CHIEN,	  et	  al.	  2004).	  Templated	  prion	  
proteins	  then	  undergo	  stable	  changes	  in	  structure	  and	  function	  to	  enter	  an	  amyloid-­‐like	  
state	  that	  is	  propagated	  and	  passed	  from	  mother	  cells	  to	  their	  daughters	  in	  a	  molecular	  
chaperone-­‐dependent	   manner	   	   (CHIEN,	   et	   al.	   2004).	   Yeast	   prions	   thereby	   constitute	  
cytoplasmically	  transmitted,	  protein-­‐based	  elements	  of	  inheritance	  that	  are	  dominant	  in	  
genetic	   crosses	   (prions	   are	   denoted	   by	   brackets,	   italics	   and	   capital	   letters	   to	   reflect	  
these	  properties).	  	  
The	  yeast	  prion	   [RNQ+]	   is	  determined	  by	   the	  conformational	   state	  of	   the	  Rnq1	  
protein,	  which	  contains	  a	  C-­‐terminal	  asparagine-­‐	  and	  glutamine-­‐rich	  prion	  domain	  and	  
an	   N-­‐terminal	   non-­‐prion	   forming	   domain	   	   (DERKATCH,	   et	   al.	   2000;	   SONDHEIMER,	   et	   al.	  
2000).	   The	   native	   form	  of	   Rnq1	   has	   no	   known	  normal	   biological	   function	   and	   is	   non-­‐
essential.	   Yet,	   the	   [RNQ+]	   prion	   can	   have	   important	   effects	   on	   yeast	   cells	   because	   it	  
influences	  certain	  other	  proteins	  to	  convert	  to	  amyloid-­‐like	  states	  	  (MERIIN,	  et	  al.	  2002;	  
OSHEROVICH,	  et	  al.	  2001;	  TANEJA,	  et	  al.	  2007).	  For	  example,	  [RNQ+]	  prions	  are	  required	  for	  
the	  initial	  conversion	  of	  native	  Sup35	  to	  the	  [PSI+]	  state.	  Indeed	  [RNQ+]	  constitutes	  the	  
cytoplasmically	   inherited	   factor	   known	  as	   [PIN+]	   (PSI	   inducible)	   and	   is	   the	  only	   known	  
yeast	  prion	  that	  is	  commonly	  found	  in	  wild	  strains	  	  (DERKATCH,	  et	  al.	  2001;	  NAKAYASHIKI,	  et	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al.	  2005).	  [RNQ+]	  prions	  also	  cause	  the	  exon	  1	  fragment	  of	  huntingtin	  protein,	  containing	  
glutamine	  repeats,	   to	  become	  toxic	   in	  yeast	   	   (MERIIN,	  et	  al.	  2002).	  Thus,	   [RNQ+]	  prions	  
can	   interact	   with	   other	   amyloid-­‐forming	   proteins	   and	   thereby	   help	   drive	   their	  
conversion	  into	  benign	  or	  toxic	  amyloid-­‐like	  species.	  	  	  
	  
Results	  
Overexpression	  of	  Rnq1	  is	  toxic	  in	  [RNQ+]	  cells	  	  
We	   recently	   discovered	   that	   moderate	   (i.e.	   ~5	   to	   10-­‐fold)	   overexpression	   of	  
Rnq1	  from	  the	  GAL1	  promoter	  was	  severely	  toxic	  in	  cells	  that	  harbored	  the	  [RNQ+]	  prion	  
(Figure	   C2.1a;	   top,	   growth	   of	   serially	   diluted	   liquid	   cultures	   on	   agar;	   bottom,	   protein	  
levels	  detected	  by	  Western	  blotting).	  This	  was	  surprising	  because	  Rnq1	  overexpression	  
was	   not	   toxic	  when	   endogenous	   Rnq1	  was	   in	   the	   [rnq-­‐]	   non-­‐prion	   conformation.	  Nor	  
was	   it	   toxic	   in	   cells	   carrying	   a	   deletion	   of	   the	   RNQ1	   gene,	   ∆rnq1	   (Figure	   C2.1a).	   Cell	  
growth	   defects	   observed	  were	  more	   extreme	   than	   any	  we	   have	   observed	  with	   other	  
misfolded	  proteins	  in	  yeast	  	  (COOPER,	  et	  al.	  2006;	  DUENNWALD,	  et	  al.	  2006).	  At	  this	  modest	  
level	  of	  Rnq1	  overexpression	  approximately	  25%	  of	  [RNQ+]	  cells	  were	  dead	  within	  4hrs,	  
as	   determined	   by	   percentage	   of	   colony	   forming	   units	   and	   dye	   exclusion	   (data	   not	  
shown).	  Toxicity	  was	  accompanied	  by	  the	  accumulation	  of	  Rnq1	  aggregates	  that	  stained	  
with	   the	   common	   amyloid	   diagnostic	   dye	   thioflavin	   T	   (Figure	   C2.1b).	   Rnq1	  
overexpression	  was	  found	  to	  be	  toxic	  in	  [RNQ+]	  laboratory	  strains	  (W303,	  74D-­‐694,	  BY23	  
and	   BY4741),	   clinical	   strains	   (YJM269,	   YJM421,YJM436	   and	   YJM653),	   a	   fermentation	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strain	   (Y12)	   and	  wine	   strains	   (I14,T73	   and	  WE372)(Taipale	   and	   Lindquist,	   unpublished	  
observations).	  Thus,	  Rnq1	  toxicity	  is	  pervasive	  and	  not	  strain	  specific.	  	  
Although	   not	   quite	   as	   deadly,	   a	   C-­‐terminal	   Rnq1-­‐YFP	   fusion	   protein	   behaved	  
similarly	   to	  untagged	  Rnq1	  and	  exhibited	   the	  same	  pattern	  of	   toxicity:	   toxic	   in	   [RNQ+]	  
cells,	  but	  not	  in	  [rnq-­‐]	  or	  ∆rnq1	  cells.	  This	  allowed	  us	  to	  correlate	  changes	  in	  toxicity	  with	  
changes	   in	  protein	  distribution	   (Figure	  C2.1c	  and	  Supplemental	  Figure	  C2.1).	  Rnq1-­‐YFP	  
was	  distributed	  throughout	  the	  cytosol	  in	  [rnq-­‐]	  or	  ∆rnq1	  cells.	  Using	  low-­‐	  and	  high-­‐copy	  
plasmids	   that	   express	   Rnq1-­‐YFP	   at	   different	   levels,	   we	   found	   that	   toxicity	   positively	  
correlated	  with	  the	  degree	  of	  overexpression	  (Supplemental	  Figure	  C2.1a).	  Western	  of	  
cell	   lysates	   separated	   by	   SDD-­‐AGE	   (semidenaturing-­‐detergent-­‐agarose	   gel	  
electrophoresis)	  demonstrated	  that	  in	  [RNQ+],	  but	  not	  [rnq-­‐]	  cells,	  Rnq1-­‐YFP	  assembled	  
into	  a	  SDS-­‐resistant	  high	  molecular	  weight	  species	  typical	  of	  amyloid	  assemblies	  of	  yeast	  
prions	   	   (KRYNDUSHKIN,	  et	  al.	  2003)	   (Figure	  C2.1d	  and	  Supplemental	  Figure	  C2.1b).	  Yet,	  a	  
pool	  of	  soluble	  Rnq1-­‐YFP,	  which	  ran	  at	  the	  position	  of	  a	  monomer	  on	  SDD-­‐AGE	  gels,	  was	  
also	  present	  in	  [RNQ+]	  cells.	  
Growth	  of	  [RNQ+]	  cells	  overexpressing	  just	  the	  non-­‐prion-­‐forming	  domain	  or	  just	  
the	   prion-­‐forming	  domain	   of	   Rnq1,	   amino	   acids	   1-­‐153	   and	   154-­‐405,	   respectively,	  was	  
not	  hindered	  (Supplemental	  Figure	  C2.1c).	  When	  the	  prion-­‐forming	  domain	  is	  expressed	  
on	  its	  own,	   it	  assembles	  into	  an	  SDS-­‐resistant	  species	  that	  runs	  as	  an	  amyloid	  on	  SDD-­‐
AGE	  gels	  (Supplemental	  Figure	  C2.1d).	  Therefore,	  the	  mechanism	  for	  Rnq1	  toxicity	  does	  





Figure	  C2.1:	  	  Overexpression	  of	  Rnq1	  is	  toxic	  to	  [RNQ+]	  cells.	  
(a)	  The	  effect	  of	  Rnq1	  overexpression	  on	  yeast	  cell	  viability	  in	  the	  presence	  and	  absence	  
of	  the	  [RNQ+]	  prion.	  (b)	  Thioflavin-­‐T	  staining	  of	  Rnq1	  in	  [RNQ+],	  [rnq-­‐]	  and	  ΔRnq1	  cells.	  	  
Fixed	   yeast	   were	   decorated	   with	   α-­‐Rnq1	   sera	   that	   was	   detected	   with	   a	   fluorescent	  
secondary	   antibody.	   The	   same	   cells	   were	   simultaneously	   stained	   with	   the	   amyloid	  
indicator	   dye,	   thioflavin-­‐T.	   (c)	   Visualization	   of	   the	   aggregation	   state	   of	   Rnq1-­‐YFP	   by	  
fluorescence	  microscopy.	   (d)	   The	  assembly	   status	  of	  Rnq1-­‐YFP	  as	  determined	  by	  SDD-­‐




The	   toxicity	  of	  Rnq1	  overexpression	   in	   the	  presence	  of	   the	   [RNQ+]	  prion	  might	  
seem	  similar	  to	  the	  toxicity	  of	  overexpressed	  Sup35	   in	  the	  presence	  of	   its	  prion	  [PSI+].	  
Overexpression	   of	   Sup35	   is	   toxic	   in	   [PSI+]	   cells	   as	   it	   drives	   too	  much	   of	   the	   essential	  
Sup35	  protein	  into	  an	  inactive	  amyloid	  conformation	  	  (DERKATCH,	  et	  al.	  1997).	  In	  contrast,	  
Rnq1	   toxicity	   cannot	  be	  due	   to	  an	   inhibition	  of	  Rnq1	   function	  as	  deletion	  of	   the	  gene	  
encoding	  Rnq1	  has	  no	  detectable	  effect	  on	  yeast	  growth	  under	  hundreds	  of	  conditions	  
tested	   (T.F.	   Outeiro	   and	   S.L.,	   unpublished	   data).	   Furthermore,	   in	   contrast	   to	   Sup35,	  
expression	   of	   Rnq1’s	   non-­‐prion	   domain	   does	   not	   rescue	   the	   toxicity	   caused	   by	   Rnq1	  
overexpression	  (data	  not	  shown).	  	  
	   	  
The	  Hsp40	  Sis1	  can	  suppress	  Rnq1	  toxicity	  
	   Sis1,	  an	  essential	  Hsp40	  chaperone,	  is	  required	  for	  the	  propagation	  of	  the	  [RNQ+]	  
prion	  state	   	   (SONDHEIMER,	  et	  al.	  2001).	  Sis1	  specifies	  Hsp70	  function	  and	   is	  required	  for	  
protein	  synthesis,	  protein	  folding	  and	  cell	  stress	  protection	  	  (FAN,	  et	  al.	  2004;	  ZHONG,	  et	  
al.	   1996).	   Overexpressing	   Sis1	   by	   as	   little	   as	   3-­‐fold	   strongly	   suppressed	   Rnq1	   toxicity	  
(Figure	   C2.2a).	   To	   examine	   whether	   other	   chaperones	   were	   capable	   of	   suppressing	  
Rnq1	   toxicity,	   an	  expression	   library	  of	  4954	  yeast	   genes	  was	   screened	   	   (COOPER,	   et	  al.	  
2006).	   Sis1	  was	   the	   only	   chaperone	   in	   this	   library	   able	   to	   protect	   from	   Rnq1	   toxicity	  
(data	  not	  shown).	  This	  library	  includes,	  among	  many	  other	  chaperones,	  Ydj1,	  a	  member	  
of	   the	   large	   Hsp40	   family	   that	   is	   closely	   related	   to	   Sis1.	   It	   also	   includes	   Hsp70	   Ssa1	  
(Hsp70)	  and	  Hsp104,	  which	  assist	   in	  shearing	  [RNQ+]	  prions	  to	  form	  seeds	  required	  for	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propagation	  of	  the	  [RNQ+]	  state	  	  (ARON,	  et	  al.	  2007)	  .	  Therefore,	  the	  effect	  of	  Sis1	  on	  the	  
toxicity	  of	  Rnq1	  overexpression	  is	  unique.	  	  
Sis1	  not	  only	  promotes	   [RNQ+]	  prion	   formation,	  but	   it	   remains	  stably	  bound	  to	  
the	  prion	  in	  a	  1:1	  complex	  	  (LOPEZ,	  et	  al.	  2003).	  This	  could	  provide	  an	  explanation	  for	  the	  
toxicity	   of	   overexpressed	   Rnq1:	   elevation	   of	   [RNQ+]	   prion	   levels	   could	   kill	   cells	   by	  
sequestering	  Sis1	  away	  from	  its	  essential	  substrates.	  But	  this	  explanation	   is	  unlikely	  as	  
cells	   in	  which	  Sis1	   is	  depleted	  by	  nearly	  100	   fold	  grow	   for	  extended	   time	  periods	  and	  
exhibit	  delayed	  lethality	  	  (LUKE,	  et	  al.	  1991).	  In	  contrast,	  cells	  start	  to	  die	  within	  4h	  of	  the	  
induction	  of	  Rnq1	  overexpression.	  
To	  directly	  eliminate	  the	  possibility	  that	  cell	  death	  is	  due	  to	  sequestration	  of	  Sis1	  
we	   deleted	   the	   domain	   of	   Sis1	   that	   is	   required	   for	   interaction	   with	   the	   prion,	   the	  
glycine-­‐	   and	  phenylalanine-­‐rich	   (G/F)	   region	   	   (LOPEZ,	   et	   al.	   2003).	   	   A	   Sis1	  ∆G/F	   variant	  
fails	  to	  promote	  the	  propagation	  of	  [RNQ+],	  but	  can	  carry	  out	  Sis1’s	  essential	  functions.	  
We	   overexpressed	   Sis1	   ∆G/F,	   and	   found	   that	   unlike	   Sis1,	   it	   could	   not	   suppress	   Rnq1	  
toxicity.	  
	  
Sis1-­‐mediated	  amyloid	  formation	  protects	  from	  Rnq1	  toxicity	  	  
The	  toxicity	  produced	  by	  overexpression	  of	  Rnq1	  represents	  a	  dominant	  gain-­‐of-­‐
function	  that	  requires	  endogenous	  Rnq1	  protein	  to	  be	  in	  a	  [RNQ+]	  prion	  conformation.	  It	  
may	   be	   Sis1's	   ability	   to	   facilitate	   [RNQ+]	   prion	   propagation	   that	   ameliorates	   Rnq1	  
toxicity.	   Indeed,	   the	   suppression	   of	   Rnq1	   toxicity	   by	   Sis1	   overexpression	   was	  
accompanied	  by	  a	  substantial	  increase	  in	  the	  formation	  of	  SDS-­‐resistant	  [RNQ+]	  amyloid	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(Figure	   C2.2b).	   This	   seemed	   to	   be	   accompanied	   by	   a	   decrease	   in	   the	   pool	   of	  
unassembled	  SDS-­‐sensitive	  Rnq1.	  We	  have	  found,	  however,	  that	  although	  SDD-­‐AGE	  is	  a	  
reliable	  method	   for	   quantitatively	   detecting	   SDS-­‐resistant	   species	   it	   is	   not	   reliable	   for	  
SDS-­‐soluble	   species.	   To	   examine	   SDS-­‐soluble	   species	   we	   employed	   gel	   filtration	  
chromatography.	   As	   shown	   in	   Figure	   C2.2c,	   a	   large	   pool	   of	   unassembled	   Rnq1-­‐YFP	  
accumulated	   upon	   Rnq1-­‐YFP	   overexpression	   (Figure	   C2.2c,	   compare	   top	   and	   middle	  
chromatographs).	   Suppression	   of	   Rnq1	   toxicity	   by	   Sis1	   correlated	   with	   a	   dramatic	  
decrease	  in	  unassembled	  Rnq1-­‐YFP	  pools	  and	  a	  corresponding	  increase	  in	  the	  pools	  of	  
assembled	   forms	   (Figure	   C2.2c,	   compare	  middle	   and	   bottom	   chromatographs).	   These	  
results	  suggest	  that	  cytotoxic	  Rnq1	  conformers	  accumulate	  when	  levels	  of	  Rnq1	  protein	  
exceed	   the	   cells	   capacity	   to	   efficiently	   promote	   the	   template-­‐driven	   formation	   of	   the	  
SDS-­‐resistant	   [RNQ+]	   prion	   species.	   To	   test	   this	   hypothesis	   we	   asked	   if	   Rnq1	   toxicity	  





Figure	  C2.2:	  Sis1	  overexpression	  protects	  against	  Rnq1	  toxicity.	  	  
(a)	   The	   effect	   of	   Sis1	   or	   Sis1ΔG/F	   overexpression	   on	   Rnq1	   toxicity.	   The	   control	   lane	  
shows	   the	   strains	   grown	   under	   non-­‐inducing	   conditions.	   (b)	   The	   effect	   of	   Sis1	  
overexpression	  on	  the	  formation	  of	  SDS-­‐resistant	  [RNQ+]	  conformers	  as	  determined	  by	  
SDD-­‐AGE.	   (c)	   Gel	   filtration	   analysis	   of	   intracellular	   pools	   of	   endogenous	   versus	  
overexpressed	  Rnq1-­‐YFP.	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Identification	  of	  the	  Sis1	  binding	  site	  in	  Rnq1	  
	   First,	  we	   identified	  and	  mutated	   the	  chaperone-­‐binding	  motif	   that	  Sis1	  uses	   to	  
interact	  with	  Rnq1.	  A	  peptide	  array	  was	  created	  that	  contained	  25	  residue	  N-­‐acetylated	  
peptides	  spanning	  the	  entire	  Rnq1	  amino	  acid	  sequence.	  This	  array	  was	  incubated	  with	  
purified	   Sis1,	   washed,	   and	   Sis1-­‐interacting	   peptides	   were	   identified	   by	   Western	   blot	  
after	  transfer	  of	  bound	  chaperone	  to	  nitrocellulose	  (Supplemental	  Figure	  C2.2a).	  Tight	  	  
binding	  of	  Sis1	  was	  only	  observed	  with	  a	  few	  neighboring	  Rnq1	  peptides	  and	  these	  were	  
located	  in	  the	  non-­‐prion	  forming	  domain.	  
	   The	   amino	   acid	   sequence	   of	   this	   region	   is	   conserved	   in	   all	   known	   Rnq1	  
homologues	   and	   contains	   a	   classic,	   hydrophobic	   chaperone-­‐binding	   motif,	   LGKLALL	  
(Figure	   C2.3a	   and	   Supplemental	   Figure	   C2.2b)	   	   (RUDIGER,	   et	   al.	   1997).	   Hsp40	   proteins	  
stimulate	  the	  binding	  of	  their	  Hsp70	  co-­‐chaperones	  to	  specific	  substrates.	   Indeed,	  Sis1	  
stimulated	   binding	   of	   its	   Hsp70	   co-­‐chaperone,	   Ssa1,	   to	   the	   peptides	   containing	   this	  
motif	   in	   an	   ATP-­‐dependent	   manner	   (Figure	   C2.3b).	   Thus,	   Sis1	   forms	   a	   functional	  
chaperone:	  substrate	  complex	  with	  peptides	  containing	  this	  chaperone-­‐binding	  motif.	  
Next,	   to	   reduce	   the	   efficiency	   of	   Sis1’s	   interaction	   with	   [RNQ+],	   we	   replaced	  
hydrophobic	  leucine	  residues	  in	  the	  Rnq1	  chaperone-­‐binding	  motif	  with	  alanines	  (L91A,	  
L94A,	   and	   L97A).	   As	   demonstrated	   by	   co-­‐immunoprecipitation,	   the	   capacity	   of	   Rnq1-­‐
GFP	  to	  interact	  with	  Sis1,	  was	  strongly,	  but	  not	  completely,	  reduced	  by	  these	  mutations	  






Figure C2.3: Sis1 binding to a conserved chaperone-binding 
motif in the non-prion domain of Rnq1. 
(a)	  A	  schematic	  showing	   the	  domain	  structure	  of	  Rnq1.	  The	  underlined	  region	   in	  non-­‐
prion	  domain	  of	  Rnq1	  represents	  a	  chaperone	  binding	  motif	   identified	  via	  screening	  a	  
cellulose	   peptide	   array	   (see	   Supplemental	   Figure	   C2.2).	   (b)	  Sis1	   dependent	   binding	   of	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Hsp70	  Ssa1	  to	  the	  peptide	  in	  the	  Rnq1	  peptide	  array	  that	  is	  bound	  most	  strongly	  by	  Sis1.	  
(c)	  Mutation	  L94A	  in	  the	  chaperone-­‐binding	  motif	  reduces	  the	  ability	  of	  Sis1	  to	  form	  co-­‐
immunoprecipitable	  complexes	  with	  Rnq1-­‐GFP	  in	  [RNQ+]	  cells.	  Rnq1-­‐GFP	  was	  expressed	  
using	   the	   CUP1	   promoter.	   Levels	   of	   the	   indicated	   proteins	   in	   c	   were	   visualized	   by	  
Western	  blot	  analysis	  (WB).	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Mutations	  in	  the	  Sis1	  binding	  site	  of	  Rnq1	  interfere	  with	  [RNQ+]	  amyloid	  assembly	  
	   To	   determine	   if	   the	   Rnq1	   chaperone-­‐binding	  motif	   mutants	   were	   defective	   in	  
assembly	   of	   [RNQ+]	   amyloid,	  we	   expressed	   them	   as	   Rnq1-­‐GFP	   fusions	   from	   an	   extra-­‐
chromosomal	   plasmid	   in	   cells	   expressing	  wild	   type	   Rnq1	   in	   its	   prion	   state.	   The	   L91A,	  
L94A,	  and	  L97A	  mutations	  were	  expressed	  at	   levels	  similar	  to	  those	  of	  wild	  type	  Rnq1	  
using	   the	   CUP1	   promoter,	   but	   they	   had	   a	   reduced	   capacity	   to	   form	   fluorescent	   foci	  
(Supplemental	  Figure	  C2.2c).	  An	  L45A	  mutation,	  which	   is	  also	   located	   in	  the	  non-­‐prion	  
forming	   domain,	   but	   lies	   outside	   of	   the	   chaperone-­‐binding	   motif,	   had	   no	   detectable	  
effect	  on	   the	  assembly	  of	   [RNQ+]	  prions	   (Supplemental	   Figure	  C2.2c).	   	   Further,	   a	   time	  
course	  analysis	  by	  SDD-­‐AGE	  (Figure	  C2.4a)	  and	  pulse-­‐chase	  (Supplemental	  Figure	  C2.2d)	  
revealed	  that	  the	  rate	  at	  which	  newly	  synthesized	  Rnq1-­‐GFP	  protein	  was	  converted	  into	  
SDS-­‐resistant	   conformers	   in	   vivo	   was	   reduced	   several	   fold	   by	   the	   L94A	   mutation	   in	  
comparison	  to	  the	  wild-­‐type	  protein.	  	  In	  addition,	   in	  vitro,	  purified	  Rnq1	  L94A	  could	  be	  
templated	  by	  prion	  “seeds”	  present	  in	  [RNQ+]	  cell	  extracts	  to	  form	  SDS-­‐resistant	  species	  
(Figure	  C2.4b).	  However,	  it	  was	  templated	  and	  converted	  to	  an	  SDS-­‐resistant	  form	  with	  




Figure	  C2.4:	  Mutations	   in	  the	  chaperone-­‐binding	  motif	  of	  Rnq1	  reduce	  the	  efficiency	  
of	  [RNQ+]	  amyloid	  assembly.	  
(a)	  Kinetics	   of	  Rnq1-­‐GFP	   L94A	   assembly	   into	   SDS-­‐resistant	   aggregates	   in	   [RNQ+]	   yeast	  
determined	  by	  SDD-­‐AGE.	  Rnq1-­‐GFP	   fusions	  were	  expressed	  using	   the	  CUP1	  promoter.	  
(b)	  [RNQ+]	  seed	  dependent	  assembly	  of	  purified	  Rnq1-­‐His	  and	  Rnq1-­‐His	  L94A	  into	  SDS-­‐
resistant	  amyloid.	  (c)	  Growth	  of	  5	  fold	  serial	  dilutions	  of	  [RNQ+]	  strains	  in	  which	  WT	  or	  
L94A	   Rnq1	   was	   overexpressed	   from	   the	   GAL1	   promoter.	   	   Where	   indicated,	   Sis1	   was	  
overexpressed	  from	  the	  GPD	  promoter.	  	  Lower	  panels	  show	  the	  relative	  expression	  level	  




Finally,	  we	  asked	  whether	  the	   impairment	  of	  Rnq1	  amyloid	  assembly	   increased	  
the	   toxicity	   of	   Rnq1	   overexpression.	   As	   we	   hypothesized,	   Rnq1	   L94A	  was	  more	   toxic	  
than	  Rnq1	  WT	  when	  overexpressed	  in	  [RNQ+]	  cells	  (Figure	  C2.4c).	  A	  triple	  mutant,	  Rnq1	  
L94A-­‐L96A-­‐L97A,	  was	  even	  more	   toxic	   than	  Rnq1	  L94A	   (data	  not	   shown).	  As	  expected	  
from	  the	  fact	  that	  the	  Rnq1	  L94A	  mutation	  impaired,	  but	  did	  not	  eliminate	  interaction	  
with	   Sis1,	   overexpression	   of	   Sis1	   3-­‐fold	   was	   still	   able	   to	   suppress	   the	   toxicity	   of	   the	  
mutant	  protein	  (Figure	  C2.4c).	  	  
	   Thus	   far,	   we	   have	   shown	   that	   interfering	   with	   the	   assembly	   of	   Rnq1	   into	   the	  
[RNQ+]	  amyloid	  state	  is	  extremely	  toxic.	  Toxicity	  occurs	  when	  Rnq1	  expression	  is	  higher	  
than	   normal	   (Figure	   C2.1	   and	   C2.2)	   or	   when	   mutations	   in	   Rnq1	   interfere	   with	   the	  
efficiency	  of	  Sis1	  interaction	  (Figure	  C2.3	  and	  C2.4).	  	  In	  addition,	  depletion	  of	  Sis1	  from	  
the	   cytosol	   reduces	   the	   efficiency	   of	   [RNQ+]	   prion	   assembly	   and	   exacerbates	   Rnq1	  
toxicity	   (Supplemental	   Figure	   C2.3).	   	   These	   collective	   data	   indicate	   that	   the	   efficient	  
conversion	  of	  native	  Rnq1	  into	  its	  SDS-­‐resistant	  amyloid	  form	  prevents	  the	  accumulation	  
of	  a	  toxic	  Rnq1	  conformer.	  
	  
Suppression	  of	  Rnq1	  toxicity	  by	  Sis1	  requires	  [RNQ	  +]	  prion	  assembly	  	  
Rnq1	   L94A	   exhibits	   a	   higher	   propensity	   than	   Rnq1	   WT	   to	   form	   SDS-­‐soluble	  
aggregates	  when	  [RNQ+]	  assembly	  is	  impeded	  via	  depletion	  of	  Sis1	  (Supplemental	  Figure	  
C2.3).	  The	  inability	  of	  cells	  to	  maintain	  Rnq1	  L94A	  in	  a	  soluble	  state	  correlates	  with	  the	  
enhanced	   toxicity	   of	   the	   L94A	  mutant.	   In	   this	   sense	  Rnq1	   L94A	   is	   similar	   to	   alleles	   of	  
amyloidogenic	   proteins	   whose	   subtle	   defects	   in	   folding	   kinetics	   cause	   devastating	  
 61 
protein	  conformational	  diseases	  	  (CARRELL,	  et	  al.	  1997).	  Thus,	  we	  wondered	  if	  Rnq1	  L94A	  
would	  assume	  a	  toxic	  conformation	  in	  the	  absence	  of	  templating	  by	  [RNQ+]	  prion	  seeds.	  
Indeed,	   overexpression	   of	   Rnq1	   L94A,	   but	   not	   Rnq1	   WT,	   was	   toxic	   in	   [rnq-­‐]	   strains	  
(Figure	  C2.5a).	  Hence,	  a	  small	  amino	  acid	  substitution	  can	  cause	  Rnq1	  to	  be	  toxic	  even	  in	  
the	  absence	  of	  [RNQ+]	  amyloid	  formation.	  	  	  
Sis1-­‐dependent	  [RNQ+]	  amyloid	  formation	  appears	  to	  protect	  cells	  from	  toxicity	  
caused	   by	   overexpression	   of	   Rnq1.	   If	   amyloid	   formation	   is	   a	   critical	   aspect	   of	   Sis1’s	  
ability	  to	  suppress	  Rnq1	  toxicity,	  then	  Sis1	  overexpression	  should	  not	  protect	  [rnq-­‐]	  cells	  
from	  Rnq1	  L94A	  mediated	  death	  as	  these	  cells	  lack	  the	  [RNQ+]	  prion	  seeds	  required	  for	  
amyloid	  assembly.	  Indeed,	  overexpression	  of	  Sis1,	  which	  binds	  Rnq1	  L94A	  with	  reduced	  
efficiency,	  protected	  [RNQ+],	  but	  not	  [rnq-­‐]	  strains,	  from	  Rnq1	  L94A	  toxicity.	  This	  finding	  
further	   confirms	   that	  Rnq1	   toxicity	   is	   not	   caused	  by	   sequestration	  of	   Sis1	   into	   [RNQ+]	  
prion	  complexes.	  Furthermore,	  the	  presence	  of	  the	  [RNQ+]	  prion	  assembly	  pathway	  and	  
Sis1	  overexpression	  are	  both	  required	  for	  the	  suppression	  of	  Rnq1	  toxicity.	  	  
	  
Rnq1	  L94A	  does	  not	  form	  prion	  amyloids	  in	  [rnq-­‐]	  cells	  
	   To	   rule	   out	   the	   possibility	   that	   Rnq1	   L94A	   assembled	   into	   [RNQ+]	   prions	  
spontaneously	   in	   [rnq-­‐]	   cells	  we	   compared	   its	   assembly	   status	   to	   that	   of	   Rnq1	  WT	   in	  
[rnq-­‐]	  strains	  (Figure	  C2.5b-­‐e).	   	   In	  [rnq-­‐]	  cells,	  Rnq1	  L94A	  exhibited	  a	  higher	  propensity	  
than	   Rnq1	   WT	   to	   coalesce	   into	   foci	   (Figure	   C2.5b).	   Gel-­‐filtration	   chromatography	  
showed	   that	   Rnq1	   L94A	   formed	   high	   molecular	   weight	   aggregates	   in	   these	   cells	  
(Supplemental	   Figure	   C2.4).	   Notably,	   these	   aggregates	   were	   not	   SDS-­‐resistant	   and	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(Figure	   C2.5c)	   were	   unable	   to	   bind	   the	   amyloid	   indicator	   thioflavin-­‐T	   (Figure	   C2.5d).	  
Thus,	  Rnq1	  toxicity	  is	  not	  related	  to	  the	  accumulation	  of	  excess	  pools	  of	  [RNQ+]	  amyloid	  
and	  may	  be	  caused	  by	  a	  SDS-­‐soluble	  Rnq1	  species.	  
As	   small	  prion	   seeds	   in	   the	   form	  of	  detergent	   soluble	  prefibrillar	   species	   could	  
have	  escaped	  detection	  by	  SDD-­‐AGE	  and	  thioflavin-­‐T	  staining,	  we	  applied	  another	  test	  
for	  the	  existence	  of	  such	  forms	  of	  Rnq1	  L94A	  in	  [rnq-­‐]	  cell	  extracts	  (Figure	  C2.5e).	  	  Prion	  
seeds	   in	   cell	   extracts	   can	   be	   sensitively	   detected	   through	   their	   ability	   to	   catalyze	   the	  
conversion	  of	  exogenously	  added	  native	  prion	  protein	  into	  SDS	  resistant	  amyloid.	  Prion	  
seeds	  were	  readily	  detected	  in	  lysates	  of	  [RNQ+]	  cells	  overexpressing	  Rnq1	  L94A	  (Figure	  
C2.4b).	  However,	  extracts	  of	  [rnq-­‐]	  cells	  that	  contained	  toxic	  levels	  of	  Rnq1	  L94A	  failed	  
to	   seed	   assembly	   of	   purified	   His-­‐Rnq1	   or	   His-­‐Rnq1-­‐L94A	   into	   SDS-­‐resistant	   amyloid	  
(Figure	  C2.5e).	  	  
The	   Rnq1	   L94A	   assemblies	   in	   [rnq-­‐]	   cells	   fail	   to	   meet	   three	   classification	  
standards	  of	  [RNQ+]	  amyloid.	  They	  are	  SDS-­‐soluble,	  they	  do	  not	  stain	  with	  Thioflavin-­‐T,	  
and	  they	  do	  not	  seed	  polymerization	  of	  soluble	  Rnq1	  protein.	  Rnq1	  L94A	  is	  more	  lethal	  
than	  Rnq1	   and	   can	   assume	  a	   toxic	   conformation	   in	   the	   absence	  of	   [RNQ+]	   templates.	  
Rescue	  from	  Rnq1	  L94A	  toxicity	  requires	  Sis1	  overexpression	  and	  active	  propagation	  of	  
the	   [RNQ+]	   prion.	   	   Therefore,	   it	   appears	   that	   the	   conversion	   of	   Rnq1	   L94A	   to	   [RNQ+]	  






Figure	  C2.5:	  Rnq1	  L94A	  toxicity	  and	  assembly	  status	  in	  [rnq-­‐]	  yeast.	  
(a)	   Growth	   of	   5	   fold	   serial	   dilutions	   of	   [rnq-­‐]	   strains	   in	   which	  WT	   or	   L94A	   Rnq1	   was	  
overexpressed	   from	   the	   GAL1	   promoter.	   Sis1	   was	   overexpressed	   from	   the	   GPD	  
promoter.	   (b)	   Fluorescent	   foci	   formed	  by	  Rnq1-­‐YFP	  and	  Rnq1-­‐YFP	  L94A	   in	   [RNQ+]	   and	  
[rnq-­‐]	  cells.	  (c)	  SDD-­‐AGE	  analysis	  of	  aggregates	  formed	  by	  Rnq1-­‐YFP	  and	  Rnq1-­‐YFP	  L94A	  
in	  [RNQ+]	  and	  [rnq-­‐]	  cells.	  (d)	  Thioflavin-­‐T	  staining	  of	  untagged	  Rnq1	  and	  Rnq1	  L94A	  in	  
[RNQ+]	  and	  [rnq-­‐]	  cells.	  	  Fixed	  yeast	  were	  decorated	  with	  α-­‐Rnq1	  sera	  that	  was	  detected	  
with	  a	  fluorescent	  secondary	  antibody.	  The	  same	  cells	  were	  simultaneously	  stained	  with	  
the	  amyloid	  indicator	  dye,	  thioflavin-­‐T.	  (e)	  Cell	  extracts	  from	  [rnq-­‐]	  cells	  overexpressing	  
either	  Rnq1	  or	  Rnq1	  L94A	  were	  incubated	  with	  purified	  Rnq1-­‐His	  or	  Rnq1-­‐His	  L94A.	  	  The	  
assembly	   status	   of	   purified	   Rnq1-­‐His	   was	   determined	   by	   SDD-­‐AGE.	   As	   a	   control,	   the	  
assembly	   status	   of	   purified	   Rnq1-­‐His	   incubated	   with	   [RNQ+]	   cell	   extract	   was	   also	  




Our	  data	  suggest	  a	  model	  in	  which	  efficient	  chaperone-­‐dependent	  conversion	  of	  
soluble	   Rnq1	   into	   SDS-­‐resistant	   [RNQ+]	   amyloid	   is	   critical	   to	   prevent	   the	   formation	   of	  
other	  toxic	  Rnq1	  conformers.	  	  We	  demonstrate	  that	  toxic	  Rnq1	  conformers	  accumulate	  
in	  a	  non-­‐amyloid	  form	  when	  [RNQ+]	  assembly	  is	  made	  inefficient	  by	  multiple	  means.	  We	  
propose	   that	   non-­‐productive	   templating	   of	   Rnq1	   monomers	   by	   [RNQ+]	   seeds	  
predisposes	   Rnq1	   to	   leave	   the	   amyloid	   pathway	   and	   accumulate	   as	   a	   toxic	   species,	  
whose	  exact	  nature	  is	  not	  yet	  clear.	  Templating	  of	  native	  proteins	  to	  form	  amyloid	  is	  a	  
basic	   feature	   of	   amyloidogenesis	   and	   we	   suggest	   that	   inefficiencies	   in	   this	   process	  
contribute	   to	   the	   proteotoxicity	   associated	   with	   certain	   protein	   conformational	  
diseases.	  This	  templating	  model	  explains	  how	  amyloid	  formation	  can	  serve	  a	  protective	  
function	   while	   the	   [RNQ+]	   prion	   state	   is	   a	   prerequisite	   for	   toxicity	   of	   the	   Rnq1	   WT	  
protein.	  	  
One	  of	  Sis1's	  functions	  in	  [RNQ+]	  prion	  propagation	  appears	  to	  be	  promoting	  the	  
shearing	  of	  [RNQ+]	  amyloid	  fibers	  into	  smaller	  pieces,	  thereby	  creating	  new	  surfaces	  to	  
more	  efficiently	  seed	  the	  assembly	  of	  the	  prion	   	   (ARON,	  et	  al.	  2007).	  This	  reaction	  also	  
requires	  Hsp104	  and	  Hsp70.	  Hence,	  binding	  of	  Sis1	  to	  the	  non-­‐prion	  forming	  domain	  of	  
full-­‐length	   Rnq1	   may	   help	   facilitate	   this	   shearing	   process.	   However,	   since	  
overexpression	   of	   Hsp70	   and	   Hsp104	   do	   not	   suppress	   Rnq1	   toxicity,	   Sis1	   may	   have	  
additional	  functions	  in	  [RNQ+]	  prion	  propagation	  that	  do	  not	  overlap	  with	  those	  of	  other	  
chaperones.	   	   Sis1	   stably	   associates	  with	   assembled	   [RNQ+]	   conformers	   in	   a	   1:1	  molar	  
ratio	  	  (LOPEZ,	  et	  al.	  2003).	  	  Therefore,	  Sis1’s	  binding	  to	  the	  non-­‐prion	  forming	  domain	  has	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the	   potential	   to	   stabilize	   [RNQ+]	   prions	   in	   a	   conformation	   that	   is	   optimal	   for	   efficient	  
amyloid	  fibril	  growth.	  
Many	   neurodegenerative	   diseases	   involve	   the	   accumulation	   of	   intracellular	  
and/or	  extracellular	  amyloid	  protein	  aggregates.	   In	  the	  past,	   these	  amyloid	  aggregates	  
were	  thought	  to	  be	  the	  cytotoxic,	  disease-­‐causing	  protein	  conformer.	  However,	  recent	  
studies	  have	  begun	  to	  question	  this	  view.	  As	  one	  striking	  example	   in	  mice,	  deletion	  of	  
the	  GPI-­‐anchor	  of	  the	  prion	  protein,	  PrP,	  leads	  to	  massive	  extracellular	  amyloid	  plaque	  
formation	   in	   mice	   injected	   with	   infective	   scrapie,	   but	   causes	   no	   overt	   clinical	  
manifestations	   of	   scrapie	   	   (CHESEBRO,	   et	   al.	   2005).	   Furthermore	   it	   has	   been	   suggested	  
that	  neurodegenerative	  diseases	  are	  caused	  by	  the	  ability	  of	  very	  different	  proteins	  to	  
adopt	  common	  toxic	  non-­‐amyloid	  conformers	  such	  as	  protofibrils	  or	  soluble	  oligomers	  	  
(CAUGHEY,	   et	   al.	   2003;	   HAASS,	   et	   al.	   2007).	   Hence,	   amyloid	   formation	   may	   serve	   to	  
convert	  oligomeric	  amyloid	  precursors	  into	  a	  highly	  stable	  non-­‐toxic	  form	  	  (PICCARDO,	  et	  
al.	  2007).	  	  	  	  	  	  	  
While	  amyloid	  itself	  is	  not	  toxic,	  its	  interaction	  with	  soluble	  protein	  forms	  could	  
give	  rise	  to	  pathogenic	  species	  via	  non-­‐productive	  templating.	  Case	  in	  point,	  when	  GPI-­‐
anchorless	  PrP	  was	  expressed	  together	  with	  PrP	  WT,	  it	  accelerated	  scrapie	  disease	  and	  
resulted	   in	   increased	  deposits	  of	  both	  amyloid	  and	  non-­‐amyloid	  proteinase-­‐K	  resistant	  
PrP	  (PrPres)	  	  (CHESEBRO,	  et	  al.	  2005).	  Similarly,	  in	  yeast	  the	  toxicity	  of	  Huntington	  exon	  1	  
depends	  on	   the	   [RNQ+]	  prion	   state	   	   (DUENNWALD,	   et	  al.	   2006;	  MERIIN,	   et	  al.	   2002).	  This	  
concept	  may	  even	  extend	  to	  the	  heterokaryon	  incompatibility	  mediated	  by	  the	  [Het-­‐s]	  
prion	  in	  Podospora	  anserina	  	  (COUSTOU-­‐LINARES,	  et	  al.	  2001).	  HET-­‐s	  in	  its	  prion	  form	  only	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leads	  to	  cell	  death	  when	  co-­‐expressed	  with	  the	  HET-­‐S	  allele	  that	  cannot	  form	  amyloid.	  
Templating	  of	  the	  non-­‐amyloidogenic	  HET-­‐S	  protein	  by	  [Het-­‐s]	  prion	  seeds	  could	  lead	  to	  
the	  formation	  of	  a	  toxic	  species,	  while	  templating	  of	  HET-­‐s	  protein	  would	  result	   in	  the	  
non-­‐toxic	  prion	  amyloid	  species.	  	  
The	   aggregation	   state	   and	   toxicity	   of	   aggregation-­‐prone	   proteins	   is	   strongly	  
modulated	   by	   host	   factors	   such	   as	   Hsp70	   and	   its	   associated	   co-­‐chaperones,	   but	   the	  
mechanisms	   for	   chaperone	   function	   in	   this	   process	   is	   just	   being	   defined	   	   (CYR,	   et	   al.	  
2002).	  	  Molecular	  chaperones	  generally	  act	  to	  antagonize	  protein	  aggregation;	  yet,	  our	  
observations	   that	   chaperone-­‐dependent	   assembly	   of	   amyloid	   conformers	   can	   be	  
cytoprotective	  provide	   a	  different	   view	  of	   the	   cytoprotective	   effects	   of	   chaperones	   in	  
neurodegenerative	  disease.	  Thus,	  molecular	  chaperones	  can	  antagonize	  protein	  toxicity	  
in	  conformational	  disorders	  by	  two	  different	  mechanisms:	  they	  can	  solubilize	  misfolded	  
proteins	  or	  aid	  in	  sequestering	  them	  into	  benign,	  amyloid-­‐like	  species.	  The	  most	  central	  
aspect	   of	   antagonizing	   toxicity	   of	   misfolded	   proteins	   appears	   to	   be	   preventing	  
accumulation	   of	   the	   detergent	   soluble	   misfolded	   species	   rather	   than	   preventing	   the	  
formation	  of	  amyloid	  conformers.	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Materials	  and	  Methods	  
Strains	  and	  Plasmids:	  W303,	  MATa	  can1-­‐100	  ade2-­‐1,	  his3-­‐11,15	  leu2-­‐3,112	  ura3-­‐1	  trp1-­‐
1;	   W303Δrnq1,	   MATa	   can1-­‐100	   ade2-­‐1	   his3-­‐11,15	   leu2-­‐3,112	   ura3-­‐1	   trp1-­‐1	  
Δrnq1:KanMX4;	   74D-­‐694,	   MATa	   ade1-­‐14	   trp1-­‐289	   his3Δ-­‐300	   ura3-­‐52	   leu2-­‐3,112;	  
BY4741,	   MATa	   his3∆1	   leu2∆0	  met15∆0	   ura3∆0;	  W303Δsis1,	  MATa	   ade2-­‐1	   his3-­‐11,15	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leu2-­‐3,112	  ura3-­‐1	   trp1-­‐1	  ssd1-­‐d2	  sis1::HIS	  pRS316-­‐SIS1.	  All	   the	  above	  strains	  harbored	  
Rnq1	  in	  its	  [RNQ+]	  form	  and	  the	  generation	  of	  isogenic	  [rnq-­‐]	  strains	  was	  accomplished	  
via	  sequential	  passage	  of	  cells	  on	  plates	  containing	  3	  mM	  guanidinium-­‐HCl	  	  (EAGLESTONE,	  
et	   al.	   2000).	   BY,	   W303	   and	   74D-­‐694	   strains	   were	   utilized	   to	   take	   advantage	   of	   the	  
different	  markers	  or	   gene	  deletions.	   Identical	   results	  were	  obtained	   in	   studies	   carried	  
out	  with	  both	  of	  these	  strains,	  so	  Rnq1	  toxicity	  is	  not	  strain	  specific.	  	  
Strains	   were	   transformed	   with	   plasmids	   and	   cultured	   in	   synthetic	   media	   as	  
previously	  described	  	  (CAPLAN,	  et	  al.	  1991).	  	  Plasmids	  that	  express	  the	  indicated	  protein	  
under	  control	  of	  the	  GAL1	  promoter	  include	  pRS416-­‐RNQ1,	  pRS416-­‐RNQ1-­‐YFP,	  pRS426-­‐
RNQ1-­‐YFP	  and	  pYES3-­‐SIS1,	  termed	  pGAL1-­‐SIS1.	  All	  Rnq1	  truncations	  were	  expressed	  as	  
YFP	   fusions	   under	   control	   of	   the	   GAL1	   promoter	   using	   the	   pRS416	   plasmid.	   Plasmids	  
that	   express	   RNQ1	   under	   control	   of	   the	   CUP1	   promoter	   include	   pRS316-­‐RNQ1-­‐GFP,	  
pRS315-­‐RNQ1-­‐GFP.	   The	   strains	   used	   were	   not	   sensitive	   to	   500	   µM	   CuSO4.	   The	  
glyceraldehyde-­‐3-­‐phosphate	   dehydrogenase	   (GPD)	   promoter	   controlled	   expression	   of	  
SIS1	  in	  pRS414-­‐SIS1	  and	  pRS414-­‐sis1Δg/f.	  	  The	  QuikChange	  site-­‐directed	  mutagenesis	  kit	  
(Stratagene)	  was	  used	   to	   create	   the	   indicated	  point	  mutations	   in	  RNQ1.	  The	  pDEST17	  
vector	  was	  used	  to	  express	  His-­‐Rnq1	  WT	  and	  L94A	  in	  BL21AI	  cells.	  
	  
Analysis	  of	  Rnq1	  cytotoxicity:	  W303	  strains	  harboring	  pRS416-­‐RNQ1	  or	  pRS416-­‐RNQ1-­‐
YFP	  were	  grown	  overnight	  in	  synthetic	  drop-­‐out	  media	  containing	  2	  %	  raffinose	  before	  
5-­‐fold	  serial	  dilutions	  were	  spotted	  on	  plates	  containing	  either	  2	  %	  galactose	  or	  glucose.	  	  
Alternatively,	   strains	   that	   harbored	   pRS316-­‐RNQ1-­‐GFP	   or	   pRS315-­‐RNQ1-­‐GFP	   were	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cultured	   overnight	   in	   synthetic	  media	   containing	   glucose	   before	   serial	   dilutions	   were	  
spotted	  on	  agarose	  plates	  that	  contained	  500	  µM	  CuS04.	   	  Plates	  were	  incubated	  for	  3-­‐5	  
days	  at	  30	  ºC	  and	  then	  photographed.	  
	  
Screening	  of	  a	  Rnq1	  peptide	  array:	  A	  25mer	  Rnq1	  cellulose	  bound	  peptide	  array	  was	  
prepared	   by	   automated	   spot	   synthesis	   and	   screened	   essentially	   as	   described	   by	  	  
(RUDIGER,	  et	  al.	  1997).	  The	  25mer	  Rnq1	  cellulose	  bound	  peptide	  array	  was	  prepared	  by	  
automated	   spot	   synthesis	   (Jerini	   Peptide	   Technologies).	   	   The	   array	   was	   screened	  
according	   the	   manufactures	   instructions	   with	   100	   nM	   Sis1	   or	   Hsp70	   Ssa1	   in	   the	  
presence	  or	  absence	  of	  1	  mM	  EDTA	  or	  Mg-­‐ATP.	  	  Bound	  chaperones	  were	  transferred	  to	  
a	   nitrocellulose	   membrane	   and	   the	   peptide	   spots	   were	   identified	   by	   Western	   blot.	  	  
Hsp70	   Ssa1	   bound	   a	   number	   of	   different	   peptides	   that	   contained	   clusters	   of	  
hydrophobic	  amino	  acids	  (data	  not	  shown),	  yet	  peptides	  27-­‐30	  were	  the	  only	  peptides	  
that	  Sis1	  bound	  reproducibly	  with	  high	  affinity.	  In	  addition,	  peptide	  28,	  which	  contains	  
residues	  82-­‐106	  of	  Rnq1,	  was	  the	  only	  peptide	  that	  was	  bound	  by	  Hsp70	  Ssa1	  in	  a	  Sis1	  
and	  ATP	  dependent	  manner	  (Figure	  C2.3b).	  	  	  
	  
Pulse-­‐chase	  analysis	  of	   [RNQ+]	  prion	  formation:	  Pulse	   labeling	  of	  yeast	  to	  analyze	  the	  
kinetics	  of	  Rnq1	  assembly	   in	  74D-­‐694	  cultures	  was	  performed	  essentially	  as	  described	  
by	   	   (LUKE,	  et	  al.	  1991).	  74D-­‐694	  cultures	  were	  grown	  overnight	   in	  synthetic	  media	  and	  
then	   diluted	   and	   starved	   in	   methionine	   free	   media.	   	   Log	   phase	   cultures	   were	   first	  
supplemented	  with	  50	  µM	  CuS04	  to	  induce	  Rnq1-­‐GFP	  or	  Rnq1-­‐GFP	  L94A	  expression	  for	  1	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hr	  before	  the	  addition	  of	  Trans35S-­‐label	  (100	  µCi/ml).	  	  Cultures	  were	  labeled	  for	  10	  min,	  
then	   1	  mg/ml	   of	   cold	  methionine	  was	   added	   and	   cells	   were	  washed.	   	   Cultures	   were	  
incubated	   for	   the	   indicated	   time	   period	   at	   30°C	   before	   samples	  were	   collected.	   	   Cell	  
lysis	  was	  achieved	  by	  glass	  bead	  disruption	   in	  a	  buffer	  composed	  of	  50	  mM	  Hepes	  pH	  
7.4,	   150	  mM	  NaCl,	   1	  mM	  EDTA,	   0.1%	   Tween-­‐20,	   2	  mM	  phenylmethysulfonyl	   fluoride	  
and	   a	   protease	   inhibitor	   cocktail	   mixture.	   Cell	   debris	   was	   removed	   and	   the	   resulting	  
lysate	  was	  spun	  at	  4	  ºC	  at	  165,000	  ×	  g	  for	  45	  min	  in	  a	  TLA-­‐100	  rotor	  (Beckman	  Coulter).	  
Rnq1-­‐GFP	  present	  in	  the	  supernatant	  and	  pellet	  fractions	  was	  then	  immuneprecipitated	  
with	   α-­‐GFP	   (Roche)	   in	   the	   presence	   of	   0.1%	   SDS.	   35S-­‐labeled	   proteins	   in	  
immuneprecipitates	  were	  resolved	  by	  SDS-­‐PAGE	  and	  detected	  by	  autoradiography.	  	  
	  
Analysis	  of	  [RNQ+]	  prion	  formation	  by	  fluorescence	  microscopy:	  Assembly	  of	  Rnq1-­‐GFP	  
into	   fluorescent	   foci	   that	   represent	   prion	   amyloids	   was	   preformed	   essentially	   as	  
described	  by	   	   (FAN,	   et	   al.	   2004).	   To	   examine	   the	   assembly	   of	   newly	   synthesized	  Rnq1	  
into	  of	  [RNQ+]	  prions	  Rnq1-­‐GFP	  expression	  was	  induced	  from	  the	  CUP1	  promoter	  by	  the	  
addition	  of	  50	  µM	  CuSO4	   to	   log-­‐phase	   cultures	  and	   live	   cells	  were	  photographed	  1	  hr	  
later.	   To	   examine	   the	   aggregation	   pattern	   of	   Rnq1,	   Rnq1-­‐GFP	   or	   Rnq1-­‐YFP	   under	  
condition	  where	  growth	  defects	  are	  observed,	  protein	  expression	  under	  control	  of	  the	  
CUP1	  or	  GAL1	  promoter	  was	   induced	  by	   the	   addition	  of	   either	   500	  µM	  CuSO4	   or	   2	  %	  
galactose,	  respectively,	  and	  4	  hrs	  later	  live	  cells	  were	  photographed.	  
	  	  Indirect	   immunofluorescence	   of	   Rnq1	   and	   thioflavin-­‐T	   staining	   of	   Rnq1	  
aggregates	   were	   performed	   as	   follows.	   Log	   phase	   cells	   harboring	   pRS416-­‐RNQ1	   that	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were	  cultured	  in	  synthetic	  raffinose	  media	  were	  supplemented	  with	  2	  %	  galactose	  for	  4	  
hrs	   to	   induce	   expression	   of	   either	   Rnq1	   or	   Rnq1	   L94A.	   	   Cells	   were	   fixed	   with	   4%	  
formaldehyde	   for	   1	   hr	   and	   washed	   twice	   in	   buffer	   containing	   1.2	   M	   sorbitol	   before	  
being	   converted	   to	   spheroplasts	   via	   45	  min	   incubations	   at	   30ºC	   in	   the	   presence	   of	   5	  
mg/ml	  zymolyase-­‐20T.	   	  Cells	  were	  then	  permeabilized	  in	  phosphate	  buffer	  saline	  (PBS)	  
containing	  0.1%	  Triton	  X-­‐100	  for	  5	  min.	  	  Cells	  were	  washed	  and	  incubated	  with	  PBS	  that	  
contained	  0.001%	  Thioflavin-­‐T	  for	  10	  min.	  Next,	  thioflavin-­‐T	  stained	  cells	  were	  washed	  4	  
times	  and	  incubated	  in	  PBS	  containing	  1.0%	  BSA	  and	  0.025%	  Triton	  X-­‐100.	  	  Blocked	  cells	  
were	   then	   incubated	   with	   polyclonal	   rabbit	  α-­‐Rnq1	   (1:50	   dilution)	   for	   1	   hr	   and	   then	  
washed	  4	   times.	   	   Cells	  were	   then	  decorated	  with	   goat	  α-­‐rabbit	   conjugated	  Texas	  Red	  
(1:1000)	   second	   antibody	   (Molecular	   Probes).	   Decorated	   cells	   were	   spotted	   on	   glass	  
slides	   and	   photographed	   with	   a	   Nikon	   fluorescence	   microscope	   and	   images	   were	  
processed	  with	  Metamorph	  and	  Adobe	  Photoshop	  Software.	  
	  
Semi-­‐denaturing	  detergent	  agarose	  gel	  electrophoresis	  (SDD-­‐AGE):	  Rnq1	  assembly	  into	  
SDS-­‐resistant	   [RNQ+]	   prions	   was	   monitored	   by	   SDD-­‐AGE	   as	   previously	   described	  	  
(KRYNDUSHKIN,	   et	   al.	   2003)	   with	   the	   following	   exceptions.	   	   Cells	   were	   lysed	   in	   buffer	  
containing	   2%	   SDS,	   5%	   glycerol,	   75	   mM	   Tris-­‐HCl	   pH	   6.8,	   2	   mM	   EDTA,	   8%	   2-­‐
mercaptoethanol,	   0.05%	   coomassie	   blue,	   2	   mM	   phenylmethysulfonyl	   fluoride	   and	   a	  
protease	   inhibitor	   cocktail	   (Roche).	   	   Proteins	   resolved	   by	   the	   1.5%	   agarose	   gel	   were	  
electrophoretically	  transferred	  to	  PVDF	  in	  a	  submerged	  transfer	  apparatus	  for	  1.5	  hrs	  at	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24	  V.	   	   PVDF	  membranes	  were	   then	   decorated	  with	  α-­‐GFP	   and	   bands	  were	   visualized	  
with	  ECL	  reagent.	  	  
	  
Rnq1	  co-­‐immunoprecipitation:	  Expression	  of	  Rnq1-­‐GFP	  in	  log	  phase	  cells	  harboring	  the	  
indicated	   form	   of	   pRS316-­‐Rnq1-­‐GFP	   was	   induced	   by	   supplementation	   with	   50	   µM	  
CuSO4.	   	   Cell	   extracts	   were	   prepared	   1	   hr	   later	   under	   the	   non-­‐denaturing	   conditions	  
described	  above	  for	  the	  pulse-­‐chase	  analysis.	  	  Cell	  debris	  was	  removed	  by	  centrifugation	  
and	  the	  resulting	  supernatant	  was	  supplemented	  with	  either	  α-­‐Sis1	  or	  α-­‐GFP.	  	  Samples	  
were	  incubated	  at	  4ºC	  for	  1	  hr	  before	  being	  supplemented	  with	  pre-­‐blocked	  protein	  G	  
agarose	   beads.	   	   After	   1	   hr,	   the	   beads	   were	   isolated	   by	   centrifugation	   and	   washed	   3	  
times	  with	   lysis	  buffer.	   	   Immuneprecipitated	  proteins	  were	   resolved	  by	  SDS-­‐PAGE	  and	  
detected	  by	  western	  blot.	  	  	  
	  
Size	   Exclusion	   Chromatography:	   [RNQ+]	   or	   [rnq-­‐]	   cells	   were	   grown	   overnight	   in	  
synthetic	   media	   at	   30°C.	   Rnq1-­‐YFP	   expression	   was	   induced	   by	   the	   addition	   of	   2	   %	  
galactose	  for	  4	  hrs	  prior	  to	  the	  collection	  of	  100	  OD	  units	  of	  cells.	   	  Proteins	  in	  extracts	  
created	   with	   a	   non-­‐denaturing	   lysis	   buffer	   were	   resolved	   on	   a	   Superose	   12S	   sizing	  
column	  (Pharmacia).	   Indicated	  proteins	   in	  column	  fractions	  were	  detected	  by	  Western	  
blot.	  	  	  
	  
Rnq1	  toxicity	  and	  [RNQ+]	  assembly	  in	  Sis1	  depleted	  cells:	   	  A	  strain	  in	  which	  Rnq1-­‐GFP	  
expression	  was	  controlled	  by	  the	  CUP1	  promoter	  and	  Sis1	  expression	  was	  controlled	  the	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GAL1	  promoter	  was	  constructed	  by	  transforming	  W303∆sis1	  with	  pRS315-­‐Rnq1-­‐GFP	  and	  
pGAL1-­‐SIS1.	  	  To	  examine	  [RNQ+]	  toxicity	  at	  different	  Sis1	  levels,	  strains	  were	  generated	  
by	  the	  plasmid	  shuffle	  technique	  	  (BOEKE,	  et	  al.	  1987)	  and	  then	  grown	  on	  synthetic	  drop-­‐
out	  plates	  containing	  2%	  galactose.	  A	  single	  colony	  was	  picked,	  diluted	  into	  sterile	  H20	  
and	   5-­‐fold	   serial	   dilutions	   were	   spotted	   onto	   plates	   containing	   either	   galactose	   or	  
glucose	  in	  the	  presence	  of	  500	  µM	  CuSO4.	  	  To	  examine	  the	  effect	  that	  depletion	  of	  Sis1	  
had	  on	  [RNQ+]	  assembly,	  transformants	  grown	  on	  galactose	  plates	  were	  transferred	  to	  
liquid	  media	  containing	  either	  glucose	  or	  galactose	  and	  cultured	  overnight	  at	  30ºC.	  	  Cells	  
were	   then	   diluted	   and	   grown	   an	   additional	   12	   hrs.	   	   Rnq1-­‐GFP	   expression	   was	   then	  
induced	   by	   the	   addition	   of	   500	   µM	   CuSO4	   and	   the	   formation	   of	   SDS-­‐resistant	   [RNQ
+]	  
particles	  was	  measured	  by	  SDD-­‐AGE.	  	  To	  demonstrate	  that	  Sis1	  depleted	  cells	  were	  still	  
capable	  of	  [RNQ+]	  prion	  assembly,	  Sis1	  levels	  were	  restored	  by	  spotting	  cells	  cultured	  in	  
glucose	  media	  back	  onto	  synthetic	  galactose	  plates.	   	  After	  the	  restoration	  of	  Sis	  levels,	  
[RNQ+]	  assembly	  was	  monitored	  as	  described	  by	  SDD-­‐AGE.	  
	  
Seeded	  polymerization	  of	  purified	  Rnq1:	  Purified	  Rnq1-­‐His	  was	  added	  to	  lysates	  of	  the	  
indicated	  strains.	  Assembly	  was	  monitored	  by	  SDD-­‐AGE.	  Also	  see	  	  	  (SHORTER,	  et	  al.	  2006).	  
His-­‐Rnq1	  WT	  and	  L94A	  were	  expressed	  from	  pDEST17	  vector	  in	  BL21AI	  cells	  for	  4	  
hrs	  at	  30	  ºC	  followed	  by	  lysis	  in	  a	  buffer	  that	  contained	  6	  M	  guanidium-­‐HCl	  and	  100	  mM	  	  
potassium	  phospate	  buffer	  pH	  7.0.	  	  His-­‐Rnq1	  was	  purified	  by	  standard	  techniques	  on	  Ni-­‐
NTA	  agarose	  that	  was	  washed	  with	  8	  M	  urea	  and	  100	  mM	  potassium	  phosphate	  buffer	  
pH	  7.0.	  	  His-­‐Rnq1	  was	  eluted	  with	  the	  same	  buffer	  at	  pH	  3.0,	  concentrated	  by	  methanol	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precipitation	   and	   stored	   at	   -­‐80	   °C.	   Prior	   to	   use	   His-­‐Rnq1	   was	   resuspended	   in	   6	   M	  
guanidium-­‐HCl	   and	   filtered	   through	   a	   Microcon	   YM-­‐100	   spin-­‐column.	   	   Yeast	   extracts	  
containing	   [RNQ+]	   seeds	   were	   prepared	   as	   follows.	   The	   indicated	   form	   of	   Rnq1	   was	  
expressed	  from	  the	  GAL1	  promoter	  for	  4	  hrs.	  	  Cells	  were	  isolated	  by	  centrifugation	  and	  
extracts	  were	  created	  by	  bead	  disruption	  in	  buffer	  composed	  of	  40	  mM	  Hepes,	  pH	  7.5,	  
150	  mM	  KCL,	  2	  mM	  DTT,	  5%	  glycerol,	  8	  mM	  PMSF,	  10	  mg/ml	  aprotinin,	  and	  10	  mg/ml	  
leupeptin.	  	  An	  aliquot	  of	  purified	  Rnq1	  was	  adjusted	  to	  a	  final	  concentration	  of	  5	  µM	  in	  
cell	   lysate	   and	   incubated	   at	   25	   ºC	   for	   30	  min,	  without	   agitation.	   	   Samples	  were	   then	  
analyzed	  by	  SDD-­‐AGE	  as	  described	  above.	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Supplemental	   Figure	   C2.1:	   Factors	   influencing	   Rnq1	   toxicity	   include	   the	   expression	  
level	  and	  presence	  of	  a	  carboxy-­‐terminal	  tag.	  
(a)	   Comparison	   of	   the	   toxicity	   of	   untagged	   Rnq1	   to	   Rnq1-­‐YFP	   that	   is	   expressed	   at	  
different	   levels.	   (b)	   SDD-­‐AGE	   analysis	   of	   the	   assembly	   status	   of	   Rnq1-­‐YFP	   expressed	  
from	  low	  and	  high	  copy	  expression	  vectors.	  The	  bottom	  panel	  represents	  Western	  blots	  
depicting	  Rnq1-­‐YFP	   levels	   in	  the	   indicated	  extracts.	   (c)	  The	  effect	  on	  growth	  of	   [RNQ+]	  
yeast	  caused	  by	  overexpression	  of	  full	   length	  and	  truncated	  Rnq1-­‐YFP	  fusion.	   	  Rnq1	  1-­‐
153	   corresponds	   to	   the	   Rnq1	   N-­‐terminal	   non-­‐prion	   forming	   domain.	   	   Rnq1	   153-­‐405	  
corresponds	   to	   the	  Rnq1	  C-­‐terminal	   prion-­‐forming	  domain.	   Spots	   that	   contain	  10-­‐fold	  
serial	  dilutions	  of	   indicated	  yeast	  strains	  were	  positioned	  horizontally	  across	  the	  plate.	  	  
The	  lower	  panel	   is	  a	  western	  blot	  of	  cell	  extracts	  that	  express	  the	  indicated	  YFP	  fusion	  
with	  GFP	  anti-­‐sera.	  (d)	  SDS-­‐resistance	  of	  Rnq1-­‐GFP	  or	  PrD-­‐GFP	  fusions	  expressed	  under	  




Supplemental	  Figure	  C2.2:	  Mutation	  of	  the	  chaperone-­‐binding	  motif	  slows	  the	  rate	  of	  
Rnq1	  assembly	  into	  [RNQ+]	  prions.	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(a)	  Peptide	  spots	   in	  a	  25-­‐residue	  Rnq1	  peptide	  array	  that	  were	  bound	  by	  purified	  Sis1.	  	  
Shown	  is	  a	  schematic	  of	  the	  Rnq1	  peptide	  array	  in	  which	  circles	  represent	  the	  peptide	  
spots	  starting	  at	  amino	  acid	  1	  of	  Rnq1	  and	  sequentially	  shift	  in	  register	  by	  3	  amino	  acids	  
until	   the	   terminal	   peptide.	   	   Filled	   circles	   represent	   peptide	   spots	   where	   Sis1	   binding	  
could	   be	   detected	   as	   significant	   levels	   above	   background.	   The	   darkness	   of	   the	   spots	  
correlates	  with	   the	   intensity	  of	  Sis1	  binding	  signal.	   (b)	  Comparison	  of	   the	  Sis1	  binding	  
site	  in	  Rnq1	  with	  similar	  regions	  in	  the	  two	  known	  Rnq1	  homologs	  from	  C.	  glabrata	  and	  
E.	   gossypii.	   	   The	   hydrophobic	   core	   within	   the	   peptide	   identified	   in	   b	   is	   conserved	  
between	  species	  both	  in	  sequence	  as	  well	  as	  in	  proximity	  to	  the	  carboxy-­‐terminal,	  Q/N	  
rich	   prion-­‐forming	   domain.	   	   The	   term	   aa	   is	   an	   abbreviation	   for	   amino	   acid.	   	   (c)	  
Fluorescence	  microscopy	  of	   live	  [RNQ+]	  cells	  after	  the	  indicated	  form	  of	  Rnq1-­‐GFP	  was	  
expressed	  for	  1	  hr.	  Rnq1-­‐GFP	  is	  under	  the	  control	  of	  the	  CUP1	  promoter.	  Expression	  was	  
induced	  using	  50	  µM	  CuSO4.	  (d)	  Pulse-­‐Chase	  analysis	  of	  the	  assembly	  of	  nascent	  Rnq1	  
into	   pelletable	   [RNQ+]	   prions.	   [RNQ+]	   cells	   were	   labeled	   with	   35S-­‐translabel.	   At	   the	  
indicated	   times	   cells	   were	   lysed	   and	   fractionated	   by	   centrifugation	   with	   an	   airfuge.	  	  
Rnq1-­‐GFP	  present	  in	  supernatant	  and	  pellet	  fractions	  of	  cell	  extracts	  was	  then	  isolated	  
by	  immuneprecipitation	  with	  α-­‐GFP	  sera.	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Supplemental	   Figure	   C2.3:	   Depletion	   of	   Sis1	   hinders	   assembly	   of	   nascent	   Rnq1-­‐GFP	  
into	  SDS-­‐resistant	  [RNQ+]	  aggregates.	  
(a)	  The	  influence	  of	  Rnq1-­‐GFP	  and	  Rnq1-­‐GFP	  L94A	  overexpression	  on	  cell	  viability	  when	  
Sis1	  levels	  are	  maintained	  or	  depleted.	  A	  [RNQ+]	  Δsis1	  strain	  that	  harbored	  pGAL1-­‐SIS1	  
was	   grown	   on	   plates	   that	   contained	   galactose	   or	   glucose	   as	   the	   carbon	   source	   to	  
maintain	   Sis1	   at	   close	   to	   normal	   or	   to	   deplete	   Sis1	   levels.	   The	   same	   approach	   was	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previously	  used	  to	  characterize	  the	  effect	  of	  Sis1	  depletion	  on	  cell	  growth	  	  (LUKE,	  et	  al.	  
1991).	  Rnq1-­‐GFP	  and	  Rnq1-­‐GFP	  L94A	  were	  expressed	   from	   the	  CUP1	  promoter	   in	   the	  
presence	  of	  500	  µM	  CuSO4.	  Rnq1-­‐GFP	  expression	  the	  CUP1	  promoter	  produces	  a	  lower	  
concentration	  of	  protein	   than	   the	  GAL1	  promoter	   	   (ROMANOS,	   et	  al.	   1992)	   .	   	   Thus,	   the	  
growth	  defects	  observed	  when	  Rnq1-­‐GFP	  is	  expressed	  from	  the	  CUP1	  are	  not	  as	  severe	  
as	  when	  Rnq1-­‐GFP	   is	  overexpressed	   from	  the	  GAL1	  promoter	   (compare	  Supplemental	  
Figure	  C2.1a	  to	  Figure	  S3a).	  Sis1	  was	  depleted	  from	  a	  Dsis1	  strain,	  which	  was	  maintained	  
by	   a	   pGAL1-­‐SIS1	   plasmid,	   by	   shifting	   the	   strain	   from	   galactose	   to	   glucose	   medium.	  
Consistent	  with	   a	  previous	   report	   	   (LUKE,	   et	   al.	   1991),	   the	  near	   complete	  depletion	  of	  
Sis1	   did	   not	   cause	   yeast	   to	   exhibit	   growth	   defects	   on	   its	   own,	   but	   it	   did	   exacerbate	  
Rnq1-­‐GFP	   cytotoxicity.	   Further,	   this	   effect	   was	   far	   more	   severe	   for	   the	   L94A	  mutant	  
than	   for	  wild-­‐type	  Rnq1.	   (b)	  Coalescence	  of	  Rnq1-­‐GFP	  and	  Rnq1-­‐GFP	  L94A	   into	   foci	   in	  
Sis1	  depleted	  cells.	  (c)	  SDD-­‐AGE	  analysis	  of	  Rnq1-­‐GFP	  and	  Rnq1-­‐GFP	  L94A	  assembly	  into	  
SDS-­‐resistant	  conformers	  at	  normal	  and	  low	  Sis1	  levels.	  	  The	  lower	  panels	  depict	  levels	  
of	  the	  indicated	  proteins	  as	  determined	  by	  Western	  blot.	  These	  data	  demonstrate	  that	  
the	  foci	  formed	  by	  Rnq1	  L94A	  under	  toxic	  conditions	  are	  sensitive	  to	  SDS-­‐treatment,	  and	  
thus,	   do	   not	   appear	   to	   represent	   [RNQ+]	   prions.	   (d)	   Restoration	   of	   [RNQ+]	   prion	  
formation	  in	  Sis1	  depleted	  cells	  upon	  reintroduction	  of	  normal	  Sis1	  expression.	  Bottom	  
panels	  depict	   Sis1	  and	  PGK	   levels	   in	   the	   indicated	  extracts	   as	  determined	  by	  Western	  
blot.	  	  Data	  in	  panel	  (d)	  indicate	  that	  defects	  in	  the	  assembly	  of	  Rnq1	  and	  Rnq1	  L94A	  into	  
SDS-­‐resistant	   species	   observed	   upon	   depletion	   of	   Sis1,	   are	   not	   resultant	   from	   curing	  




Supplemental	   Figure	   C2.4:	   Analysis	   of	   the	   mobility	   of	   Rnq1	   L94A	   in	   extracts	   from	  
[RNQ+]	  and	  [rnq-­‐]	  strains	  by	  gel	  filtration	  chromatography.	  
Rnq1-­‐YFP	  L94A	  was	  expressed	  from	  the	  GAL1	  promoter	  for	  4	  hrs	  in	  the	  indicated	  strain.	  	  
Extracts	  were	  prepared	  under	  native	  buffer	  conditions	  and	  loaded	  onto	  a	  Superose	  12S	  
column.	  The	  mobility	  of	  Rnq1-­‐YFP	  L94A	  was	  determined	  with	  Western	  blot	  of	   column	  








Toxic	  overexpression	  of	  the	  prion	  Rnq1	  
causes	  a	  cell	  cycle	  arrest	  
by	  sequestering	  the	  












The	  accumulation	  of	  intrinsically	  disordered	  proteins	  in	  aggregates	  is	  associated	  
with	   a	   variety	   of	   human	   diseases.	   Indeed,	   intrinsic	   protein	   disorder	   is	   an	   important	  
determinant	  of	  the	  gain-­‐of-­‐function	  proteotoxicity	  of	  overexpressed	  proteins.	  The	  yeast	  
prion	  protein	  Rnq1	  is	  intrinsically	  disordered	  and	  profoundly	  toxic	  when	  overexpressed	  
in	   strains	   carrying	   the	   [RNQ+]	   prion	   amyloid	   conformation.	  Here,	  we	  demonstate	   that	  
Rnq1	  toxicity	  results	  in	  a	  Mad2-­‐mediated	  mitotic	  cell	  cycle	  arrest.	  Rnq1	  overexpression	  
results	  in	  the	  formation	  of	  a	  monopolar	  spindle	  due	  to	  a	  defect	  in	  the	  duplication	  of	  the	  
spindle	   pole	   body,	   the	   yeast	   centrosome.	   We	   found	   that	   increased	   levels	   of	   Rnq1	  
induced	  the	  mis-­‐localization	  of	  the	  core	  spindle	  pole	  body	  component	  Spc42	  to	  the	  IPOD	  
(insoluble	  protein	  deposit).	  Moderate	  overexpression	  of	  Spc42	  suppressed	  Rnq1	  toxicity	  
confirming	   that	   the	  effect	  of	  Rnq1	  on	   Spc42	   localization	   is	   responsible	   for	   its	   toxicity.	  
Our	   work	   illustrates	   how	   intrinsically	   disordered	   proteins	   can	   result	   in	   proteotoxicity	  
due	   to	   illicit	   interactions	   with	   essential	   proteins.	   The	   IPOD	   appears	   to	   be	   the	   yeast	  
equivalent	   of	   the	   centrosome-­‐associated	   aggresomes	   of	   higher	   eukaryotes	   and	   our	  
findings	  provide	  the	  first	  link	  between	  the	  IPOD	  and	  the	  spindle	  pole	  body.	  
	  
Introduction	  
	   Amyloids	  are	  β-­‐sheet-­‐rich	  fibrous	  structures	  that	  can	  be	  formed	  by	  proteins	  with	  
many	  different	  amino	  acid	  sequences	   (CHITI,	  et	  al.	  2006).	  Their	   formation	   is	  associated	  
with	  a	  wide	  variety	  of	  human	  diseases	  (ROSS,	  et	  al.	  2005).	  Yet,	  with	  the	  exception	  of	  the	  
systemic	   amyloidoses,	   amyloids	   are	   no	   longer	   thought	   to	   be	   the	   primary	   source	   of	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toxicity	   (KAYED,	   et	   al.	   2003;	   TREUSCH,	   et	   al.	   2009).	   Rather,	   it	   is	   the	   propensity	   of	   these	  
amyloidogenic	   proteins	   to	   form	   soluble	   oligomers	   that	   provides	   a	   common	   thread	  
underlying	   their	   gain	   of	   function	   toxicities.	   Furthermore,	   these	   proteins	   are	   often	  
intrinsically	   disordered.	   Intrinsic	   protein	  disorder	   is	   the	  best	   predictor	  of	   gene	  dosage	  
sensitivity	   and	   may	   enable	   detrimental	   mass-­‐action-­‐driven	   interaction	   promiscuity	  
(VAVOURI,	   et	  al.	   2009).	   Indeed,	   the	   toxicity	  of	  artificial	  β-­‐sheet	  proteins	   is	  mediated	  by	  
their	  ability	  to	   interact	  with	  disordered	  proteins	  that	  occupy	  essential	  hub	  positions	   in	  
cellular	  protein	  networks	  (OLZSCHA,	  et	  al.	  2011).	  	  
Yeast	  provides	  a	  particularly	  interesting	  class	  of	  proteins	  for	  studying	  the	  cellular	  
impacts	   of	   intrinsically	   disordered	   proteins.	   Yeast	   prion	   proteins	   are	   intrinsically	  
disordered	   proteins	   that	   can	   stably	   exist	   in	   soluble	   or	   self-­‐perpetuating	   amyloid	  
conformations	  (SHORTER,	  et	  al.	  2005;	  WICKNER,	  et	  al.	  2004).	  Once	  a	  prion	  protein	  adopts	  
an	  amyloid	  state	   its	  self-­‐templating	  properties	  allow	  it	   to	  function	  as	  a	  cytoplasmically	  
inherited	  protein-­‐based	  genetic	  element	  	  (CHIEN,	  et	  al.	  2004;	  COX,	  et	  al.	  2003;	  LIEBMAN,	  et	  
al.	  1999;	  SHORTER,	  et	  al.	  2005;	  TUITE,	  et	  al.	  2003;	  WICKNER,	  et	  al.	  2007).	  	  
Seven	   yeast	   prions	   have	   been	   identified	   (ALBERTI,	   et	   al.	   2009;	   DU,	   et	   al.	   2008;	  
NEMECEK,	   et	   al.	   2009;	   PATEL,	   et	   al.	   2009;	   SONDHEIMER,	   et	   al.	   2000;	   WICKNER	   1994)	   and	  
evidence	   indicates	   that	   several	   other	   yeast	   proteins	   are	   capable	   of	   forming	   amyloid-­‐
based	   prions	   (ALBERTI,	   et	   al.	   2009).	   These	   prion	   proteins	   are	   characterized	   by	   the	  
presence	   of	   a	   “prion	   domain”,	   enriched	   in	   asparagine	   and	   glutamine	   amino	   acid	  
residues,	  which	  is	  intrinsically	  disordered	  but	  can	  adopt	  an	  amyloid	  conformation	  (CHIEN,	  
et	  al.	  2004;	  SHORTER,	  et	  al.	  2005;	  WICKNER,	  et	  al.	  2007).	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Rnq1	  contains	  such	  a	  prion	  domain	  (SONDHEIMER,	  et	  al.	  2000)	  and	  its	  [RNQ+]	  prion	  
state	  enables	  the	  formation	  of	  other	  prions	  (DERKATCH,	  et	  al.	  2001;	  DERKATCH,	  et	  al.	  2000;	  
OSHEROVICH,	  et	  al.	  2001;	  TANEJA,	  et	  al.	  2007).	  (Prion	  status	  is	  denoted	  by	  brackets,	  italics	  
and	   capital	   letters	   to	   reflect	   a	   prion’s	   dominant,	   non-­‐Mendelian	   genetic	   properties.)	  
[RNQ+]	  also	  enables	  the	  glutamine-­‐expanded	  exon	  one	  fragment	  of	  huntingtin	  to	  adopt	  
a	   toxic	   conformation	  when	  expressed	   in	   yeast	   (MERIIN,	   et	   al.	   2002).	   In	   part	  Rnq1	  may	  
influence	   the	   aggregation	   of	   other	   proteins	   based	   on	   its	   localization	   to	   the	   IPOD	  
(insoluble	  protein	  deposit)	  (KAGANOVICH,	  et	  al.	  2008;	  TYEDMERS,	  et	  al.	  2010).	  
In	   yeast,	   misfolded	   proteins	   can	   accumulate	   at	   two	   distinct	   sites,	   the	   JUNQ	  
(juxta-­‐nuclear	  quality	  control	  compartment)	  and	  the	  IPOD	  (KAGANOVICH,	  et	  al.	  2008).	  The	  
JUNQ	  forms	  mostly	  upon	  inhibition	  of	  the	  proteasome	  and	  contains	  poly-­‐ubiquitinated	  
proteins	   targeted	   for	   proteasomal	   degradation.	   The	   IPOD	   co-­‐localizes	   with	   the	   pre-­‐
autophagosomal	   structure	   at	   the	   vacuole	   and	   holds	   amyloidogenic	   proteins,	   such	   as	  
yeast	  prions	  and	  ectopically	  expressed	  mutant	  huntingtin	  fragments	  (KAGANOVICH,	  et	  al.	  
2008;	  TYEDMERS,	  et	  al.	  2010).	  
Both	   JUNQ	  and	   IPOD	  share	   features	  with	   the	  aggresome	  of	  higher	  eukaryotes.	  
Aggresomes	   are	   highly	   structured	   protein	   deposits	   that	   are	   actively	   formed	   near	  
centrosomes	   through	   dynein-­‐dependent	   retrograde	   transport	   of	   protein	   aggregates	  
along	   microtubules	   (GARCIA-­‐MATA,	   et	   al.	   1999;	   JOHNSTON,	   et	   al.	   2002;	   JOHNSTON,	   et	   al.	  
1998).	  Neither,	  JUNQ	  nor	  IPOD,	  has	  been	  shown	  to	  associate	  with	  the	  spindle	  pole	  body	  
(SPB),	  the	  yeast	  equivalent	  of	  the	  centrosome.	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We	   have	   previously	   reported	   that	   overexpression	   of	   Rnq1	   is	   benign	   in	   cells	  
whose	  endogenous	  Rnq1	  is	  in	  the	  soluble	  state,	  but	  is	  extremely	  toxic	  if	  the	  endogenous	  
protein	  is	  in	  the	  [RNQ+]	  state	  (DOUGLAS,	  et	  al.	  2008).	  Rnq1	  toxicity	  is	  an	  intriguing	  model	  
for	  amyloid	  and	  protein	  disorder	  associated	  gain-­‐of-­‐fucntion	  proteotoxicity,	  as	  deletion	  
of	  RNQ1	  has	  no	  effect	  on	  cell	  growth.	  Intriguingly,	  the	  amyloid	  form	  of	  Rnq1	  was	  not	  the	  
toxic	   species,	   but	   rather	   Rnq1	   amyloid	   formation	   was	   protective.	   Enhancing	   Rnq1	  
amyloid	   formation	   by	   co-­‐overexpression	   of	   the	   Hsp40	   co-­‐chaperone	   Sis1,	   which	   co-­‐
assembles	  with	  the	  amyloid,	  restored	  cell	  growth.	  In	  complementary	  experiments,	  Rnq1	  
mutants	  with	  a	  decreased	  ability	   to	   interact	  with	  Sis1	  exhibited	   increased	   toxicity	  and	  
formed	   non-­‐amyloid	   aggregates.	   Hence,	   amorphous	   non-­‐amyloid	   aggregates	   or	  
oligomeric	  species	  formed	  by	  this	  intrinsically	  disordered	  protein	  caused	  the	  associated	  
toxicity	  (DOUGLAS,	  et	  al.	  2008).	  
Here	  we	   investigated	   the	  mechanism	   by	  which	   Rnq1	   overexpression	   results	   in	  
toxicity.	  We	  conducted	  two	  genome-­‐wide	  screens	  for	  suppressors	  of	  Rnq1	  toxicity	  and	  
examined	   the	   gene	   expression	   profile	   elicited	   by	   Rnq1	   overexpression.	   Rnq1	   toxicity	  
results	  in	  a	  mitotic	  cell	  cycle	  arrest	  and	  a	  monopolar	  mitotic	  spindle.	  We	  show	  that	  Rnq1	  
overexpression	   causes	   the	   mislocalization	   of	   the	   core	   spindle	   pole	   body	   component	  
Spc42.	  Rnq1	  toxicity	  preempts	  SPB	  duplication	  and	  triggers	  cell	  cycle	  arrest.	  
	  
Results	  
RNQ1	  and	  HSP104	  are	  the	  only	  non-­‐essential	  genes	  strictly	  required	  for	  Rnq1	  toxicity	  
and	  the	  [RNQ+]	  prion	  state	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To	  characterize	  Rnq1	  toxicity,	  we	  conducted	  two	  unbiased	  genome-­‐wide	  screens	  
for	  genetic	  suppressors.	  First,	  we	  screened	  the	  two	  haploid	  deletion	  libraries,	  Mat	  a	  and	  
Mat	   α	   (WINZELER,	   et	   al.	   1999),	   for	   non-­‐essential	   genes	   that	   are	   required	   for	   Rnq1-­‐
induced	   toxicity.	   These	   libraries	   contain	   deletions	   of	   all	   the	   non-­‐essential	   yeast	   ORFs	  
and,	  importantly,	  were	  generated	  independently	  using	  two	  [RNQ+]	  strains	  (WINZELER,	  et	  
al.	   1999).	  Of	   the	  deletions	   that	   suppressed	  Rnq1	   toxicity,	   only	  69	  were	   found	   in	  both	  
libraries	   suggesting	   that	  most	  putative	   suppressors	   resulted	   from	   spontaneous	   loss	  of	  
the	   Rnq1	   prion.	   Indeed,	   after	   prion	   reintroduction	   into	   these	   strains,	   only	   twelve	  
deletions	  were	  still	   capable	  of	   suppressing	  Rnq1	   toxicity.	  These	   included,	  as	  expected,	  
the	  two	  non-­‐essential	  genes	  previously	  known	  to	  be	  required	  for	  the	  [RNQ+]	  prion	  state:	  
RNQ1	   itself	  and	  HSP104.	  The	  AAA+	  ATPase	  Hsp104,	  which	  shears	  amyloid	   to	  generate	  
heritable	  prion	  seeds,	  is	  required	  for	  prion	  inheritance	  	  (COX,	  et	  al.	  2003;	  TAGUCHI,	  et	  al.	  
2010).	  
To	  definitively	  show	  that	  the	  effect	  on	  Rnq1	  toxicity	  was	  due	  to	  the	  deletions,	  we	  
re-­‐created	   the	   identified	   deletions	   in	   two	   distinct	   yeast	   strains,	   BY	   and	  W303.	   Aside	  
from	   the	  HSP104	   and	  RNQ1	   deletions,	   only	   three	   of	   the	   re-­‐created	   deletions,	   ksp1Δ,	  
pml39Δ	   and	   spf1Δ,	   had	   a	  modest	   effect	   on	  Rnq1	   toxicity	   (Table	   C3.1	  &	   Supplemental	  
Figure	   C3.1).	   While	   our	   screen	   did	   not	   identify	   genes	   required	   for	   Rnq1	   toxicity,	   it	  
suggests	   that	   no	   non-­‐essential	   gene,	   aside	   from	   Hsp104	   and	   Rnq1,	   is	   individually	  
required	   for	   the	  maintenance	  of	   the	   [RNQ+]	   prion	   state.	   This	   result	   is	   supported	  by	   a	  
recently	  published	  screen	  that	  used	  [PSI+]	  induction	  as	  a	  readout	  of	  the	  Rnq1	  prion	  state	  
(MANOGARAN,	   et	   al.	   2010).	   In	   addition,	   as	   no	  deletion	   could	   specifically	   abrogate	  Rnq1	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toxicity	   the	   toxicity	   is	   not	  mediated	   by	   a	   Rnq1	  modulated	   gain-­‐of-­‐function	   of	   a	   non-­‐
essential	  gene.	  	  	  
	  
Overexpression	  of	  a	  diverse	  group	  of	  genes	  can	  suppress	  Rnq1	  toxicity	   	  
We	  have	  previously	   shown	   that	   Sis1	  overexpression	   can	  alleviate	  Rnq1	   toxicity	  
by	   facilitating	   amyloid	   formation	   (DOUGLAS,	   et	   al.	   2008).	   Hence,	   we	   screened	   a	   yeast	  
overexpression	   library	   to	   identify	   further	   genes	   that	   modulate	   Rnq1	   toxicity.	   The	  
plasmid-­‐based	   overexpression	   library	   contains	   yeast	   ORFs	   controlled	   by	   the	   inducible	  
GAL1	  promoter	  and	  has	  been	  previously	  used	  to	  identify	  modifiers	  of	  toxicity	  induced	  by	  
expression	   of	   alpha-­‐synuclein	   (COOPER,	   et	   al.	   2006;	   GITLER,	   et	   al.	   2009),	   a	   protein	  
implicated	  in	  Parkinson’s	  disease.	  	  
We	   identified	  20	  putative	  hits	  whose	  overexpression	   suppressed	  Rnq1	   toxicity.	  
Nine	  of	   the	  twenty	  genes	  had	  no	  effect	  on	  GAL1-­‐driven	  YFP	  expression	   (Supplemental	  
Figure	   C3.2),	   showing	   that	   their	   suppression	   of	   Rnq1	   toxicity	   is	   not	   due	   to	   their	  
repression	  of	  GAL1-­‐mediated	  gene	  expression	   (Table	  C3.1).	   The	  Hsp40	  Sis1,	  which	  we	  
had	   identified	   as	   a	   suppressor	   previously	   (DOUGLAS,	   et	   al.	   2008)	   was	   among	   the	   nine	  
validated	   suppressors.	   The	   other	   screen	   hits	   were	  GPG1,	  HRR25,	  MSA1,	  NSP1,	  NVJ1,	  
SPC29,	   THI2	   and	   YNL208w.	   The	   screen	   hit	  GPG1,	   which	   has	   recently	   been	   shown	   to	  
antagonize	   prion	   formation	   (ISHIWATA,	   et	   al.	   2009),	   suppressed	   the	   toxicity	   created	   by	  
Rnq1	  overexpression	  as	  strongly	  as	  SIS1	  (Figure	  C3.1a).	  Overall	  the	  suppressors	  were	  not	  
enriched	   in	   any	   particular	   functional	   categories,	   although	   three	   have	   functions	  
connecting	   them	   loosely	   to	   the	   cell	   cycle	   (HRR25,	  MSA1	  &	  SPC29).	  Notably,	   however,	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the	  suppressors	  were	  enriched	  for	  proteins	  with	  prion	  domains	  (Table	  C3.2)	  (ALBERTI,	  et	  







Deletion	  screen	   KSP1	   Ser/thr	   protein	   kinase;	   nuclear	   translocation	   required	   for	  haploid	  filamentous	  growth	  
	   PML39	   Protein	   required	   for	   nuclear	   retention	   of	   unspliced	   pre-­‐mRNAs	  
	   SPF1	   P-­‐type	   ATPase,	   ion	   transporter	   of	   the	   ER	   membrane	  involved	  in	  ER	  function	  and	  Ca2+	  homeostasis	  
Overexpression	  
screen	  
GPG1	   Proposed	   gamma	   subunit	   of	   the	   heterotrimeric	   G	   protein;	  overproduction	  causes	  prion	  curing	  
	   HRR25	   Protein	   kinase	   involved	   in	   regulating	   diverse	   events	  including	   vesicular	   trafficking,	   DNA	   repair,	   and	  chromosome	  segregation	  
	   MSA1	   Activator	   of	   G1-­‐specific	   transcription	   factors;	   involved	   in	  regulation	  of	  the	  timing	  of	  cell	  cycle	  initiation	  
	   NSP1	   Essential	   component	   of	   the	   nuclear	   pore	   complex,	   which	  mediates	  nuclear	  import	  and	  export	  
	   NVJ1	   Nuclear	   envelope	   protein,	   involved	   in	   nuclear	  microautophagy	  	  
	   SIS1	   Type	  II	  HSP40	  co-­‐chaperone	  that	  interacts	  with	  the	  HSP70	  protein	  Ssa1p	  
	   SPC29	   Inner	  plaque	  spindle	  pole	  body	  (SPB)	  component;	  required	  for	  SPB	  duplication	  
	   THI2	   Zinc	   finger	   protein	   of	   the	   Zn(II)2Cys6	   type,	   probable	  transcriptional	  activator	  of	  thiamine	  biosynthetic	  genes	  
	   YNL208w	   Protein	  of	  unknown	  function	  	  
	  
Table	  C3.1:	  Suppressors	  of	  Rnq1	  toxicity	  identified	  in	  screens	  of	  the	  deletion	  and	  
overexpression	  libraries.	  Functional	  Annotations	  are	  based	  on	  the	  Saccharomyces	  
Genome	  Database.	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  Proteins	  with	  prion-­‐like	  domains	  do	  not	  affect	  Rnq1	  amyloid	  formation	  
Amyloid	  formation	  can	  be	  protective	  and	  overexpression	  of	  proteins	  with	  prion-­‐
like	  domains	  has	  been	  shown	  to	  increase	  the	  induction	  of	  [PSI+]	  (DERKATCH,	  et	  al.	  2001;	  
DERKATCH,	  et	  al.	  2004;	  OSHEROVICH,	  et	  al.	  2001).	  Thus,	  we	  next	  asked	  whether	  the	  genes	  
identified	   as	   overexpression	   suppressors	   of	   Rnq1	   toxicity	   affected	   Rnq1	   amyloid	  
formation.	   We	   used	   semi-­‐denaturing	   agarose	   gels	   to	   analyze	   the	   lysates	   of	   cells	  
expressing	  both	  Rnq1	  and	  individual	  suppressors	  (BAGRIANTSEV,	  et	  al.	  2006;	  HALFMANN,	  et	  
al.	  2008).	  In	  these	  semi-­‐denaturing	  gels,	  the	  detergent-­‐resistant	  amyloid	  species	  formed	  
by	   prion	   proteins	   run	   as	   broad	   high-­‐molecular-­‐weight	   bands.	   Detergent-­‐sensitive	  
species,	  such	  as	  prefibrillar	  oligomers	  and	  disordered	  aggregates,	  are	  dissolved	  and	  run	  
as	  bands	  corresponding	  to	  the	  size	  of	  the	  particular	  protein	  monomer.	  As	  suggested	  by	  
the	   flow	   cytometry	   analysis	   (Supplemental	   Figure	   C3.2),	   by	   standard	   SDS-­‐PAGE	   based	  
western	  blotting	  the	  suppressors	  had	  no	  effect	  on	  levels	  of	  overexpressed	  Rnq1	  (Figure	  
C3.1b).	   Sis1	   overexpression,	   as	   we	   reported	   previously,	   increased	   Rnq1	   amyloid	  
conformation	   (Figure	   C3.1b)	   (DOUGLAS,	   et	   al.	   2008).	   In	   contrast,	   Gpg1	   decreased	   the	  
amount	   of	   amyloid	   and	   increased	   the	   amount	   of	   soluble	   Rnq1.	   The	   suppressors	  with	  
prion-­‐like	  domains,	  Hrr25,	  Nsp1	  and	  YNL208w,	  did	  not	  affect	  Rnq1	  amyloid	   formation	  






Figure	  C3.1:	  Overexpression	  suppressors	  of	  Rnq1	  toxicity.	  	  
(A)	  Strains	  expressing	  individual	  genes	  that	  suppress	  Rnq1	  toxicity	  and	  that	  do	  not	  affect	   GAL1-­‐mediated	   expression	   were	   serially	   diluted	   and	   spotted	   on	   a	   non-­‐inducing	   control	   plate	   and	   an	   inducing	   assay	  plate.	  NAM8,	  which	  decreases	  GAL1-­mediated	  expression,	  served	  as	  a	  positive	  control	  for	  rescue.	  (B)	  SDD-­‐AGE	  analysis	  of	   the	  effect	  of	   the	  OE	  screen	  hits	  on	  Rnq1-­‐YFP	  amyloid	   formation.	  SIS1	   increased	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the	   formation	   of	   SDS-­‐resistant	   Rnq1-­‐YFP	   species;	   GPG1	   decreased	   it.	   Rnq1-­‐YFP	  expression	   levels	   were	   examined	   in	   the	   same	   samples	   by	   standard	   SDS-­‐PAGE,	  followed	  by	  western	  blot	  analysis.	  We	  probed	  for	  the	  housekeeping	  protein	  Pgk1	  to	  ensure	  equal	  sample	  loading.	  	  Samples	  were	  induced	  for	  six	  hours.	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Suppressors	  with	  prion-­‐like	  domains	  co-­‐localize	  with	  Rnq1	  inclusions	  
Next,	  we	  asked	  if	  the	  suppressors	  alter	  Rnq1	  toxicity	  by	  direct	  associations	  with	  
Rnq1.	  We	   created	   C-­‐terminal	   cerulean	   fusions	   of	   the	   screen	   hits	   and	   examined	   their	  
localization	  with	  respect	  to	  the	  Rnq1-­‐YFP	  fusion.	  GAL1-­‐mediated	  Rnq1-­‐YFP	  expression	  in	  
a	  [RNQ+]	  background	  results	  in	  the	  formation	  of	  a	  single	  focus	  proximal	  to	  the	  vacuole,	  
consistent	  with	  localization	  to	  the	  IPOD	  compartment	  (KAGANOVICH,	  et	  al.	  2008).	  Sis1,	  as	  
expected	   based	   on	   its	   tight	   interaction	  with	   [RNQ+]	   species	   (SONDHEIMER,	   et	   al.	   2001),	  
localized	   to	   Rnq1-­‐YFP	   inclusions	   (Figure	   C3.2a).	   Gpg1,	   which	   lacks	   prion-­‐like	  
characteristics,	   was	   found	   in	   very	   small	   foci	   that	   partially	   co-­‐localized	   with	   Rnq1-­‐YFP	  
deposits	   (Figure	   C3.2a).	   The	   formation	   of	   these	   Gpg1	   foci	   also	   occurred	   in	   a	   [rnq-­‐]	  
background	  and	  as	  such	  was	  independent	  of	  Rnq1	  amyloid	  formation	  (data	  not	  shown).	  
Suppressors	  without	  prion-­‐like	  domains,	  aside	   from	  Sis1	  and	  Gpg1,	  did	  not	   co-­‐localize	  
with	  Rnq1-­‐YFP	  deposits.	  The	  suppressors	  containing	  prion-­‐like	  domains	  co-­‐localized	  with	  
the	   Rnq1-­‐YFP	   inclusions	   (Figure	   C3.2b).	   In	   contrast	   to	   Ggp1,	   the	   localization	   of	  
suppressors	   of	  with	   prion-­‐like	   domains	   to	   an	   inclusion	  was	   dependent	   on	   the	   [RNQ+]	  
prion,	  as	  they	  displayed	  diffuse	  fluorescence	  in	  a	  [rnq-­‐]	  background	  (Table	  C3.2).	  These	  
results	   suggest	   that	  proteins	  with	  prion	  domains	   suppress	  Rnq1	   toxicity	  by	   interacting	  
with	  Rnq1	  and	  preventing	  it	  from	  making	  other	  toxic	  interactions.	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Figure	  C3.2:	  Co-­‐localization	  of	  OE	  screen	  hits	  with	  Rnq1.	  	  
(A)	  We	  tested	   if	  Sis1	  and	  Gpg1,	  which	  both	  affect	  Rnq1	  amyloid	  formation,	  co-­‐localize	  
with	   Rnq1-­‐YFP	   inclusion.	   Co-­‐localization	  was	   assayed	   using	   N-­‐terminal	   Cerulean	   Gpg1	  
and	   Sis1	   fusions	   in	   conjunction	   with	   Rnq1-­‐YFP.	   Sis1	   co-­‐localizes	   very	   well	   with	   Rnq1.	  
Gpg1	  forms	  small	  foci,	  in	  both	  [RNQ+]	  and	  [rnq-­‐]	  strain	  backgrounds,	  which	  partially	  co-­‐
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localize	  with	  Rnq1.	  (B)	  Next,	  we	  examined	  the	  localization	  of	  the	  remaining	  screen	  hits	  
including	  the	  screen	  hits	  containing	  prion	  domains.	  OE	  screen	  hits	  with	  prion	  domains,	  
Hrr25,	  Nsp1	  and	  YNL208w,	   co-­‐localized	  with	  Rnq1.	   Screen	  hits	  without	  prion	  domains	  
did	  not	  co-­‐localize	  with	  Rnq1-­‐YFP	  inclusions.	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Screen	  hit	   Contains	  prion	  
domain	  
Co-­‐localization	  with	  Rnq-­‐
YFP	  in	  [RNQ+]	  
Foci	  formation	  in	  
[rnq-­‐]	  cells	  
KSP1	   +	   -­‐	   -­‐	  
PML39	   -­‐	   -­‐	   -­‐	  
SPF1	   -­‐	   -­‐	   -­‐	  
GPG1	   -­‐	   +	   +	  
HRR25	   +	   +	   -­‐	  
MSA1	   -­‐	   -­‐	   -­‐	  
NSP1	   +	   +	   -­‐	  
NVJ1	   -­‐	   -­‐	   -­‐	  
SIS1	   -­‐	   +	   -­‐	  
SPC29	   -­‐	   -­‐	   -­‐	  
THI2	   -­‐	   -­‐	   -­‐	  
YNL208w	   +	   +	   -­‐	  
	  
Table	  C3.2:	  Overexpression	   screen	  hits	  with	  prion-­‐like	  domains	   co-­‐localize	  with	  Rnq1-­‐
YFP	  aggregates.	  Four	  of	  the	  hits	  from	  the	  deletion	  and	  overexpression	  screens	  contain	  
prion	  domains.	  The	  three	  proteins	  with	  prion	  domains	  identified	  in	  the	  overexpression	  
screen,	  Hrr25,	  Nsp1	  and	  Ynl208w,	  co-­‐localized	  with	  Rnq1	  inclusions.	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Rnq1	  toxicity	  results	  in	  down-­‐regulation	  of	  cytokinetic	  genes	  
	   Next,	  we	  performed	  microarray-­‐based	  gene	  expression	  analysis	  to	  elucidate	  the	  
transcriptional	  response	  triggered	  by	  Rnq1	  toxicity.	  As	  Rnq1	  overexpression	  is	  toxic	  in	  a	  
[RNQ+]	  background,	  but	  shows	  no	  effect	  in	  a	  [rnq-­‐]	  background,	  we	  analyzed	  the	  effect	  
of	  Rnq1	  overexpression	  on	  gene	  expression	  in	  two	  isogenic	  strains	  that	  differed	  solely	  in	  
their	  Rnq1	  prion	  state.	  We	  expressed	  Rnq1	  from	  a	  single	  copy	  plasmid	  under	  control	  of	  
the	  GAL1	  promoter	   in	   the	   [RNQ+]	  and	   [rnq-­‐]	  backgrounds	   for	   four,	   six	  and	  eight	  hours	  
before	  harvesting	  the	  cells	  and	  isolating	  their	  RNA.	  	  
Interestingly,	   only	   a	   few	   genes	  were	   differentially	   expressed	   between	   the	   two	  
strains	  (Supplemental	  Table	  C3.1).	  As	  might	  be	  expected,	  Rnq1	  overexpression	  resulted	  
in	   the	   elevated	   transcription	   of	   several	   chaperones	   and	   stress	   related	   proteins	   (Table	  
C3.3),	   but	   did	   not	   trigger	   a	   complete	   heat	   shock	   response.	   In	   addition	   to	   chaperones	  
known	  to	   influence	  yeast	  prion	  amyloid	  formation,	  GPG1	  and	  BTN2	  were	  up-­‐regulated	  
upon	  Rnq1	  toxicity	  (Supplemental	  Table	  C3.1).	  As	  mentioned	  and	  in	  part	  shown	  above,	  
Gpg1	  overexpression	  can	  antagonize	  amyloid	  formation	  (ISHIWATA,	  et	  al.	  2009).	  Similarly,	  
Btn2	   overexpression	   has	   been	   shown	   to	   counteract	   inheritance	   of	   [URE3],	   the	   prion	  
form	  of	  Ure2,	  and	  to	  co-­‐localize	  with	  both	  Sup35	  and	  Rnq1	  prion	  deposits	  (KRYNDUSHKIN,	  
et	  al.	  2008).	  	  	  
	  While	  the	  genes	  up-­‐regulated	  in	  response	  to	  Rnq1	  toxicity	  indicate	  a	  response	  to	  
protein	   folding	   stress,	   a	   large	   fraction	   of	   down-­‐regulated	   genes	   is	   involved	   in	  
cytokinesis.	   Together	   with	   the	   fact	   that	   several	   suppressors	   have	   cellular	   functions	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related	  to	  the	  cell	  cycle,	  this	  suggests	  that	  Rnq1	  toxicity	  maybe	  related	  to	  a	  defect	  in	  cell	  





Categories	  of	  genes	  changed	  2-­‐fold	  upon	  Rnq1	  overexpression	  




frequency	   P-­‐value	   Gene(s)	  








4/13,	  30.8%	   11/7167,	  0.2%	   4.90E-­‐08	   CTS1,	  DSE2,	  DSE4,	  
SCW11	  








5/27,	  18.5%	   11/7167,	  0.2%	   1.98E-­‐08	   CTS1,	  DSE1,	  DSE2,	  
DSE4,	  SCW11	  




Table	  C3.3:	  Categories	  of	  genes	  changed	  2-­‐fold	  upon	  Rnq1	  overexpression.	  	  
Genes	   that	  changed	  more	   than	  2-­‐fold	   in	   the	   [RNQ+]	   strain	   in	  comparison	   to	   the	   [rnq-­‐]	  
strain	  were	  analyzed	  for	  GO-­‐term	  enrichment.	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Rnq1	  overexpression	  causes	  cell	  cycle	  arrest	  in	  mitosis	  
Based	  on	  the	  gene	  expression	  data,	  we	  next	  tested	  whether	  Rnq1	  toxicity	  caused	  
defects	   in	  cell	  cycle	  progression.	  When	  Rnq1	  was	  overexpressed	  for	  eight	  hours	   in	  the	  
[RNQ+]	   background,	  many	   cells	   arrested	  with	   large	   buds,	   i.e.	   presented	   as	   dumbbell-­‐
shaped	  cells	  (Figure	  C3.3a),	  indicative	  of	  a	  cell	  cycle	  arrest	  (HARDWICK	  1998;	  NYBERG,	  et	  al.	  
2002).	   To	   define	   the	   precise	   arrest	   point	   we	   next	  measured	   DNA	   content	   using	   flow	  
cytometry.	   Switching	  mid-­‐log	   cultures	   from	   non-­‐inducing	   raffinose	  media	   to	   inducing	  
galactose	  media	  had	  the	  effect	  of	  roughly	  synchronizing	  the	  cultures	   in	  G1	  as	  the	  cells	  
adjusted	   to	   the	   new	   carbon	   source.	   In	   contrast	   to	   [rnq-­‐]	   cultures,	   [RNQ+]	   cultures	  
overexpressing	   Rnq1	   became	   enriched	   in	   cells	   with	   2N	   DNA	   content	   (Figure	   C3.3b	   &	  
Supplemental	  Table	  C3.2).	  We	  further	  delineated	  the	  Rnq1	  induced	  arrest	  by	  examining	  
cells	   carrying	  a	  Hof1-­‐GFP	   fusion.	  Hof1,	  which	   regulates	   actomyosin	   ring	  dynamics	   and	  
septin	  localization,	  is	  specifically	  degraded	  at	  the	  end	  of	  mitosis	  (BLONDEL,	  et	  al.	  2005).	  In	  
cells	  arrested	  due	   to	  overexpression	  of	  Rnq1,	  Hof1-­‐GFP	  accumulated	  at	   the	  bud	  neck,	  




Figure	  C3.3:	  Rnq1	  overexpression	  induces	  a	  MAD2-­‐dependent	  cell	  cycle	  arrest.	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(A)	   Rnq1	   overexpression	   in	   a	   [RNQ+]	   background	   results	   in	   a	   cell-­‐cycle	   arrest	   at	   the	  
G2/M	  transition,	  i.e.	  cells	  arrest	  just	  prior	  to	  cytokinesis	  and	  take	  on	  a	  dumbbell	  shape.	  
Deletion	   of	   RAD9,	   component	   of	   the	   DNA	   damage	   checkpoint,	   has	   no	   effect	   on	   the	  
Rnq1-­‐induced	   arrest.	   On	   the	   contrary,	   deletion	   of	  MAD2,	   component	   of	   the	   spindle	  
checkpoint,	  allows	  cells	  to	  “escape”	  arrest	  and	  to	  start	  rebudding.	  Arrowheads	  indicate	  
rebudded	  cells.	  
(B)	   Cell	   cycle	   profiles	   of	   cells	   overexpressing	   Rnq1	   reveal	   that	   Rnq1	   toxicity	   coincides	  
with	   an	   increase	   in	   cells	  with	   2N	  DNA	   content	   beginning	   at	   4h	   post	   induction.	   In	   the	  
MAD2	  deletion	  the	  right-­‐hand	  shoulder	  of	  the	  2N	  peak	  is	  considerably	  extended	  at	  6h.	  
This	  is	  indicative	  of	  cells	  being	  able	  to	  “escape”	  arrest	  and	  to	  rebud.	  	  
(C)	   Hof1p	   facilitates	   cytokinesis	   and	   is	   degraded	   once	   cytokinesis	   is	   completed.	   Cells	  
arrested	  due	  to	  Rnq1	  overexpression	  accumulate	  Hof1	  (bottom	  panel),	  detected	  using	  a	  
Hof1-­‐GFP	  fusion,	  illustrating	  that	  these	  cells	  arrested	  just	  prior	  to	  cytokinesis.	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A	   large	  budded	  cell	  cycle	  arrest	  can	  be	  triggered	  by	  either	  DNA	  damage	  or	   the	  
spindle	  checkpoint.	  To	  determine	  which	  of	  these	  two	  cell	  cycle	  phenomena	  contributes	  
to	  the	  Rnq1-­‐induced	  arrest,	  we	  examined	  gene	  Rnq1	  toxicity	  in	  strains	  deleted	  for	  either	  
the	   DNA	   damage,	   rad9Δ	   (WEINERT,	   et	   al.	   1988),	   or	   the	   spindle	   checkpoint,	   mad2Δ	  
(HARDWICK,	  et	  al.	  1999),	  were	  abrogated.	  In	  the	  absence	  of	  damage	  to	  DNA	  or	  the	  spindle	  
apparatus,	   deletion	   of	   these	   two	   genes	   has	   no	   effect	   on	   cell	   cycle	   progression.	  
Overexpression	  of	  Rnq1	  in	  rad9Δ	  cells	  resulted	  in	  the	  accumulation	  of	  dumbbell-­‐shaped	  
cells	   (Figure	  C3.3a)	  and	  DNA-­‐content	  profiles	   identical	   to	   the	  ones	  observed	  with	  wild	  
type	   [RNQ+]	   cells	   (Figure	  C3.3b).	   In	   contrast,	  mad2Δ	  cells	   revealed	  an	   increase	   in	   cells	  
with	  a	  DNA	  content	  higher	  than	  2N	  (Figure	  C3.3b).	  Light	  microscopy	  showed	  that	  many	  
of	  the	  mad2Δ	  cells	  arrested	  upon	  Rnq1	  overexpression	  had	  begun	  to	  rebud.	  In	  wild	  type	  
[RNQ+]	  cells,	  only	  8.6%	  (STDev	  2.6)	  of	  arrested	  cells	  began	  rebud,	  while	  in	  mad2Δ	  cells,	  
22.4%	   (STDev	   2.7)	   formed	   additional	   buds.	   This	   indicates	   that	   Rnq1	   overexpression	  
specifically	   triggers	   the	   spindle	   checkpoint	   that	   then	  mediates	   the	  observed	   cell	   cycle	  
arrest.	  	  
	  
Rnq1	  toxicity	  results	  in	  arrest	  with	  a	  monopolar	  spindle	  
To	   elucidate	   how	   Rnq1	   triggers	   the	   spindle	   checkpoint,	   we	   assessed	   spindle	  
formation	   by	   immuno-­‐staining	   cells	   overexpressing	   Rnq1	   for	   tubulin.	   [rnq-­‐]	   cells	  
displayed	  a	  range	  of	  spindle	  morphologies	  as	  expected	  for	  unsynchronized	  cells	  dividing	  
normally	   (Figure	  C3.4a).	   In	   contrast,	   [RNQ+]	   cells	   that	  had	  arrested	  due	   to	  Rnq1	  over-­‐
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expression	  showed	  an	  aster	  of	  microtubules	  localized	  proximal	  to	  the	  bud	  neck	  (Figure	  
C3.4a).	  	  This	  is	  indicative	  of	  cells	  arresting	  with	  a	  monopolar	  spindle.	  	  
The	   spindle	   pole	   body	   (SPB)	   is	   the	  microtubule	   organizing	   center	   (MTOC),	   the	  
budding	   yeast	   equivalent	   of	   the	   centrosome	   (JASPERSEN,	   et	   al.	   2004).	   A	   monopolar	  
spindle	   can	   be	   caused	   by	   a	   defect	   in	   SPB	   duplication	   or	   a	   failure	   in	   separation	   after	  
duplication	  (JASPERSEN,	  et	  al.	  2004).	  The	  SPB	  spans	  the	  nuclear	  envelope	  and	  is	  duplicated	  
during	   the	  G1	   phase	   of	   the	   cell	   cycle.	  While	   duplication	   itself	   occurs	   early	   in	   the	   cell	  
cycle,	  defects	   in	  duplication	  are	  not	  detected	  until	   the	  absence	  of	  a	   functional	  bipolar	  
spindle	  triggers	  the	  spindle	  checkpoint	  (JASPERSEN,	  et	  al.	  2004).	  
We	   used	   cryo	   electron	   microscopy	   (EM)	   to	   determine	   if	   the	   arrest	   with	   a	  
monopolar	  spindle	  was	  caused	  by	  a	  failure	  in	  SPB	  duplication	  or	  in	  the	  separation	  of	  the	  
duplicated	  SPBs.	  Cells	  overexpressing	  Rnq1,	  whose	  endogenous	  protein	  was	  in	  the	  [rnq-­‐]	  
conformation	  developed	  regular	  elongated	  spindles	   (Figure	  C3.4b).	   In	  contrast,	   [RNQ+]	  
cells	   contained	  microtubule	   asters	   originating	   from	   a	   single	   unduplicated	   SPB	   (Figure	  
C3.4b).	   This	   suggests	   that	   Rnq1	   toxicity	   impedes	   SPB	   duplication,	   potentially	   by	  
sequestration	  of	  SPB	  components	  or	  aberrant	  interaction	  with	  the	  duplicating	  SPB	  itself.	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Figure	  C3.4:	  Rnq1	  toxicity	  results	  in	  arrest	  with	  a	  monopolar	  spindle.	  	  
(A)	  Tubulin	  immunostaining	  of	  cells	  overexpressing	  Rnq1	  reveals	  that	  [rnq-­‐]	  cells	  formed	  
regular	  spindles,	  whereas	  [RNQ+]	  cells	  arrested	  with	  a	  monopolar	  spindle.	  	  
(B)	  Cryo	  electron	  microscopy	  revealed	  that	   [RNQ+]	  cells	  arrested	  with	  an	  unduplicated	  
spindle	  pole	  body.	  Arrowheads	  indicate	  spindle	  pole	  bodies.	  The	  observed	  spindle	  pole	  
body	  morphologies	  were	  consistent	  with	  those	  previously	  observed	  for	  mutants	  of	  the	  
core	  spindle	  body	  component	  Spc42.	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Rnq1	  overexpression	  causes	  mislocalization	  of	  Spc42	  
	  	   Architecturally,	   the	   SPB	   consists	   of	   three	   plaques:	   an	   outer	   plaque	   facing	   the	  
cytoplasm,	  a	  central	  plaque	  spanning	  the	  nuclear	  membrane,	  and	  an	  inner	  plaque	  facing	  
the	  nucleoplasm	  (JASPERSEN,	  et	  al.	  2004).	  We	  examined	  the	   localization	  of	  spindle	  body	  
components	  belonging	   to	  each	  of	   these	  structural	  elements	  using	  strains	   in	  which	   the	  
endogenous	   genes	   were	   GFP-­‐tagged	   (HOWSON,	   et	   al.	   2005):	   The	   outer	   plaque	  
components	   Cnm67,	  Nud1	   and	   Spc72;	   the	   inner	   and	   outer	   plaque	   component	   Spc97;	  
and	  the	  central	  plaque	  components	  Spc29,	  Spc42	  and	  Spc110	  (JASPERSEN,	  et	  al.	  2004).	  In	  
[rnq-­‐]	   cells,	   these	   proteins	   localized	   to	   two	   bright	   foci	   representing	   the	   properly	  
duplicated	  spindle	  pole	  bodies	  (see	  Figure	  C3.5b).	  In	  arrested	  [RNQ+]	  cells,	  most	  of	  the	  
SPB	   components	   localized	   to	   a	   single	   focus,	   the	   unduplicated	   SPB.	   In	   contrast,	   Spc42	  
localized	  to	  the	  unduplicated	  SPB	  and	  also	  localized	  to	  a	  separate	  fainter	  deposit	  within	  
the	  mother	  cell	  (Figure	  C3.5a).	  	  
The	  faint	  deposit	  formed	  by	  Spc42	  was	  reminiscent	  of	  prion	  protein	  aggregates	  
deposited	   at	   the	   IPOD	   (TYEDMERS,	   et	   al.	   2010)	   suggesting	   that	   Spc42	   localized	   to	   the	  
inclusion	  formed	  by	  Rnq1.	  We	  tested	  for	  Rnq1::Spc42	  co-­‐localization	  using	  a	  mCherry-­‐
tagged	   Rnq1	   construct	   in	   combination	   with	   the	   Spc42-­‐GFP	   fusion	   strain.	   The	   Rnq1-­‐
mCherry	   fusion	  was	  still	   able	   to	   induce	  arrest	   in	   [RNQ+]	   cells	  and,	   indeed,	  co-­‐localized	  
with	  Spc42	  deposits	  in	  the	  arrested	  cells	  (Figure	  C3.5b).	  We	  also	  asked	  if	  Rnq1-­‐mCherry	  
co-­‐localized	  with	   other	   SPB	   components	   and	   found	   that	   only	   Spc42	   co-­‐localized	  with	  
Rnq1	  (Figure	  C3.5b)	  indicating	  that	  the	  effect	  of	  Rnq1	  is	  specific	  to	  Spc42.	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Spc42	   is	   a	   highly	   phosphorylated	   coiled	   coil	   protein	   that	   is	   assembled	   into	   a	  
crystal-­‐like	   structure	   at	   the	   core	   of	   the	   SPB	   (BULLITT,	   et	   al.	   1997).	   Interestingly,	   the	  
macrostructure	   of	   Spc42	   is	   reminiscent	   of	   the	   highly	   organized	   structure	   of	   amyloid	  
fibers.	  However,	   it	   is	  unlikely	  that	  the	  interaction	  of	  Rnq1	  and	  Spc42	  is	  amyloid	  based.	  
We	   have	   previously	   shown	   that	   the	   Rnq1	   mutant	   L94A	   can	   induce	   toxicity	   in	   the	  
absence	   of	   the	   [RNQ+]	   prion	   state	   and	   without	   the	   formation	   of	   amyloid	   species	  
(DOUGLAS,	  et	  al.	  2008).	  We	  tested	  the	  effect	  of	  the	  Rnq1	  L94A	  mutant	  and	  found	  that	  it	  
also	   induced	   cell	   cycle	   arrest	   and	  Spc42	  mislocalization	   in	   a	   [rnq-­‐]	   background	   (Figure	  
C3.5c).	   Hence,	   non-­‐amyloid	   assemblies	   of	   Rnq1	   caused	   cytotoxicity	   by	   inducing	   the	  
mislocalization	  of	  Spc42.	  	  
	  
Elevated	  expression	  of	  Spc42	  suppresses	  Rnq1	  toxicity	  
The	   highly	   specific	   mislocalization	   of	   Spc42	   that	   is	   produced	   by	   Rnq1	   over-­‐
expression	   provides	   a	   logical	   explanation	   for	   the	   Rnq1-­‐induced	   defect	   in	   SPB	  
duplication.	  Indeed,	  the	  morphologies	  of	  the	  unduplicated	  spindle	  pole	  bodies	  in	  Rnq1	  
arrested	  cells	  observed	  by	  EM	  were	  strikingly	  similar	  to	  those	  seen	   in	  cells	  with	  Spc42	  
mutations	  (Figure	  C3.4b)	  (DONALDSON,	  et	  al.	  1996).	  Furthermore,	  as	  described	  above	  the	  
SPB	   component	   Spc29	   was	   one	   of	   the	   overexpression	   suppressors	   identified	   in	   our	  
screen.	   Spc29	   directly	   interacts	   with	   Spc42	   in	   the	   central	   plaque	   of	   the	   SPB	   and	   is	  
thought	  to	  recruit	  Spc42	  during	  SPB	  duplication	  (ADAMS,	  et	  al.	  1999;	  ELLIOTT,	  et	  al.	  1999).	  
Spc29	   overexpression	   likely	   counteracts	   the	   ability	   of	   Rnq1	   to	   misdirect	   Spc42	   by	  
directing	  it	  to	  its	  proper	  localization.	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SPC42	   itself	   was	   not	   part	   of	   the	   library	   used	   for	   our	   overexpression	   screen	  
(which	  encompassed	  ~90%	  of	   the	  known	  yeast	  ORFs).	  Regardless,	  we	  would	  not	  have	  
identified	   Spc42	   as	   a	   suppressor	   as	   its	   overexpression	   using	   the	   GAL1	   promoter	   is	  
profoundly	  toxic	  on	  its	  own	  (DONALDSON,	  et	  al.	  1996).	  Therefore,	  as	  a	  final	  test	  of	  the	  root	  
cause	  of	   Rnq1	   toxicity,	  we	   cloned	   Spc42	   and	  expressed	   it	   and	  other	   SPB	   components	  
under	   the	   control	   of	   the	   constitutive	   SUP35	   promoter,	   which	   produces	   a	   more	  
moderate	   level	   of	   overexpression.	   When	   expressed	   from	   the	   same	   promoter,	   Spc29	  	  
partially	  restored	  cell	  growth.	  Expression	  of	  other	  SPB	  components,	  including	  Spc72	  and	  
Spc97,	  had	  no	  effect.	  Expression	  of	  Spc42,	  however,	  strongly	  suppressed	  toxicity	  (Figure	  
C3.6).	  Therefore,	  Rnq1	  overexpression	  in	  [RNQ+]	  cells	  causes	  a	  mis-­‐localization	  of	  Spc42	  
to	   Rnq1	   non-­‐amyloid	   inclusions	   thereby	   diminishing	   the	   amount	   of	   soluble	   Spc42	  
needed	  for	  SPB	  duplication	  and	  causing	  a	  cell	  cycle	  arrest.	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Figure	  C3.5:	  Rnq1	  overexpression	  induces	  mislocalization	  of	  Spc42	  to	  inclusions.	  	  
(A)	   We	   examined	   how	   Rnq1	   overexpression	   affected	   the	   localization	   of	   Spc42-­‐GFP.	  
While	  Spc42-­‐GFP	   in	  control	  cells	   is	   found	   in	  one	  or	   two	  small	  bright	   foci,	   representing	  
individual	  spindle	  pole	  bodies,	  it	  was	  found	  in	  one	  small	  bright	  focus	  and	  a	  larger	  fainter	  
inclusion	  in	  cells	  subject	  to	  Rnq1	  toxicity.	  	  
(B)	  Next,	  we	  asked	  if	  the	  faint	  Spc42-­‐GFP	  deposits	  found	  in	  Rnq1	  overexpressing	  prion-­‐
plus	   cells	   coincided	   with	   Rnq1	   inclusions.	   We	   induced	   Rnq1	   toxicity	   using	   a	   Rnq1-­‐
mCherry	   fusion	  and	  found	  that	  Spc42-­‐GFP	   localized	  to	  the	   inclusions	   formed	  by	  Rnq1-­‐
mCherry.	  This	  Rnq1	   induced	  change	   in	   localization	  appears	   to	  be	   specific	   to	  Spc42,	  as	  
other	  spindle	  body	  components	  (Spc29,	  Spc72	  and	  Spc97)	  did	  not	  co-­‐localize	  with	  Rnq1.	  	  
(C)	  Overexpression	  of	  the	  Rnq1	  L94A	  mutant	  causes	  Spc42	  mislocalization	  and	  cell	  cycle	  
arrest.	   The	   Rnq1	  mutant	   L94A	   is	   toxic	   even	   in	   prion-­‐minus	   cells,	  where	   it	   forms	   non-­‐
amyloid	   aggregates	   (DOUGLAS,	   et	   al.	   2008).	   The	   Rnq1	   L94A	   mutant	   caused	   Spc42	  
mislocalization	   and	   the	   formation	   of	   dumbbell-­‐shaped	   cells	   in	   both	   [rnq-­‐]	   and	   [RNQ+]	  




Figure	  C3.6:	  Elevated	  expression	  of	  Spc42	  can	  suppress	  Rnq1	  toxicity.	  	  
Moderate	  overexpression	  of	  Spc42	  completely	  suppressed	  Rnq1	  toxicity.	  Ectopic	  Spc72	  
and	  Spc97	  expression	  had	  no	  effect	  on	  Rnq1	  toxicity.	  Spc29,	  one	  of	  the	  OE	  screen	  hits,	  
partially	  suppressed	  toxicity.	  Spc29	  recruits	  Spc42	  to	  the	  duplicating	  spindle	  pole	  body	  
and	  likely	  can	  counteract	  the	  mislocalization	  of	  Spc42	  induced	  by	  Rnq1.	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Discussion	  
Cells	   constantly	   struggle	   to	  maintain	   protein	   homeostasis,	   targeting	  misfolded	  
proteins	  for	  chaperone-­‐mediated	  refolding,	  proteasomal	  degradation	  or	  inclusion	  body	  
formation	  (ROSS,	  et	  al.	  2005).	  The	  formation	  of	  inclusions	  appears	  to	  present	  the	  last	  line	  
in	   the	   cellular	   defense	   against	   proteotoxicity	   as	   inclusions	   such	   as	   aggresomes	   form	  
once	  proteasomal	  capacity	  has	  been	  exceeded	  (JOHNSTON,	  et	  al.	  1998;	  KAGANOVICH,	  et	  al.	  
2008).	  Aggresomes	  are	  actively	  formed	  near	  the	  centrosome	  through	  dynein-­‐dependent	  
retrograde	   transport	   of	   protein	   aggregates	   along	   microtubules	   (GARCIA-­‐MATA,	   et	   al.	  
1999;	   JOHNSTON,	  et	  al.	  2002;	   JOHNSTON,	  et	  al.	  1998).	   Inclusion	  body	   formation	  serves	   to	  
“sweep”	   the	  cytoplasm	  of	  potentially	   toxic	  misfolded	  protein	  species	  preventing	   them	  
from	  aberrantly	  interacting	  with	  other	  proteins	  	  (KOPITO	  2000)	  and	  also	  appears	  to	  play	  
an	   important	   role	   in	   facilitating	   the	  asymmetric	   inheritance	  of	  protein	  damage	  during	  
cell	  division	  (FUENTEALBA,	  et	  al.	  2008;	  RUJANO,	  et	  al.	  2006).	  
	  In	   yeast,	   misfolded	   proteins	   accumulate	   at	   two	   distinct	   sites.	   Ubiquitinated	  
proteins	   are	   targeted	   to	   a	   juxtanuclear	   quality	   control	   compartment,	   termed	   JNQ,	  
whereas	  amyloidogenic	  proteins	  are	  target	  to	  the	  IPOD	  (KAGANOVICH,	  et	  al.	  2008).	  Both	  
compartments	   have	   features	   of	   aggresomes,	   but	   the	   IPOD	   has	   been	   likened	   to	  
aggresomes	  as	  protein	  targeting	  to	  this	  structure	  is	  mediated	  by	  the	  actin	  cytoskeleton	  
(GANUSOVA,	   et	   al.	   2006)	   and	   the	   IPOD	   plays	   a	   role	   in	   the	   asymmetric	   inheritance	   of	  
amyloidogenic	  proteins	  (KRYNDUSHKIN,	  et	  al.	  2008;	  TYEDMERS,	  et	  al.	  2010).	  Yet,	  aggresomes	  
form	  in	  proximity	  to	  centrosomes,	  the	  mammalian	  MTOC,	  and	  no	  link	  between	  the	  IPOD	  
and	  the	  SPB	  had	  been	  reported	  (MATHUR,	  et	  al.	  2010).	  A	  fragment	  of	  mutant	  huntingtin	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exon	   1,	   103QP,	   has	   been	   shown	   to	   co-­‐localize	   with	   the	   yeast	   SPB	   and	   to	   form	   an	  
aggresome-­‐like	  structure	  (WANG,	  et	  al.	  2009),	  but	  no	  connection	  between	  the	  IPOD	  and	  
the	  SPB	  was	  observed.	  	  
We	  used	  the	   intrinsically	  disordered	  and	  amyloidogenic	  protein	  Rnq1	  to	  model	  
gain-­‐of-­‐function	  proteotoxicity	   in	  yeast.	  Rnq1	   toxicity	   resulted	   in	  a	  down-­‐regulation	  of	  
genes	   involved	   in	   cytokinesis	   and	   subsequent	   experiments	   showed	   that	   Rnq1	   toxicity	  
resulted	   in	   a	   Mad2-­‐dependent	   cell	   cylce	   arrest.	   [RNQ+]	   cells	   overexpressing	   Rnq1	  
arrested	   with	   a	   monopolar	   spindle	   and	   an	   unduplicated	   SPB.	   We	   found	   that	   Rnq1	  
induced	   mis-­‐localization	   of	   the	   core	   SPB	   component	   Spc42	   to	   the	   IPOD.	   Moderate	  
overexpression	   of	   Spc42	   and	   the	   overexpression	   screen	   hit	   Spc29	   counteracted	   the	  
defect	   induced	  by	  Rnq1.	   The	   interaction	   of	   Rnq1	  of	   Spc42	   is	   not	   amyloud	  based	   as	   a	  
Rnq1	  mutant	   capable	   of	   forming	   non-­‐amyloid	   aggregates	   in	   a	   [rnq-­‐]	   background	   also	  
resulted	   in	   the	   toxic	  mislocalization	   of	   Spc42.	   Consequently,	   non-­‐amyloid	   aggregates,	  
which	   may	   associate	   with	   amyloid	   species	   at	   the	   IPOD	   in	   [RNQ+]	   cells,	   are	   the	  
proteotoxic	   species	   in	   the	   case	   of	   Rnq1	   (Figure	   C3.7).	   Our	   findings	   represent	   a	   novel	  
connection	   between	   centrosome-­‐associated	   aggresomes	   and	   their	   apparent	   yeast-­‐
equivalent,	   the	   IPOD.	   Especially,	   as	  Rnq1	  has	  been	   shown	   to	   affect	   targeting	  of	  other	  
amyloidogenic	  or	  damaged	  proteins	  to	  the	  IPOD	  (DERKATCH,	  et	  al.	  2000;	  TYEDMERS,	  et	  al.	  
2010).	  	  
It	  appears	  that	  MTOCs,	  centrosomes	  and	  SPBs,	  play	  a	  role	  in	  the	  sensing	  and	  the	  
subsequent	   asymmetric	   inheritance	   of	   protein	   damage.	   Centrosome–associated	  
aggresomes	   did	   not	   affect	   mitotic	   cell	   division,	   yet	   the	   presence	   of	   multiple	   non-­‐
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aggresomal	  inclusions	  strongly	  impaired	  mitosis	  (RUJANO,	  et	  al.	  2006).	  Furthermore,	  heat	  
shock	   induces	   the	   aggresome-­‐like	   deposition	   of	   protein	   aggregates	   at	   centrosomes	  
(BARRAU,	  et	  al.	  1978;	  VIDAIR,	  et	  al.	  1996)	  and	  causes	  defects	  in	  cell	  cycle	  progression	  (HUT,	  
et	   al.	   2005).	   Similarly,	  mutants	   of	   heat	   shock	   factor	   1,	  which	   coordinates	   the	   cellular	  
response	   to	   heat	   stress,	   result	   in	   a	   G2/M	   arrest	   and	   defects	   in	   SPB	   duplication	   at	  
elevated	  temperatures	   (MORANO,	  et	  al.	  1999;	  ZARZOV,	  et	  al.	  1997).	  As	  centrosomes	  and	  
SPBs	  are	  themselves	  asymmetrically	  inherited	  (MACARA,	  et	  al.	  2008)	  they	  could	  facilitate	  
the	   asymmetric	   inheritance	   of	   associated	   protein	   inclusions.	   Furthermore,	   excessive	  
protein	  damage,	  such	  as	  heat	  shock	  or	  Rnq1	  overexpression,	  may	  interfere	  with	  MTOC	  
function	  to	  ensure	  that	  mitosis	  does	  not	  proceed	  before	  the	  asymmetric	  inheritance	  of	  
the	  protein	  damage	  in	  question	  is	  secured.	  	  
Overexpression	  of	  Rnq1	  certainly	  represents	  an	  extreme	  case	  of	  proteotoxicity,	  
especially	  as	  cells	  generally	  cannot	  overcome	  the	  defect	  in	  SPB	  duplication	  that	  it	  elicits	  
(CHIAL,	  et	  al.	  1999;	  JASPERSEN,	  et	  al.	  2004).	  We	  tested	  if	  Spc42	  localization	  was	  affected	  by	  
other	  proteotoxic	  stresses	  such	  as	  heat	  shock	  or	  growth	  in	  the	  presence	  of	  menadione	  
or	  paraquat	  (AGUILANIU,	  et	  al.	  2003;	  TYEDMERS,	  et	  al.	  2010).	  Although	  these	  conditions	  did	  
to	  some	  extent	  result	  in	  cell	  cycle	  arrests	  and	  aberrant	  Spc42-­‐GFP	  localization	  (data	  not	  
shown),	  these	  phenotypes	  were	  not	  as	  striking	  and	  not	  as	  easily	  classified	  as	  the	  arrest	  
caused	  by	  Rnq1.	  Certainly,	  more	  sensitive	  tools	  to	  monitor	  Spc42	  assembly	  into	  the	  SPB	  
core	  and	  Spc42’s	  interaction	  with	  misfolding	  intrinsically	  disordered	  proteins	  are	  needed	  
to	  determine	  if	  Spc42	  can	  act	  as	  sensor	  of	  protein	  damage.	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Figure	  C3.7:	  Model	  of	  Rnq1	  toxicity.	  
As	  an	  intrinsically	  disordered	  protein	  Rnq1	  transitions	  between	  folded,	  unfolded	  and	  
misfolded	  protein	  conformations.	  In	  the	  presence	  of	  [RNQ+]	  prion	  seeds	  it	  will	  adopt	  the	  
templated	  amyloid	  conformation.	  Overexpression	  of	  Rnq1	  exceeding	  the	  capacity	  for	  
amyloid	  formation	  results	  in	  the	  formation	  of	  non-­‐amyloid	  aggregates	  capable	  of	  
sequestering	  Spc42	  away	  from	  its	  proper	  localization	  at	  the	  SPB.	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   In	  addition	  to	  the	  cell	  biological	  characterization	  of	  Rnq1	  toxicity,	  we	  conducted	  
two	  genome-­‐wide	  screens	  for	  genes	  that	  could	  suppress	  Rnq1	  toxicity.	  Importantly,	  
these	  screens	  also	  served	  to	  indentify	  genes	  involved	  in	  yeast	  prion	  maintenance.	  
Formerly	  Rnq1	  prion	  status	  was	  determined	  by	  the	  rate	  of	  [PSI+]	  induction,	  but	  toxicity	  
induced	  by	  Rnq1	  overexpression	  provides	  a	  robust	  and	  more	  direct	  assessment	  of	  Rnq1	  
prion	  status.	  We	  found	  that	  no	  non-­‐essential	  gene,	  aside	  from	  Hsp104	  and	  Rnq1,	  is	  
absolutely	  required	  for	  the	  maintenance	  of	  the	  Rnq1	  prion.	  Our	  overexpression	  screen	  
yielded	  Gpg1,	  which	  can	  antagonize	  prion	  formation	  of	  several	  yeast	  prions	  (ISHIWATA,	  et	  
al.	  2009),	  and	  genes	  with	  prion-­‐like	  domains,	  which	  co-­‐localized	  with	  Rnq1	  inclusions.	  
The	  latter	  likely	  reduce	  toxicity	  by	  interacting	  with	  Rnq1	  aggregates	  and	  forming	  a	  
“shield”	  that	  limits	  Rnq1’s	  ability	  to	  induce	  mislocalization	  of	  Spc42.	  
We	  found	  that	  in	  addition	  to	  chaperones	  known	  to	  be	  protein	  stress	  responsive,	  
GPG1	  and	  BTN2	  were	  up-­‐regulated	  upon	  Rnq1	  overexpression	  in	  [RNQ+]	  cells.	  Btn2	  has	  
been	  shown	  to	  influence	  the	  inheritance	  of	  the	  [URE3]	  prion	  and	  to	  co-­‐localize	  with	  the	  
prion	  forms	  of	  Sup35	  and	  Rnq1.	  While	  Btn2	  co-­‐localized	  with	  Rnq1,	   its	  overexpression	  
did	  not	  affect	  [RNQ+]	  maintenance	  (KRYNDUSHKIN,	  et	  al.	  2008),	  suggesting	  why	  we	  did	  not	  
identify	  it	  as	  a	  suppressor	  in	  our	  overexpression	  screen.	  Btn2	  mediates	  late	  endosome-­‐
Golgi	  sorting	  (KAMA,	  et	  al.	  2007)	  and	  has	  been	  postulated	  to	  influence	  prion	  inheritance	  
by	   facilitating	   the	   formation	   of	   aggresome-­‐like	   inclusions	   (KRYNDUSHKIN,	   et	   al.	   2008).	  
Gpg1	  is	  the	  proposed	  gamma	  subunit	  of	  the	  heterotrimeric	  G	  protein	  (HARASHIMA,	  et	  al.	  
2002).	   Yet,	   Gpg1	   shares	   no	   homology	   with	   other	   G	   protein	   gamma	   subunits	   and	   its	  
functional	   annotation	   is	   based	   on	   yeast	   two	   hybrid	   interactions	  with	   other	   G	   protein	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components.	   The	   up-­‐regulation	   of	   both	   BTN2	   and	   GPG1	   may	   represent	   an	  
uncharacterized	   cellular	   response	   to	   certain	   types	   of	   proteotoxicity.	   Indeed,	   their	  
expression	   patterns	   correlate	   with	   those	   of	   chaperones	   involved	   in	   protein	   folding	  
(BTN2,	  7.72e-­‐08)	  and	  response	  to	  temperature	  stimulus	   (GPG1,	  7.16e-­‐04)	   (HIBBS,	  et	  al.	  
2007).	   It	   will	   be	   interesting	   to	   see	   how	   these	   two	   proteins	   function	   in	   concert	   with	  
chaperones	  such	  as	  Hsp104	  and	  Sis1	  to	  counteract	  the	  toxicity	  of	  intrinsically	  disordered	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  Material	  and	  Methods:	  	  
Strains	   and	   Plasmids:	  W303	   MAT	   a	   and	   α,	   can1-­‐100,	   ade2-­‐1,	   his3-­‐11,15	   leu2-­‐3,112,	   ura3-­‐1,	   trp1-­‐1	   and	   BY4741	  MAT	   a,	   his3∆1,	   leu2∆0,	   met15∆0,	   ura3∆0,	   and	  Y7092	   Mat	   α,	   can1∆::STE2pr-­‐Sp_his5,	   lyp1∆,his3∆1,	   leu2∆0,	   ura3∆0,	  met15∆0,LYS2+	  (TONG,	   et	  al.	  2006).	  As	  well	  as	  strains	   from	  the	  GFP	   library,	  which	  are	   based	  on	   the	  BY	  background	   and	   contain	   a	  GFP	   tag	   integrated	  using	   the	  His3	  marker	  (HOWSON,	  et	  al.	  2005).	  Deletion	  strains	  were	  recreated	  following	  previously	  published	  methods	  and	  primers	  (WINZELER,	  et	  al.	  1999).	  The	  strains	  harbored	  Rnq1	  in	   its	   [RNQ+]	   form	  and	   the	  generation	  of	   isogenic	   [rnq-­]	   strains	  was	  accomplished	  via	   sequential	   passage	   of	   cells	   on	   plates	   containing	   3	   mM	   guanidinium-­‐HCl	  	  (EAGLESTONE,	   et	  al.	  2000).	  Strains	  were	   transformed	  with	  plasmids	  and	  cultured	   in	  synthetic	  media	  as	  previously	  described	  	  (CAPLAN,	  et	  al.	  1991).	  Plasmids	  that	  express	  the	   indicated	   protein	   under	   control	   of	   the	   GAL1	   promoter	   include	   pRS416-­‐RNQ1	  (WT	   and	   L94A),	   pRS416-­‐RNQ1-­YFP,	   pRS426-­‐RNQ1-­YFP,	   pAG416-­‐RNQ1-­mCherry,	  pRS305-­‐RNQ1,	   pRS305-­‐YFP	   and	   pBY011	   (CEN,	   URA3,	   AmpR,	   GAL	   regulated)	  overexpression	   library	   constructs	   (COOPER,	   et	  al.	   2006).	  Plasmids	   that	  utilizing	   the	  
SUP35	  promoter	   include	   pAG415	   constructs	   containing	   SPC29,	   SPC42,	   SPC72,	   and	  
SPC97.	   Cerulean	   fusions	   of	   the	   screen	   hits	   were	   generated	   using	   overexpression	  library	  clones,	  gateway	  cloning	  and	  a	  pAG415	  N-­‐terminal	  Cerulean	  vector	  (ALBERTI,	  
et	  al.	  2007).	  	  
Analysis	  of	  Rnq1	  cytotoxicity:	   To	  measure	   the	  effect	  of	   the	   re-­‐created	  deletions,	  indicated	   deletions	   strains	   carrying	   pRS426-­‐RNQ1-­‐YFP	   were	   assayed.	   The	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overexpression	  screen	  was	  carried	  out	  in	  a	  BYxW303	  diploid.	  Strains	  tested	  carried	  an	   integrated	   pRS305-­‐RNQ1	   construct	   and	   the	   indicated	   constructs	   from	   the	  overexpression	   library.	   Spc42	   rescue	   was	   assayed	   using	   BY	   Spc42-­‐GFP	   strains	  harboring	  pRS416-­‐RNQ1	  and	  spindle	  pole	  body	  components	  on	  a	  SUP35	  promoter	  controlled	  pAG415	  plasmid.	  We	  observed	  similar	  rescue	  of	  Rnq1	  toxicity	  by	  Spc29	  and	   Spc42	   in	   the	   BY	   and	   W303	   backgrounds.	   For	   all	   these	   assays	   strains	   were	  grown	  overnight	  in	  synthetic	  drop-­‐out	  media	  containing	  2	  %	  glucose	  before	  5-­‐fold	  serial	  dilutions	  were	  spotted	  on	  plates	  containing	  either	  2	  %	  galactose	  or	  glucose.	  Plates	  were	  incubated	  for	  2-­‐3	  days	  at	  30	  ºC	  and	  then	  photographed.	  	  
Semi-­denaturing	   detergent	   agarose	   gel	   electrophoresis	   (SDD-­AGE):	   Rnq1	  assembly	   into	   SDS-­‐resistant	   [RNQ+]	   prions	   was	   monitored	   by	   SDD-­‐AGE	   as	  previously	  described	  (HALFMANN,	  et	  al.	  2008).	  Cells	  were	   lysed	  in	  buffer	  containing	  50mM	   Hepes	   pH7.5,	   150mM	   NaCl,	   2.5	   mM	   EDTA,	   1%	   Triton	   X-­‐100,	   30mM	   NEM,	  1mM	   PMSF	   and	   a	   protease	   inhibitor	   cocktail	   (Roche)	   using	   glass	   beads.	   Lysates	  were	  spun	  clear	  of	  debris	  and	  mixed	  with	  2x	  sample	  buffer	  (1xTAE,	  10%	  glycerol,	  2%	  SDS,	  bromophenol	  blue).	  Samples	  were	  run	  on	  a	  the	  1.5%	  agarose	  gel	  containing	  1x	  TAE	  and	  0.1%	  SDS	   in	   running	  buffer	  with	   the	  same	  concentrations	  of	  TAE	  and	  SDS.	   	   	  The	  gel	  was	  blotted	  onto	  Hybond-­‐C	  membrane	  and	  then	  probed	  with	  α-­‐GFP.	  Bands	  were	  visualized	  with	  ECL	  reagent.	  	  	  
Cell	   cycle	   profiling:	   Freshly	   streaked	   cells	   were	   grown	   overnight	   at	   30	   ºC	   in	  synthetic	  media	  lacking	  uracil	  and	  containing	  2%	  raffinose.	  Cells	  were	  diluted	  to	  an	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OD	  600	  of	  0.2	  and	  grown	  for	  an	  additional	  3h	  in	  the	  raffinose	  media.	  Cells	  were	  then	  washed	  and	  Rnq1	  expression	  was	  induced	  for	  the	  indicated	  time	  intervals	  in	  media	  lacking	  uracil	  and	  containing	  2%	  galactose.	  After	  induction	  cells	  were	  spun	  down	  in	  15ml	  screw	  cap	  tubes	  and	  resuspended	  in	  3ml	  dH20.	  The	  cells	  were	  fixed	  through	  the	  addition	  of	  7	  ml	  of	  95%	  EtOH	  and	  overnight	  incubation	  at	  4	  °C	  whilst	  rotating.	  After	  fixation	  cells	  were	  spun	  down	  and	  resuspended	  in	  5ml	  50mM	  sodium	  citrate	  (pH	  7.4).	  Cells	  were	  spun	  down	  again,	  resuspended	  in	  1	  ml	  of	  50mM	  sodium	  citrate	  containing	   0.25	  mg/ml	   boiled	   RNase	   A	   (QIAGEN)	   and	   incubated	   at	   50	   °C	   for	   one	  hour.	  50ul	  of	  20	  mg/ml	  Proteinase	  K	  (Invitrogen)	  were	  added	  before	  an	  additional	  1h	  incubation	  at	  50°	  C.	  After	  this	  incubation	  1	  ml	  of	  50mM	  sodium	  citrate	  containing	  16	  ug/ml	  propidium	  iodide	  was	  added	  before	  cells	  were	  incubated	  overnight	  at	  4	  °C.	  DNA	  content	  of	  these	  cells	  was	  measure	  using	  on	  a	  Caliber	  II	  flow	  cytometer	  and	  the	  resulting	  Data	  were	  analyzed	  using	  FlowJo	  software.	  	  	  
Immunostaining:	   Strains	  were	   pregrown	   in	   raffinose	  media	   over	   night	   and	   then	  induced	  in	  galactose	  media	  for	  8	  hours	  (5ml	  OD600	  0.2).	  Cells	  were	  spun	  down	  and	  resuspended	   in	   1ml	   3.7%	   formaldehyde	   (37%	   formaldehyde	   in	   0.1M	   KPi	  (potassium	  phosphate	  buffer)	  pH6.4)	  after	  removal	  of	  supernatant.	  Cells	  were	  fixed	  over	  night	  at	  4	  °C.	  After	  the	  fixation	  cells	  were	  washed	  three	  time	  in	  1ml	  0.1M	  KPi	  pH	   6.4	   and	   then	   resuspended	   in	   1ml	   1.2M	   sorbitol-­‐citrate	   buffer	   (1L:	   218.6g	  sorbitol,	  17.40g	  anyhydorus	  K2HPO4,	  7g	  citric	  acid;	  filter	  sterilize).	  Cells	  were	  spun	  down	  again	  and	  resuspended	  in	  200ul	  of	  digestion	  mix	  (200ul	  1.2M	  sorbitol-­‐citrate,	  20ul	   glusolase	   and	  2ul	   10mg/ml	   zymolase).	   Cells	  were	   incubated	   in	   the	   digestion	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mix	   for	   45min	   at	   30	   °C.	   During	   the	   incubation	   5ul	   0.1%	   polylysine	  was	   added	   to	  each	  well	  of	  a	  30	  well	  slide	  (Thermo	  ER-­‐212W).	  After	  5min	  of	  incubation	  the	  slides	  was	  washed	  with	  distilled	  water	  and	  allowed	   to	  air	  dry	   completely.	  Digested	  cells	  were	   spun	   down	   at	   3,000	   rpm	   for	   3min	   and	   gently	   resuspended	   in	   1ml	   sorbitol-­‐citrate.	  Cells	  were	  spun	  down	  again	  and	   then	  resuspended	   in	  a	  volume	  of	  sorbitol	  citrate	  dependent	  on	  cell	  pellet	  size	   (15-­‐50ul).	  5ul	  of	  cells	  was	  added	   to	  each	  well	  and	   incubated	   for	   10min.	   Cells	   were	   removed	   from	   the	   side	   of	   the	   well	   using	   a	  vacuum	  tip.	  If	  the	  cell	  density	  was	  low,	  as	  revealed	  by	  light	  microscopy,	  more	  cells	  were	  added.	  The	  slides	  were	  then	  incubated	  in	  ice-­‐cold	  methanol	  for	  3min,	  followed	  by	  10sec	  in	  ice-­‐cold	  acetone.	  Acetone	  was	  shook	  off	  and	  slides	  air-­‐dried.	  4ul	  of	  1:200	  anti-­‐tubulin	  antibody	  (kind	  gift	  of	  the	  Hochwagen	  lab)	  in	  PBS/BSA	  (1%	  BSA,	  0.04M	  K2HPO4,	   0.01M	   KH2PO4,	   0.15M	   NaCl,	   0.1%	   NaN3;	   for	   100ml:	   1g	   BSA,	   4ml	   1M	  K2HPO4,	   1ml	   1M	   KH2PO4,	   15ml	   1M	   NaCl,	   1ml	   10%	   NaN3,	   sterilized	   water	   to	  100ml)	   were	   added	   to	   each	   well.	   Slide	   was	   incubated	   over	   night	   at	   room	  temperature	   in	   a	   wet	   chamber.	   After	   the	   incubation	   the	   antibody	   was	   removed	  using	  a	  vacuum	  tip	  and	  each	  well	  was	  washed	  3	  times	  with	  PBS/BSA.	  Then	  4ul	  of	  the	  secondary	  antibody,	  1:100	  anti-­‐mouse	  FITC,	  was	  added	  to	  each	  well	  and	  incubated	  for	  2	  hours.	  Subsequently,	  each	  well	  was	  washed	  4	  times	  with	  PBS/BSA.	  1ul	  of	  DAPI-­‐MOUNT	  was	  added	  to	  each	  well	  prior	  to	  adding	  the	  coverslip	  and	  sealing	  the	  slide	  with	  nail	  polish.	  	  Images	   were	   taken	   on	   a	   Zeiss	   Aviovert.	   Final	   images	   were	   assembled	   from	   the	  different	   channels	   (GFP	   and	   DAPI)	   in	   Adobe	   Photoshop.	   Brightness	   and	   contrast	  were	  adjusted	  equally	  for	  all	  images.	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Deletion	   library	  screen	   for	  suppressors	  of	  Rnq1	  toxicity:	  The	  Mat	  a	  and	  alpha	  deletion	  libraries	  contain	  independently	  generated	  deletions	  of	  roughly	  all	  the	  non-­‐essential	   yeast	   gene	   arrayed	   in	   96-­‐well	   format	   (WINZELER,	   et	   al.	   1999).	   We	  transformed	   the	   libraries	   with	   the	   pRS426-­‐RNQ1-­YFP	   construct	   and	   screened	   for	  strains	   with	   improved	   growth	   in	   comparison	   to	   the	   parental	   BY	   strain.	  Transformation	  and	  screening	  was	  carried	  out	  as	  described	  previously	  (TYEDMERS,	  et	  
al.	   2008).	   The	   screen	   resulted	   in	   526	   putative	   hits	   in	   the	   Mat	   a	   library	   and	   426	  putative	  hits	  in	  the	  Mat	  alpha	  library.	  69	  were	  found	  in	  both	  libraries.	  We	  used	  the	  synthetic	   genetic	   array	   (SGA)	   strain	   7092	   (TONG,	   et	   al.	   2006)	   to	   reintroduce	   the	  [RNQ+]	  state	  in	  each	  of	  these	  deletions.	  We	  mated	  a	  [RNQ+]	  SGA	  strain	  carrying	  the	  pRS426-­‐RNQ1-­YFP	   construct	   to	   the	   set	   of	   69	   deletions.	   We	   then	   selected	   for	  diploids,	  sporulated	  them,	  selected	  for	  haploids	  carrying	  the	  deletion	  and	  the	  Rnq1-­‐YFP	  construct,	  and	  then	  tested	  the	  extent	  of	  Rnq1	  toxicity	  in	  said	  haploids.	  Twelve	  deletion	   strains	   still	   exhibited	   suppression	   of	   Rnq1	   toxicity	   after	   this	   prion	  reintroduction	  or	  could	  not	  be	  analyzed	  in	  this	  fashion	  due	  to	  mating	  defects.	  	  We	   recreated	   these	   twelve	   deletions	   in	   BY	   and	  W303	   using	   previously	   published	  primer	  sets	  (WINZELER,	  et	  al.	  1999)	  and	  tested	  their	  ability	  to	  suppress	  Rnq1	  toxicity.	  	  	  
Overexpression	   library	   screen	   for	   suppressors	   of	   Rnq1	   toxicity:	   The	  overexpression	  library	  screened	  contains	  ~5800	  full-­‐length	  sequence	  verified	  yeast	  ORFs	   in	   the	  galactose-­‐inducible	  Gateway	  expression	  plasmid	  pBY011	   (CEN,	  URA3,	  AmpR)	  (COOPER,	  et	  al.	  2006).	  The	  library	  is	  arrayed	  in	  96-­‐well	  format.	  Plasmid	  DNA	  was	  prepared	  by	  pin	  inoculation	  into	  deep	  well	  96-­‐well	  plates	  containing	  1.8ml	  LB-­‐
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AMP,	  growth	  over	  night	  at	  37	   °C	  and	  96-­‐well	  mini	  preps	  using	  a	  Qiagen	  BioRobot	  8000.	  Library	  DNA	  was	   transformed	   into	   the	  BY	  strain	   to	  create	  a	   library	  of	  yeast	  strains	   carrying	   the	   inducible	   overexpression	   constructs.	   Transformations	   were	  carried	  out	  using	  a	  standard	  lithium	  acetate	  transformation	  protocol	  adapted	  for	  a	  96-­‐well	   format.	   We	   mated	   a	   W303	   strain	   carrying	   an	   integrated	   pRS305-­‐RNQ1	  construct	   to	   the	   library.	   Post	   mating	   we	   selected	   for	   diploids	   carrying	   both	   the	  library	   plasmid	   and	   the	   Rnq1	   integration	   and	   then	   examined	   their	   growth	   on	  galactose	   plates	   inducing	   both	   the	   expression	   of	   the	   library	   clone	   and	   Rnq1.	   62	  putative	   suppressors	   were	   identified	   after	   2-­‐4	   days	   of	   growth	   at	   30	   °C.	   These	  putative	  hits	  were	  retested	  in	  the	  diploid	  screening	  strain	  and	  a	  haploid	  strain.	  The	  effects	   of	   twenty	   of	   these	   suppressors	   reproduced.	   We	   eliminated	   hits	   that	   have	  known	  effects	  on	  GAL	   induction.	  To	   further	   exclude	   false-­‐positive	   suppressors	  we	  used	   flow	   cytometry	   to	   measure	   the	   expression	   of	   YFP	   in	   their	   presence.	   The	  identity	  of	  suppressors	  was	  verified	  by	  sequencing.	  	  
Flow	   cytometry:	   A	  W303	   strain	   carrying	   YFP	   integrated	   at	   the	   LEU2	   locus	   was	  transformed	  with	  the	  putative	  Rnq1	  toxicity	  suppressors.	  The	  resulting	  strains	  were	  grown	   in	   glucose	   media	   in	   a	   96	   well	   format,	   diluted	   into	   galactose-­‐containing	  inducing	  media	  [5ul	  culture	  added	  to	  120ul	  media],	  and	  incubated	  over	  night	  at	  30	  °C	  with	  mild	  shaking.	  These	  overnight	  cultures	  were	  diluted	  20fold	  into	  water	  and	  YFP	  levels	  were	  measured	  using	  a	  Guava	  flow	  cytometer.	  Each	  strain	  was	  measured	  3	  times	  and	  5000	  cells	  were	  counted	  each	  time.	  The	  whole	  experiment	  was	  repeated	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3	  times.	  Values	  are	  averages	  of	  these	  3	  experiments	  and	  reported	  in	  percent	  of	  the	  vector	  control	  strain	  YFP	  levels.	  
Fluorescence	  Microscopy:	  Co-­‐localization	  of	  Rnq1	  and	  screen	  hits	  was	  examined	  in	  BY	  strains	  expressing	  Rnq1-­‐YFP	  and	  N-­‐terminal	  Cerulean	  fusions	  of	  suppressors.	  Strains	  were	   grown	   in	   raffinose	  media	   overnight	   and	   expression	   of	  Rnq1	   and	   the	  screen	  hits	  was	  induced	  in	  galactose	  media	  for	  4h	  prior	  to	  microscopy.	  To	  study	  the	  Rnq1-­‐induced	  cell	  arrest	  cells	  again	  were	  pre-­‐grown	  in	  raffinose	  media	  but	   then	   induced	   in	   galactose	   media	   for	   at	   least	   8h.	   The	   effect	   of	   Rnq1	   on	   the	  localization	   of	   Hof1-­‐GFP	   and	   Spc42-­‐GFP,	   as	   well	   as	   other	   spindle	   pole	   body	  components,	  was	  tested	  in	  GFP	  library	  strains	  (HOWSON,	  et	  al.	  2005).	  Co-­‐localization	  of	   Rnq1-­‐mCherry	  with	   spindle	   pole	   body	   components	  was	   examined	   in	   the	   same	  fashion.	  Microscopy	   was	   conducted	   using	   a	   Zeiss	   Axiovert	   microscope.	   Brightness	   and	  contrast	  were	  adjusted	  equally	  for	  all	  images.	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Supplemental	  Figure	  C3.1:	  Deletions	  that	  suppress	  Rnq1	  toxicity.	  
The	  Mat	  a	  and	  α	  deletion	   libraries	  were	  screened	   for	  deletions	  able	   to	  suppress	  Rnq1	  
toxicity.	   Several	   deletions	   were	   identified	   in	   both	   libraries.	   These	   were	   mated	   and	  
sporulated	   to	   reintroduce	   the	   [RNQ+]	   state	   and	   then	   retested	   for	   Rnq1	   toxicity	  
suppression.	   Deletions,	   that	   still	   suppressed	   Rnq1	   toxicity	   after	   re-­‐introduction	   of	   the	  
prion	   state,	   were	   recreated	   in	   BY	   and	   W303	   strains.	   The	   recreated	   BY	   deletions	  
suppressing	  Rnq1	  toxicity	  are	  shown.	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Supplemental	  Figure	  C3.2:	  Effect	  of	  OE	  screen	  hits	  on	  GAL1-­‐mediated	  YFP	  expression.	  
An	   overexpression	   library	   was	   screened	   for	   suppressors	   of	   Rnq1	   toxicity.	   This	   library	  
contains	   individual	   ORFs	   under	   control	   of	   the	   inducible	   GAL1	   promoter,	   which	   also	  
controls	   the	   overexpression	   of	   Rnq1.	   We	   eliminated	   false	   positive	   hits	   that	   affect	  
expression	   from	   the	   GAL1	   promoter	   by	   determining	   their	   effect	   on	   GAL1-­‐mediated	  
expression	  of	  YFP	  using	  flow	  cytometry.	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Genes	  changed	  2-­‐fold	  upon	  Rnq1	  overexpression	  
Up	  after	  6h	   Down	  after	  6h	   Up	  after	  8h	   Down	  after	  8h	  
ARG1	   ALD4	   BTN2	   ALD4	  
FMP16	   CRP1	   DBF2	   CTS1	  
HSP104	   CTS1	   FBP1	   DSE1	  
MBF1	   DSE2	   FMP16	   DSE2	  
SIS1	   DSE4	   GND2	   DSE4	  
SSA4	   EGT2	   GPG1	   EGT2	  
YDL038C	   GSY2	   HSP104	   FET3	  
YGP1	   HO	   HSP12	   FIT2	  
	   HPF1	   HSP26	   GSY1	  
	   PHO84	   IDP2	   HTA2	  
	   PRY3	   MBF1	   HXT3	  
	   REE1	   NCA3	   HXT6	  
	   SCW11	   PCK1	   HXT7	  
	   	   PIR3	   INO1	  
	   	   RPL32	   LSP1	  
	   	   SFC1	   MRP1	  
	   	   SIS1	   PDH1	  
	   	   SSA4	   PHO84	  
	   	   YGP1	   PLB2	  
	   	   YJL144W	   PRY3	  
	   	   YLR040C	   PSA1	  
	   	   YPS3	   RGI1	  
	   	   YRO2	   SCW11	  
	   	   	   SIM1	  
	   	   	   SIT1	  
	   	   	   SUN4	  
	   	   	   YDR133C	  
	  
Supplemental	   Table	   C3.1:	   Genes	   up-­‐	   or	   down-­‐regulated	   upon	   Rnq1	   overexpression.	  
Rnq1	  was	   overexpressed	   in	   [rnq-­‐]	   and	   [RNQ+]	   strains.	   Shown	   are	   genes	   that	   changed	  
more	   than	   2-­‐fold	   in	   the	   [RNQ+]	   strain	   in	   comparison	   to	   the	   [rnq-­‐]	   strain.	   Genes	   are	  
grouped	   by	   time	   point	   and	   directionality	   of	   the	   change	   in	   their	   expression.	   We	   also	  
measured	  gene	  expression	  after	  four	  hours	  of	  Rnq1	  overexpression,	  but	  at	  that	  point	  we	  
found	  no	  significant	  changes	  in	  gene	  expression.	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Sample	  &	   DNA	  Content	  
Time	  of	  Rnq1	  induction	   %	  1N	   %	  2N	  
[rnq-­‐]	  0h	   42.1	   52.6	  
[rnq-­‐]	  2h	   66.8	   30.4	  
[rnq-­‐]	  4h	   40.8	   54.5	  
[rnq-­‐]	  6h	   38.4	   54.2	  
[RNQ+]	  0h	   44.8	   51.4	  
[RNQ+]	  2h	   65.7	   31.3	  
[RNQ+]	  4h	   32.4	   62.8	  
[RNQ+]	  6h	   19.4	   69.9	  
Δrad9	  [RNQ+]	  0h	   42.9	   53.1	  
Δrad9	  [RNQ+]	  2h	   64.9	   31.9	  
Δrad9	  [RNQ+]	  4h	   33.3	   62.3	  
Δrad9	  [RNQ+]	  6h	   16.7	   77.8	  
Δmad2	  [RNQ+]	  0h	   51.5	   42.5	  
Δmad2	  [RNQ+]	  2h	   70.5	   27	  
Δmad2	  [RNQ+]	  4h	   35.7	   60.6	  
Δmad2	  [RNQ+]	  6h	   22.1	   60.6	  
	  
Supplemental	  Table	  C3.2:	  Quantification	  of	  cell	  cycle	  profiling	  of	  strain	  overexpressing	  
Rnq1.	  
In	   [RNQ+]	   strains	  Rnq1	  overexpression	  results	   in	  an	   increased	  number	  of	  cells	  with	  2N	  
DNA	   content.	   This	   suggests	   that	   Rnq1	   overexpression	   results	   in	   a	   cell	   cycle	   arrest	  
between	  S-­‐phase	  and	  G1.	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Abstract	  
Aβ	   (amyloid	   beta	   peptide)	   is	   a	   key	   contributor	   to	   Alzheimer’s	   disease.	   We	  
modeled	  Aβ	  toxicity	  in	  yeast	  by	  directing	  the	  peptide	  to	  the	  secretory	  compartment	  and	  
performed	  an	  unbiased	  genome-­‐wide	  screen	  for	  toxicity	  modifiers.	  The	  screen	  identified	  
PICALM,	   a	   highly	   validated	   genetic	   risk	   factor	   for	   sporadic	   AD.	   PICALM,	   and	   other	  
genetic	  hits	  with	  diverse	  cellular	   functions,	  modulated	  Aβ	  toxicity	   in	  the	  glutamatergic	  
neurons	  of	  C.	  elegans.	  Further,	  PICALM	  protected	  cultured	  rat	  cortical	  neurons	  against	  
exogenously	  applied	  Aβ	  oligomers,	  cross-­‐validating	  different	  approaches	  for	  inducing	  Aβ	  
toxicity.	   Aβ	   caused	   defects	   in	   clathrin-­‐mediated	   endocytosis	   and	   receptor	   trafficking.	  
PICALM	  and	  other	  hits	  partially	  corrected	  it.	  Our	  work	  establishes	  a	  direct	  link	  between	  
Aβ,	   endocytosis,	   and	  human	  AD	   risk	   factors	   and	  provides	   a	   new	   route	   to	   deciphering	  
mechanisms	  underlying	  AD.	  
Introduction	  
	   The	  incidence	  of	  neurodegenerative	  diseases	  will	  rise	  precipitously	  as	  the	  world’s	  
population	   ages	   	   (HEBERT,	   et	   al.	   2003).	   Discovering	   how	   to	   mitigate	   these	   diseases	   is	  
complicated	   by	   their	   late	   onset	   and	   complex	   etiology.	   Hence,	  model	   organisms	   are	   a	  
necessity	   for	   elucidating	   the	   molecular	   underpinnings	   of	   these	   pathologies	   and	  
developing	   therapeutic	   strategies.	   Yeast	   cells	   lack	   the	   highly	   specialized	   processes	   of	  
neuronal	   cells	   and	   the	   intricacies	   of	   cell:cell	   communication	   that	   modulate	   many	  
different	   aspects	   of	   neuropathology.	   They	   therefore	   provide	   a	   “living	   test	   tube”	   to	  
assess,	   in	   an	   isolated	   cellular	   context,	   the	   intrinsic	   pathogenic	   properties	   of	   disease-­‐
associated	   polypeptides.	  When	   these	   impinge	   on	   common	   features	   of	   eukaryotic	   cell	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biology	  	  (KHURANA,	  et	  al.	  2010),	  yeast	  offers	  unequaled	  genetic	  tools	  for	  the	  discovery	  of	  
toxicity	  modifiers	  and	  their	  mechanisms	  of	  action.	  
	   	  We	  previously	   generated	  a	   yeast	  model	   for	   the	   toxicity	  of	  α-­‐synuclein	   (α-­‐syn)	  	  
(OUTEIRO,	  et	  al.	  2003),	  a	  protein	  whose	  aggregation	  is	  a	  hallmark	  of	  Parkinson’s	  Disease	  
(PD),	  dementia	  with	  Lewy	  Bodies,	  and	  Multiple	  Systems	  Atrophy.	  α-­‐syn	  caused	  multiple	  
defects	   in	  Rab-­‐regulated	  vesicle	   trafficking	   	   (COOPER,	   et	  al.	   2006;	  GITLER,	   et	  al.	   2008),	  a	  
finding	  since	  corroborated	  in	  several	  neuronal	  studies	  	  (THAYANIDHI,	  et	  al.	  2010;	  WINSLOW,	  
et	   al.	   2010).	   It	   also	   caused	   defects	   in	   mitochondrial	   function,	   a	   hallmark	   of	   PD.	   An	  
unbiased	  genome-­‐wide	  yeast	  screen	   identified	  genes	  of	  diverse	  function	  that	  suppress	  
α-­‐syn	   toxicity	   in	  yeast	  as	  well	  as	   in	  dopaminergic	  neurons	  of	  both	  nematodes	  and	   rat	  
primary	  cultures	  	  (GITLER,	  et	  al.	  2009).	  PARK9,	  whose	  mutation	  causes	  parkinsonism	  with	  
dementia,	   was	   one	   of	   these	   modifiers	   and	   experiments	   in	   yeast	   established	   that	   it	  
protects	   cells	   from	  manganese	   exposure,	   a	   risk	   factor	   in	   Parkinsonism	   	   (GITLER,	   et	   al.	  
2009).	  High-­‐throughput	   yeast	   screens	   identified	   small	  molecules	   that	   protect	   neurons	  
not	  only	   from	  α-­‐syn	  but	  also	  from	  rotenone,	  a	  mitochondrial	  poison	  that	  can	  result	   in	  
PD-­‐like	  symptoms	  (SU,	  et	  al.	  2009).	  Thus,	  α-­‐syn	  impinges	  on	  vulnerabilities	  common	  to	  
all	  eukaryotic	  cells,	  to	  which	  particular	  neurons	  are	  simply	  more	  sensitive.	  
	   Here	  we	  report	  findings	  with	  a	  yeast	  model	  of	  the	  cellular	  toxicity	  induced	  by	  the	  
Aβ	  peptide.	  According	  to	  the	  amyloid	  cascade	  hypothesis,	  Aβ	  is	  causal	  in	  both	  sporadic	  
and	   familial	   AD	   	   (HARDY,	   et	   al.	   2002).	   Extracellular	   amyloid	   plaques	   and	   oligomeric	  
species	  of	  Aβ	  are	  a	  hallmark	  of	  post	  mortem	  AD	  brains.	  Intracellular	  Aβ	  forms,	  perhaps	  
representing	  an	  earlier	  stage	  of	  pathogenesis,	  have	  also	  been	   identified	   	   (KNOBLOCH,	  et	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al.	  2007;	  WALSH,	  et	  al.	  2000).	  Oligomeric	  species	  of	  Aβ,	  broadly	  believed	  to	  be	  the	  most	  
toxic	   forms	   of	   the	   peptide,	   can	   be	   detected	   with	   a	   conformation-­‐specific	   antibody	  	  
(KAYED,	  et	  al.	  2003).	  This	  antibody	  also	  recognizes	  toxic	  oligomeric	  forms	  of	  several	  other	  
amyloidogenic	   proteins	   associated	   with	   neurodegenerative	   diseases,	   but	   not	   their	  
monomeric	   or	   amyloid	   forms.	   Strikingly,	   the	   antibody	   recognizes	   oligomeric	  
intermediates	  that	  form	  during	  the	  assembly	  of	  a	  yeast	  prion	  protein	  Sup35,	  but	  not	  its	  
monomeric	   or	   amyloid	   forms	   	   (KAYED,	   et	   al.	   2003;	   SHORTER,	   et	   al.	   2004).	   Since	   these	  
proteins	  share	  no	  amino	  acid	  sequence	  homology,	  these	  findings	  suggest	  that	  the	  toxic	  
misfolding	   of	   Aβ	  might	   represent	   an	   ancient	   type	   of	   protein-­‐misfolding	   problem	   that	  
confronts	  many	  eukaryotic	  cells.	  
	   A	   definitive	   diagnosis	   of	   AD	   requires	   the	   presence	   of	   both	   Aβ	   plaques	   and	  
neurofibrillary	   tangles	   of	   tau,	   a	   microtubule-­‐binding	   protein	   	   (LAFERLA	   2010).	   Yet,	   Aβ	  
appears	  to	  act	  upstream,	  leading	  not	  only	  to	  tau	  pathology	  	  (ITTNER,	  et	  al.	  2010;	  LEWIS,	  et	  
al.	  2001;	  ROBERSON,	  et	  al.	  2007;	  VOSSEL,	  et	  al.	  2010),	  but	  other	  pathological	   features	  of	  
AD,	   including	   memory	   impairment	   and	   cell	   death	   	   (ITTNER,	   et	   al.	   2010;	   VOSSEL,	   et	   al.	  
2010).	   Indeed,	   targeting	  Aβ	  oligomers	  by	  passive	   immunization	  with	   the	  anti-­‐oligomer	  
antibody	   NAB61	   improves	   learning	   and	   memory	   in	   an	   AD	   mouse	   model	   	   (LEE,	   et	   al.	  
2006).	  While	  connections	  between	  Aβ	  and	  tau	  are	  steadily	  being	  unraveled,	  connections	  
between	  Aβ	  and	  AD	  risk	  factors	   identified	   in	  genome-­‐wide	  association	  studies	  (GWAS)	  
remain	  uncertain.	  Herein,	  we	  establish	  a	  platform	  for	  discovering	  and	  analyzing	  genetic	  
modifiers	  of	  Aβ	  toxicity	  that	  has	  already	  provided	  mechanistic	  insights	  and	  might	  aid	  the	  
development	  of	  new	  therapeutic	  strategies.	  
	   140	  
Results	  
A	  yeast	  model	  of	  Aβ	  toxicity	  
	   In	   the	   nervous	   system	   the	   most	   toxic	   form	   of	   Aβ,	   Aβ	   1-­‐42,	   is	   generated	   by	  
successive	  proteolytic	  cleavage	  of	  APP,	  the	  transmembrane	  amyloid	  precursor	  protein,	  
by	  the	  β-­‐	  and	  γ-­‐secretases	  	  (SELKOE,	  et	  al.	  2007;	  THINAKARAN,	  et	  al.	  2008).	  APP	  processing	  
primarily	  occurs	   in	   the	   secretory	  network,	  with	   the	   release	  of	  Aβ	   into	   the	   trans-­‐Golgi,	  
endosomal	   compartments	   and	   extracellular	   space.	   There,	   it	   interacts	  with	   the	  plasma	  
membrane	  and	   is	  subject	  to	  endocytosis	   	   (THINAKARAN,	  et	  al.	  2008).	  To	  recapitulate	  the	  
multi-­‐compartment	  trafficking	  of	  Aβ	  in	  a	  yeast	  cell,	  we	  fused	  an	  ER	  targeting	  signal	  that	  
is	   processed	   with	   high	   efficiency	   to	   the	   N-­‐terminus	   of	   the	   human	   Aβ	   1-­‐42	   sequence	  
(ssAβ	   1-­‐42,	   supplementary	  methods	   on	   line).	  With	   neither	   an	   ER	   retention	   sequence,	  
nor	   any	   other	   amino	   acids	   remaining	   after	   cleavage	   of	   the	   targeting	   sequence,	   the	  
peptide	   will	   transit	   through	   the	   secretory	   pathway	   and	   be	   released	   from	   the	   cell.	  
Critically,	   however,	   the	   yeast	   cell	   wall	   will	   restrain	   its	   diffusion,	   allowing	   Aβ	   1-­‐42	   to	  
interact	  with	  the	  plasma	  membrane	  and	  be	  subject	  to	  endocytosis.	  	  
	   The	   expression	   of	   ssAβ	   1-­‐42	   from	   a	   high-­‐copy	   plasmid,	   using	   a	   galactose-­‐
inducible	   (GAL1)	   promoter,	   decreased	   growth	   when	   yeast	   cells	   were	   shifted	   from	  
glucose	  to	  galactose	  (Figure	  C4.1A).	  ssAβ	  1-­‐40,	  an	  APP	  cleavage	  product	  that	  is	  less	  toxic	  
to	  neurons	  and	  in	  various	  AD	  models	  	  (LUHESHI,	  et	  al.	  2007),	  was	  also	  less	  toxic	  in	  yeast.	  
BPTI,	  a	  small	  protein	  commonly	  used	  to	  study	  secretion,	  and	  even	  a	  BPTI	  variant	  known	  
to	  misfold	  in	  the	  ER	  were	  much	  less	  toxic	  	  (KOWALSKI,	  et	  al.	  1998).	  The	  ER	  resident	  protein	  
Pdi1	  slowed	  growth	  minimally.	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   We	   next	   constructed	   stable	   screening	   strains	   by	   integrating	  multiple	   copies	   of	  
the	   ssAβ	  1-­‐42	   construct	   into	   the	  genome.	  We	  selected	   strains	  exhibiting	   intermediate	  
levels	  of	  toxicity	  to	  enable	  the	  identification	  of	  enhancers	  and	  suppressors	  in	  the	  same	  
screen	  and	  to	  allow	  analysis	  of	  Aβ	  induced	  cellular	  defects	  under	  circumstances	  where	  
they	  are	  still	  amenable	  to	  amelioration	  (Figure	  C4.1B).	  These	  strains	  produced	  a	  peptide	  
of	   the	   expected	   size	   for	   Aβ	   1-­‐42,	   along	   with	   higher	   molecular	   weight	   Aβ	   oligomers	  
(Figure	  C4.1C	  and	  Supplemental	  Figure	  C4.1).	  We	  confirmed	  the	  localization	  of	  Aβ	  to	  the	  
secretory	  system	  by	  immunostaining	  (Figure	  C4.1F	  and	  Supplemental	  Figure	  C4.2).	  	  
	   Soluble	   Aβ	   oligomers	   are	   increasingly	   recognized	   as	   the	   most	   detrimental	   Aβ	  
species	  in	  AD	  	  (KAYED,	  et	  al.	  2003;	  LI,	  et	  al.	  2009).	  	  We	  detected	  oligomeric	  species	  of	  Aβ	  
using	   the	   above-­‐mentioned	   NAB61	   antibody	   (Figure	   C4.1D)	   (LEE,	   et	   al.	   2006).	   These	  
species	  disappeared	  upon	  boiling	  in	  LDS	  (Supplemental	  Figure	  C4.1).	  We	  further	  verified	  
the	  presence	  of	  oligomeric	  Aβ	  species	  using	  an	  indirect	  ELISA	  assay	  (Figure	  C4.1E),	  based	  
on	   a	   monoclonal	   IgM	   anti-­‐Aβ	   antibody	   (OMAB)	   specific	   for	   soluble	   Aβ	   oligomers	  	  
(LINDHAGEN-­‐PERSSON,	  et	  al.	  2010).	  Oligomer	   levels	  were	  much	   lower	   in	   the	  strain	  with	  a	  
single,	  non-­‐toxic,	  copy	  of	  ssAβ	  1-­‐42	  and	  undetectable	  in	  vector-­‐only	  controls.	  
	   142	  
	  
Figure	  C4.1:	  Expression	  of	  Aβ	  in	  the	  yeast	  secretory	  compartment.	  	  
(A)	   Comparison	  of	   ssAβ	  1-­‐42	   toxicity	  with	   ssAβ	  1-­‐40,	   ssBPTI	   (WT	  and	  C51A)	  and	  Pdi1.	  
ssAβ	   1-­‐42	   was	   more	   toxic	   than	   ssAβ	   1-­‐40	   and	   other	   proteins,	   all	   targeted	   to	   the	  
secretory	  pathway	  with	  the	  signal	  sequence	  of	  Kar2.	  Proteins	  were	  expressed	  using	  the	  
inducible	  GAL1	  promoter	  and	  a	  high	  copy	  number	  plasmid.	  Strains	  carrying	  the	  plasmids	  
were	   serially	   diluted	   and	   spotted	   on	   inducing	   (galactose)	   and	   non-­‐inducing	   (glucose)	  
media.	   (B)	   Construction	   of	   stable	   ssAβ	   1-­‐42	   strains	   for	   a	   genetic	   screen.	   A	   single	  
	   143	  
integrated	   genomic	   copy	   of	   ssAβ	   1-­‐42	   was	   not	   toxic,	   but	   the	   integration	   of	   several	  
copies	  of	  the	  construct	  resulted	  in	  robust	  toxicity.	  (C)	  Aβ	  1-­‐42	  expression	  was	  detected	  
by	   immunoblot	  analysis	  using	   the	  6E10	  Aβ-­‐specific	  antibody.	  Samples	  were	  not	  boiled	  
before	  loading	  on	  the	  gel.	  See	  Supplemental	  Figure	  C4.1	  for	  the	  loss	  of	  oligomeric	  forms	  
after	  boiling	   in	   LDS.	   	   (D)	   Immunoblot	  with	  NAB61,	   an	  antibody	   specific	   for	   soluble	  Ab	  
oligomers,	   detects	   oligomers	   in	   unboiled	   samples.	   (E)	  An	   indirect	   ELISA	   assay	   using	   a	  
monoclonal	   Aβ	   oligomer-­‐specific	   antibody	   (OMAB)	   detects	   significant	   levels	   of	   Aβ	  
oligomers	   in	   the	  1xAβ	  strain	  and,	  more	  so,	   in	   the	  screening	  strains	   (n=5;	  error	  bars	   to	  
small	  to	  be	  visible;	  **	  =	  p<0.01,	  based	  on	  Dunnett’s	  test).	  (F)	  Immunostaining	  for	  ssAβ	  1-­‐
42	   reveals	   localization	   to	   the	   ER/secretory	   compartment.	   Aβ	   was	   detected	   in	   the	   ER	  
(ring	  surrounding	  the	  nucleus,	  stained	  blue	  with	  DAPI)	  and	  in	  small	  foci	  throughout	  the	  
cell	  (arrowheads).	  The	  scale	  bar	  is	  5µm	  and	  all	  figures	  are	  on	  the	  same	  scale.	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Screen	  for	  genetic	  modifiers	  of	  Aβ	  toxicity	  
	   We	   transformed	   a	   screening	   strain	  with	   an	   overexpression	   library	   of	   5532	   full	  
length	  ORFs	  (~90%	  of	  yeast	  ORFs)	  regulated	  by	  the	  same	  inducible	  promoter	  used	  for	  Aβ	  
expression.	  The	  transformed	  strains	  were	  arrayed	  in	  media	  that	  prevented	  induction	  of	  
either	  Aβ	  or	  the	  putative	  modifiers,	  and	  then	  plated	  (four	  replicates	  each)	  onto	  media	  
that	   supported	  different	   levels	   of	  mitochondrial	   respiration	  under	   inducing	   conditions	  
(see	  Supplemental	  Table	  C4.1	  for	  further	  details).	  Plasmids	  that	  decreased	  or	  increased	  
growth	   in	   cells	   expressing	   Aβ	   (Supplemental	   Figure	   C4.3)	   were	   retested	   in	   an	  
independently	  generated	  Aβ	  screening	  strain	  and	  filtered	  to	  remove	  genes	  that	  affected	  
expression	   from	   the	  GAL1	   promoter	   (Supplemental	   Figure	  C4.4)	  or	  affected	  growth	   in	  
the	  absence	  of	  Aβ.	  	  
	   We	   identified	   23	   suppressors	   and	   17	   enhancers	   of	   Aβ	   toxicity	   (Supplemental	  
Table	   C4.1).	   Only	   a	   few	   modifiers	   were	   strongly	   affected	   by	   the	   state	   of	   respiration	  
(Supplemental	  Table	  C4.1).	  The	  screen	  hits	  comprised	  a	  wide	  range	  of	  cellular	  functions.	  
Numerous	   hits	   had	   sequence	   similarity	   to	   human	   genes	   and	   twelve	   had	   very	   clear	  
human	   homologs	   (determined	   by	   HomoloGene	   or	   by	   analogous	   functionality	   [SLA1	   –	  
SH3KBP1]	  (STAMENOVA,	  et	  al.	  2004))(Table	  C4.1).	  We	  focused	  further	  analysis	  on	  these,	  as	  
their	  high	  degree	  of	  functional	  conservation	  made	  them	  more	  likely	  to	  be	  relevant	  to	  Aβ	  
toxicity	  in	  other	  model	  organisms	  and,	  ultimately,	  in	  humans.	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Yeast	  Aβ	  
Suppressors	   Cellular	  Function	   Human	  Homolog	  
C.	  elegans	  
Homolog	  
YAP1802	   Endocytosis	   PICALM	   unc-­‐11*	  
INP52	   Endocytosis	   SYNJ1	   unc-­‐26*	  
SLA1	   Endocytosis	   SH3KBP1	   Y44E3A.4*	  
RTS1	   Phosphatase	  regulation	   PPP2R5C	   pptr-­‐2*	  
ADE12	   Adenylosuccinate	  synthesis	   ADSSL1	   C37H5.6b*	  
CRM1	   Nuclear	  protein	  export	   XPO1	   xpo-­‐1*	  
GRR1	   Ubiquitination	   FBXL2	   C02F5.7	  
VPS9	   Vesicle	  transport	   RABGEF1	   rabx-­‐5	  
Yeast	  Aβ	  
Enhancers	   	   	  
	  
PBS2	   Osmotic	  stress	  response	   MAP2K4	   mkk-­‐4*	  
KEM1	   RNA	  processing	   XRN1	   xrn-­‐1	  
MVP1	   Vacuolar	  sorting	   SNX8	   lst-­‐4	  
PMT2	   Mannosylation	   POMT2	   -­‐	  
(*	  Genes	  tested	  in	  the	  C.	  elegans	  model)	  
	  
Table	  C4.1:	  Modifiers	  of	  Aβ	  toxicity	  with	  clear	  human	  homologs.	  
Yeast	  genes	  with	  clear	  human	  and	  nematode	  homologs	  were	  identified	  in	  an	  unbiased	  
screen	  of	  5,532	  single	  copy	  plasmids	  carrying	  yeast	  ORFs	  under	  the	  control	  of	  the	  GAL1	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   Notably,	   three	   of	   the	   twelve	   have	   functions	   related	   to	   clathrin-­‐mediated	  
endocytosis	  (YAP1802,	  SLA1	  &	  INP52;	  P=3.89e-­‐4)	  and	  seven	  are	  functionally	  associated	  
with	  the	  cytoskeleton	  (YAP1802,	  SLA1,	   INP52,	  CRM1,	  GRR1,	  KEM1	  &	  RTS1;	  P=6.06e-­‐8).	  
Importantly,	   none	   had	   been	   identified	   in	   our	   previous	   screen	   for	   modifiers	   of	  α-­‐syn	  
toxicity	  (COOPER,	  et	  al.	  2006;	  GITLER,	  et	  al.	  2009),	  establishing	  their	  specificity	  for	  the	  type	  
of	  toxicity	  caused	  by	  our	  ssAβ	  construct.	  
	  
Modifiers	  of	  Aβ	  toxicity	  are	  associated	  with	  AD	  susceptibility	  	  
	   Remarkably,	  several	  human	  homologs	  of	  the	  yeast	  hits	  have	  strong	  connections	  
to	  AD	  or	  Aβ	  toxicity	  in	  other	  experimental	  systems	  and	  human	  patients.	  	  
The	  PBS2	   homolog	  MAP2K4,	   part	   of	   the	   JNK	   pathway,	   is	   activated	   in	   response	   to	   Aβ	  
oligomer	   administration	   to	   cultured	   cortical	   neurons	   	   (BOZYCZKO-­‐COYNE,	   et	   al.	   2001).	  
Synaptojanin,	  the	   INP52	  homolog,	  has	  also	  been	  shown	  to	  modulate	  the	  toxicity	  of	  Aβ	  
oligomers,	  although	  through	  a	  reduction	  in	  its	  activity	  rather	  than	  an	  increase	  as	  in	  our	  
screen	  (BERMAN,	  et	  al.	  2008).	  	  
	   Most	   strikingly,	   the	   human	   homolog	   of	   YAP1802,	   PICALM,	   is	   a	   confirmed	   risk	  
factor	  for	  sporadic	  AD	  	  (HAROLD,	  et	  al.	  2009;	  LAMBERT,	  et	  al.	  2009).	  Indeed,	  initial	  reports	  
that	  PICALM	   is	  associated	  with	  AD	  susceptibility	  at	  a	  genome-­‐wide	  level	  of	  significance	  
have	  been	  replicated	  in	  12	  independent	  AD	  case-­‐control	  samples	  (BERTRAM,	  et	  al.	  2010).	  
PICALM	  is	  currently	  the	  third	  ranked	  AD	  risk	  factor	  on	  Alzgene	  	  (BERTRAM,	  et	  al.	  2007).	  	  
To	   assess	   the	   potential	   clinical	   relevance	   of	   other	  modifiers	   of	   Aβ	   toxicity,	  we	  
asked	   whether	   the	   eleven	   screen	   hits	   with	   highly	   conserved	   human	   homologs	   show	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evidence	  of	  association	  with	  susceptibility	  for	  AD	  or	  AD-­‐related	  pathologic	  burden.	  First,	  
we	   examined	   association	   with	   AD	   susceptibility	   using	   data	   from	   a	   published	   family-­‐
based	   GWAS	   	   (BERTRAM,	   et	   al.	   2008)	   performed	   on	   the	   National	   Institute	   of	   Mental	  
Health	  (NIMH)	  Genetics	  Alzheimer’s	  Disease	  Initiative	  Study	  	  (BLACKER,	  et	  al.	  1997).	  Using	  
a	  family-­‐based	  association	  test,	  we	  discovered	  a	  suggestive	  association	  of	  XPO1	  (CRM1	  
homolog,	  rs6545886,	  P=0.003)	  with	  AD	  susceptibility	  (See	  supporting	  online	  material	  for	  
methodological	  details,	  Supplemental	  Table	  C4.2).	  
Next,	  we	  leveraged	  genotyping	  with	  extensive	  clinical	  and	  pathological	  data	  from	  
two	  large	  epidemiological	  studies	  of	  aging,	  cognition,	  and	  AD:	  the	  Religious	  Orders	  Study	  
(ROS)	  and	  the	  Rush	  Memory	  and	  Aging	  Project	  (MAP)(See	  supporting	  online	  material	  for	  
methodological	   details,	   Supplemental	   Tables	   C4.3-­‐6)	   (36-­‐38).	   Using	   a	   quantitative	  
summary	  measure	  of	  global	  AD	  pathologic	  burden	  available	   in	  these	  cohorts,	  counting	  
both	   amyloid	   plaques	   and	   NFTs,	   we	   found	   that	   two	   additional	   loci	   identified	   by	   our	  
yeast	   screen,	   ADSSL1	   (ADE12	   homolog,	   rs1128880,	   P=0.001)	   and	   RABGEF1	   (VPS9	  
homolog,	   rs17566701,	   P=0.002)	   showed	   evidence	   of	   association	   with	   AD	  
neuropathology	   (Supplemental	   Table	   C4.6).	   Both	   loci	   also	   harbored	   suggestive	  
association	  signals	  with	  episodic	  memory	  decline	  (Supplemental	  Table	  C4.5).	  	  	  
	  
C.	  elegans	  model	  of	  Aβ	  toxicity	  	  
	   The	   connection	   between	  PICALM	   and	  Aβ	   toxicity	   in	   our	   yeast	  model,	   together	  
with	   these	   other	   suggestive	   connections,	   encouraged	   us	   to	   establish	   a	   new	   genetic	  
model	   to	   directly	   test	   the	   effects	   of	   Aβ	   toxicity	   modifiers	   in	   a	   neuronal	   setting.	   The	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nematode	  C.	  elegans	  has	  been	  previously	  employed	  to	  investigate	  Aβ	  toxicity	  	  (COHEN,	  et	  
al.	  2006;	  LINK	  1995)	  in	  body	  wall	  muscle	  cells.	  To	  test	  our	  genetic	  modifiers	  in	  neurons,	  
we	  first	  created	  stable	  transgenic	  lines	  that	  express	  Aβ	  1-­‐42	  in	  glutamatergic	  neurons,	  a	  
neuronal	   subtype	  particularly	   vulnerable	   in	  AD.	   The	  Aβ	   transgene	  was	   integrated	   into	  
worm	   chromosomal	   DNA	   to	   ensure	   the	   same	   extent	   of	   Aβ	   1-­‐42	   expression	   in	   all	  
glutamatergic	  neurons.	  We	  used	  the	  eat-­‐4	  promoter,	  which	  controls	  expression	  of	  the	  
BNPI	  vesicular	  glutamate	  transporter	  and,	  again,	  targeted	  Aβ	  to	  the	  secretory	  pathway	  
without	  a	  retention	  signal.	  	  
	   C.	  elegans	  is	  renowned	  for	  its	  highly	  stereotypical	  cell	  lineages.	  Wild-­‐type	  worms	  
invariably	   have	   five	   glutamatergic	   neurons	   in	   their	   tails.	   These	   are	   conveniently	  
visualized	   in	   transgenic	   animals	   that	   also	   carry	   an	   eat-­‐4-­‐regulated	   GFP	   transgene.	  
Expression	  of	  ssAβ	  resulted	  in	  the	  loss	  of	  these	  GFP-­‐marked	  glutamatergic	  neurons	  in	  an	  
age-­‐related	   manner:	   at	   day	   three	   only	   48%	   of	   worms	   had	   five	   intact	   glutamatergic	  
neurons,	  and	  at	  day	  seven	  only	  25%	  did	  (Figure	  C4.2B).	  To	  test	  the	  genetic	  modifiers,	  we	  
established	  three	  independent	  stable	  transgenic	  lines	  for	  each	  gene	  (Table	  C4.1).	  Again	  
the	   eat-­‐4	   promoter	   was	   used	   to	   control	   expression.	   First,	   we	   tested	   the	   C.	   elegans	  
homologs	  of	  the	  three	  yeast	  genes	  involved	  in	  clathrin-­‐mediated	  endocytosis,	  including	  
the	   homologs	   of	   Synaptojanin	   and	   the	   AD	   risk	   factor	   PICALM.	   All	   three,	   the	   worm	  
YAP1802/PICALM	   homolog,	   the	   worm	   INP52/Synaptojanin	   homolog,	   and	   the	   worm	  
SLA1/SH3KBP1	   homolog,	   increased	   the	   percentage	   of	   worms	   with	   five	   intact	  
glutamatergic	  neurons	  (Figure	  C4.2A	  &	  B).	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   Next,	  we	  tested	  hits	   involved	   in	  a	  diverse	  array	  of	  other	  cellular	  pathways.	  The	  
yeast	  RTS1	  gene	  encodes	  a	  phosphatase	  regulatory	  subunit	  that	  controls	  several	  stress-­‐
response	  pathways.	  The	  ADE12	  gene	  product	  catalyzes	  the	  first	  step	  in	  the	  synthesis	  of	  
adenosine	  monophosphate	  from	  inosine	  5-­‐monophosphate.	  The	  C.	  elegans	  homologs	  of	  
RTS1/PPP2R5C	   and	   ADE12/ADSSL1	   suppressed	   the	   Aβ-­‐induced	   loss	   of	   glutamatergic	  
neurons	  (Figure	  C4.2A).	   	  We	  were	  unable	  to	  clone	  the	  worm	  homolog	  of	  CRM1,	  which	  
encodes	  a	  highly	  conserved	  nuclear	  export	  receptor.	  	  However,	  expression	  of	  the	  highly	  
homologous	  human	  XPO1	  gene	  significantly	  protected	  nematode	  glutamatergic	  neurons	  
from	  Aβ	   toxicity	   (Figure	  C4.2A).	   	   Finally,	  we	  asked	   if	   the	  effects	  of	  a	  genetic	  enhancer	  
also	   translated	   to	   the	   neuronal	   environment.	   Indeed,	   the	   C.	   elegans	   homolog	   of	  
PBS2/MAP2K4,	   a	   MAP	   kinase	   involved	   in	   stress	   responses,	   increased	   neuronal	   loss	  
(Figure	  C4.2A	  &	  B).	  We	  were	  unable	   to	   clone	   the	  worm	  homologs	   of	  GRR1	  and	  VPS9	  
(Table	  C4.1).	  	  
	   Every	   gene	  we	   tested	   in	  C.	   elegans	  modified	  Aβ	   toxicity	   in	   the	   same	  direction	  
(suppression	  vs.	  enhancement)	  in	  glutamatergic	  neurons	  as	  they	  did	  in	  yeast.	  The	  effect	  
of	  each	  of	   the	  candidate	  genes	  was	  statistically	   robust	   (p	  <	  0.05)	   for	  both	   the	  modest	  
neuronal	   toxicity	  evinced	  at	   three	  days	  and	  the	  more	  severe	   toxicity	  at	  seven	  days.	   In	  
contrast,	   expression	  of	   two	   control	   proteins,	  mCherry	   and	   LacZ,	   had	  no	  effect	   (Figure	  
C4.2A).	   The	   modifiers	   did	   not	   alter	   the	   levels	   of	   Aβ	   mRNA,	   as	   determined	   by	   semi-­‐
quantitative	   RT-­‐PCR	   (Supplemental	   Figure	   C4.5).	   Thus,	   the	   effects	   of	   the	   genetic	  
modifiers	  can	  be	  attributed	  to	  modification	  of	  Aβ	  toxicity	  itself.	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Figure	  C4.2:	  Hits	  from	  the	  screen	  modify	  the	  toxicity	  of	  Aβ	  in	  C.	  elegans	  glutamatergic	  
neurons	  in	  the	  same	  direction	  as	  they	  do	  in	  yeast.	  	  
(A)	  A	  new	  animal	  model	  of	  Aβ	  toxicity.	  Aβ	  1-­‐42,	  carrying	  a	  signal	  sequence	  targeting	  it	  to	  
the	   secretory	   compartment,	   was	   expressed	   in	   glutamatergic	   neurons	   that	   were	   also	  
expressing	   GFP.	   Neuronal	   death	   increased	   from	   50%	   at	   day	   3	   to	   75%	   at	   day	   7,	  
establishing	  that	  this	  worm	  model	  exhibits	  age-­‐dependent	  neurodegeneration.	  Control	  
genes	  mCherry	  and	  lacZ	  had	  no	  effect	  on	  Aβ-­‐induced	  neurodegeneration.	  Bar	  patterns	  
indicate	   distinct	   functional	   categories	   (crosshatches	   for	   endocytic	   genes).	   The	   genetic	  
modifiers	   tested	   influenced	   Aβ	   toxicity	   significantly	   (p	   <	   0.05,	   Student’s	   t-­‐Test).	   XPO1	  
was	   derived	   from	   human	   cDNA.	   Each	   gene	   was	   tested	   in	   three	   independently	  
established	   transgenic	   lines.	   (B)	   Representative	   examples	   of	   worms	   scored	   in	   Figure	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C4.2A	   at	   the	   third	   day	   of	   development.	   Arrowheads	   indicate	   neuronal	   cell	   bodies,	  
marked	  by	  transgenic	  expression	  of	  GFP.	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PICALM	  suppresses	  the	  toxicity	  of	  soluble	  Aβ	  oligomers	  in	  rat	  cortical	  neurons	  	  
	   Next,	  we	  asked	   if	   the	   toxicity	  elicited	  by	   targeted	  expression	  of	  Aβ	  1-­‐42	   in	   the	  
secretory	   compartment	   of	   yeast	   and	   in	   nematode	   glutamatergic	   neurons	   correlated	  
with	   the	   toxicity	   of	   soluble	   Aβ	   1-­‐42	   oligomers	   externally	   applied	   to	   neuronal	   cells.	  
Oligomeric	   Aβ	   1-­‐42	   species	   are	   found	   naturally	   in	   AD	   and	   thought	   to	   be	   causal	   in	  
disease.	   Oligomeric	   species	   generated	   using	   synthetic	   peptide	   are	   increasingly	  
employed	   with	   tissue	   culture	   cells	   and	   primary	   neuronal	   cultures	   to	   investigate	   Aβ	  
proteotoxicity	   (BERMAN,	   et	   al.	   2008;	   BOZYCZKO-­‐COYNE,	   et	   al.	   2001;	   KAYED,	   et	   al.	   2003).	  	  
Whether	  the	  acute	  toxicities	  observed	  in	  such	  cell	  cultures	  (massive	  cellular	  death	  after	  
as	   little	  as	  24	  hrs)	  are	  subject	   to	  modification	  by	   the	  same	  human	  genetic	   risk	   factors	  
that	   alter	   disease	   onset	   after	   many	   decades	   of	   life	   has	   only	   begun	   to	   be	   explored	  
(TROMMER,	  et	  al.	  2005).	  
	   To	   analyze	   a	   neuronal	   population	   particularly	   relevant	   to	   AD,	   we	   prepared	  
primary	   cultures	   from	   rat	   cortical	   neurons.	   Soluble	   Aβ	   oligomers	   prepared	   from	  
synthetic	   peptide	   were	   extremely	   toxic	   to	   these	   cells	   (Figure	   C4.3,	   GFP	   control	  
infections).	  Transfection	  with	   lentivirus	  engineered	  to	  express	  PICALM	   rescued	  toxicity	  
in	  a	  dose-­‐dependent	  manner	  (Figure	  C4.3).	  RAB1,	  a	  gene	  that	  we	  have	  previously	  shown	  
to	   protect	   neurons	   from	  α-­‐syn	   induced	   toxicity	   (COOPER,	   et	   al.	   2006),	   was	   unable	   to	  
diminish	   the	   cell	   death	   induced	  by	  Aβ	  oligomers	   (Figure	  C4.3).	   Thus,	   the	   efficacy	  of	   a	  
gene	  identified	  in	  yeast	  as	  a	  modifier	  of	  Aβ	  toxicity	  is	  recapitulated	  in	  neurons.	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Figure	  C4.3:	  PICALM	  protects	  cultured	  rat	  cortical	  neurons	  from	  exogenously	  applied	  
Aβ	  oligomers.	  	  
Cortical	  neuron	  cultures	  prepared	  from	  rat	  embryos	  at	  embryonic	  day	  18	  were	  cultured	  
for	   5	   days,	   transduced,	   cultured	   for	   13	   days,	   and	   then	   incubated	   for	   20	   hours	   with	  
750nM	   of	   soluble	   Aβ	   oligomers	   prepared	   from	   synthetic	   peptide	   (See	   Supplemental	  
Materials	   for	   details).	   	   Cell	   viability	   was	   assessed	   by	   ATP	   content.	   Infection	   with	   a	  
PICALM	   lentiviral	   construct	   diminished	   toxicity	   in	   a	   dose-­‐dependent,	   statistically	  
significant	  manner.	  The	  GFP	  control	  and	  RAB1,	  a	  suppressor	  of	  neuronal	  α-­‐syn	  toxicity,	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had	  no	  significant	  effect.	  Data	  are	  representative	  of	  three	  independent	  experiments	  and	  
shown	  as	  mean	  +/-­‐	  SEM	  (	  *,	  	  p<0.05;	  **,	  p<0.01,	  based	  on	  Dunnett’s	  test).	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Effect	  of	  Aβ	  on	  endocytosis	  and	  trafficking	  	  	  
Having	   validated	   our	   approach	   to	   the	   discovery	   of	   Aβ	   toxicity	   modifiers,	   we	  
returned	  to	  yeast	  to	  investigate	  the	  mechanistic	  connections	  between	  Aβ	  and	  the	  three	  
modifiers	   that	   affect	   the	   same	   cellular	   process,	   clathrin-­‐mediated	   endocytosis.	   The	  
member	  of	  this	  class	  with	  a	  clear	  risk	  association	  to	  AD,	  PICALM,	  has	  been	  postulated	  to	  
affect	  disease	  through	  modifications	  of	  APP	  trafficking.	  However,	  our	  cells	  express	  Aβ	  1-­‐
42	  directly,	  establishing	  a	  link	  between	  PICALM	  and	  Aβ	  toxicity	  itself.	  	  
	   Endocytosis	  might	  modulate	  Aβ	   toxicity	   simply	  by	   shunting	   toxic	  Aβ	   species	   to	  
cellular	   compartments	   where	   they	   are	   inherently	   less	   toxic	   or	   are	   more	   subject	   to	  
degradation.	  On	  the	  other	  hand,	  Aβ	  might	  specifically	   impair	  the	  endocytic	  machinery,	  
with	  an	  increase	  in	  this	  function	  then	  being	  required	  to	  ameliorate	  that	  defect.	  To	  assay	  
the	   impact	  of	  Aβ	  on	  the	  trafficking	  of	  a	  substrate	  of	  endocytosis	  we	  examined	  Ste3,	  a	  
mating	  pheromone	  receptor	  that	  is	  targeted	  to	  the	  plasma	  membrane.	  In	  the	  absence	  of	  
its	   mating	   hormone	   ligand,	   Ste3	   is	   constitutively	   endocytosed	   and	   degraded	   in	   the	  
vacuole	   (MALDONADO-­‐BAEZ,	   et	   al.	   2008).	   As	   expected	   from	   previous	   work,	   a	   Ste3-­‐YFP	  
fusion	   was	   primarily	   localized	   to	   the	   vacuole	   in	   our	   control	   strain.	   In	   Aβ	   -­‐expressing	  
strains	  Ste3-­‐YFP	  was	  instead	  found	  in	  foci	  surrounding	  the	  vacuole.	  Thus,	  Aβ	  caused	  an	  
explicit	  defect	  in	  the	  endocytic	  trafficking	  of	  this	  receptor	  (Figure	  C4.4A).	  	  
	   All	   three	   of	   the	   Aβ	   toxicity	   modifiers	   that	   function	   in	   endocytic	   trafficking,	  
Yap1802,	  Inp52	  and	  Sla1,	  reversed	  the	  defect	  in	  Ste3-­‐YFP	  trafficking.	  Since	  the	  proteins	  
encoded	  by	   these	   genes	   function	   in	  multi	   protein	   complexes,	   and	   since	   several	   other	  
gene	  products	  modified	  Aβ	  toxicity	  in	  ways	  that	  might	  impinge	  on	  endocytic	  trafficking,	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one	  would	  not	  expect	  a	  complete	  phenotypic	  reversal	   from	  the	  overexpression	  of	  any	  
one	  protein.	  Indeed,	  vacuolar	  localization	  was	  restored	  in	  some	  cells,	  but	  by	  no	  means	  
all	  (Figure	  C4.4A	  &	  Supplemental	  Figure	  C4.6).	  	  
Next,	  we	  monitored	  endocytic	  trafficking	  in	  a	  yeast	  strain	  in	  which	  clathrin	  light	  
chain	   was	   endogenously	   tagged	   with	   GFP	   (Clc1-­‐GFP).	   As	   expected,	   the	   control	   strain	  
exhibited	  only	  a	  few	  faint	  foci	  of	  Clc1-­‐GFP	  	  (SUN,	  et	  al.	  2007).	  Aβ	  dramatically	  perturbed	  
clathrin	   localization,	   increasing	  the	  number	  and	  brightness	  of	   foci	  but	  decreasing	  their	  
size	   (Figure	   C4.4B	  &	   Supplemental	   Figure	   C4.7A).	   	   This	   confirmed	   the	   effect	   of	   Aβ	  on	  
endocytic	  trafficking.	   	  Further,	  the	  small	   foci	  of	  Clc1-­‐GFP	  in	  the	  Aβ	  strain	  suggested	  an	  
effect	  on	  the	  processing	  of	  endocytic	  intermediates.	  	  
Yap1802	   and	   Sla1	   promote	   clathrin	   assembly	   	   (MALDONADO-­‐BAEZ,	   et	   al.	   2008),	  
while	  Inp52	  facilitates	  fission	  and	  uncoating	  of	  clathrin	  vesicles	  	  (STEFAN,	  et	  al.	  2005).	  This	  
suggested	   that	   the	  genetic	  modifiers	  might	   ameliorate	  endocytic	   trafficking	   in	  distinct	  
ways.	   Indeed,	  Yap1802,	   the	  yeast	  PICALM	  homolog,	   increased	  the	  number	  of	  clathrin-­‐
containing	  foci	  (Figure	  C4.4B).	  Sla1	  subtly	  increased	  them	  (Supplemental	  Figure	  C4.7B).	  
Inp52,	   the	   homolog	   of	   Synaptojanin,	   decreased	   them	   (Figure	   C4.4B).	   Thus,	   all	   three	  
endocytic	   modifiers	   attenuate	   the	   Aβ	   induced	   trafficking	   defect	   by	   increasing	   flux	  
through	  the	  endocytic	  pathway.	  Yap1802	  and	  Sla1	  did	  so	  by	  increasing	  the	  assembly	  of	  
clathrin-­‐coated	  vesicles,	  Inp52	  by	  increasing	  processing	  of	  those	  vesicles.	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Figure	  C4.4:	  Aβ	  causes	  defects	  in	  endocytosis	  and	  receptor	  protein	  trafficking.	  	  
(A)	  Aβ	  1-­‐42	  caused	  a	  defect	  in	  the	  trafficking	  of	  Ste3-­‐YFP,	  a	  hormonal	  receptor	  protein.	  
In	  controls	  Ste3-­‐YFP	  was	  trafficked	  to	  the	  vacuole;	  in	  contrast	  Aβ	  expression	  resulted	  in	  
the	  accumulation	  of	  Ste3-­‐YFP	  in	  cytoplasmic	  foci.	  Co-­‐expression	  of	  YAP1802,	  INP52	  and	  
SLA1	  (Supplemental	  Figure	  C4.6)	  suppressed	  this	  effect.	  Ste3-­‐YFP	  was	  expressed	  from	  a	  
construct	  integrated	  in	  either	  a	  control	  or	  a	  screening	  strain	  using	  the	  constitutive	  GPD	  
promoter.	   (B)	  Expression	  of	   ssAβ	   1-­‐42	   in	   a	   strain	  with	  GFP-­‐tagged	   clathrin	   light	   chain	  
(Clc1-­‐GFP)	   resulted	   in	   an	   increase	   of	   Clc1-­‐GFP	   foci,	   representing	   endocytic	  
intermediates.	  Co-­‐expression	  of	  YAP1802	  enhanced,	  and	   INP52	   reversed,	   the	  effect	  of	  
Aβ.	   SLA1	   subtly	   enhanced	   foci	   formation	   (Supplemental	   Figure	   C4.7B).	   The	   screening	  
strain,	   with	   integrated	   copies	   of	   ssAβ	   1-­‐42,	   was	   mated	   to	   cells	   expressing	   Clc1-­‐GFP	  
strain	   and	   transformed	   with	   single	   copy	   control	   and	   test	   plasmids.	   INP52,	   YAP1802,	  
SLA1	  and	  ssAβ	  were	  expressed	  using	  the	  inducible	  GAL1	  promoter.	  Scale	  bars	  are	  5µm	  
and	  all	  figures	  are	  on	  the	  same	  scale.	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Conclusions	  and	  Perspectives	  	  	  
	   The	   treatments	   available	   for	   Alzheimer's	   disease	   are	   few	   and	   their	   efficacy	  
limited.	   The	   complexity	   of	   deciphering	   how	   best	   to	   rescue	   neuronal	   function	   in	   the	  
context	   of	   the	   whole	   brain	   is	   of	   staggering	   proportions.	   Our	   model	   enabled	   us	   to	  
conduct	   an	  unbiased	   screen	  of	   the	  entire	   yeast	   genome	   for	  Aβ	   toxicity	  modifiers.	  We	  
connected	  a	  diverse	  group	  of	  genes	  and	  pathways	  to	  Aβ	  toxicity	   in	  a	  manner	  that	  has	  
clear	  relevance	  to	  neurons	  and	  human	  disease.	  These	  connections	  are	  conserved	  across	  
a	  billion	  years	  of	  evolution	  and	  can	  counteract	  both	  the	  extracellular	  administration	  of	  
Aβ	   oligomers	   to	   cortical	   neurons	   and	   the	   targeted	   expression	   of	   Aβ	   in	   the	   secretory	  
compartment	  of	  yeast	  and	  nematode	  neurons.	  This	  confirms	  previous	  suggestions	  that	  
the	  toxic	  conformers	  of	  Aβ	  are	  related	  to	  very	  ancient	  problems	  in	  protein	  homeostasis	  	  
(COHEN,	  et	  al.	  2006;	  KAYED,	  et	  al.	  2003).	  	  	  
	   Of	  the	  twelve	  most	  highly	  conserved	  modifiers,	  three	  affected	  clathrin-­‐mediated	  
endocytosis	   (Table	  C4.1),	  establishing	  this	  process	  as	  a	  key	  point	  of	  vulnerability	  to	  Aβ	  
toxicity.	   Neurons	   would	   naturally	   be	   particularly	   vulnerable	   to	   such	   a	   defect	   as	   they	  
must	  constantly	  recycle	  neurotransmitters	  and	  receptors	  	  (JUNG,	  et	  al.	  2007).	  Indeed,	  as	  
this	  manuscript	  was	  being	  submitted,	   two	  GWAS	  analyses	   identified	  CD2AP	  as	  a	  novel	  
AD	   risk	   factor	   (HOLLINGWORTH,	   et	  al.	   2011;	  NAJ,	   et	  al.	   2011).	   This	  protein	   functions	   in	  a	  
complex	   with	   SH3KBP1	   (also	   known	   as	   CIN85)	   (GAIDOS,	   et	   al.	   2007),	   the	   functional	  
homolog	  of	  our	  Aβ	  modifier	  SLA1,	   linking	  actin	  dynamics	   to	  endocytosis.	   In	   total,	   four	  
AD	   risk	   factors	   (PICALM,	   BIN1,	   CD2AP,	   and	   CD33)	   are	   involved	   in	   endocytosis	  
	   159	  
(HOLLINGWORTH,	   et	   al.	   2011;	  NAJ,	   et	   al.	   2011);	   a	   process	  we	  establish	   is	   affected	  by	  Aβ	  
toxicity.	  
	   Yeast	   cells	   to	   not	   express	   a	   recognizable	   homolog	   of	   Tau,	   a	   microtubule	  
associated	  protein	  that	  is	  a	  key	  component	  of	  Aβ	  toxicity	  in	  AD.	  	  It	  is	  notable,	  however,	  
that	   seven	   of	   the	   twelve	   conserved	   modifiers	   are	   functionally	   associated	   with	   the	  
cytoskeleton,	   suggesting	   a	  more	   deeply	   rooted	   connection	   between	   the	   cytoskeleton	  
and	  Aβ	  toxicity,	  likely	  involving	  its	  roles	  in	  vesicle	  trafficking.	  The	  connections	  between	  
Aβ	  toxicity	  and	  the	  modifiers	  with	  more	  diverse	  cellular	  functions	  are	  at	  present	  unclear.	  
However,	  if	  the	  associations	  we	  uncovered	  in	  human	  GWAS	  analyses	  for	  SNPs	  in	  XPO1,	  
ADSSL1	  and	  RABGEF1	  prove	  valid,	  the	  high	  degree	  of	  conservation	  in	  these	  genes	  should	  
make	  their	  roles	  in	  AD	  risk	  also	  accessible	  to	  analysis	  in	  yeast.	  
	   In	  recent	  years	  a	  number	  of	  neuronal	  models	  of	  AD	  have	  emerged,	  offering	  an	  
unprecedented	   opportunity	   for	   preclinical	   evaluation	   of	   therapeutic	   strategies.	   Our	  
yeast	  model	  provides	  a	  new	  tool	   to	   funnel	  genetic	   leads	   into	   these	  systems.	   It	   should	  
also	  provide	  a	  means	   for	   screening	   large	   chemical	   libraries	   for	   compounds	   that	  might	  
target	   the	   basic	   underlying	   cellular	   toxicities	   of	   Aβ	   1-­‐42.	   	   Combined	   with	   genetic	  
analyses,	   this	   may	   facilitate	   a	   personalized	   medical	   approach	   to	   this	   profoundly	  
devastating	  and	  complex	  disease.	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Materials	  and	  Methods	  
Constructs,	  strains	  and	  growth	  conditions	  
The	   ssAβ1-­‐42	   construct	   consists	   of	   attB	   sites	   for	   Gateway	   cloning	   the	   Kar2	   signal	  
sequence	   and	   the	   Aβ1-­‐42	   sequence.	   The	   Aβ	   sequence	   was	   codon	   optimized	   for	  
expression	  in	  yeast.	  The	  entire	  construct	  was	  synthesized	  and	  cloned	  into	  the	  Gateway	  
entry	  vector	  pDONR221.	  








ACCCAGCTTTCTTGTACAAAGTGGT	  (Gateway	  flanking	  region)	  
The	  same	  approach	  was	  used	  to	  generate	  the	  ssAβ1-­‐40	  construct.	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The	  BPTI	  WT	  and	  C51A	  constructs	  were	  the	  kind	  gift	  of	  Dane	  Wittrup	  	  (KOWALSKI,	  
et	  al.	  1998).	  The	  original	  BPTI	  construct	  do	  contain	  a	  signal	  sequence,	  but	  we	  replaced	  it	  
with	  the	  Kar2	  signal	  sequence	   in	  order	  to	  target	  them	  in	  the	  same	  manner	  as	  Aβ.	  The	  
Kar2ss	   sequence	   and	   Gateway	   flanking	   regions	   were	   added	   to	   the	   BPTI	   ORFs	   using	  
overlap	  extension	  PCR.	  	  
The	  Pdi1	  gene	  is	  part	  of	  the	  overexpression	  library	  used	  in	  the	  screen.	  The	  Pdi1	  
gene	  was	  gateway	  cloned	  into	  the	  pDONR221	  entry	  vector.	  The	  Aβ	  and	  BPTI	  constructs	  
as	   well	   as	   Pdi1	   were	   cloned	   into	   the	   pAG	   Gal	   p426	   vector	   (ALBERTI,	   et	   al.	   2007).	  
Constructs	  were	  transformed	  into	  W303	  Mat	  α,	  can1-­‐100,	  his3-­‐11,15,	  leu2-­‐3,112,	  trp1-­‐
1,	  ura3-­‐1,	  ade2-­‐1	  using	  a	  standard	  lithium	  acetate	  transformation	  protocol.	  
To	  generate	  ssAβ1-­‐42	  screening	  strains	  the	  ssAβ1-­‐42	  construct	  was	  moved	  to	  a	  pAG	  Gal	  
p305	  expression	  vector	  	  (ALBERTI,	  et	  al.	  2007).	  The	  plasmid	  was	  digested	  using	  BstX1,	  gel	  
purified	   and	   transformed	   into	  W303.	   The	   transformation	  was	   carried	  out	   in	   duplicate	  
and	   the	   level	   of	   growth	   of	   16	   transformants	   each	   was	   tested	   on	   synthetic	   deficient	  
media	  lacking	  leucine	  with	  galactose.	  Two	  strains	  from	  the	  independent	  transformations	  
where	  chosen	  as	  screening	  strains	  based	  on	  their	  robust	  yet	   intermediate	  toxicity	  that	  
would	   allow	   for	   the	   identification	   of	   both	   suppressors	   and	   enhancers.	   Several	  
transformants	   that	   showed	   no	   toxicity	   were	   chosen	   as	   1xssAβ	   controls.	   The	   control	  
strain	  for	  wild	  type	  yeast	  growth	  is	  carrying	  a	  Gal	  inducible	  YFP	  integrated	  in	  the	  same	  
fashion	  as	  the	  ssAβ1-­‐42	  constructs.	  
For	   spotting	   assays	   strains	   were	   grown	   over	   night	   at	   30°C	   in	   3ml	   SD	   media	  
lacking	   the	   relevant	   amino	   acids	   and	   containing	   glucose.	   Cell	   concentrations	   (OD600)	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were	  adjusted	  in	  a	  96-­‐well	  plate	  to	  that	  of	  the	  strain	  with	  the	  lowest	  concentration.	  Cells	  
were	   then	   5-­‐fold	   serially	   diluted	   and	   spotted	   on	   SD	   media	   containing	   glucose	  




Strains	  were	  grown	  in	  synthetic	  deficient	  media	  lacking	  leucine	  and	  uracil	  (SD-­‐Leu-­‐Ura)	  
with	   raffinose	   overnight	   at	   30°C.	   Cultures	   were	   the	   diluted	   into	   inducing	   media	  
containing	  galactose	  (OD600	  0.2)	  and	  grown	  for	  8h.	  Cells	  were	  spun	  down	  for	  5min	  at	  
3,000rpm.	  For	  preparation	  of	  yeast	  lysates,	  yeast	  pellets	  were	  resupsended	  in	  200	  µL	  of	  
yeast	   lysis	  buffer	  (50	  mM	  HEPES	  pH	  7.5,	  150	  mM	  NaCl,	  2.5	  mM	  EDTA,	  1%	  v/v	  Triton-­‐X	  
100	   with	   protease	   inhibitors).	   To	   this	   solution,	   200	   µL	   of	   glass	   beads	   (Aldrich)	   were	  
added,	   and	   the	   yeast	   were	   bead	   beated	   for	   3	   minutes	   on	   maximum	   speed	   at	   4°C.	  
Afterwards,	   the	   sample	   was	   retrieved	   by	   puncturing	   a	   hole	   in	   the	   bottom	   of	   the	  
eppendorf	  tube	  and	  spinning	  the	  samples	  into	  a	  new	  tube	  at	  6,000	  rpm	  for	  15	  seconds.	  
The	  supernatant	  was	  transferred	  to	  a	  new	  tube,	  and	  this	  solution	  was	  used	  as	  the	  lysate.	  	  
	  
Western	  Blot	  Protocol	  
For	   the	  western	  blot,	   the	  protein	  concentrations	   in	   the	  yeast	   lysates	  were	  normalized	  
using	  the	  results	  from	  a	  BCA	  assay	  (Pierce).	  After	  normalization,	  samples	  were	  loaded	  on	  
a	   4-­‐12%	   Bis-­‐Tris	   gel	   (Invitrogen)	   and	   run	   at	   150	   V	   for	   approximately	   50	   minutes.	  
Subsequently,	   the	  samples	  were	   transferred	   to	  0.2	  micron	  PVDF	  membrane	   (Bio-­‐Rad).	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After	   the	   transfer	   was	   completed,	   the	   membrane	   was	   blocked	   with	   5%	   milk	   in	   PBS	  
overnight.	   The	  membrane	  was	   briefly	  washed	  with	   PBS	   before	   the	   primary	   antibody,	  
6E10	  (Covance)	  was	  added	  at	  a	  1:1,000	  dilution	  in	  5%	  milk	  in	  PBS.	  The	  primary	  antibody	  
was	  allowed	  to	   incubate	  for	  2.5	  hours,	  after	  which	  the	  blot	  was	  washed	  4	  x	  5	  minutes	  
with	   PBS.	   The	   anti-­‐mouse	   secondary	   (DyLight,	   Rockland)	   was	   added	   at	   a	   1:10,000	  
dilution	  in	  5%	  milk	  in	  PBS	  for	  1	  hour.	  The	  blot	  was	  washed	  4	  x	  5	  minutes	  with	  PBS.	  The	  
blot	  was	  scanned	  using	  the	  Licor	  Odyssey	  Scanner.	  
For	  detection	  of	  oligomers	  using	  the	  NAB61	  antibody,	  the	  antibody	  was	  diluted	  1:500	  in	  
5%	  milk	   in	  PBS	  and	   incubated	  with	   the	  blot.	  Subsequently,	   the	  blot	  was	  washed	  4	  x	  5	  
minutes	   with	   PBS.	   The	   anti-­‐mouse	   secondary	   (DyLight,	   Rockland)	   was	   added	   at	   a	  
1:10,000	  dilution	  in	  5%	  milk	  in	  PBS	  for	  1	  hour.	  The	  blot	  was	  washed	  4	  x	  5	  minutes	  with	  
PBS.	  The	  blot	  was	  scanned	  using	  the	  Licor	  Odyssey	  Scanner.	  
	  
Indirect	  ELISA	  Protocol	  
The	   indirect	   ELISA	   using	   the	   OMAB	   oligomer	   specific	   antibody	   was	   performed	   as	  
described	   in	   Lindhagen-­‐Persson	   et	   al.	   	   (LINDHAGEN-­‐PERSSON,	   et	   al.	   2010).	   Briefly,	   the	  
oligomer	   specific	   monoclonal	   OMAB	   antibody	   (Agrisera	   AB,	   Vännäs,	   Sweden)	   was	  
diluted	   to	   a	   concentration	   corresponding	   to	   5	   ug/ml	   and	   was	   coated	   to	   a	   96	   well	  
polystyrene	   microtiterplate	   (F96	   Nunc	   immunosorp,	   Denmark)	   overnight.	   Unspecific	  
sites	  were	  blocked	  using	  5%	  dry	  milk	  dissolved	  in	  PBS.	  	  Frozen	  yeast	  lysates	  were	  thawed	  
on	  ice	  and	  centrifuged	  at	  20,000	  g	  for	  5	  minutes	  followed	  3	  serial	  dilutions	  in	  PBS.	  The	  
plate	   coated	  with	  OMAB	  antibody	  was	  washed	  with	  water	   and	  100	  µl	   of	   the	   samples	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was	  applied	  in	  5	  replicates.	  The	  samples	  were	  incubated	  at	  room	  temp	  for	  25	  minutes,	  
and	  the	  plate	  was	  subsequently	  washed	  4	  x	  with	  PBS	  containing	  0.15%	  Tween	  20.	  Bound	  
Aβ	  was	  detected	  using	  a	  polyclonal	  rabbit	  anti-­‐Aβ	  antibody	  (antibody	  AS08	  357,	  Agrisera	  
AB,	  Vännäs	  Umeå)	  that	  was	  dissolved	  in	  blocking	  buffer	  at	  a	  1:2,000	  dilution.	  The	  rabbit	  
antibody	  was	   allowed	   to	   incubate	   for	   30	  minutes,	   after	   which	   the	   plate	  was	  washed	  
with	  PBS	  containing	  0.15%	  Tween	  20.	  A	  secondary	  anti-­‐rabbit	   IgG-­‐HRP	  (GE-­‐healthcare,	  
Buckinghamshar,	  UK)	  dissolved	  in	  blocking	  buffer	  was	  used	  to	  detect	  bound	  rabbit	  IgG.	  
Before	   addition	   of	   the	   detection	   reagent,	   excess	   secondary	   anti-­‐rabbit	   IgG-­‐HRP	   was	  
removed	   by	  washing	  with	   PBS	   containing	   0.15%	   Tween	   20.	   The	   plate	  was	   developed	  
using	  100	  µl	  EC-­‐blue®	  (Medicago,	  Uppsala,	  Sweden).	  Measurements	  were	  made	  at	  400	  
nm	   and	   600	   nm,	   and	   the	   absorption	   ratio	   between	   600nm	   and	   400	   nm	  was	   used	   to	  




Strains	   were	   pregrown	   in	   raffinose	   media	   over	   night	   and	   then	   induced	   in	   galactose	  
media	  for	  8	  hours	  (5ml	  OD600	  0.2).	  Cells	  were	  spun	  down	  and	  resuspended	  in	  1mL3.7%	  
formaldehyde	   (37%	   formaldehyde	   in	   0.1M	   KPi	   (potassium	   phosphate	   buffer)	   pH6.4)	  
after	  removal	  of	  supernatant.	  Cells	  were	  fixed	  over	  night	  at	  4°C.	  After	  the	  fixation	  cells	  
were	  washed	   three	   time	   in	  1mL	  0.1M	  KPi	  pH	  6.4	  and	   then	   resuspended	   in	  1mL	  1.2M	  
sorbitol-­‐citrate	   buffer	   (1L:	   218.6g	   sorbitol,	   17.40g	   anyhydorus	   K2HPO4,	   7g	   citric	   acid;	  
filter	  sterilize).	  Cells	  were	  spun	  down	  again	  and	  resuspended	  in	  200µl	  of	  digestion	  mix	  
	   171	  
(200µL	   1.2M	   sorbitol-­‐citrate,	   20µL	   glusolase	   and	   2µL	   10mg/mL	   zymolase).	   Cells	   were	  
incubated	   in	   the	   digestion	   mix	   for	   45min	   at	   30°C	   .	   During	   the	   incubation	   5µL	   0.1%	  
polylysine	  was	  added	  to	  each	  well	  of	  a	  30	  well	  slide	  (Thermo	  ER-­‐212W).	  After	  5min	  of	  
incubation	  the	  slides	  was	  washed	  with	  distilled	  water	  and	  allowed	  to	  air	  dry	  completely.	  
Digested	  cells	  were	  spun	  down	  at	  3,000	  rpm	  for	  3min	  and	  gently	   resuspended	   in	  1mL	  
sorbitol-­‐citrate.	   Cells	   were	   spun	   down	   again	   and	   then	   resuspended	   in	   a	   volume	   of	  
sorbitol	   citrate	   dependent	   on	   cell	   pellet	   size	   (15-­‐50µL).	   Five	  µL	   of	   cells	  was	   added	   to	  
each	  well	  and	  incubated	  for	  10min.	  Cells	  were	  removed	  from	  the	  side	  of	  the	  well	  using	  a	  
vacuum	  tip.	  If	  the	  cell	  density	  was	  low,	  as	  revealed	  by	  light	  microscopy,	  more	  cells	  were	  
added.	  The	  slides	  were	  then	  incubated	  in	  ice-­‐cold	  methanol	  for	  3min,	  followed	  by	  10sec	  
in	  ice-­‐cold	  acetone.	  Acetone	  was	  shook	  off	  and	  slides	  air-­‐dried.	  As	  the	  primary	  antibody	  
4µL	  of	  1:200	  6E10	  in	  PBS/BSA	  (1%	  BSA,	  0.04M	  K2HPO4,	  0.01M	  KH2PO4,	  0.15M	  NaCl,	  0.1%	  
NaN3;	  for	  100mL:	  1g	  BSA,	  4mL	  1M	  K2HPO4,	  1mL	  1M	  KH2PO4,	  15mL	  1M	  NaCl,	  1mL	  10%	  
NaN3,	   sterilized	  water	   to	   100mL)	  were	   added	   to	   each	  well.	   Slide	  was	   incubated	   over	  
night	   at	   room	   temperature	   in	   a	  wet	   chamber.	   After	   the	   incubation	   the	   antibody	  was	  
removed	  using	  a	  vacuum	  tip	  and	  each	  well	  was	  washed	  3	  times	  with	  PBS/BSA.	  Then	  4µL	  
of	   the	   secondary	   antibody,	   1:100	   anti-­‐mouse	   FITC,	   was	   added	   to	   each	   well	   and	  
incubated	  for	  2	  hours.	  Subsequently,	  each	  well	  was	  washed	  4	  times	  with	  PBS/BSA.	  One	  
µL	  of	  DAPI-­‐MOUNT	  was	  added	  to	  each	  well	  prior	  to	  adding	  the	  coverslip	  and	  sealing	  the	  
slide	  with	  nail	  polish.	  	  
For	   co-­‐immunostaining	   cells	  were	  processed	  as	  described	  above	  but	   incubated	  
with	   1:200	   6E10	   and	   1:100	   rabbit	   anti-­‐GFP	   in	   PBS/BSA	   and	   subsequently	   1:100	   anti-­‐
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mouse	  Alexa	  Fluor	  594	  and	  1:100	  anti-­‐rabbit	  Alexa	  Fluor	  488	  in	  PBS/BSA	  simultaneously.	  
The	  GFP-­‐tagged	  strains	  are	  part	  of	  the	  yeast	  GFP	  library	  	  (HOWSON,	  et	  al.	  2005).	  
Images	  were	  taken	  on	  a	  Zeiss	  Aviovert.	  Final	  images	  were	  assembled	  from	  the	  different	  
channels	   (GFP,	   DAPI	   and	   dsRed)	   in	   Adobe	   Photoshop.	   Brightness	   and	   contrast	   were	  
adjusted	  equally	  for	  all	  images.	  
	  
Screen	  for	  modifiers	  of	  Aβ	  toxicity	  
The	  overexpression	  library	  screened	  contains	  ~5800	  full-­‐length	  sequence	  verified	  yeast	  
ORFs	  in	  the	  galactose-­‐inducible	  Gateway	  expression	  plasmid	  pBY011	  (CEN,	  URA3,	  AmpR)	  	  
(OUTEIRO,	   et	   al.	   2003).	   The	   library	   is	   arrayed	   in	   96-­‐well	   format.	   Plasmid	   DNA	   was	  
prepared	   by	   pin	   inoculation	   into	   deep	   well	   96-­‐well	   plates	   containing	   1.8mL	   LB-­‐AMP,	  
growth	  over	  night	   at	  37°C	  and	  96-­‐well	  mini	  preps	  using	  a	  Qiagen	  BioRobot	  8000.	   The	  
DNA	  was	  transformed	  into	  a	  ssAβ	  screening	  strain	  (ssAβ1-­‐42	  p305)	  carrying	  a	  Gal4-­‐ER-­‐
VP16	  plasmid	   (CEN,	  HIS3,	  AmpR),	  which	  allows	   for	  expression	   from	  GAL	  promoters	  on	  
carbon	   sources	   other	   than	   galactose	   in	   the	   presence	   of	   estradiol	   in	   the	   yeast	   media	  	  
(QUINTERO,	  et	  al.	  2007).	  Neither	  estradiol	  nor	  the	  Gal4-­‐ER-­‐VP16	  plasmid	  had	  an	  effect	  on	  
Aβ	   toxicity	   on	   its	   own.	   Transformations	   were	   carried	   out	   using	   a	   standard	   lithium	  
acetate	   transformation	  protocol	  adapted	   for	  a	  96-­‐well	   format	  and	  automation	  using	  a	  
Tecan	  Evo	  150	   liquid	  handling	   robot.	  Transformants	  were	  grown	   in	   synthetic	  deficient	  
media	  lacking	  histidine,	  leucine,	  and	  uracil	  (SD-­‐His-­‐Leu-­‐Ura)	  with	  glusose	  overnight.	  The	  
cells	  were	  then	  diluted	   in	  water	  and	  spotted	  on	  SD-­‐His-­‐Leu-­‐Ura	  agar	  plates	  containing	  
glucose	   alone	   (control),	   galactose	   alone,	   glucose	  plus	   1µM	  estradiol	   (Sigma	  E1024)	   or	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glycerol	  plus	  1µM	  estradiol	  using	  a	  Singer	  RoToR	  pinning	   robot	  and	   long	  96-­‐well	  pins.	  
Putative	   enhancers	   and	   suppressors	  were	   identified	   after	   2-­‐4	  days	  of	   growth	   at	   30°C.	  
Putative	   screen	   hits	   were	   cherry	   picked	   from	   the	   plasmid	   library,	   retransformed	   into	  
two	   independent	   derived	   ssAβ	   screening	   strains	   and	   retested	   on	   the	   three	   screening	  
conditions	   in	   two	   independently	   derived	   strains.	  We	  eliminated	  hits	   that	   have	   known	  
effects	  on	  GAL	  induction	  and	  genes	  whose	  overexpression	  has	  previously	  been	  shown	  to	  
be	   toxic.	   To	   further	   exclude	   false-­‐positive	   suppressors	   we	   used	   flow	   cytometry	   to	  
measure	   the	   expression	   of	   YFP	   in	   their	   presence.	   To	   further	   exclude	   false-­‐positive	  
enhancers	   that	   cause	   a	   general	   inhibition	   when	   overexpressed	   we	   examined	   their	  
effects	   in	   the	   YFP	   control	   strain,	   which	   has	   no	   growth	   impairment.	   The	   identity	   of	  
confirmed	  modifiers	  was	  verified	  by	  sequencing.	  
	  
Flow	  cytometry	  
A	  strain	  carrying	  an	  integrated	  YFP	  was	  transformed	  with	  the	  putative	  Aβ	  suppressors.	  
The	  resulting	  strains	  were	  grown	  in	  glucose	  media	  in	  a	  96-­‐well	  format,	  diluted	  into	  the	  
various	   inducing	  media	   (galactose,	   glucose	   +1µM	   estradiol,	   glycerol	   +	   1µM	   estradiol)	  
[5µL	  culture	  added	  to	  120µL	  media],	  and	  incubated	  over	  night	  at	  30°C	  with	  mild	  shaking.	  
These	  overnight	  cultures	  were	  diluted	  20fold	  into	  water	  and	  YFP	  levels	  were	  measured	  
using	  a	  Guava	   flow	  cytometer.	  Each	  strain	  was	  measured	  3	  times	  and	  5000	  cells	  were	  
counted	  for	  each	  well.	  The	  whole	  experiment	  was	  repeated	  3	  times.	  Values	  are	  averages	  
of	  these	  3	  experiments	  and	  reported	  in	  percent	  of	  the	  vector	  control	  strain	  YFP	  levels.	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Analysis	  of	  ROS	  and	  MAP	  data	  sets	  
We	  leveraged	  available	  genotyping,	  and	  extensive	  clinical	  and	  pathological	  data	  
from	  two	  large	  epidemiological	  studies	  of	  aging,	  cognition,	  and	  AD:	  the	  Religious	  Orders	  
Study	   (ROS)	   and	   the	   Rush	   Memory	   and	   Aging	   Project	   (MAP).	   These	   studies	   enlisted	  
more	   than	   2,300	   older	   persons,	   without	   dementia	   at	   baseline,	   who	   were	   clinically	  
evaluated	  annually	  and	  who	  agreed	  to	  brain	  donation	  upon	  death.	  Nearly	  900	  autopsies	  
have	  been	  completed.	  Recent	  studies	   in	   these	  cohorts	  demonstrate	  how	   intermediate	  
AD-­‐related	   cognitive	   and	   pathological	   phenotypes	   can	   enhance	   power	   for	   genetic	  
association	  analysis	  (6-­‐8).	  For	  our	  study,	  we	  utilized	  a	  combined	  cohort	  of	  1,593	  ROS	  and	  
MAP	   subjects	   with	   longitudinal	   neuropsychiatric	   assessments	   and	   genome-­‐wide	  
genotyping,	  and	  a	  nested	  pathological	  cohort	  including	  651	  brain	  autopsies	  (Table	  S3).	  
We	   initially	   determined	  whether	   the	  modifiers	   correspond	   to	   loci	   that	   impact	  
susceptibility	   for	  episodic	  memory	  decline,	  a	   cardinal	   feature	  of	  AD.	   In	  ROS	  and	  MAP,	  
rate-­‐of-­‐change	  in	  memory	  performance	  is	  characterized	  based	  on	  repeated	  assessment	  
of	  7	  neuropsychiatric	  tests,	  and	  our	  analyses	  were	  additionally	  adjusted	  for	  age,	  gender	  
and	   years	   of	   education.	  We	   implemented	   a	   locus-­‐based	   association	   test	   for	  memory	  
decline,	   considering	   all	   common	   single	   nucleotide	   polymorphisms	   (SNPs)	   at	   each	  
candidate	  locus,	   including	  both	  directly	  genotyped	  and	  imputed	  variants,	  based	  on	  the	  
HapMap	   reference	   	   (FRAZER,	   et	   al.	   2007)	   (Table	   S4	   &	   S5).	   We	   tested	   if	   the	   observed	  
associations	  were	   significant,	   by	   performing	   a	   permutation	   procedure	   to	   compute	   an	  
empirical	  P-­‐value	  (Pperm),	  adjusting	  for	  the	  multiple	  tests	  performed	  at	  each	  locus.	  Aside	  
from	   PICALM	   (rs7128598,	   p-­‐value=1.6x10-­‐4,	   Pperm=0.012),	   several	   other	   loci	   harbored	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SNPs	   suggesting	   association	   with	   memory	   decline,	   but	   these	   results	   did	   not	   remain	  
significant	  following	  permutation	  (Table	  S5).	  	  
We	  investigated	  whether	  our	  modifiers	  are	  associated	  with	  the	  development	  of	  
AD	  neuropathology.	  These	  analyses	  used	  a	  quantitative	  summary	  measure	  of	  global	  AD	  
pathologic	   burden,	   based	   on	   counts	   of	   amyloid	   plaques	   and	   NFTs	   on	   brain	   tissue	  
sections.	  The	   relation	  of	  SNPs	  with	   this	  continuous	  measure	  of	  pathology	  were	   tested	  
using	   linear	  regression,	  adjusting	  for	  age	  at	  the	  time	  of	  death.	  Notably,	  these	  analyses	  
indicate	   association	   of	   2	   additional	   loci	   identified	   by	   our	   yeast	   screen,	   ADSSL1	  
(rs1128880,	  P=0.001,	  Pperm=0.031)	  and	  RABGEF1	  (rs17566701,	  P=0.002,	  Pperm=0.038)	  
with	   AD	   neuropathology	   (Table	   S6).	   Both	   of	   these	   loci	   also	   harbored	   suggestive	  
association	  signals	  with	  episodic	  memory	  decline	  in	  the	  larger	  clinical	  cohort,	  showing	  a	  
statistical	  trend	  toward	  significance	  following	  the	  permutation	  procedure	  (Table	  S5).	  	  
	  
Soluble	  Oligomer	  Preparation	  for	  Cortical	  Cell	  Culture	  
Soluble	   oligomers	   were	   prepared	   as	   in	   Kayed	   et	   al.	   	   (KAYED,	   et	   al.	   2003).	   In	   brief,	  
lyophilized	   Ab	   1-­‐42	   (American	   Peptide	   Company)	  was	   resuspended	   in	   200µL	   of	   	   HFIP	  
(1,1,1,3,3,3-­‐Hexafluoro-­‐2-­‐propanol,	  Aldrich),	  and	  this	  solution	  was	  bath	  sonicated	  for	  30	  
minutes.	  Subsequently,	  100µL	  of	  the	  HFIP	  solution	  was	  added	  to	  900µL	  of	  ddH2O	  in	  a	  
siliconized	  eppendorf	  tube.	  This	  solution	  was	  incubated	  at	  room	  temperature	  for	  10-­‐20	  
minutes.	   After	   the	   room	   temperature	   incubation,	   the	   HFIP	   in	   the	   sample	   was	  
evaporated	  using	  a	  gentle	  stream	  of	  N2	  for	  approximately	  20	  minutes.	  The	  samples	  were	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allowed	   to	   incubate	   at	   room	   temperature	   for	   48	  hours,	   after	  which	   they	  were	   frozen	  
and	  stored	  at	  -­‐80°C.	  
	  
Rat	  primary	  cortical	  cultures	  
Cultures	  were	  prepared	  based	  on	  Lesuisse	  and	  Martin	   	   (LESUISSE,	  et	  al.	  2002).	  Embryos	  
were	  harvested	  by	  cesarean	  section	  from	  anesthetized	  pregnant	  Sprague-­‐Dawley	  rats	  at	  
embryonic	   day	   18.	   Cerebral	   cortices	   were	   isolated	   and	   dissociated	   with	   Accumax	  
digestion	   for	   20	  min	   at	   37°C	   and	   triutration	  with	   Pasteur	   pipette.	   Poly-­‐ornithine	   and	  
lamine-­‐coated	  96-­‐well	  plates	  were	  seeded	  with	  4x104	  cells	   in	  neurobasal	  medium	  (Life	  
Technologies)	  supplemented	  with	  B27	  (Life	  Technologies),	  0.5mM	  glutamine,	  25µM	  β–
mercaptoethanol,	  penicillin	  (100	  IU/mL)	  and	  streptomycin	  (100µg/mL).	  One	  third	  of	  the	  
medium	  was	  changed	  every	  3	   to	  4	  days.	  Aβ	   oligomer	   (final	   concentration	  750	  nM)	  or	  
vehicle	  was	  added	  to	  the	  lentivirus-­‐transduced	  cultures	  in	  96-­‐well	  plates	  at	  DIV	  18.	  As	  a	  
surrogate	  marker	  of	  cell	  viability,	  cellular	  ATP	  content	  was	  measured	  after	  20	  hours	  of	  
Aβ	  oligomer	  incubation	  using	  ViaLight	  Plus	  kit	  (Lonza).	  
	  
Lentivirus	  production	  and	  transduction	  to	  rat	  primary	  cortical	  cultures	  
pLENTI6/V5	   DEST	   (Invitrogen)	   lentivirus	   expression	   vector	   was	   used	   to	   generate	  
lentivirus	  encoding	  GFP,	  PICALM	  and	  RAB1.	  Lentiviral	  constructs	  were	  packaged	  into	  
virus	   via	   lipid-­‐mediated	   transient	   transfection	   of	   the	   expression	   constructs	   and	  
packaging	  plasmids	   (pMD2.G	  and	  psPAX2)	   to	  293	  cells.	  Lentivirus	  was	  purified	  and	  
concentrated	  using	  Lenti-­‐X	  Maxi	  Purification	  kit	  and	  LentiX	  Concentrator	  	  (Clontech)	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according	   to	   the	  manufacturer's	   protocol.	   Lentivirus	   titer	   was	   determined	   using	  
QuickTiter	  Lentivirus	  titer	  kit	  	  (Lentivirus-­‐	  Associated	  HIV	  p24;	  Cell	  Biolabs)	  according	  
to	   the	  manufacturer's	  protocol.	  Rat	   cortical	   cultures	  were	   transduced	  with	  various	  
multiplicities	  of	  infection	  (MOI)	  of	  lentivirus	  at	  DIV	  5.	  	  
	  
Microscopy	  of	  Clc1-­‐GFP	  and	  Ste3-­‐YFP	  
We	  created	  our	  own	  version	  of	  the	  Ste3	  localization	  assay	  	  (MALDONADO-­‐BAEZ,	  et	  al.	  2008)	  
by	   generating	   a	  GPD-­‐driven	   Ste3-­‐YFP	   construct,	   using	   the	   Ste3	   plasmid	   from	  our	  ORF	  
library	   and	   a	   GPD	   p303	   vector	   from	   the	   pAG	   collection	   	   (ALBERTI,	   et	   al.	   2007),	   and	  
integrating	   it	   into	   an	   ssAβ	   1-­‐42	   screening	   strain	   as	   well	   as	   a	   control	   strain.	   For	   all	  
microscopy	  experiments	  strain	  were	  pre-­‐cultured	  in	  raffinose	  media	  and	  then	  induced	  in	  
galactose	   media.	   We	   tested	   the	   effect	   of	   selected	   modifiers	   by	   transforming	   these	  
strains	  with	  the	  modifiers	  and	  analyzing	  them	  in	  the	  same	  fashion.	  	  
To	   examine	   the	   effects	   of	   Aβ	   on	   endocytosis	   we	   used	   the	   clathrin	   light	   chain	  
(Clc1)-­‐GFP	  strain	  from	  the	  GFP	  library	  	  (HOWSON,	  et	  al.	  2005).	  In	  experiments	  to	  examine	  
the	   effects	   of	   Aβ	   alone	   we	   transformed	   the	   GFP-­‐fusion	   strain	   with	   the	   ssAβ	   1-­‐42	  
construct	  on	  a	  multi	   copy	   vector	   and	   the	   corresponding	   vector	   control.	  We	  also	  used	  
GFP-­‐fusion	  strain	  of	  other	  endocytic	  proteins	  (Abp1,	  Sla1	  and	  Sla2)	  and	  observed	  similar	  
Aβ-­‐induced	   changes	   in	   localization	   as	   with	   Clc1-­‐GFP	   (data	   not	   shown);	   yet	   the	  
fluorescence	  of	  these	  fusions	  was	  rather	  low.	  
To	  test	  the	  effects	  of	  screen	  hits	  on	  the	  Clc1-­‐GFP	  Aβ	  phenotype,	  we	  mated	  the	  
Clc1-­‐GFP	  fusion	  strain	  to	  a	  set	  of	  Aβ	  screening	  strains	  carrying	  individual	  modifiers.	  We	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used	   this	   approach	   as	   expression	   of	   two	   genes	   from	  plasmids,	   one	  with	   varying	   copy	  
number,	  can	  lead	  to	  inconsistent	  results	  when	  examining	  individual	  cells;	  as	  it	  is	  the	  case	  
for	  microscopy.	  Furthermore,	  the	  GFP-­‐fusion	  strains	  on	  their	  own	  are	  incompatible	  with	  
integration	  constructs	  due	  to	  their	  complete	  deletion	  of	  auxotrophic	  markers.	  While	  Aβ	  
toxicity	  was	  reduced	  in	  the	  resulting	  diploid,	  ssAβ	  1-­‐42	  expression	  resulted	  in	  the	  same	  
Clc1-­‐GFP	  phenotype.	  	  
For	   both	   assays,	   we	   found	   that	  modifiers	   alone	   had	   no	   effect	   on	   localization.	  
Expression	  was	   induced	   for	  16h	  and	  GFP	  or	   YFP	   fluorescence	  monitored	  using	  a	   Zeiss	  
Axiovert	  microscope.	  Brightness	  and	  contrast	  were	  adjusted	  equally	  for	  all	  images.	  
	  
C.	  elegans	  experiments:	  
Plasmid	  &	  Constructs	  
The	   following	   cDNAs	   were	   cloned	   into	   pDONR221	   using	   Gateway	   Technology	  
(Invitrogen,	  San	  Diego,	  CA):	  ssAβ	  1-­‐42	  (Chris	  Link,	  University	  of	  Colorado);	  gfp	  and	   lacZ	  
(Andy	   Fire,	   Stanford	   University);	   mCherry;	   C13G3.3,	   C32E8.10,	   and	   C37H5.6	   (Worm	  
ORFeome	  collection	   from	  Marc	  Vidal)	   	   (LAMESCH,	   et	  al.	   2004);	  XPO1	   (human	  ORFeome	  
collection	  from	  Marc	  Vidal)	  	  (LAMESCH,	  et	  al.	  2007);	  and	  JC8.10,	  Y44E3A.4,	  and	  F42G10.2.	  	  
JC8.10,	  Y44E3A.4,	   and	  F42G10.2	  were	   isolated	   from	  our	  C.	  elegans	   cDNA	   library.	   	   The	  
cDNAs	  were	   verified	   by	   DNA	   sequencing,	   and	   subsequently	   cloned	   into	   pDEST-­‐EAT-­‐4.	  
pDEST-­‐EAT-­‐4	  was	  generated	  by	  PCR	  amplification	  of	  a	  eat-­‐4	  promoter,	  double	  digestion	  
of	   the	  promoter	  and	  pDEST-­‐UNC-­‐54	  using	  BplI	   and	  KpnI,	  and	   replacement	  of	  a	  unc-­‐54	  
promoter	  in	  pDEST-­‐UNC-­‐54	  with	  a	  eat-­‐4	  promoter	  via	  ligation	  reaction.	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Nematode	  Strains	  
Nematodes	  were	  maintained	  following	  standard	  procedures	  (BRENNER	  1974).	  To	  make	  a	  
worm	   ssAβ	   1-­‐42	   model	   UA162	   [baEx107;	   Peat-­‐4::ssAβ	   1-­‐42,	   Peat-­‐4::gfp,	   Pmyo-­‐
2::mCherry],	   50	   µg/mL	   of	   Peat-­‐4::ssAβ	   1-­‐42	   and	   Peat-­‐4::gfp	   as	   well	   as	   2.5	   µg/mL	   of	  
Pmyo-­‐2::mCherry	   were	   injected	   into	   wildtype	   N2	   (Bristol)	   worms.	   	   This	   strain	   was	  
integrated	  by	  using	  Spectrolinker	  XL-­‐1500	  (Spectronics	  Corporation,	  Westbury,	  NY)	  and	  
outcrossed	   three	   times	   to	   N2	  worms	   to	   generate	   UA166	   [baInl32;	   Peat-­‐4::ssAβ	   1-­‐42,	  
Peat-­‐4::gfp,	   Pmyo-­‐2::mCherry].	   	   For	   neuroprotection	   analysis,	   three	   stable	   lines	   of	  
UA163	  [baEx108;	  [Peat-­‐4::C13G3.3,	  rol-­‐6	  (su1006)],	  UA164	  [baEx109;	  [Peat-­‐4::C32E8.10,	  
rol-­‐6	  (su1006)],	  and	  UA165	  [baEx110;	  [Peat-­‐4::C37H5.6,	  rol-­‐6	  (su1006)]	  were	  made	  and	  
crossed	   with	   UA166	   [baInl32;	   Peat-­‐4::ssAβ	   1-­‐42,	   Peat-­‐4::gfp,	   Pmyo-­‐2::mCherry]	   to	  
generate	  UA167	   {[baInl32;	  Peat-­‐4::ssAβ	  1-­‐42,	  Peat-­‐4::gfp,	  Pmyo-­‐2::mCherry];	  baEx108;	  
[Peat-­‐4::C13G3.3,	   rol-­‐6	   (su1006)]},	   UA168	   {[baInl32;	   Peat-­‐4::ssAβ	   1-­‐42,	   Peat-­‐4::gfp,	  
Pmyo-­‐2::mCherry];	  baEx109;	   [Peat-­‐4::C32E8.10,	   rol-­‐6	   (su1006)]},	   and	  UA169	   {[baInl32;	  
Peat-­‐4::ssAβ	   1-­‐42,	   Peat-­‐4::gfp,	   Pmyo-­‐2::mCherry];	   baEx110;	   [Peat-­‐4::C37H5.6,	   rol-­‐6	  
(su1006)]}.	  	  Furthermore,	  three	  stable	  lines	  of	  UA170	  {[baInl32;	  Peat-­‐4::ssAβ	  1-­‐42,	  Peat-­‐
4::gfp,	   Pmyo-­‐2::mCherry];	  baEx111;	   [Peat-­‐4::JC8.10,	   rol-­‐6	   (su1006)]},	   UA171	   {[baInl32;	  
Peat-­‐4::ssAβ	   1-­‐42,	   Peat-­‐4::gfp,	   Pmyo-­‐2::mCherry];	   baEx112;	   [Peat-­‐4::Y44E3A.4,	   rol-­‐6	  
(su1006)]},	   UA172	   {[baInl32;	   Peat-­‐4::ssAβ	   1-­‐42,	   Peat-­‐4::gfp,	   Pmyo-­‐2::mCherry];	  
baEx113;	   [Peat-­‐4::XPO1,	   rol-­‐6	   (su1006)]},	   UA173	   {[baInl32;	   Peat-­‐4::ssAβ	   1-­‐42,	   Peat-­‐
4::gfp,	   Pmyo-­‐2::mCherry];	   baEx114;	   [Peat-­‐4::F42G10.2,	   rol-­‐6	   (su1006)]},	   UA174	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{[baInl32;	  Peat-­‐4::ssAβ	  1-­‐42,	  Peat-­‐4::gfp,	  Pmyo-­‐2::mCherry];	  baEx115;	  [Peat-­‐4::mCherry,	  
rol-­‐6	  (su1006)]},	  and	  UA175	  {[baInl32;	  Peat-­‐4::ssAβ	  1-­‐42,	  Peat-­‐4::gfp,	  Pmyo-­‐2::mCherry];	  
baEx116;	  [Peat-­‐4::lacZ,	  rol-­‐6	  (su1006)]}	  were	  generated	  by	  directly	  injecting	  50	  µg/mL	  of	  




For	   analysis	   of	   putative	   ssAβ	   1-­‐42	   toxicity	  modifiers,	   the	   transgenic	  worms	  were	   age-­‐
synchronized	  	  (LEWIS,	  et	  al.	  1995),	  transferred	  onto	  NGM	  plates,	  and	  grown	  at	  20°C	  for	  3	  
or	  7	  days.	  	  For	  each	  trial,	  30	  worms	  were	  transferred	  to	  a	  2%	  agarose	  pad,	  immobilized	  
with	   2	   mM	   levamisole,	   and	   scored.	   	   Worms	   were	   considered	   rescued	   when	   all	   five	  
glutamatergic	  neurons	  were	  intact	  and	  had	  no	  visible	  signs	  of	  degeneration.	  	  Each	  stable	  
line	  was	  analyzed	  three	  times	  (for	  a	  total	  of	  90	  worms/transgenic	  line).	  	  Three	  separate	  
transgenic	  lines	  were	  analyzed	  per	  gene	  (for	  a	  total	  of	  270	  animals/gene).	  Imaging	  and	  
statistics	  were	  performed	  as	  described	  previously	  	  (HAMAMICHI,	  et	  al.	  2008).	  	  
Semi-­‐quantitative	  RT-­‐PCR	  
RNA	   isolation	   and	   semi-­‐quantitative	   RT-­‐PCR	   were	   performed	   as	   described	   previously	  	  
(HAMAMICHI,	   et	   al.	   2008).	   Briefly,	   total	   RNAs	   were	   isolated	   from	   50	   L3-­‐staged	   worms,	  
amplified	  using	  SuperScript	   III	  RT	   	   (Invitrogen)	  with	  oligo	  dT	  primers,	  and	  treated	  with	  
amplification	   grade	   RNase-­‐free	   DNase	   I	   (Invitrogen)	   as	   well	   as	   RNase	   H	   (Invitrogen)	  
following	  the	  manufacture’s	  protocol.	  	  The	  following	  primers	  were	  designed	  for	  the	  PCR:	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cdk-­‐5	   	   Primer	  1:	  	   5’	  ggg-­‐gat-­‐gat-­‐gag-­‐ggt-­‐gtt-­‐cca-­‐agc	  3’	  
Primer	  2:	  	   5’	  ggc-­‐gac-­‐cgg-­‐cat-­‐ttg-­‐aga-­‐tct-­‐ctg-­‐c	  3’	  
	  
The	  trangenes	  were	  PCR	  amplified	  by	  using	  primer	  sequences	  specific	  to	  unc-­‐54	  3’UTR	  
and	  each	  respective	  open	  reading	  frame.	  
unc-­‐54	  3’UTR	   Primer	  1:	  	   5’	  gac-­‐tta-­‐gaa-­‐gtc-­‐aga-­‐ggc-­‐acg-­‐ggc	  3’	  
ssAb	  1-­‐42	  	   Primer	  2:	   5’	  atg-­‐cat-­‐aag-­‐gtt-­‐ttg-­‐ctg-­‐gca-­‐ctg-­‐ttc-­‐ttt-­‐atc	  3’	  
C13G3.3	   Primer	  2:	   5’	  gag-­‐aaa-­‐cag-­‐gca-­‐atg-­‐gga-­‐aac-­‐ccg-­‐c	  3’	  
C32E8.10	   Primer	  2:	   5’	  gct-­‐gct-­‐cca-­‐ttc-­‐gga-­‐tat-­‐cca-­‐aat-­‐gc	  3’	  
C37H5.6	   Primer	  2:	   5’	  gga-­‐gta-­‐acg-­‐act-­‐gga-­‐cgt-­‐aaa-­‐cgt-­‐cg	  3’	  
JC8.10	   	   Primer	  2:	   5’	  gat-­‐cga-­‐cct-­‐cgt-­‐cca-­‐cca-­‐tca-­‐gc	  3’	  
Y44E3A.4	   Primer	  2:	   5’	  cac-­‐tga-­‐tca-­‐ggt-­‐cgc-­‐cga-­‐act-­‐gc	  3’	  
F42G10.2	   Primer	  2:	   5’	  cat-­‐gac-­‐gcc-­‐ggt-­‐tgt-­‐cag-­‐ccg	  3’	  
XPO1	   	   Primer	  2:	   5’	  gtg-­‐aca-­‐gac-­‐act-­‐tca-­‐cat-­‐act-­‐gct-­‐gg	  3’	  
mCherry	   Primer	  2:	   5’	  gat-­‐gaa-­‐ctt-­‐cga-­‐gga-­‐cgg-­‐cgg-­‐c	  3’	  
lacZ	   	   Primer	  2:	   5’	  gcc-­‐tta-­‐ctg-­‐ccg-­‐cct-­‐gtt-­‐ttg-­‐acc	  3’	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Supplemental	  Figure	  C4.1:	  Immunoblot	  analysis	  of	  strains	  expressing	  Aβ.	  	  
Aβ	   1-­‐42	   expression	   was	   detected	   by	   immunoblot	   analysis	   using	   the	   6E10	   Aβ-­‐specific	  
antibody.	  Samples	  were	  loaded	  with	  and	  without	  prior	  boiling	  in	  LDS	  sample	  buffer.	  We	  
detected	  higher	  molecular	  weight	  species	  of	  Aβ	  corresponding	  to	  trimers	  and	  tetramers	  
only	   in	   the	   unboiled	   samples	   indicating	   that	   these	   species	   are	   non-­‐covalent	   Aβ	  
oligomers.	  
	   185	  
	  
Supplemental	   Figure	   C4.2:	   Localization	   of	   Aβ	   to	   the	   endoplasmic	   reticulum	   and	  
vesicular	  compartment.	  	  
To	  establish	  that	  our	  targeting	  scheme	  for	  Aβ	  was	  effective,	  we	  immunostained	  cells	  for	  
Aβ	  and	  an	  ER	  marker,	  as	  well	  as	  two	  markers	  for	  ER-­‐Golgi	  vesicles.	  ssAβ	  was	  expressed	  
in	   the	   indicated	   GFP-­‐tagged	   strains	   using	   a	   GAL1-­‐driven	   high	   copy	   number	   plasmid.	  
Sec61,	   an	   ER	   marker,	   is	   a	   component	   of	   the	   ER	   protein	   transport	   channel.	   Aβ	   co-­‐
localized	  with	  Sec61.	  Sec13,	  part	  of	  the	  COPII	  vesicle	  coat,	  and	  Sec21,	  part	  of	  the	  COPI	  
vesicle	   coat,	   are	   markers	   for	   ER-­‐Golgi	   vesicles.	   Aβ	   showed	   weak	   co-­‐localization	   with	  
Sec21,	  but	  no	  co-­‐localization	  with	  Sec13.	  The	  scale	  bar	  is	  5µM	  and	  all	  figures	  are	  on	  the	  
same	  scale.	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Supplemental	  Figure	  C4.3:	  Example	  of	  a	  screening	  plate.	  	  
Yeast	  strains	  carrying	  the	  ssAβ	  construct	  and	  the	  Gal4-­‐ER-­‐VP16	  transcription	  factor	  were	  
transformed	  with	  a	  plasmid	   library	  containing	  a	  genome-­‐wide	  collection	  of	  ORFs.	  Each	  
transformant	   was	   spotted	   4	   times	   in	   a	   square	   array	   using	   a	   Singer	   RoToR	   robot	   on	  
media	   containing	   galactose,	   glucose	   and	   estradiol,	   glycerol	   and	   estradiol	   or	   glucose	  
alone	   as	   a	   non-­‐inducing	   growth	   control.	   Enhancers	   resulted	   in	   decreased	   growth	   and	  
suppressors	  in	  increased	  growth,	  examples	  are	  boxed.	  Empty	  quadrants	  on	  the	  plate	  are	  
the	  result	  of	  empty	  wells	  in	  the	  plasmid	  library.	  
	   187	  
	  
Supplemental	  Figure	  C4.4:	  Effect	  of	  suppressors	  on	  YFP	  expression	  levels.	  	  
Putative	   suppressors	   may	   decrease	   Aβ	   toxicity	   by	   decreasing	   GAL1-­‐mediated	  
expression.	   We	   assessed	   whether	   any	   of	   the	   identified	   suppressors	   affected	   GAL1-­‐
mediated	   expression	   by	   assaying	   the	   expression	   of	   Yellow	   Fluorescent	   Protein	   (YFP)	  
under	   the	   control	   of	   a	  GAL1	   promoter.	   Putative	   suppressors	  were	   transformed	   into	   a	  
strain	   carrying	   an	   integrated	   GAL1-­‐controlled	   YFP	   construct	   and	   the	   Gal4-­‐ER-­‐VP16	  
transcription	  factor.	  The	  effect	  of	  putative	  hits	  on	  YFP	  expression	  levels	  was	  quantified	  
using	   flow	   cytometry	   after	   overnight	   growth	   in	   one	   of	   three	   media	   conditions:	  
galactose,	   glucose	   with	   estradiol	   or	   glycerol	   with	   estradiol.	   Hits	   that	   significantly	  
decreased	  the	  levels	  of	  YFP	  in	  comparison	  to	  the	  vector	  control	  were	  eliminated	  as	  false	  
positives	   (i.e.	  HAA1,	   LEU3	   and	  VHR1).	  We	   did	   not	   eliminate	   suppressors	   that	   showed	  
activity	  on	  all	  three	  media	  conditions,	  even	  if	  YFP	  expression	  levels	  were	  lower	  on	  one	  of	  
the	  growth	  conditions.	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Supplemental	  Table	  C4.1:	   	  Suppressors	  and	  enhancers	  of	  Aβ	  toxicity	   identified	  in	  the	  
yeast	  screen.	  	  
We	   constructed	   yeast	   strains	   with	   an	   intermediate	   level	   of	   Aβ	   expression	   and	  
corresponding	   toxicity	   that	   allowed	   us	   to	   identify	   in	   the	   same	   screen	   genes	   that	  
alleviated	  or	  enhanced	  toxicity	  when	  overexpressed	   (see	  Materials	  and	  Methods).	   	  Aβ	  
toxicity	  is	  likely	  to	  be	  influenced	  by	  mitochondrial	  function	  in	  neurons	  	  (CHEN,	  et	  al.	  2010;	  
GIBSON,	  et	  al.	  2010).	  We	  took	  advantage	  of	  the	  fact	  that	  the	  extent	  to	  which	  yeast	  rely	  
on	  mitochondrial	   respiration	   is	   carbon	   source	   dependent,	   thereby	   allowing	   us	   to	   test	  
the	   full	   library	   of	  ORFs	   at	   different	   levels	   of	   respiration.	   In	   glucose,	   cells	   ferment	   and	  
respiration	  remains	  low	  until	  all	  glucose	  is	  converted	  to	  ethanol.	  	  In	  galactose	  respiration	  
is	   moderately	   active.	   	   In	   glycerol,	   cells	   are	   completely	   dependent	   on	   respiration	   for	  
growth.	  To	  determine	  if	  the	  effect	  of	  putative	  modifiers	  on	  Aβ	  toxicity	  depended	  on	  the	  
level	   of	   mitochondrial	   respiration,	   we	   conducted	   our	   screen	   on	   the	   three	   different	  
carbon	  sources	  mentioned:	  glucose,	  galactose	  and	  glycerol.	  The	  expression	  of	  both	  ssAβ	  
and	   the	   library	   of	   yeast	   ORFs	   were	   under	   control	   of	   the	   GAL1	   promoter.	   To	   induce	  
expression	   in	   glucose	   and	   glycerol,	   we	   employed	   a	   chimeric	   Gal4-­‐Estrogen	   Receptor-­‐
VP16	   transcription	   factor	   that	   enables	   induction	   of	   the	   GAL1	   promoter	   through	   the	  
addition	  of	   the	  estrogen	  estradiol	   	   (QUINTERO,	   et	  al.	   2007).	  We	  plated	   the	   ssAβ	   strains	  
carrying	  two	  plasmids,	  the	  Gal4-­‐ER-­‐VP16	  transcription	  factor	  on	  one	  and	  individual	  yeast	  
ORFs	   on	   the	   other,	   on	   media	   containing	   galactose,	   glucose	   +	   estradiol,	   or	   glycerol	   +	  
estradiol.	  	  We	  also	  plated	  cells	  on	  glucose	  alone	  as	  a	  non-­‐inducing	  growth	  control.	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Suppressors	   increased	   growth	   relative	   to	   a	   vector	   control	   on	   the	   indicated	  
conditions;	  enhancers	  decreased	  it	  (see	  Fig.	  S3	  for	  an	  example	  of	  a	  screening	  plate).	  The	  
function	   and	   localization	   of	   the	   gene	   products	   identified	   as	   modifiers	   are	   based	   on	  
Saccharomyces	  Genome	  Database	  (SGD)	  gene	  summaries.	  
	   Only	   a	   few	  of	   the	  modifiers,	   specifically	  SLA1,	  RTG3,	  NAB3,	   SLF1,	   FCY21,	  VPS9,	  
GRR1,	   YBL086c,	   IVY1,	   PBS2,	   PKC1	   and	   MVP1,	   were	   strongly	   affected	   by	   the	   state	   of	  
mitochondrial	   respiration.	   	   However,	   the	   fact	   that	   most	   of	   the	   suppressors	   and	  
enhancers	  were	  reproduced	  on	  all	  three	  media	  indicates	  the	  robustness	  of	  their	  affects	  
on	  Aβ	  toxicity.	  
	  
Gene	   SNP	   Chr.	   Position1	   MAF2	   Fams3	   FBAT-­‐GEE4	  
PICALM	   rs10501603	   11	   85,359,564	   0.23	   172	   0.03	  
PICALM	   rs615887	   11	   85,367,689	   0.24	   159	   0.01	  
PICALM	   rs597446	   11	   85,452,707	   0.39	   215	   0.03	  
PICALM	   rs568755	   11	   85,483,910	   0.32	   193	   0.04	  
PICALM	   rs659023	   11	   85,502,507	   0.35	   206	   0.29	  
PPP2R5	   rs11625483	   14	   101,321,490	   0.38	   206	   0.86	  
PPP2R5	   rs1746598	   14	   101,333,217	   0.08	   77	   0.72	  
PPP2R5	   rs8016207	   14	   101,366,968	   0.18	   149	   0.98	  
PPP2R5	   rs8015021	   14	   101,379,446	   0.08	   63	   0.21	  
PPP2R5	   rs10873529	   14	   101,481,601	   0.28	   179	   0.14	  
ADSSL1	   rs4983386	   14	   104,281,252	   0.46	   239	   0.29	  
XPO1	   rs7563678	   2	   61,653,462	   0.4	   216	   0.17	  
XPO1	   rs778755	   2	   61,692,688	   0.45	   216	   0.07	  
XPO1	   rs17010833	   2	   61,714,960	   0.05	   48	   0.42	  
XPO1	   rs6545886	   2	   61,733,522	   0.11	   109	   0.003	  
SYNJ1	   rs845022	   21	   32,920,977	   0.42	   187	   0.61	  
SYNJ1	   rs845006	   21	   32,953,727	   0.06	   60	   0.68	  
SYNJ1	   rs928754	   21	   33,006,701	   0.48	   195	   0.6	  
FBXL20	   rs755500	   17	   34,663,391	   0.26	   175	   0.09	  
RABGEF1	   rs12537474	   7	   65,749,172	   0.08	   136	   0.64	  
XRN1	   rs1552340	   3	   143,498,288	   0.42	   225	   0.33	  
	   192	  
POMT2	   rs8009261	   14	   76,810,128	   0.44	   210	   0.56	  
POMT2	   rs3783986	   14	   76,832,625	   0.4	   203	   0.59	  
POMT2	   rs1861889	   14	   76,833,554	   0.08	   72	   0.66	  
POMT2	   rs4899651	   14	   76,854,215	   0.25	   178	   0.29	  
SNX8	   rs7805462	   7	   2,122,849	   0.32	   192	   0.62	  
MAP2K4	   rs1468501	   17	   11,862,669	   0.26	   184	   0.75	  
MAP2K4	   rs976244	   17	   11,897,717	   0.21	   171	   0.93	  
MAP2K4	   rs9907196	   17	   11,925,064	   0.2	   167	   0.98	  
MAP2K4	   rs4791490	   17	   11,989,069	   0.19	   145	   0.16	  
MAP2K4	   rs7208899	   17	   12,075,716	   0.06	   54	   0.94	  
1Physical	  position	  from	  Build	  27	  NCBI36/Hg18	   	   	   	   	  
2Minor	  allele	  frequency	  (MAF)	   	   	   	   	  
3Number	  of	  informative	  families	  from	  FBAT-­‐GEE	  analysis	   	   	   	   	  
4P-­‐value	  from	  family-­‐based	  association	  test	  (FBAT)	   	   	   	   	  
	  
Supplemental	   Table	   C4.2:	   	   Genome-­‐wide	   FBAT-­‐GEE	   association	   results	   from	   NIMH	  
cohort.	  
To	   test	   for	   support	   for	   a	   genetic	   association	   between	   AD	   and	   our	   eleven	   candidate	  
genes	  we	   revisited	   the	   family-­‐based	   genome-­‐wide	   association	   screen	   (GWAS)	   analysis	  	  
(BERTRAM,	   et	   al.	   2008)	   performed	   on	   the	   National	   Institute	   of	   Mental	   Health	   (NIMH)	  
Genetics	   Alzheimer’s	   Disease	   Initiative	   Study	   	   (BLACKER,	   et	   al.	   1997).	   The	   sample	  
consisted	   of	   1,217	   participants	   from	   439	   families	   of	   self-­‐reported	   European	   ancestry.	  
Genotyping	   was	   prepared	   with	   the	   GeneChip	   Human	   Mapping	   500K	   Array	   Set	   from	  
Affymetrix.	  Within	  the	  eleven	  gene	  regions,	  plus	  a	  50kb	  window	  proximally	  and	  distally,	  
133	   SNPs	   passed	   quality	   control	   assessment	   (using	   PLINK	   v1.07)	   and	  were	   tested	   for	  
association	  using	  a	  family-­‐based	  association	  test	  (FBAT	  v3.6)	  approach.	  	  	  	  
The	  FBAT	  method	  is	  similar	  in	  design	  to	  a	  classic	  transmission	  disequilibrium	  test	  
method	  in	  which	  the	  genotype	  distribution	  in	  the	  affected	  is	  compared	  to	  its	  expected	  
distribution	  under	   the	  null	  hypothesis.	  To	  optimize	  statistical	  power,	  age	  of	  onset	  and	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AD	  affection	  status	  were	  tested	  together	  as	  a	  combined	  outcome	  variable,	  by	  use	  of	  the	  
multivariate	   extension	   of	   the	   FBAT-­‐approach,	   FBAT-­‐GEE	   (Generalized	   Estimating	  
Equation).	  We	  assumed	  an	  additive	  genetic	  model	  to	  test	   for	  association	  between	  our	  
outcome	  variable	  and	  genotype.	  
Table	   S2	   contains	   a	   subset	   of	   tested	   SNPs	   from	   the	   genome-­‐wide	   FBAT-­‐GEE	  
association	   analysis	   that	   was	   pruned	   based	   on	   linkage	   disequilibrium.	   Pruning	   was	  
performed	   with	   the	   “indep”	   command	   in	   PLINK	   which	   reduces	   a	   set	   of	   SNPs	   into	   a	  
subset	   that	   are	   in	   approximate	   linkage	   equilibrium	  with	   each	   other.	   	   Selection	   of	   the	  
subset	   is	  based	  on	   the	   variance	   inflation	   factor	  1/(1-­‐R2),	  R2	   is	   the	  multiple	   correlation	  
coefficient	  for	  a	  SNP	  being	  regressed	  on	  all	  other	  SNPs	  concurrently.	  Additional	  features	  
of	   the	   pruning	   are	   described	   on	   the	   PLINK	   website	   under	   the	   LD-­‐base	   SNP	   pruning	  
sections.	  
The	   association	   for	   the	   XPO1	   SNP	   rs6545886	   is	   robust	   to	   a	   Bonferroni	  
adjustment	  for	  the	  4	  independent	  SNPs	  tested	  at	  each	  locus	  (Padj=0.003	  *	  4	  =	  0.012).	  
	  
	  	   Clinical	   Pathological	  
n	   1593	   651	  
age1	   85	   87.9	  
female	  (%)	   69.4	   62.4	  
AD2	  (%)	   22.1	   40.9	  
1Age	  at	  last	  evaluation	  (clinical)	  or	  death	  (pathological)	  
2Clinical	  diagnosis	  of	  Alzheimer's	  disease	  based	  on	  NINCDS	  criteria	  (probable	  or	  possible)	  	  
	  
Supplemental	  Table	  C4.3:	  	  Cohort	  demographics	  and	  characteristics.	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Clinical,	   pathological	   and	   genotype	   data	   from	   the	   Religious	   Orders	   Study	   and	   Rush	  
Memory	   and	   Aging	   Project	   were	   used	   to	   clinically	   validate	   significance	   of	   our	   screen	  
results.	   Age	   indicates	   the	   time	   of	   last	   evaluation	   for	   the	   clinical	   cohort,	   and	   time	   of	  
death	   for	   the	   pathology	   cohort.	   AD	   clinical	   diagnosis	   was	   based	   on	   NINCDS	   criteria,	  











YAP1802	   PICALM	   11	   85296132	  -­‐	  85507756	   211	   187	  
RTS1	   PPP2R5C	   14	   101295924	  -­‐	  101513830	   218	   144	  
ADE12	   ADSSL1	   14	   104211578	  -­‐	  104334692	   123	   42	  
CRM1	   XPO1	   2	   61508572	  -­‐	  61668922	   160	   45	  
INP52	   SYNJ1	   21	   32872943	  -­‐	  33072148	   199	   109	  
GRR1	   FBXL20	   17	   34620365	  -­‐	  34861402	   241	   80	  
VPS9	   RABGEF1	   7	   65793077	  -­‐	  65963883	   171	   78	  
KEM1	   XRN1	   3	   143458138	  -­‐	  143699543	   241	   66	  
PMT2	   POMT2	   14	   76761051	  -­‐	  76906970	   146	   148	  
MVP1	   SNX8	   7	   2211164	  -­‐	  2370625	   160	   67	  
PBS2	   MAP2K4	   17	   11814859	  -­‐	  12037776	   223	   114	  
1Based	  on	  RefSeq	  gene	  consensus,	  plus	  a	  50kb	  window	  both	  proximally	  and	  distally.	  
	  
Supplemental	   Table	   C4.4:	   	   Human	   loci	   tested	   for	   associations	  with	   intermediate	  AD	  
cognitive	  and	  neuropathologic	  phenotypes.	  	  
We	   comprehensively	   evaluated	   both	   genotyped	   and	   imputed	   common	   variation	   at	  
human	  homologs	  for	  11	  out	  of	  12	  of	  the	  top	  results	  of	  our	  yeast	  screen.	  We	  were	  unable	  
to	   evaluate	   the	   human	   functional	   homolog	   of	   Sla1,	   SH3KBP1,	   due	   to	   imprecise	  
imputation	  on	   the	  X	  chromosome.	  At	  each	   locus,	  all	  SNPs	   from	  the	  quality-­‐controlled,	  
genome-­‐wide	   genotyping	   dataset	   were	   extracted	   from	   RefSeq-­‐based	   genomic	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coordinates,	  inclusive	  of	  a	  50kb	  genomic	  window,	  both	  proximal	  and	  distal.	  The	  size	  of	  
each	  locus	  analyzed	  and	  the	  resultant	  number	  of	  SNPs	  tested	  is	  shown.	  
	  
1Strongest	  SNP	  association	  observed	  at	  each	  locus.	  
2minor/reference	  allele	  
3Empirically-­‐determined	   P-­‐value	   from	   permutation	   test.	   Significant	   results	   (P<0.05)	  
boldfaced;	  Suggestive	  results	  (P<0.1)	  asterisked.	  
	  
Supplemental	  Table	  C4.5:	  	  Locus	  associations	  with	  episodic	  memory	  decline.	  	  
Using	   PLINK	   software,	   each	   locus-­‐based	   SNP	   set	   was	   evaluated	   for	   associations	   with	  
rate-­‐of-­‐change	   in	   episodic	   memory	   performance	   within	   the	   combined	   ROS	   and	  MAP	  
clinical	   cohort,	   based	   on	   repeated	   assessments	   of	   7	   neuropsychiatric	   tests.	   Linear	  
regression	  analyses	  were	  adjusted	  for	  baseline	  age,	  gender,	  and	  years	  of	  education.	  For	  
each	  locus,	  this	  analysis	  defines	  the	  strongest,	  independent	  marker	  SNP.	  For	  each	  such	  
SNP,	  the	  minor/reference	  allele	  (A1),	  allele	  frequency	  (Frq),	  effect	  size	  (Beta	  &	  95%	  CI),	  
as	  well	  as	  P-­‐value	  (P)	  are	  shown.	  In	  order	  to	  determine	  if	  the	  observed	  locus	  association	  





best	  SNP1	   A12	   Frq	   Beta	  (95%	  CI)	   P	   Pperm
3	  
YAP1802	   PICALM	   rs7128598	   G	   0.25	   -­‐0.016	  (-­‐0.025	  to	  -­‐0.008)	   1.59E-­‐04	   0.012	  
RTS1	   PPP2R5C	   rs10873529	   G	   0.27	   0.009	  (0.001	  to	  0.017)	   0.029	   0.614	  
ADE12	   ADSSL1	   rs11851852	   T	   0.03	   -­‐0.033	  (-­‐0.055	  to	  -­‐0.011)	   0.003	   0.072*	  
CRM1	   XPO1	   rs967968	   C	   0.47	   0.010	  (0.003	  to	  0.017)	   0.007	   0.079*	  
INP52	   SYNJ1	   rs13339977	   T	   0.02	   0.026	  (0.001	  to	  0.052)	   0.045	   0.559	  
GRR1	   FBXL20	   rs11657409	   T	   0.27	   -­‐0.009	  (-­‐0.018	  to	  0.0004)	   0.062	   0.476	  
VPS9	   RABGEF1	   rs13224487	   G	   0.01	   0.045	  (0.012	  to	  0.077)	   0.007	   0.076*	  
KEM1	   XRN1	   rs6440083	   G	   0.29	   0.011	  (0.003	  to	  0.019)	   0.005	   0.062*	  
PMT2	   POMT2	   rs2042045	   A	   0.34	   -­‐0.010	  (-­‐0.018	  to	  -­‐0.003)	   0.009	   0.299	  
MVP1	   SNX8	   rs4721548	   G	   0.44	   -­‐0.006	  (-­‐0.014	  to	  0.001)	   0.086	   0.816	  
PBS2	   MAP2K4	   rs7221795	   A	   0.08	   -­‐0.017	  (-­‐0.030	  to	  -­‐0.004)	   0.012	   0.230	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permuted	  1000	  times,	   in	  order	  to	  determine	  an	  empirical	  P-­‐value	  (Pperm),	  adjusting	  for	  
the	   number	   of	   SNPs	   tested	   at	   each	   locus.	   The	   results	   was	   considered	   significant	   for	  
Pperm<0.05	  (bold);	  whereas	  Pperm<0.1	  was	  interpreted	  as	  suggestive	  (asterisk).	  Of	  the	  11	  
loci	   evaluated,	   PICALM	  was	   found	   to	   be	   associated	   with	   decline	   in	   episodic	   memory	  






best	  SNP1	   A12	   Frq	   Beta	  (95%	  CI)	   P	   Pperm
3	  
YAP1802	   PICALM	   rs7950477	   T	   0.02	   0.219	  (0.068	  to	  0.371)	   0.005	   0.157	  
RTS1	   PPP2R5C	   rs6575881	   T	   0.005	   -­‐0.364	  (-­‐0.680	  to	  -­‐0.048)	   0.024	   0.548	  
ADE12	   ADSSL1	   rs1128880	   G	   0.48	   0.098	  (0.039	  to	  0.156)	   0.001	   0.031	  
CRM1	   XPO1	   rs2518934	   C	   0.44	   -­‐0.042	  (-­‐0.085	  to	  0.0002)	   0.052	   0.357	  
INP52	   SYNJ1	   rs7284048	   A	   0.08	   0.056	  (-­‐0.024	  to	  0.137)	   0.172	   0.951	  
GRR1	   FBXL20	   rs16968748	   G	   0.02	   -­‐0.165	  (-­‐0.335	  to	  0.006)	   0.059	   0.513	  
VPS9	   RABGEF1	   rs17566701	   T	   0.48	   -­‐0.067	  (-­‐0.111	  to	  -­‐0.024)	   0.002	   0.038	  
KEM1	   XRN1	   rs13101141	   A	   0.06	   -­‐0.045	  (-­‐0.137	  to	  0.046)	   0.331	   0.970	  
PMT2	   POMT2	   rs2287385	   A	   0.16	   0.077	  (0.021	  to	  0.133)	   0.007	   0.244	  
MVP1	   SNX8	   rs3807428	   A	   0.05	   -­‐0.095	  (-­‐0.190	  to	  -­‐0.001)	   0.048	   0.630	  
PBS2	   MAP2K4	   rs12603093	   C	   0.25	   0.040	  (-­‐0.009	  to	  0.089)	   0.107	   0.916	  
1Strongest	  SNP	  association	  observed	  at	  each	  locus.	  
2minor/reference	  allele	  
3Empirically-­‐determined	   P-­‐value	   from	   permutation	   test.	   Significant	   results	   (P<0.05)	  
boldfaced;	  Suggestive	  results	  (P<0.1)	  asterisked.	  
	  
Supplemental	  Table	  C4.6:	  	  Locus	  associations	  with	  global	  AD	  pathology.	  	  
Using	  PLINK	  software,	  each	   locus-­‐based	  SNP	  set	  was	  evaluated	   for	  associations	  with	  a	  
quantitative	   measure	   of	   global	   AD	   pathology	   within	   the	   combined	   ROS	   and	   MAP	  
autopsy	   cohort,	   based	   on	   averaged	   counts	   of	   neuritic	   plaques,	   diffuse	   plaques,	   and	  
neurofibrillary	  tangles	  from	  5	  brain	  regions.	  Linear	  regression	  analyses	  were	  adjusted	  for	  
age	  at	  the	  time	  of	  death.	  For	  each	  locus,	  this	  analysis	  defines	  the	  strongest,	  independent	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marker	  SNP.	  For	  each	  such	  SNP,	  the	  minor/reference	  allele	  (A1),	  allele	  frequency	  (Frq),	  
effect	  size	  (Beta	  &	  95%	  CI),	  as	  well	  as	  P-­‐value	  (P)	  are	  shown.	  In	  order	  to	  determine	  if	  the	  
observed	  locus	  association	   is	  significance,	  a	  permutation	  test	  was	  performed,	   in	  which	  
phenotype	   labels	   were	   permuted	   1000	   times,	   in	   order	   to	   determine	   an	   empirical	   P-­‐
value	   (Pperm),	   adjusting	   for	   the	   number	   of	   SNPs	   tested	   at	   each	   locus.	   The	   results	  was	  
considered	  significant	   for	  Pperm<0.05	   (bold).	  ADSSL1	  and	  RABGEF1	  were	  each	   found	   to	  
harbor	  significant	  signals	  of	  association	  with	  the	  global	  AD	  pathology	  measure.	  
	  
	  
Supplemental	  Figure	  C4.5:	  Analysis	  of	  transgene	  expression	  in	  worm	  strains.	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We	   conducted	   semi-­‐quantitative	   RT-­‐PCR	   to	   ensure	   that	   transgenes	   did	   not	   influence	  
ssAβ	   1-­‐42	   expression	   in	  C.	   elegans.	  We	   could	   not	  measure	   Aβ	   levels	   by	  western	   blot	  
analysis	  as	  we	  expressed	  Aβ	  in	  only	  specific	  cells	  per	  animal.	  The	  PCR	  was	  conducted	  by	  
using	   primers	   designed	   to	   amplify	   cdk-­‐5	   (control),	   Aβ,	   and	   indicated	   transgenic	  
modifiers	  of	  Aβ	  induced	  neurodegeneration.	  For	  all	  primers,	  a	  N2	  wildtype	  strain	  served	  
as	  both	  a	  positive	  (cdk-­‐5)	  and	  negative	  (Aβ	  and	  transgenes)	  control.	  The	  ssAβ	  transgene	  
of	   the	   Aβ	   strain	   (UA166)	   was	   integrated	   into	   worm	   chromosomal	   DNA	   to	   maintain	  
steady	  Aβ	  expression	   level	   in	  the	  entire	  organism	  (see	  Materials	  and	  Methods).	   	  Using	  
UA166	   strain,	   9	   additional	   transgenic	   strains	   expressing	   homologs	   of	   Aβ	   toxicity	  
modifiers	   identified	   in	   yeast	   were	   generated.	   Expression	   levels	   of	   the	   corresponding	  
modifiers	  varied	  since	  the	  transgenes	  remained	  as	  extrachromosomal	  arrays.	  To	  address	  
the	  discrepancies,	  we	  generated	  3	  independent	  lines	  for	  each	  of	  the	  9	  transgenic	  strains.	  
Importantly,	  co-­‐expression	  of	  the	  modifiers	  did	  not	  change	  the	  ssAβ	  expression	  level.	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Supplemental	   Figure	  C4.6:	  Aβ	   toxicity	  modifiers	  modulate	   the	  Aβ-­‐induced	   change	   in	  
Ste3-­‐YFP	  trafficking.	  
To	  examine	  the	  effect	  of	  Aβ	  on	  endocytosis	  and	  protein	  trafficking,	  we	  created	  our	  own	  
version	   of	   the	   Ste3	   localization	   assay	   	   (MALDONADO-­‐BAEZ,	   et	   al.	   2008).	   The	   mating	  
pheromone	   receptor	   Ste3p	   is	   constitutively	   targeted	   to	   the	  plasma	  membrane,	  but	   in	  
the	  absence	  of	  its	  ligand	  it	  is	  endocytosed	  and	  degraded	  in	  the	  vacuole.	  We	  generated	  a	  
Ste-­‐YFP	   under	   the	   control	   of	   the	   constitutive	   GPD	   promoter	   and	   integrated	   into	   a	  
control	   and	   an	   ssAβ	   1-­‐42	   screening	   strain.	   ssAβ	   1-­‐42	   expression	   changed	   Ste3-­‐YFP	  
localization	   from	  mostly	   vacuolar	   to	   cytoplasmic	   foci	   surrounding	   the	   vacuole,	   clearly	  
showing	  that	  Aβ	  causes	  a	  defect	  in	  Ste3-­‐YFP	  trafficking.	  We	  then	  examined	  the	  effects	  of	  
modifiers	   involved	   in	   endocytosis.	   The	   endocytic	   genes	   YAP1802,	   INP52	   and	   SLA1	  
reversed	  the	  effect	  induced	  by	  Aβ.	  SLA1	  functions,	  as	  YAP1802,	  in	  clathrin	  assembly.	  As	  
such	   these	   endocytic	   suppressors	   reversed	   the	   effect	   of	   Aβ	   by	   increasing	   endocytic	  
trafficking.	  	  
Interestingly,	  modifiers	  that	  had	  little	  effect	  on	  growth	  of	  ssAβ	  1-­‐42	  strains	  under	  
these	   growth	   conditions,	   such	   as	   SLA1	   (Table	   S1),	   still	   modulated	   the	   Aβ	   induced	  
phenotypes.	  The	  scale	  bar	  is	  5µM	  and	  all	  figures	  are	  on	  the	  same	  scale.	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Supplemental	   Figure	  C4.7:	  Aβ	   toxicity	  modifiers	  modulate	   the	  Aβ-­‐induced	   change	   in	  
clathrin	  localization.	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(A)	  We	  expressed	  ssAβ	  1-­‐42	   in	  strain	  carrying	  a	  haploid	  clathrin	   light	  chain	  GFP	  fusion	  
(Clc1-­‐GFP).	  ssAβ	  1-­‐42	  expression	  resulted	  in	  an	  increase	  in	  the	  number	  and	  brightness	  of	  
Clc1-­‐GFP	   foci,	  while	  also	  decreasing	   their	   size.	  Since	   this	  GFP-­‐fusion	  strain,	  part	  of	   the	  
GFP	   library	   (HOWSON,	   et	   al.	   2005),	   is	   incompatible	   with	   our	   ssAβ	   1-­‐42	   integration	  
construct,	  we	  used	  a	  GAL-­‐driven	  multi	  copy	  vector.	  	  
(B)	   Next,	   we	   examined	   the	   effects	   of	   suppressors	   with	   annotated	   functions	   in	  
endocytosis	   on	   this	   Aβ-­‐induced	   phenotype.	   But	   expression	   of	   ssAβ	   1-­‐42	   from	   a	  multi	  
copy	  vector,	  whose	  numbers	  can	  vary	  from	  cell	  to	  cell,	  and	  expression	  of	  the	  modifiers	  
from	  an	  additional	  plasmid	  resulted	  in	  a	  large	  variation	  in	  the	  observed	  phenotypes.	  To	  
achieve	  robust	  Aβ	  toxicity	  in	  the	  Clc1-­‐GFP	  background,	  we	  hence	  mated	  one	  of	  the	  ssAβ	  
1-­‐42	   screening	   strains	   to	   the	  Clc1-­‐GFP	   strain.	  While	  Aβ	   toxicity	  was	  attenuated	   in	   the	  
diploid,	  it	  still	  induced	  the	  change	  in	  Clc1-­‐GFP	  localization.	  We	  then	  tested	  the	  effects	  of	  
the	   modifiers	   in	   this	   background.	   YAP1802,	   involved	   in	   clathrin	   cage	   assembly	  
(MALDONADO-­‐BAEZ,	   et	   al.	   2008),	   enhanced	   the	   Aβ-­‐induced	   phenotype;	   Clc1-­‐GFP	   foci	  
became	   more	   plentiful,	   brighter	   and	   smaller.	   In	   contrast,	   INP52,	   involved	   in	   clathrin	  
vesicle	   fission	  and	   recycling	   (STEFAN,	   et	  al.	   2005),	   reversed	   the	  Aβ-­‐induced	  phenotype.	  
SLA1	  increases	  the	  number	  of	  foci,	  consistent	  with	  its	  role	  in	  clathrin	  assembly,	  but	  the	  
effect	  is	  subtle.	  Consequently,	  the	  Clc1-­‐GFP	  foci	  likely	  represent	  endocytic	  intermediates	  
that	   accumulate	   upon	   ssAβ	   1-­‐42	   expression.	   YAP1802	   counteracts	   this	   defect	   by	  
increasing	   vesicle	   formation,	   while	   INP52	   acts	   to	   complete	   the	   fission	   of	   otherwise	  
stalled	  vesicles.	  As	  such	  both	  proteins	  result	  in	  an	  increased	  flux	  through	  the	  endocytic	  





Prion	  induction	  involves	  an	  ancient	  system	  for	  
the	  sequestration	  of	  aggregated	  proteins	  and	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When	  the	  translation	  termination	  factor	  Sup35	  adopts	  the	  prion	  state,	  [PSI+],	  the	  read-­‐
through	  of	  stop	  codons	  increases,	  uncovering	  hidden	  genetic	  variation	  and	  giving	  rise	  to	  new,	  
often	   beneficial	   phenotypes.	   Evidence	   suggests	   that	   prion	   induction	   involves	   a	   process	   of	  
maturation,	   but	   this	   has	   never	   been	   studied	   in	   detail.	   To	   do	   so,	  we	  used	   a	   visually	   tractable	  
prion	  model	  consisting	  of	  the	  Sup35	  prion	  domain	  fused	  to	  GFP	  (PrD-­‐GFP)	  and	  overexpressed	  it	  
to	   achieve	   induction	   in	   many	   cells	   simultaneously.	   PrD-­‐GFP	   first	   assembled	   into	   Rings	   as	  
previously	  described.	  Rings	  propagated	   for	  many	  generations	  before	   the	  protein	   transitioned	  
into	  a	  Dot	   structure.	  Dots	   transmitted	   the	   [PSI+]	   phenotype	   through	  mating	  and	  meiosis,	   but	  
Rings	   did	   not.	   Surprisingly,	   the	   underlying	   amyloid	   conformation	   of	   PrD-­‐GFP	  was	   identical	   in	  
Rings	   and	  Dots.	  However,	   by	  electron	  microscopy	  Rings	   consisted	  of	   very	   long	  uninterrupted	  
bundles	  of	   fibers,	  whereas	  Dot	   fibers	  were	  highly	   fragmented.	  Both	   forms	  were	  deposited	  at	  
the	   IPOD,	   a	   biologically	   ancient	   compartment	   for	   the	   deposition	   of	   irreversibly	   aggregated	  
proteins,	   that	   we	   propose	   is	   the	   site	   of	   de	   novo	   prion	   induction.	   We	   find	   that	   oxidatively	  
damaged	  proteins	  are	  also	  localized	  there,	  helping	  to	  explain	  how	  proteotoxic	  stresses	  increase	  
the	   rate	   of	   prion	   induction.	   Curing	   PrD-­‐GFP	   prions,	   by	   inhibiting	   Hsp104’s	   fragmentation	  
activity,	   reversed	  the	   induction	  process:	  Dot	  cells	  produced	  Rings	  before	  PrD-­‐GFP	  reverted	  to	  
the	   soluble	   state.	   Thus,	   formation	   of	   the	   genetically	   transmissible	   prion	   state	   is	   a	   two-­‐step	  
process	   that	   involves	  an	  ancient	   system	   for	   the	  asymmetric	   inheritance	  of	  damaged	  proteins	  





Prions	  are	  self-­‐perpetuating	  protein	  conformations	  that	  store	  and	  transmit	  phenotypic	  
information	   independently	   of	   nucleic	   acids.	   In	   fungi,	   they	   act	   as	   protein-­‐based	   elements	   of	  
heredity,	   stably	   propagating	   their	   altered	   protein	   conformations	   and	   associated	   phenotypes	  
(CHERNOFF	  2007;	  SHORTER,	  et	  al.	  2005).	  
In	   Saccharomyces	   cerevisiae,	   seven	   prions	   are	   known	   (HALFMANN,	   et	   al.	   2010)	   and	  
evidence	  indicates	  that	  numerous	  other	  yeast	  proteins	  are	  capable	  of	  forming	  prions	  (ALBERTI,	  et	  
al.	   2009).	   The	   proteins	   have	   different	   molecular	   functions	   and	   produce	   different	   prion	  
phenotypes.	   Although	   they	   share	   no	   sequence	   homology,	   their	   prion	   domains	   (PrDs)	   are	  
enriched	   in	  asparagine	  and	  glutamine	   residues.	  These	  PrDs	  can	  adopt	   self-­‐perpetuating	  prion	  
conformations	  that	  are	  amyloids.	  They	  template	  the	  conversion	  of	  soluble	  prion	  proteins	  of	  the	  
same	  type	  to	  the	  same	  conformation	  (CHERNOFF	  2007;	  SHORTER,	  et	  al.	  2005).	  The	  AAA+	  ATPase	  
Hsp104	  shears	  amyloid	  fibers	  to	  generate	  prion	  seeds,	  also	  referred	  to	  as	  propagons	  (COX,	  et	  al.	  
2003),	  ensuring	   inheritance	  of	   the	  prion	  state	   from	  generation	  to	  generation	   (CHERNOFF,	  et	  al.	  
1995).	  	  
The	  protein	  determinant	  for	  the	  prion	  [PSI+]	  is	  the	  translation	  termination	  factor	  Sup35.	  
Sup35’s	   PrD,	   NM,	   has	   an	   N-­‐terminal	   amyloidogenic	   domain	   (N)	   and	   a	   solubilizing	   middle	  
domain	  (M)	  (CHERNOFF	  2007;	  SHORTER,	  et	  al.	  2005).	  In	  vitro,	  purified	  PrD	  can	  form	  amyloid	  fibrils	  
on	   its	  own	   (GLOVER,	  et	  al.	  1997).	   In	  vivo,	  assembly	  of	   the	  prion	  reduces	  availability	  of	  soluble,	  
functional	  termination	  factor.	  This	  causes	  stop	  codon	  read-­‐through	  (CHERNOFF	  2007;	  SHORTER,	  et	  
al.	   2005)	   and	   results	   in	   a	   large	   array	   of	   diverse	   phenotypes	   depending	   on	   the	   genetic	  
background	   (TRUE,	   et	   al.	   2000).	   Stressful	   conditions	   alter	   protein	   folding	   homeostasis	   and	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increase	   the	   rate	  at	  which	   cells	   switch	   to	   the	  prion	   state,	   creating	  a	  bet-­‐hedging	   strategy	   for	  
survival	  in	  fluctuating	  environments	  (ALBERTI,	  et	  al.	  2009;	  HALFMANN,	  et	  al.	  2010;	  TYEDMERS,	  et	  al.	  
2008).	  
[PSI+]	  propagation	  is	  well	  studied.	  However,	  the	  spontaneous	  de	  novo	  formation	  of	  [PSI+]	  
is	  rare	  and	  poorly	  understood.	  Overexpression	  of	  Sup35,	  or	  its	  PrD,	  dramatically	  increases	  the	  
frequency	  of	  [PSI+]	  induction	  (CHERNOFF,	  et	  al.	  1993),	  offering	  an	  opportunity	  to	  investigate	  the	  
process.	  During	  prion	  induction	  two	  distinct	  aggregation	  patterns	  are	  observed:	  ribbon	  and	  ring	  
structures	   that	   extend	   throughout	   the	   cell	   and	   round	   dot	   structures	   (GANUSOVA,	   et	   al.	   2006;	  
ZHOU,	  et	  al.	  2001).	  Dots	  correspond	  to	  the	  mature	  [PSI+]	  prion	  state.	  The	  ring	  structures	  appear	  
to	   be	   a	   hallmark	   of	  de	   novo	   [PSI+]	   induction	   but	   their	   nature	   remains	   a	  mystery.	   This	   is	   the	  
subject	  of	  our	  investigation.	  
	  
Results	  
Expression	  of	  PrD-­‐GFP	  in	  a	  Sup35	  PrD	  deletion	  strain	  results	  in	  Rings	  and	  Dots	  
To	  study	  the	  de	  novo	  formation	  and	  inheritance	  of	  prion	  amyloid	  in	  vivo	  on	  a	  single-­‐cell	  
level,	   we	   employed	   a	   fusion	   of	   the	   PrD	   (NM)	  with	   GFP,	  which	   is	   soluble	   in	   [prion-­‐]	   cells	   but	  
faithfully	  propagates	  with	  the	  wild-­‐type	  Sup35	  amyloid	  in	  [PRION+]	  cells	  (PATINO,	  et	  al.	  1996).	  To	  
determine	  if	  this	  visually	  tractable	  protein	  is	  fully	  capable	  of	  forming	  a	  prion	  in	  its	  own	  right,	  we	  
expressed	  it	  from	  the	  Sup35	  promoter	  to	  maintain	  normal	  expression.	  When	  these	  cells	  were	  
mated	   to	   [psi-­‐]	   cells	   the	  protein	   remained	  soluble.	  When	  mated	   to	   [PSI+]	   cells	   it	  acquired	   the	  
prion	  state	  (Supplemental	  Figure	  A1.1),	  was	  dominant	  in	  matings	  and	  segregated	  4:0	  in	  meiosis.	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Thus,	  PrD-­‐GFP	  fully	  recapitulates	  prion	  behavior.	  However,	  as	  expected,	  spontaneous	  switches	  
to	  the	  prion	  state	  were	  too	  rare	  to	  be	  observed	  spontaneously.	  	  
To	  provide	  a	  robust	  system	  for	  studying	  prion	  induction,	  we	  placed	  the	  PrD-­‐GFP	  fusion	  
under	  the	  control	  of	  the	  GPD	  promoter,	  which	  increased	  its	  expression	  ~15	  fold,	  and	  integrated	  
a	  single	  copy	  into	  the	  genome,	  to	  keep	  expression	  uniform	  in	  each	  cell.	  We	  also	  deleted	  the	  PrD	  
from	   the	  endogenous	  SUP35	   gene,	  making	   the	   translation	   termination	  domain	   immune	   from	  
sequestration	   into	   the	   prion.	   This	   can	   be	   toxic	  when	   it	   happens	   excessively	   (CHERNOFF,	   et	   al.	  
1993;	  VISHVESHWARA,	  et	  al.	  2009).	  	  
Soon	  after	  transformation,	  while	  cells	  were	  still	   in	  micro-­‐colonies,	  they	  had	  the	  diffuse	  
GFP-­‐fluorescence	  of	  [prion-­‐]	  cells.	  In	  more	  mature	  colonies,	  a	  large	  fraction	  of	  cells	  displayed	  a	  
large	   ring-­‐,	   rod-­‐	   or	   ribbon-­‐like	   structure	   of	   PrD-­‐GFP	   fluorescence	   (collectively	   referred	   to	   as	  
“Rings”	  throughout	  this	  paper).	  This	  Ring	  pattern	  was	  inherited	  for	  many	  generations.	  After	  two	  
to	   eight	   re-­‐streaks,	   each	   representing	  ~25	   generations,	   the	   aggregation	  pattern	   changed	  and	  
PrD-­‐GFP	  was	  exclusively	  found	  in	  one	  large	  focus	  per	  cell,	  hereafter	  referred	  to	  as	  Dots	  (Figure	  
A1.1a).	   Rings	   and	   Dots	   were	   previously	   described	   during	   prion	   induction	   in	   cells	   transiently	  





Figure	  A1.1:	  Expression	  of	  PrD-­‐GFP	  at	  high	  levels	  produces	  self-­‐propagating	  Ring	  assemblies	  
that	  transition	  to	  a	  Dot	  assembly	  only	  after	  many	  generations.	  	  
(A)	   Cells	   constitutively	   expressing	   PrD-­‐GFP	   under	   control	   of	   the	  GPD	  promoter	   are	   shown	   at	  
different	   times;	   initial	   =	   immediately	   after	   transformation	   of	   the	   expression	   construct;	  
intermediate	  =	  transformants	  after	  3-­‐5	  days;	  final	  =	  transformants	  after	  ~	  10	  days	  (hundreds	  of	  
generations).	   (B)	  Haploid	  cells	  propagating	  either	  PrD-­‐GFP	  Rings	   (upper	  panel)	  or	  Dots	   (lower	  
panel).	   Cell	   divisions	   (arrows)	   were	   followed	   microscopically.	   Images	   represent	   a	   merge	   of	  
several	   focal	   planes	   of	   GFP	   fluorescence	   overlaid	   with	   single	   DIC	   focal	   plane.	   A	   dotted	   line	  
encircles	  progeny	  of	  Ring	  mothers	   that	  did	  not	   form	  any	  aggregates	  during	   the	  course	  of	   the	  
experiment.	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Propagation	  of	  Rings	  and	  Dots	  is	  independent	  of	  [RNQ+]	  
	  When	  PrD-­‐GFP	  was	  overexpressed	  in	  cells	  carrying	  a	  deletion	  of	  RNQ1,	  a	  factor	  required	  
for	  efficient	  prion	   induction	   (DERKATCH,	   et	  al.	   2001;	  OSHEROVICH,	   et	  al.	   2001;	   SONDHEIMER,	   et	  al.	  
2000),	  it	  remained	  diffuse	  (ZHOU,	  et	  al.	  2001)(Supplemental	  Figure	  A1.2).	  When	  cells	  containing	  
Rings	  or	  Dots	  were	  mated	  to	  cells	  with	  a	  RNQ	  deletion	  and	  sporulated,	  haploid	  progeny	  with	  
the	  deletion	  maintained	  their	  Rings	  and	  Dots	  (Supplemental	  Figure	  A1.3).	  Thus,	  as	  for	  the	  [PSI+]	  
prion	   itself	   (DERKATCH,	  et	  al.	  2000),	  Dots	  and	  Rings	   require	   [RNQ+]	   for	   their	   induction,	  but	  not	  
their	  propagation.	  
	  
Time-­‐lapse	  microscopy	  establishes	  stable	  asymmetric	  inheritance	  of	  both	  aggregation	  states	  
We	  followed	  the	  propagation	  of	  PrD-­‐GFP	  Rings	  and	  Dots	  for	  several	  cell	  divisions	  using	  
time-­‐lapse	   microscopy	   (Figure	   A1.1b).	   Both	   were	   faithfully	   propagated,	   but	   Rings	   were	   less	  
stable,	   frequently	  giving	  rise	  to	  progeny	  with	  diffuse	  fluorescence	  (Figure	  A1.1b,	  upper	  panel,	  
cells	  encircled	  by	  dotted	  line).	  Surprisingly,	  during	  cell	  division,	  Rings	  and	  Dots	  were	  retained	  in	  
mother	   cells.	   Visible	   assemblies	   only	   became	   detectable	   in	   daughter	   cells	   after	   the	   dividing	  
septum	  had	  formed.	  Cells	  with	  Rings	   initially	  gave	  rise	  to	  daughters	  with	  a	  single	  small	   focus,	  
much	  like	  the	  initiating	  focus	  in	  Dot	  cells,	  but	  these	  generally	  expanded	  to	  form	  a	  typical	  Ring	  




Figure	  A1.2:	  Cells	  with	  Rings	  do	  not	  induce	  the	  [PSI+]	  prion	  state	  in	  a	  mating	  partner.	  
(A)	   Haploid	   strains	   carrying	   a	   PrD	   deletion	   of	   the	   endogenous	   SUP35	   gene	   (PrD∆)	   displaying	  
diffuse	  PrD-­‐GFP	   fluorescence,	  Rings	  or	  Dots	  were	  mated	  with	   a	  wild-­‐type	   SUP35	   [psi-­‐]	   strain.	  
The	   resulting	   diploids	  were	   sporulated	   and	   tetrads	  were	   dissected.	   Spores	  with	   the	   PrD-­‐GFP	  
fusion	  were	  analyzed	  by	  fluorescence	  microscopy.	  Colony	  colors	  of	  the	  progeny,	  [psi-­‐]	  =	  red	  and	  
[PSI+]	  =	  light	  pink,	  revealed	  that	  Dots,	  but	  not	  Rings	  induced	  the	  prion	  state	  in	  wild-­‐type	  SUP35.	  
(B)	  Sup35-­‐HA	  co-­‐localizes	  with	  PrD-­‐GFP	  Rings	  and	  Dots.	  A	  [psi-­‐]	  strain	  carrying	  an	  inducible	  copy	  
of	   PrD-­‐GFP	   and	   a	   C-­‐terminally	   HA-­‐tagged	   Sup35	   (SUP35-­‐HA)	   was	   analyzed	   by	  
immunofluorescence	   and	   fluorescence	   microscopy.	   Co-­‐localization	   is	   shown	   in	   yellow	   in	  
merged	  images.	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PrD-­‐GFP	  Dots	  can	  transmit	  the	  [PSI+]	  phenotype	  but	  Rings	  cannot	  
Genetically,	  a	  defining	  feature	  of	  prions	  is	  dominance	  in	  crosses	  to	  mating	  partners.	  We	  
first	  mated	  Ring	  and	  Dot	  cells	  to	  isogenic	  partners	  whose	  RNQ1	  gene	  had	  been	  deleted	  prior	  to	  
PrD-­‐GFP	  expression.	  As	  noted	  above,	   this	  kept	   their	  PrD-­‐GFP	  protein	   in	   the	  diffuse	  non-­‐prion	  
state.	  After	  mating,	  diffuse	  PrD-­‐GFP	  converted	   to	   the	  Ring	  or	  Dot	   form	  of	   its	  mating	  partner.	  
When	  these	  diploids	  were	  sporulated,	  all	  haploid	  progeny	  of	  Dot	  matings	  contained	  Dots.	  Rings	  
were	  also	  inherited,	  albeit	  less	  faithfully	  (Supplemental	  Figure	  A1.3).	  	  
	   Next	  we	  mated	   Ring	   and	   Dot	   cells	   to	  wild-­‐type	   [psi-­‐]	   cells	   to	   determine	   if	   they	   could	  
transmit	   the	   [PSI+]	   phenotype.	  Both	  Rings	  and	  Dots	  were	  maintained	   in	   the	  diploids.	  All	   cells	  
carried	   the	  ade1-­‐14	   stop	  codon	  mutation	   (SHORTER,	  et	  al.	  2005)	  but	  because	  one	  Sup35	  allele	  
carried	  a	  PrD	  deletion,	  the	  [PSI+]	  read-­‐through	  phenotype	  could	  not	  be	  detected	  in	  the	  diploid.	  
However,	  after	  sporulation	  haploid	  progeny	  that	  received	  the	  wild-­‐type	  SUP35	  gene	  and	  whose	  
protein	  had	  acquired	   the	   [PSI+]	   state,	  were	  expected	   to	   switch	   colony	   color	   from	   red	   to	  pink	  
(Figure	  A1.2a).	  	  
In	  control	  matings,	  parents	  with	  diffuse	  PrD-­‐GFP	   fluorescence	  produced	  only	   red	   [psi-­‐]	  
progeny	  (Figure	  A1.2a,	  upper	  panel).	  Progeny	  of	  Dot	  parents	   that	  received	  only	  the	  wild-­‐type	  
Sup35	  gene	  invariably	  gave	  rise	  to	  pink	  [PSI+]	  colonies	  as	  expected	  for	  faithful	  transmission	  of	  
the	  prion	  state	  from	  PrD-­‐GFP	  to	  wild-­‐type	  Sup35	  (Figure	  A1.2a,	  lower	  panel).	  Also	  as	  expected,	  
progeny	  carrying	  both	  wild-­‐type	  Sup35	  and	  the	  PrD-­‐GFP	  over-­‐expression	  construct	  were	  never	  
recovered,	  due	  to	  excessive,	  toxic	  sequestration	  of	  Sup35	  (CHERNOFF,	  et	  al.	  1993;	  VISHVESHWARA,	  
et	   al.	   2009).	   Surprisingly,	   Ring	   cells	   produced	   no	   wild-­‐type	   Sup35	   progeny	   with	   the	   [PSI+]	  
phenotype	  (Figure	  A1.2a,	  middle).	  Furthermore,	  cells	  carrying	  both	  the	  PrD-­‐GFP	  construct	  and	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wild-­‐type	  Sup	  35	  were	  readily	  obtained	  (for	  example,	  Figure	  A1.2a,	  middle,	  spore	  III).	   In	  these	  
cells	  PrD-­‐GFP	  maintained	  its	  initial	  Ring	  pattern,	  demonstrating	  that	  Rings	  generally	  propagated	  
faithfully	  to	  progeny	  during	  meiosis.	  	  
	   A	  simple	  explanation	  might	  be	  that	  the	  PrD-­‐GFP	  in	  Ring	  cells	  does	  not	  interact	  with	  WT	  
Sup35.	  To	  test	  this	  we	  induced	  PrD-­‐GFP	  Rings	  and	  Dots	  in	  cells	  with	  HA-­‐tagged	  Sup35	  protein	  as	  
the	   only	   source	   of	   this	   essential	   protein.	   HA	   co-­‐localized	   with	   both	   Rings	   and	   Dots	   (Figure	  
A1.2b),	  eliminating	  this	  explanation.	  	  
	   	  
In	  Ring	  and	  Dot	  cells	  PrD-­‐GFP	  is	  in	  the	  same	  amyloid	  conformation	  
A	  common	  feature	  of	  prions	  is	  the	  ability	  to	  exist	  in	  several	  related,	  but	  distinct,	  amyloid	  
conformations,	   known	   as	   “prion	   strains”	   (KING,	   et	   al.	   2004;	   TANAKA,	   et	   al.	   2004).	   These	  
propagate	   with	   different	   polymerization	   and	   fragmentation	   efficiencies.	   Because	   they	   reach	  
different	  equilibria	  between	  the	  soluble	  functional	  form	  and	  the	  amyloid,	  they	  produce	  distinct	  
phenotypes	  (in	  ade1-­‐14	  cells,	  colonies	  with	  different	  shades	  of	  pink)	  (KING,	  et	  al.	  2004;	  TANAKA,	  
et	  al.	  2004;	  TANAKA,	  et	  al.	  2006).	  Thus,	  another	  explanation	  for	  our	  results	  might	  be	  that	  Rings	  
represent	   a	   different	   prion	   strain	   than	   Dots,	   one	   that	   is	   too	   “weak”	   to	   elicit	   a	   detectable	  
phenotype.	  This	  occurs,	  for	  example,	  with	  the	  [ETA+]	  variant	  of	  [PSI+]	  (ZHOU,	  et	  al.	  1999).	  
When	  crude	  cell	  lysates	  of	  all	  cell	  types	  were	  boiled	  in	  SDS	  they	  all	  produced	  a	  PrD-­‐GFP	  
band	   of	   the	   same	   intensity	   by	   SDS-­‐PAGE,	   confirming	   that	   the	   protein	   was	   expressed	   at	   the	  
same	  level	  (Figure	  A1.3a,	  top).	  When	  analyzed	  without	  boiling	  on	  semi-­‐denaturing	  agarose	  gels	  
the	  PrD-­‐GFP	  protein	  of	  both	  Ring	  and	  Dot	  cells	  migrated	  as	  high	  molecular	  weight	  SDS-­‐resistant	  
complexes	  typical	  of	  prion	  amyloids	  	  (Figure	  A1.3a,	  bottom	  left).	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Next,	  we	  tested	  the	  ability	  of	  Dots	  and	  Rings	  to	  seed	  polymerization	  of	  purified	  soluble	  
PrD,	  a	  defining	  characteristic	  of	  prions.	  Lysates	  of	  cells	  with	  diffuse	  fluorescence	  did	  not	  seed	  
polymerization.	   But	   lysates	   of	   Ring	   and	   Dot	   cells	   had	   very	   similar	   seeding	   capacities	   (Figure	  
A1.3a,	   bottom	   right):	   SDS-­‐resistant	   species	   could	   be	   detected	   almost	   immediately	   and	   their	  
sizes	  increased	  similarly	  during	  the	  course	  of	  the	  experiment.	  	  	  
Proteins	   from	   different	   prion	   strains	   transform	   [psi-­‐]	   cells	   to	   [PSI+]	   in	   a	   phenotype-­‐
specific	  manner.	  To	  minimize	  manipulations,	  crude	  extracts	  were	  introduced	  directly	  into	  [psi-­‐]	  
cells	  to	  test	  for	  such	  differences	  (KING,	  et	  al.	  2004;	  TANAKA,	  et	  al.	  2004).	  To	  our	  surprise,	  lysates	  
from	  cultures	  with	  Rings	  and	  Dots	  both	  gave	  rise	  to	  the	  same	  strong	  [PSI+]	  strain	  (Figure	  A1.3b):	  
Dot	   lysates	   induced	   the	   strong	  prion	  phenotype	   in	  71	   transformants,	   the	  weak	  phenotype	   in	  
only	  three.	  Ring	  lysates	   induced	  the	  strong	  phenotype	  in	  101	  transformants,	  the	  weak	  in	  only	  
six.	  	  
Although	   the	   stability	   of	   amyloid	   structures	   makes	   it	   extremely	   unlikely	   that	   a	   weak	  
conformation	  might	  convert	  to	  a	  strong	  one	  during	  our	  procedure	  (KING,	  et	  al.	  2004;	  TANAKA,	  et	  
al.	   2004),	   we	   considered	   the	   possibility.	   We	   eliminated	   the	   sonication	   step	   prior	   to	  
transformation	   and	   used	   several	   different	   lysis	   procedures	   without	   changing	   the	   outcome.	  
More	  definitively,	  we	  performed	  many	   similar	  experiments	  with	   lysates	   from	  bona	   fide	  weak	  
prion	   strains	  but	  never	  observed	   conversion	  of	  weak	  prion	   strains	   to	   strong.	   Thus,	  Rings	  and	  
Dots	  do	  not	  represent	  different	  prion	  conformations	  or	  strains.	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Figure	  A1.3:	  Cells	  with	  Rings	  and	  Dots	  contain	  PrD-­‐GFP	  in	  the	  same	  prion	  conformation.	  
(A)	   Upper	   panel:	   crude	   lysates	   from	   cells	   displaying	   diffuse,	   Ring	   or	   Dot	   fluorescence	   were	  
adjusted	  to	  equal	  protein	  concentrations	  and	  serial	  dilutions	   (1:2	  steps)	  were	   loaded	  onto	  an	  
SDS	  gel	  and	  analyzed	  by	  SDS-­‐PAGE	  and	  Western	  Blotting	  with	  an	  anti-­‐GFP	  antibody	   to	   reveal	  
the	  amounts	  of	  PrD-­‐GFP	   in	   the	  different	   lysates.	  Lower	  panel	   left:	   the	   three	  different	   lysates	  
were	  analyzed	  by	  semi-­‐denaturing	  agarose	  gel	  analysis	  (SDD-­‐AGE)	  followed	  by	  Western	  Blotting	  
with	   an	   anti-­‐GFP	   antibody.	   Lysates	   from	   cells	   with	   Rings	   and	   Dots,	   but	   not	   diffuse	   PrD-­‐GFP,	  
contain	  SDS-­‐resistant	  high	  molecular	  weight	  aggregates	  of	  PrD-­‐GFP.	  Lower	  panel	  right:	  purified	  
PrD-­‐His	   was	   seeded	   with	   the	   three	   different	   lysates	   in	   vitro	   and	   analyzed	   by	   SDD-­‐AGE	   and	  
Western	  Blotting	  with	  an	  anti-­‐His-­‐tag	  antibody.	  SDS-­‐resistant	  high	  molecular	  weight	  aggregates	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were	  formed	  with	  comparable	  kinetics.	  (B)	  Protein	  transformations	  of	  a	  [psi-­‐]	  tester	  strain	  (red	  
colony	  color)	  were	  performed	  with	  crude	  lysates	  from	  cells	  with	  diffuse	  PrD-­‐GFP	  fluorescence	  
or	  Rings	  and	  Dots.	  The	  prion	  status	  and	  strain	  of	  the	  transformants	  was	  determined	  by	  colony	  
color.	   Both	   types	   of	   aggregates	   induced	   a	   strong	   [PSI+]	   strain	   (light	   pink	   color)	   with	   similar	  
efficiencies.	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Aggregate	  formation	  occurs	  at	  a	  site	  specific	  to	  the	  deposition	  of	  insoluble	  aggregates	  
We	   asked	   if	   the	   differences	   in	   transmissibility	   of	   the	   [PSI+]	   phenotype	  with	   Rings	   and	  
Dots	  could	  be	  due	  to	  different	  cellular	  localizations.	  The	  vacuolar	  dye	  FM4-­‐64	  established	  that	  
PrD-­‐GFP	  Dots	  were	  localized	  adjacent	  to	  the	  vacuole	  (Figure	  A1.4a,	  left	  column).	  A	  single	  focus	  
at	   the	  vacuole	   is	  characteristic	  of	   the	  pre-­‐autophagosomal	  structure	   (PAS),	  which	  coordinates	  
autophagosome	   formation	   and	   cytoplasm-­‐to-­‐vacuole	   vesicle	   trafficking	   (HE,	   et	   al.	   2009).	  
Colocalization	  of	  a	  PrD-­‐YFP	  fusion	  and	  the	  CFP-­‐tagged	  PAS	  markers	  ATG8	  and	  ATG14	  confirmed	  
this	   localization	   (Figure	   A1.4a).	   Dots	   were	   directly	   adjacent	   to	   the	   PAS.	   Rings	   intersected	   it	  
(Figure	  A1.4a).	  	  
Recently,	  a	  perivacuolar	  PAS-­‐associated	  site	  for	  the	  deposition	  of	  irreversibly	  aggregated	  
proteins	  was	  discovered	  and	  termed	  the	  IPOD	  for	  Insoluble	  PrOtein	  Deposit	  (KAGANOVICH,	  et	  al.	  
2008).	   It	  also	  accumulates	  the	  Ure2	  and	  Rnq1	  proteins	  in	  their	  prion	  forms	  (KAGANOVICH,	  et	  al.	  
2008).	   To	   extend	   this	   characterization,	   we	   used	  mass	   spectroscopy	   to	   identify	   proteins	   that	  
were	   co-­‐immuno-­‐captured	   with	   PrD-­‐GFP	   Dots	   but	   not	   with	   soluble	   PrD-­‐GFP	   (Supplemental	  
Figure	  A1.4	  &	  Supplemental	  Table	  A1.1).	  Rnq1	  was	  among	  them	  confirming	  the	  capture	  of	  bona	  
fide	  IPOD	  substrates.	  We	  also	  found	  proteins	  known	  to	  be	  very	  sensitive	  to	  oxidative	  damage	  
(CABISCOL,	  et	  al.	  2000).	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Figure	  A1.4:	  Prion	  aggregates	  localize	  to	  the	  IPOD	  compartment	  as	  shown	  using	  markers	  for	  
the	  pre-­‐autophagosomal	  structure	  (PAS)	  and	  additional	  IPOD	  substrates.	  
Cells	   carrying	   Dots	  were	   generated	   using	   a	   genomic	   copy	   of	   GPD-­‐controlled	   PrD-­‐YFP.	  
Rings	  were	  induced	  using	  an	  analogous	  galactose-­‐inducible	  construct.	  (A)	  FM4-­‐64	  visualization	  
of	   the	  vacuolar	  membrane	   shows	   the	  perivacuolar	   localization	  of	  PrD-­‐YFP	  Dots	   (left	   column).	  
The	   localization	   of	   Rings	   and	  Dots	   to	   the	   pre-­‐autophagosomal	   structure	  was	   visualized	   using	  
centromeric	  plasmids	  expressing	  N-­‐terminal	  CFP	  fusions	  of	  ATG8	  or	  ATG14.	  (B)	  Co-­‐localization	  
of	   PrD-­‐YFP	   Dots	   with	   known	   and	   newly	   identified	   substrates	   of	   the	   IPOD	   compartment	  
(indicated	  by	  arrows).	  Genomic	  copies	  of	  PDC1	  or	  FAS1	  were	  tagged	  with	  CFP	  (columns	  1	  and	  
2),	   while	   the	   Rnq1-­‐CFP	   fusion	   was	   expressed	   from	   a	   plasmid	   under	   control	   of	   the	   Cup1	  
promoter	  (column	  3).	  Aggregation	  of	  Pdc1-­‐CFP	  or	  Fas1-­‐CFP	  was	  induced	  using	  0.1	  mM	  or	  2	  mM	  
of	   menadione,	   respectively,	   for	   4	   hours	   prior	   to	   microscopy.	   The	   Rnq1-­‐CFP	   expression	   was	  
induced	  using	  100	  µM	  Cupper	  sulfate.	  Images	  represent	  one	  single	  optical	  plane.	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CFP-­‐tagged	  versions	  of	  Rnq1	  and	   the	   two	  oxidation-­‐sensitive	  proteins,	  Fas1	   (fatty	  acid	  
synthase)	   and	   Pdc1	   (pyruvate	   decarboxylase1)	   (CABISCOL,	   et	   al.	   2000)	   were	   used	   to	   confirm	  
cellular	  co-­‐localization	  by	  microscopy.	  RNQ1-­‐CFP	  co-­‐localized	  with	  PrD-­‐YFP	  Dots	  constitutively	  
(Figure	   A1.4b).	   Fas1	   and	   Pdc1’s	   partial	   colocalization	   with	   PrD-­‐YFP	   Dots	   was	   most	   apparent	  
after	   cells	   were	   treated	   with	   the	   oxidizing	   agent	   menadione	   (CABISCOL,	   et	   al.	   2000)	   (Figure	  
A1.4b).	   Thus,	   the	   previously	   reported	   polarisome-­‐dependent	   asymmetric	   inheritance	   of	  
oxidatively	  damaged	  proteins	  (AGUILANIU,	  et	  al.	  2003;	  LIU,	  et	  al.	  2010)	  occurs	  in	  part	  at	  the	  IPOD,	  
which	  is	  also	  a	  site	  for	  prion	  accumulation.	  
	  
Number	  of	  PrD-­‐GFP	  amyloid	  fibers	  differs	  between	  Ring	  and	  Dot	  aggregates	  	  
Next	  we	   investigated	   the	  difference	  between	  Rings	  and	  Dots	  by	   transmission	  electron	  
microscopy	  (TEM).	  We	  easily	  identified	  both	  forms	  by	  their	  highly	  ordered	  fibrous	  appearance,	  
which	  closely	  resembled	  fibrils	  formed	  by	  Sup35	  or	  PrD	  in	  vitro	  (GLOVER,	  et	  al.	  1997;	  KRZEWSKA,	  et	  
al.	   2006).	   We	   confirmed	   that	   these	   assemblies	   were	   indeed	   PrD-­‐GFP	   Rings	   and	   Dots	   by	  
immuno-­‐EM	   using	   an	   antibody	   against	   GFP	   (Supplemental	   Figure	   A1.5).	   We	   also	   found	   the	  
typical	  electron-­‐dense	   foci	   formed	  by	  amorphous	  aggregates	  of	  damaged	  proteins	  at	   this	  site	  
further	  confirming	  the	  co-­‐localizations	  described	  above	  (Supplemental	  Figure	  A1.6).	  
Rings	   and	   Dots	   were	   not	   separated	   from	   the	   surrounding	   cytoplasm	   by	   any	  
compartmentalizing	  elements,	  such	  as	  membranes	  or	  cytoskeletal	  structures.	  Fibrils	  formed	   in	  
vitro	   by	   the	  Sup35	  PrD	  alone	  have	  an	  average	  diameter	  of	  ~	  11.5	  nm,	  whereas	   fibrils	  of	   full-­‐
length	  Sup35	  are	  ~	  25	  nm	  (GLOVER,	  et	  al.	  1997;	  KRZEWSKA,	  et	  al.	  2006).	  In	  cross	  sections,	  Ring	  and	  
Dot	  PrD-­‐GFP	  fibrils	  had	  identical	  doughnut-­‐like	  morphologies	  with	  a	  diameter	  of	  around	  25	  -­‐	  30	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nm	  and	  an	  inner	  core	  of	  6	  -­‐	  12	  nm	  (Supplemental	  Figure	  A1.5).	  This	  is	  consistent	  with	  the	  prion	  
domain	  forming	  the	  inner	  core	  of	  the	  fiber,	  surrounded	  by	  GFP	  molecules.	  	  
	   However,	  there	  was	  one	  profound	  difference	  between	  the	  fibrils	  in	  the	  Rings	  and	  Dots,	  
their	   length.	   Rings	   contained	   bundles	   of	   very	   long	   uninterrupted	   fibrils	   (Figure	   A1.5a,	   upper	  
panel).	  Dots	  contained	  a	  profusion	  of	  short	  fibril	  bundles	  with	  diverse	  orientations	  in	  the	  same	  
structure	   (Figure	   A1.5a,	   lower	   panel).	   Thus,	   Ring	   and	   Dot	   aggregates	   displayed	   an	   extreme	  
difference	   in	   fragmentation	   and,	   consequently,	   in	   the	   number	   of	   fibril	   ends.	   The	   cell	   lysis	  
procedure	  used	   in	  our	  protein	   transformation	  or	  seeding	  assays	   (Figure	  A1.3)	  would	  certainly	  
fragment	  the	  very	   long	  fibrils	  of	  Ring	  cells,	  eliminating	  the	  sole	  difference	  between	  Rings	  and	  
Dots.	  
In vivo, the only known protein with the capacity to sever PrD fibrils is the AAA+ ATPase 
Hsp104. Inhibition of Hsp104 increases the number of ring-bearing cells when PrD-GFP is 
overexpressed in the presence of wild-type Sup35 (ZHOU, et al. 2001). But the relationship 
between Hsp104 activity and Dots has never been examined. We inhibited Hsp104 activity in 
Dot cells by two different methods: incubation with 5 mM GdHCl, which selectively inhibits 
Hsp104’s ATPase cycle (NESS, et al. 2002) (Figure A1.5b), or expression of a dominant negative 
mutant of Hsp104 (Supplemental Figure A1.7), which is incorporated into Hsp104 hexamers and 
blocks their activity. In both cases time-lapse microscopy revealed that pre-existing Dots never 
changed, but mother cells with Dots rapidly and invariably produced daughter cells with Rings. 
These Rings also remained intact. However, within just a few divisions, all Ring-containing cells 
gave rise to progeny with diffuse PrD-GFP fluorescence. Thus, the curing of Dots by Hsp104 
inhibition mirrors their formation. The distinct states of prion maturation result from differences 
in the number of fiber fragments generated by Hsp104 and hence the number of prion seeds.	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Figure	  A1.5:	  Electron	  microscopy	  of	  Ring	  and	  Dot	  cells	   reveals	   the	  different	  degrees	  of	  PrD-­‐
GFP	  fibril	  fragmentation.	  
(A)	   Upper	   panel:	   different	  magnifications	   of	   ultrathin	   cell	   section	  with	   a	   large	  Dot	   aggregate	  
next	  to	  the	  vacuole;	  lower	  panel:	  perpendicular	  or	  parallel	  sections	  of	  a	  cell	  displaying	  PrD-­‐GFP	  
Rings.	   m:	   mitochondrion,	   n:	   nucleus,	   v:	   vacuole,	   pm:	   plasma	   membrane.	   (B)	   Time-­‐lapse	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microscopy	   of	   constitutively	   PrD-­‐GFP	   expressing	   strain	   carrying	   a	   Dot	   aggregate.	   Cells	   were	  
monitored	   for	   several	  hours	   in	   the	  presence	  of	  5	  mM	  GdHCl	   to	   inhibit	  Hsp104	  activity.	  Upon	  
inhibition	  of	  Hsp104,	  cells	  with	  Dot	  aggregates	  gave	  rise	   to	  progeny	   forming	  Ring	  aggregates.	  
Progeny	   thereof	   ultimately	   displayed	   diffuse	   fluorescence.	   Images	   show	   different	  
representative	  groups	  of	  cells	  at	  different	  time	  points	  (0,	  6,	  24	  hours)	  and	  are	  an	  overlay	  of	  a	  
single	  focal	  plane	  DIC	  image	  and	  a	  merge	  of	  fluorescence	  z-­‐stack	  images.	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Discussion	  
We	   find	   that	   prion	   induction	   by	   the	   Sup35	   PrD	   involves	   a	  maturation	   process	  with	   a	  
distinct,	  stable,	  and	  heritable	  intermediate.	  Surprisingly,	  this	  intermediate	  (Ring	  state)	  has	  all	  of	  
the	   biochemical	   characteristics	   of	   the	   mature	   prion	   (Dot	   state),	   but	   distinct	   phenotypic	  
properties.	   It	   does	   not	   confer	   a	   [PSI+]	   phenotype	   on	  meiotic	   progeny	   whose	   only	   source	   of	  
Sup35	  is	  the	  wild-­‐type	  protein,	  even	  when	  PrD-­‐GFP	  Rings	  co-­‐exist	  in	  the	  same	  cell.	  How	  might	  
we	  resolve	  this	  seeming	  paradox	  and	  also	  decipher	  the	  nature	  of	  the	  prion	  induction	  process?	  
Two	  other	  observations,	  we	  think,	  provide	  the	  key.	  	  	  
First,	  by	  electron	  microscopy,	  Ring	   fibrils	  are	   long	  and	  uninterrupted,	  Dot	   fibrils	  highly	  
fragmented.	   Indeed,	   the	   degree	   of	   fiber	   fragmentation	   is	   the	   defining	   characteristic	   for	   the	  
different	   structures,	   as	  blocking	  Hsp104’s	   fragmentation	  activity	   reverts	  Dots	   to	  Rings	  before	  
the	   assemblies	   are	   lost	   entirely.	   	   Second,	   the	   deposition	   of	   Rings	   and	   Dots	   occurs	   at	   a	   site	  
specific	  for	  the	  compartmentalization	  of	  damaged	  proteins,	  known	  as	  the	  IPOD	  (KAGANOVICH,	  et	  
al.	  2008).	  In	  cells	  undergoing	  mitosis,	  Rings	  and	  Dots	  are	  retained	  in	  mother	  cells	  but	  re-­‐form	  in	  
their	   daughters	   at	   the	   IPOD	   immediately	   after	   septum	   formation.	   The	   most	   parsimonious	  
explanation	   is	   that	  prion	  seeds,	   too	  small	   to	  be	  detected	  by	   fluorescence	   (KAWAI-­‐NOMA,	   et	  al.	  
2006),	  are	  liberated	  by	  the	  activity	  of	  Hsp104	  and	  transmitted	  to	  daughter	  cells.	  
Taking	   these	  observations	   together,	  we	  propose	  a	  model	   for	  prion	   induction	   that	  also	  
explains	   the	   distinct	   phenotypes	   and	   heritable	   nature	   of	   Rings	   and	   Dots.	   Upon	   initial	  
expression,	   PrD-­‐GFP	   is	   soluble	   but	   the	   intrinsically	   unstructured	   Sup35	   PrD	   has	   a	   high	  
propensity	   to	   misfold.	   This	   misfolded	   protein	   is	   targeted	   to	   the	   IPOD.	   Because	   nucleated	  
conformational	  conversion	  to	  the	  prion	  state	  requires	  an	  oligomeric	  intermediate	  (SERIO,	  et	  al.	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2000),	   the	   high	   local	   concentration	   of	   PrD-­‐GFP	   at	   the	   IPOD	   increases	   the	   likelihood	   of	   prion	  
induction	   (GANUSOVA,	   et	   al.	   2006).	   [RNQ+]	   prions,	   which	   are	   required	   for	   [PSI+]	   induction	  
(DERKATCH,	  et	  al.	  2001;	  OSHEROVICH,	  et	  al.	  2001;	  SONDHEIMER,	  et	  al.	  2000),	  are	  also	  located	  at	  the	  
IPOD	  and	  ready	  to	  facilitate	  nucleation	  (this	  study	  and	  (DERKATCH,	  et	  al.	  2004;	  KAGANOVICH,	  et	  al.	  
2008)).	  	  
Initially,	   only	   a	   few	  prion	   seeds	   form.	   Therefore,	   the	   rate	   at	  which	   soluble	   full	   length	  
Sup35	  is	  sequestered	  from	  translation	  is	  limited.	  Rings	  formed	  in	  this	  way	  can	  coexist	  with	  the	  
wild-­‐type	  protein	  without	  causing	  toxicity	  or	  creating	  a	  [PSI+]	  phenotype	  (Figure	  A1.2a,	  middle	  
panel,	   spore	   III).	   The	   small	   number	   of	   seeds	   creates	   long	   bundles	   of	   fibers,	  which	   appear	   as	  
Rings	   confined	   only	   by	   the	   boundary	   of	   the	   cell.	   Inheritance	   of	   a	   small	   number	   of	   seeds	   by	  
daughter	  cells	  perpetuates	  the	  Ring	  state.	  	  
	  Dots	  consist	  of	  short	  highly	  fragmented	  fibers.	  Increased	  fragmentation	  causes	  a	  larger	  
number	  of	  prion	  seeds	  to	  be	  inherited	  by	  daughters,	  explaining	  the	  more	  stable	  inheritance	  of	  
Dots	  relative	  to	  Rings	  and	  the	  ability	  to	  reliably	  transmit	  the	  prion	  state	  to	  all	  meiotic	  progeny.	  
In	   this	   case	   polymerization	   is	   limited	  by	   the	   amount	   of	   soluble	   prion	  protein	   and	  not	   by	   the	  
number	  of	  prion	  seeds.	  Thus,	  meiotic	  progeny	   inheriting	  PrD-­‐GFP	  Dots,	  whose	  only	  source	  of	  
the	  essential	  Sup35	  is	  the	  wild-­‐type	  protein,	  are	  inviable.	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Figure	  A1.6:	  Schematic	  model	  for	  the	  induction	  and	  maturation	  of	  the	  PrD-­‐GFP	  prion	  via	  a	  
long-­‐lived	  poorly	  fragmented	  fibril	  state.	  
The	  discussion	  of	  this	  appendix	  chapter	  contains	  a	  detailed	  description	  of	  this	  model	  for	  the	  
maturation	  of	  the	  PrD-­‐GFP	  prion.	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A	  remaining	  question	  is	  how	  cells	  switch	  from	  the	  transitional	  Ring	  state	  to	  the	  mature	  
prion	  state.	  One	  possibility	  is	  that	  a	  Ring-­‐containing	  mother	  rarely	  but	  stochastically	  transmits	  a	  
sufficiently	  large	  number	  of	  seeds	  to	  its	  daughter	  to	  create	  a	  profusion	  of	  shorter	  fibrils.	  Indeed,	  
the	   number	   of	  wild	   type	   [PSI+]	   propagons	   is	   known	   to	   be	   clonally	   diverse	   (COX,	   et	   al.	   2003).	  
However,	  Ring	  and	  Dot	  cells	  contain	  the	  same	  quantity	  of	  the	  fibril	  fragmenting	  protein	  Hsp104	  
(Supplemental	   Figure	   A1.8),	   which	   plays	   a	   critical	   role	   in	   [PSI+]	   inheritance	   (BORCHSENIUS,	   et	   al.	  
2006;	  BORCHSENIUS,	   et	  al.	   2001;	  CHERNOFF,	   et	  al.	   1995;	  NESS,	   et	  al.	   2002;	  WEGRZYN,	   et	  al.	   2001).	  
With	  just	  a	  few	  initiating	  fibrils,	  one	  might	  expect	  them	  to	  be	  highly	  susceptible	  to	  Hsp104,	  but	  
Hsp104’s	  remodeling	  functions	  are	  tightly	  regulated	  in	  unstressed	  cells	  (SCHIRMER,	  et	  al.	  2004).	  
Thus,	   another	   explanation	   is	   a	   heritable	   switch	   in	   the	   activity	   of	   Hsp104.	   Speculatively,	   an	  
inhibitor	  of	  Hsp104	  might	   itself	  be	  a	  prion	  –	   the	  concentration	  of	  aggregated	  proteins	  at	   the	  
iPOD	   could	   favor	   its	   switch	   to	   a	   heritable,	   non-­‐functional	   state,	   converting	   Rings	   to	   highly	  
fragmented	  mature	  prions.	  	  
	  	   However	   that	   specific	   detail	   may	   be	   resolved,	   many	   lines	   of	   evidence	   suggest	   that	  
normal	  [PSI+]	  induction,	  as	  well	  as	  the	  induction	  of	  other	  prions,	  involves	  a	  transitional	  state	  like	  
the	  one	  we	  describe.	  For	  example,	  propagons	  of	  wild-­‐type	  [PSI+]	  are	  subject	  to	  biased	  retention	  
in	  mother	  cells	  by	  a	  previously	  unknown	  mechanism	  (COX,	  et	  al.	  2003).	  Both	  Rings	  and	  Dots	  are	  
observed	   in	   cells	   with	   wild-­‐type	   Sup35	   during	   “typical”	   laboratory	   prion	   inductions	   with	  
overexpressed	  PrD	  (GANUSOVA,	  et	  al.	  2006;	  ZHOU,	  et	  al.	  2001)	  and	  Rings	  behave	  as	  an	  immature	  
transitional	   state	   with	   unstable	   inheritance.	   Further,	   in	   those	   cases	   where	   it	   has	   been	  
examined,	   the	   induction	  of	   [PSI+],	   [URE3]	   and	   [RNQ+]	  by	  over-­‐expression	  of	   their	  PrDs	   clearly	  
involves	  a	  genetically	  unstable	  intermediate.	  Cells	  initially	  segregate	  both	  [prion-­‐]	  and	  [PRION+]	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clones	   and	   only	   later	   stabilize	   to	   reliably	   produce	   [PRION+]	   colonies	   (DERKATCH,	   et	   al.	   2001;	  
DERKATCH,	   et	   al.	   2000;	   FERNANDEZ-­‐BELLOT,	   et	   al.	   2000;	   OSHEROVICH,	   et	   al.	   2001;	   SALNIKOVA,	   et	   al.	  
2005).	  Finally,	   in	  the	  absence	  of	  PrD	  over-­‐expression,	  proteotoxic	  stresses,	   including	  oxidative	  
stresses,	  increase	  the	  spontaneous	  induction	  of	  [PSI+]	  (SIDERI,	  et	  al.	  2010;	  TYEDMERS,	  et	  al.	  2008).	  
The	  more	  severe	  the	  stress	  the	  more	  efficient	  the	   induction.	  Co-­‐localization	  of	  such	  damaged	  
proteins	  at	   the	   IPOD	  could	  provide	  an	  opportunity	   for	  cross	  seeding	  akin	   to	   that	  provided	  by	  
[RNQ+].	   Subsequently,	   in	   the	   absence	   of	   PrD	   overexpression,	   the	   fragmentation	   activity	   of	  
Hsp104	   would	   be	   sufficient	   to	   free	  most	   of	   the	   assembled	   protein	   from	   the	   IPOD,	   allowing	  
direct	  cytoplasmic	  inheritance	  of	  prion	  propagons.	  
The	   concerted	   asymmetric	   retention	   of	   prion	   fibrils	   is	   tied	   to	   an	   ancient	   (but	   only	  
recently	   discovered)	   system	   for	   the	   asymmetric	   inheritance	   of	   misfolded	   damaged	   proteins.	  
Mitotic	   cells,	   ranging	   from	  bacteria,	   to	   yeast,	   to	   human	   embryonic	   stem	   cells,	   systematically	  
retain	  and	  sequester	  damaged	  and	  misfolded	  proteins	  to	  one	  cell	  during	  division	  (AGUILANIU,	  et	  
al.	  2003;	  LINDNER,	  et	  al.	  2008;	  RUJANO,	  et	  al.	  2006).	  This	   is	  thought	  to	  ensure	  the	  fitness	  of	  the	  
next	   generation	   by	   allowing	   one	   of	   the	   two	  mitotic	   products	   to	   start	   afresh	  with	   respect	   to	  
protein	   damage	   –	   segregating	   an	   aging	   (soma-­‐like)	   lineage	   from	   a	   rejuvenated	   (germ-­‐like)	  
lineage.	  We	  propose	  that	  the	  IPOD	  is	  not	  only	  a	  depository	  for	  damaged	  proteins,	  but	  plays	  a	  
critical	  positive	  role	  in	  prion	  biology	  as	  the	  cellular	  site	  of	  de	  novo	  prion	  induction.	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Material	  and	  Methods	  
Yeast	  strains,	  media,	  and	  constructs:	  Yeast	  strains	  BY4741	  (Euroscarf)	  and	  74D-­‐694	  (CHERNOFF,	  
et	  al.	  1995)	  were	  grown	  on	  standard	  synthetic	  media	  lacking	  particular	  amino	  acids/bases	  and	  
containing	   either	   D-­‐glucose	   (SD)	   or	   D-­‐galactose	   (SGal)	   as	   carbon	   source.	   Sporulation	   was	  
performed	  on	  1%	  potassium	  acetate,	  0.05%	  dextrose,	  0.1%	  yeast	  extract,	  and	  0.01%	  complete	  
amino	  acid	  mix,	  Bio101.	  Expression	  of	  PrD-­‐GFP	  (TYEDMERS,	  et	  al.	  2008)	  was	  controlled	  by	  either	  
the	  Gal1	  or	  GPD	  promoter.	  The	  expression	  plasmid	  for	  RNQ1-­‐CFP	  was	  described	  in	  (SONDHEIMER,	  
et	  al.	  2000).	  Gene	  deletions	  used	  primer	  sequences	  listed	  at	  the	  yeast	  deletion	  project	  website	  
(http://www-­‐
sequence.stanford.edu/group/yeast_deletion_project/Deletion_primers_PCR_sizes.txt).	  
Genomic	  C-­‐terminal	  Cerulean	   fusions	  were	  confirmed	  by	  PCR.	  Plasmids	  coding	   for	  N-­‐terminal	  
Cerulean	  ATG8	  or	  ATG14	  fusions	  were	  generated	  using	  Gateway	  shuttle	  vectors	  (ALBERTI,	  et	  al.	  
2007)	  and	  the	  ORFs	  from	  the	  Open	  Biosystems	  mORF	  collection.	  	  
	  
Seeding	   and	   transformation:	   The	   seeding	   efficiency	   of	   crude	   lysates	   from	   cells	   with	   diffuse	  
fluorescence,	   Rings	   or	   Dots	   was	   tested	   with	   purified	   His-­‐tagged	   protein	   using	   SDD-­‐AGE	   as	  
described	   (BAGRIANTSEV,	   et	  al.	   2006).	  The	  same	   lysates	  were	   tested	   for	   transformation	  activity	  
with	  a	  74D-­‐694-­‐derived	  strain	  containing	  an	  ADE1	  mutation	  suppressible	  by	  [PSI+]	  and	  a	  URA3	  
plasmid	  as	  described	  (TANAKA,	  et	  al.	  2004).	  Details	  are	  in	  supplementary	  methods.	  	  
	  
 231 
Microscopy:	  Cells	  were	  grown	  in	  liquid	  culture	  to	  mid-­‐log	  phase	  or	  on	  agar	  plates	  overnight	  and	  
examined	   with	   an	   Axioplan	  microscope	   with	   a	   100x	   objective	   (Zeiss)	   and	   narrow	   band	   pass	  
filters	   for	   co-­‐localization	   studies	  with	  different	   fluorescent	  proteins.	  Monoclonal	  HA	  antibody	  
(Cell	   Signaling)	   and	   a	   secondary	   anti-­‐mouse	   IgG	   antibody	   were	   coupled	   to	   alexa	   fluor	   594	  
(Invitrogen).	  Unless	  indicated,	  images	  were	  taken	  in	  one	  representative	  focal	  plane.	  Photoshop	  
was	   used	   for	   colorization,	   linear	   adjustments	   of	   brightness	   and	   contrast,	   and	   for	   creation	   of	  
composite	  and	  merged	  images.	  Time-­‐lapse	  microscopy	  was	  performed	  on	  agarose	  pads	  of	  ~	  20	  
x	   20	   x	   1	   mm,	   prepared	   by	   pouring	   ultrapure	   agarose	   (2%	   w/v)	   in	   SD	  media	   directly	   onto	   a	  
microscope	  slide.	  After	  addition	  of	  the	  cells,	  the	  pad	  was	  covered	  with	  a	  cover	  slide	  and	  sealed	  
with	  melted	  VLAP	  wax	   (1:1:1	  Vaseline	   :	   lanolin	   :	   paraffin).	   Every	  60	  –	  90	  min,	  we	  collected	  a	  
stack	   of	   12	   –	   15	   optical	   sections	   spaced	   0.4	   µm	   apart.	   	   Representative	   fluorescence	   images	  
were	  de-­‐blurred	  using	  a	  simple	  deconvolution	  algorithm,	  and	  then	  projected	  to	  one	  image.	  For	  
conventional	  and	  immunoelectron	  microscopy	  details	  see	  supplementary	  methods.	  	  
	  
Electron	  Microscopy:	   For	   conventional	   EM,	   yeast	   cells	  were	   harvested	   by	   centrifugation	   and	  
resuspended	   in	   fix	   (3	   %	   glutaraldehyde/0.1	  M	   sodium	   cacodylate/5mM	   CaCl2,	   pH	   6.8).	   Cells	  
were	  fixed	  for	  1	  hour	  at	  room	  temperature,	  washed,	  and	  resuspended	  in	  1.2	  M	  sorbitol	  in	  phos-­‐
citrate	   buffer	   (0.1	   M	   K2HPO4/0.033	   M	   citric	   acid).	   The	   fixed	   cells	   were	   then	   treated	   with	  
glucuronidase	  and	  zymolyase	  for	  1h	  to	  remove	  the	  cell	  walls,	  as	  described	  previoulsy	  (BANTA,	  et	  
al.	   1988).	  Cells	  were	  embedded	   in	  2%	  ultra-­‐low	  gelling	   temperature	   (Sigma,	   type	   IX),	   stained	  
with	  osmium/thiocarbohydrazide	  as	  previously	  described	  (BANTA,	  et	  al.	  1988),	  and	  embedded	  in	  
low-­‐viscosity	   Spurr	   plastic	   resin	   for	   48	   h	   at	   60°C.	   Sections	   (80	   nm)	  were	   cut	   on	   a	   Leica	   UCT	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ultramicrotome,	  stained	  with	  lead	  citrate	  and	  uranyl	  acetate,	  respectively;	  and	  examined	  at	  80	  
kV	  using	  a	  Philips	  EM	  410	  transmission	  electron	  microscope.	  Images	  were	  collected	  with	  a	  Soft	  
Imaging	   System	  Megaview	   III	   camera,	   and	   figures	   assembled	   in	   Adobe	   Photoshop	  with	   only	  
linear	  adjustments	  in	  brightness	  and	  contrast.	  
For	  ImmunoEM,	  cells	  were	  fixed	  in	  suspension	  for	  15	  min	  by	  adding	  an	  equal	  volume	  of	  freshly	  
prepared	  8%	  formaldehyde	  contained	  in	  100	  mM	  PO4	  buffer	  (pH	  7.4).	  The	  cells	  were	  pelleted,	  
resuspended	   in	   fresh	   fixative	   (4%	   formaldehyde/100	  mM	  PO4,	   pH	   7.4),	   and	   incubated	   for	   an	  
extra	  18	  –	  24	  hours	  at	  4	  °C.	  The	  cells	  were	  washed	  briefly	  in	  PBS	  and	  resuspended	  in	  2%	  low-­‐
gelling-­‐temperature	   agarose.	   The	   agarose	   blocks	   were	   trimmed	   into	   pieces	   of	   1	   mm3,	  
cryoprotected	  by	   infiltration	  with	  2.3	  M	  sucrose/20	  %	  polyvinyl	  pyrrolidone	   (10,000)/PBS	   (pH	  
7.4)	  for	  2	  h,	  mounted	  on	  cryopins,	  and	  rapidly	  frozen	  in	  liquid	  nitrogen.	  Ultrathin	  cryosections	  
were	  cut	  on	  a	  Leica	  UCT	  ultramicrotome	  equipped	  with	  an	  FC-­‐S	  cryoattachment	  and	  collected	  
onto	   formvar/carbon-­‐coated	  nickel	   grids.	   The	   grids	  were	  washed	   through	   several	   drops	  of	   1’	  
PBS	  containing	  2.5%	  FCS	  and	  10	  mM	  glycine	  (pH	  7.4)	  and	  then	  blocked	  in	  10%	  FCS	  for	  30	  min	  
and	   incubated	   overnight	   in	   10	   mg/ml	   chicken	   anti-­‐GFP	   antibody	   (Abcam	   Antibodies)	   and	   a	  
1:200	  dilution	  of	  rabbit	  anti-­‐a-­‐1,6	  mannose	  serum.	  After	  washing,	  the	  grids	  were	  incubated	  for	  
2	   h	   in	   12-­‐nm	   Au	   donky	   anti-­‐rabbit	   conjugate	   or	   6	   nm	   Au	   donky	   anti-­‐chicken	   (Jackson	  
ImmunoResearch).	   The	   grids	  were	  washed	   through	   several	   drops	   of	   PBS	   followed	   by	   several	  
drops	  of	  ddH2O.	  Grids	  were	  then	  embedded	  in	  an	  aqueous	  solution	  containing	  3.2%	  polyvinyl	  




Fixation	  and	  spheroblasting:	  An	  overnight	  culture	  was	  grown	  in	  selective	  media	  to	  saturation	  
and	   used	   to	   inocculate	   of	   fesh	   culture.	   8	  ml	   of	   cells	   were	   harvested	   at	   an	   OD600	   of	   0.6	   and	  
placed	  onto	  a	  bottle	   top	   filter	   (0.2	  µm	  pores).	  After	   the	   liquid	  was	  removed	  by	  vacuum,	  cells	  
were	   immediately	   resuspended	   in	   5	  ml	   of	   4%	   formaldehyde	   in	   50	  mM	  KPO4,	   pH	   6.5,	   1	  mM	  
MgCl2	   and	   incubated	   for	   2	   h	   at	   room	   temperature	   in	   a	   15	   ml	   screw	   cap	   tube.	   Cells	   were	  
collected	  by	  centrifugation	  for	  3	  min	  at	  1000	  x	  g,	  washed	  in	  50	  mM	  KPO4,	  pH	  6.5,	  1	  mM	  MgCl2	  
containing	  a	  protease	  inhibitor	  cocktail	  (Roche	  1	  836	  170)	  and	  resuspended	  in	  the	  same	  buffer	  
to	   an	  OD600	   of	   10.	   0,6	  µl	   2-­‐mercapto-­‐ethanol	   and	  7	  µl	   of	   a	   1mg/ml	   zymolyase	   T100	   solution	  
were	  added	  to	  100	  µl	  of	  cells	  and	  incubated	  for	  30	  min	  at	  30°C.	  Spheroblasts	  were	  washed	  by	  
centrifugation	  for	  2	  min	  at	  1000	  x	  g	  and	  resuspended	  carefully	  in	  100	  µl	  of	  50	  mM	  KPO4,	  pH	  6.5,	  
1	  mM	  MgCl2	  containing	  a	  protease	  inhibitor	  cocktail	  (Roche	  1	  836	  170)	  
Adhesion	  of	  cells	  to	  microscope	  slide:	  Wells	  on	  a	  cover	  slide	  were	  created	  using	  an	  adhesive	  
courier	  document	  pouch	  and	  a	  rotating-­‐head	  hole	  puncher,	  coated	  with	  0,1	  %	  polylysine	  (Sigma	  
#P-­‐1524)	  and	  washed	  3	  x	  with	  water	  before	  10	  µl	  spheroblasts/well	  were	  added.	  After	  3	  min	  of	  
adhesion,	   excess	   liquid	   was	   removed	   and	   the	   coverslip	   was	   dried	   completely	   before	   it	   was	  
immersed	  in	  precooled	  (-­‐	  20)	  acetone	  for	  5	  min.	  After	  blotting	  away	  excess	  solvent,	  the	  cover	  
slip	  was	  dried	  before	  blocking	  and	  antibody	  incubation	  steps	  followed.	  	  
Antibody	  incubation:	  For	  blocking,	  each	  well	  was	  incubated	  with	  a	  drop	  of	  PBS-­‐block	  (1%	  milk	  
powder,	  0,1%	  BSA,	  0,1%	  octyl	  glucoside)	  for	  30	  min	  before	  the	  primary	  antibody	  (monoclonal	  
mouse	  anti-­‐HA-­‐tag	  antibody	   (6E2)	   from	  cell	   signaling,	   lot	   1B	  #	  2367)	   in	  PBS-­‐block	  was	  added	  
and	  incubated	  for	  60	  min	  at	  room	  temperature	  in	  a	  humid	  chamber.	  Each	  well	  was	  washed	  8	  x	  
with	   PBS-­‐block	   before	   the	   secondary	   antibody	   (alexa	   fluor	   594	   anti-­‐mouse	   IgG	   A11062,	   lot	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#57764a	  from	  invitrogen)	  was	  added	  and	  incubated	  for	  30	  min	  in	  the	  dark.	  Subsequently,	  cells	  
were	  washed	  8	  times,	  excess	  liquid	  was	  removed	  and	  5	  µl	  of	  mounting	  media/well	  was	  added	  
before	  the	  cover	  slip	  was	  inverted	  onto	  a	  slide	  and	  sealed	  with	  nail	  polish.	  	  
	  
Cell	   lysis	   of	   strains	   displaying	   diffuse-­‐,	   Ring-­‐	   or	   Dot-­‐shaped	   aggregates	   for	   PrD-­‐seeding	  
reactions	   and	   protein	   transformations:	   Strains	   carrying	   PrD-­‐GFP	   under	   control	   of	   a	   Gal-­‐
inducible	  promoter	  and	  displaying	  diffuse,	  Ring-­‐	  or	  Dot-­‐shaped	  aggregation	  patterns	  of	  PrD-­‐GFP	  
were	  grown	  in	  SGal	  media	  to	  an	  OD	  between	  1	  -­‐2.	  For	  the	  Ring	  cultures	  this	  yielded	  the	  largest	  
fraction	  of	  cells	  displaying	  Ring	  aggregates	  (~	  70	  %).	  Harvested	  cell	  pellets	  were	  frozen	  before	  
resuspension	   in	   chilled	   lysis	   buffer	   (50	   mM	   Tris-­‐HCl,	   pH7.4,	   200	   mM	   NaCl,	   2mM	   TCEP,	   5	   %	  
glycerol,	   1	   mM	   EDTA,	   4	   mM	   PMSF,	   5	   ug/ml	   aprotinin,	   5	   ug/ml	   leupeptin	   and	   1	   tablet	   of	  
complete	  protease	  inhibitor	  cocktail	  (Roche)).	  An	  equal	  volume	  of	  glass	  beads	  was	  added	  to	  the	  
pellet	   suspension	   and	   crude	   lysates	   were	   generated	   by	   bead-­‐beating	   for	   10	   minutes	   on	   a	  
Qiagen	   tissue-­‐lyser	   .	   Crude	   lysates	   were	   pre-­‐cleared	   at	   500	   rcf	   for	   2	   min	   at	   4	   oC.	   The	   total	  
amount	  of	  PrD-­‐GFP	  in	  different	  lysates	  was	  assessed	  by	  immunoblotting	  with	  a	  GFP	  antibody.	  
	  
Protein	  Transformation:	  Yeast	  cells	  with	  an	  ADE1	  mutation	  suppressible	  by	  [PSI+]	  (MATα	  leu2-­‐
3,	  -­‐112	  his3-­‐11	  trp1-­‐1	  ura3-­‐1	  ade1-­‐14	  can1-­‐100	  [pin-­‐]	  [psi-­‐]	  [ure-­‐o])	  were	  co-­‐transformed	  with	  
PrD-­‐GFP	  from	  crude	  lysates	  of	  cells	  with	  diffuse,	  Ring-­‐	  or	  Dot-­‐	  fluorescence	  and	  a	  URA3	  plasmid	  
as	  described	  (TANAKA,	  et	  al.	  2006)	  and	  summarized	  here.	  Yeast	  cells	  were	  grown	  in	  50	  ml	  YPD	  at	  
30	  °C	  to	  OD600	  ~	  0.5	  –	  0.6.	  Cells	  were	  recovered	  by	  centrifugation	  at	  3000	  x	  g	  for	  5min	  at	  25°C,	  
washed	  once	  with	  sterile	  distilled	  water,	  once	  with	  1	  M	  sorbitol,	  and	  then	  with	  SCE	  buffer	  (1M	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sorbitol,	  10	  mM	  EDTA,	  10	  mM	  DTT,	  100	  mM	  sodium	  citrate,	  pH	  5.8).	  After	  resuspension	  in	  1ml	  
of	   SCE	   buffer,	   cells	   were	   incubated	   with	   lyticase	   (200	   units/ml)	   for	   30	   min	   at	   30	   °C.	  	  
Spheroblasts	   were	   recovered	   and	   washed	   with	   1M	   sorbitol	   followed	   by	   STC	   buffer	   (1	   M	  
sorbitol,	   10	   mM	   CaCl2,	   10	   mM	   TrisHCl,	   pH	   7.5)	   and	   finally	   resuspended	   in	   1ml	   STC	   buffer.	  
Twenty-­‐five	  microliters	   of	   crude	   lysates	   (2	  mg/mL	   total	   protein	   concentration)	   of	   yeast	   cells	  
displaying	   diffuse,	   Ring	   or	  Dot	   fluorescence	   of	   PrD-­‐GFP	  was	  mixed	  with	   a	  URA3	  plasmid	   and	  
salmon	  sperm	  DNA.Spheroblasts	  were	  added	  to	  the	  protein	  solution	  and	  incubated	  for	  30	  min	  
at	  25	  °C.	  Fusion	  of	  spheroblasts	  with	  plasmid/protein	  complexes	  was	  induced	  by	  addition	  of	  9	  
volumes	  of	  PEG-­‐buffer	  (20%	  PEG	  8000,	  10	  mM	  CaCl2,	  10	  mM	  TrisHCl,	  pH	  7.5),	  and	   incubation	  
for	  30	  min	  at	  25	  °C.	  Spheroblasts	  were	  recovered	  and	  resuspended	  in	  SOS	  buffer	  (1M	  sorbitol,	  
0.25%	   yeast	   extract,	   0.5%	   bacto-­‐peptone,	   7mM	   CaCl2,)	   and	   incubated	   for	   30	   min	   at	   30	   °C.	  	  
Recovered	   transformants	   were	   mixed	   with	   7	   ml	   URA	   dropout	   top	   agar	   (2.5%	   agar	   at	   45	   oC	  
containing	   1M	   sorbitol)	   and	   immediately	   poured	   onto	   URA	   dropout	   plates	   (containing	   1M	  
sorbitol).	  After	  incubation	  at	  30	  oC	  for	  4-­‐5	  days,	  approximately	  100	  Ura+	  colonies	  were	  randomly	  
chosen	  and	  streaked	  onto	  modified	  YEPD	  plates	  containing	  1/4	  of	  the	  standard	  amount	  of	  yeast	  
extract	  to	  enhance	  color	  phenotypes	  of	  [PSI+]	  and	  [psi-­‐]	  states.	  
	  
Seeding	   efficiency	   of	   cell	   lysates	   displaying	   different	   PrD-­‐GFP	   aggregation	   patterns:	  
Equilibrated	   crude	   lysates	   from	   cells	   displaying	   diffuse,	   Ring	   or	   Dot	   fluorescence	   of	   PrD-­‐GFP	  
were	  added	  to	  reaction	  tubes	  containing	  5	  µM	  of	  purified	  His-­‐tagged	  PrD	  in	  1xCRBB	  buffer	  (5	  
mM	  potassium	  phosphate,	  pH	  7.4,	  150	  mM	  NaCl,	  5	  µg/ml	  aprotinin	  and	  5	  µg/ml	  leupeptin).	  The	  
reactions	  were	  incubated	  at	  RT	  without	  agitation.	  Polymerization	  time	  points	  were	  harvest	  by	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adding	   2%	   SDS	   sample	   buffer	   (2x	   TAE,	   20	  %	   glycerol,	   8	  %	   SDS	   (w/v),	   bromophenol	   bue)	   and	  
snap	   freezing	   them.	   Formation	   of	   SDS	   resistant	   aggregates	   was	   assessed	   by	   SDD-­‐AGE	   and	  
probing	  with	  a	  His	  antibody	  (BAGRIANTSEV,	  et	  al.	  2006).	  
	  
Immunoprecipitation:	  Cells	  expressing	  PrD-­‐GFP	  under	  control	  of	  the	  GPD-­‐promoter	  displaying	  
diffuse	  PrD-­‐GFP	  fluorescence	  ([prd-­‐gfp-­‐])	  or	  Dots	  ([PrD-­‐GFP+])	  were	  grown	  in	  selective	  media	  to	  
an	  OD	  of	  ~	  0,6,	  harvested,	  washed	  with	  water	  and	  finally	  resuspended	  in	  spheroblasting	  buffer	  
(1	  M	  sorbitol	   ,	  0.1	  EDTA,	  0.5	  mg/ml	  zymolyase	  T-­‐100	  (Seikagaku),	  20	  mM	  DTT)	  and	   incubated	  
the	  cells	  for	  30	  min	  at	  30	  ºC	  to	  remove	  the	  cell	  wall.	  After	  pelleting	  the	  spheroblasts,	  they	  were	  
resuspended	  in	  IP	  buffer	  (50	  mM	  Hepes,	  pH	  7.5,	  150	  mM	  NaCl,	  2.5	  mM	  EDTA,	  1	  %	  Triton	  X-­‐100,	  
40	  mM	  NEM,	   1	  mM	  PMSF,	   1	   Roche	   inhibitor	  mix	   tablet/5	  ml).	   Glass	   beads	  were	   added	   and	  
beated	   in	  a	  bead	  beater	   for	  2	  min	  at	  4	  ºC.	  Lysates	  were	   incubated	  with	  an	  anti-­‐GFP	  antibody	  
and	  incubated	  for	  1.5	  hours	  at	  4	  ºC.	  Subsequently,	  BSA-­‐blocked	  Dynal	  beads	  were	  added	  to	  the	  
lystes	   and	   further	   incubated	   for	   4	   h	   at	   4	   ºC.	   After	   rigorous	  washing	  with	   IP-­‐buffer,	   proteins	  
bound	  to	  the	  beads	  were	  eluted	  with	  Laemmli	  sample	  buffer	  (50	  mM	  Tris-­‐HCl,	  pH	  6.8,	  2	  %	  BME,	  
2	  %	  SDS,	  10	  %	  glycerol)	  followed	  by	  SDS-­‐PAGE	  and	  Coomassie	  brilliant	  blue	  staining.	  	  
	  
Mass	   spectrometry:	   Proteins	   present	   in	   bands	   that	   were	   cut	   out	   of	   the	   gel,	   fragmented	   by	  
trypsin	   digest	   and	   separated	   by	   HPLC	   (Waters	   NanoAcquity)	   using	   a	   0.075	   micron	   diameter	  
column	  with	  a	  flow	  rat	  of	  250	  nl/min.	  The	  eluant	  from	  this	  was	  introduced	  into	  a	  linear	  ion	  trap	  
tandem	  mass	  spectrometer	  (Thermo	  LTQ)	  equipped	  with	  a	  nanospray	  source.	  The	  resulting	  CID	  
spectra	  were	  searched	  against	  a	  protein	  database	  using	  SEQUEST.	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Supplemental	  Figure	  A1.1:	  PrD-­‐GFP	  is	  a	  prion	  on	  its	  own	  right.	  
To	  reveal	  whether	  PrD-­‐GFP	  can	  act	  as	  an	  independent	  prion,	  haploid	  strains	  with	  a	  deletion	  of	  
PrD	  in	  the	  en-­‐	  dogenous	  SUP35	  gene	  (C(SUP35))	  that	  expressed	  PrD-­‐GFP	  under	  control	  of	  the	  
Sup35	  promoter	  (concentrations	  comparable	  to	  wild-­‐type	  Sup35	  (PrD-­‐C(SUP35))	  and	  displayed	  
diffuse	  GFP	   fluorescence	  were	   used.	   A	   first	  mating	   involved	   a	  mating	   partner	  with	  wild-­‐type	  
Sup35	  in	  [PSI+]	  to	  induce	  the	  prion	  conformation	  in	  PrD-­‐GFP	  (left	  panel).	  A	  similar	  mating	  with	  a	  
[psi-­‐]	   strain	   served	   as	   a	   control	   (right	   panel).	   Haploid	   progeny	   from	   the	   first	   mating	   that	  
contained	  the	  PrD-­‐GFP	  fusion	  and	  the	  C(SUP35)	  allele	  was	  analyzed	  by	  fluorescence	  microscopy	  
and	  revealed	  that	  only	  mating	  of	  PrD-­‐GFP	  with	  a	  [PSI+]	  strain	  resulted	  in	  formation	  of	  PrD-­‐GFP	  
aggregates	   (left	   panel,	  middle).	   Subsequently,	   this	   progeny	  was	  mated	   to	   a	   [psi-­‐]	   strain	  wild	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type	   for	   SUP35	   and	   revealed	   that	   PrD-­‐GFP	   in	   its	   ag-­‐	   gregated	   state	   could	   transmit	   the	   prion	  






Supplemental	   Figure	   A1.2:	   The	   formation	   of	   Ring	   aggregates	   and	   Dot	   aggregates	   requires	  
HSP104	  and	  RNQ1.	  	  
Constitutive	   expression	   PrD-­‐GFP	   under	   control	   of	   the	   GPD	   promoter	   (compare	   with	   Fig.	   A)	  
results	  in	  Ring-­‐	  and	  Dot	  aggregates	  in	  a	  control	  strain	  (wild	  type),	  but	  only	  diffuse	  fluorescence	  
or	  in	  a	  strain	  with	  the	  deletion	  of	  RNQ1	  (rnq1Δ)	  or	  HSP104	  (hsp104Δ).	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Supplemental	   Figure	   A1.3:	  Both	   Ring	   and	   Dot	   aggregates	   can	   propagate	   in	   the	   absence	   of	  
Rnq1.	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Haploid	  strains	  carrying	  a	  PrD	  deletion	  in	  the	  endogenous	  SUP35	  gene	  that	  expressed	  PrD-­‐GFP	  
under	  control	  of	  the	  GPD	  promoter	  and	  displayed	  mostly	  Rings	  (A)	  or	  only	  Dots	  (B)	  were	  mated	  
to	  an	  equivalent	  strain	  that	  carried	  ad-­‐	  ditionally	  a	  deletion	  of	  RNQ1	  and	  displayed	  diffuse	  PrD-­‐
GFP	  fluorescence	  (compare	  with	  Fig.	  S2).	  The	  resulting	  diploids	  were	  analyzed	  by	  fluorescence	  
mi-­‐	   croscopy	   and	   displayed	   mostly	   Ring-­‐aggregates	   (A,	   left)	   or	   only	   Dots	   (B,	   left).	   After	  
sporulation	  and	  tetrad	  analysis,	  spores	  were	  genotyped	  by	  PCR	  to	  detect	  segregation	  of	  wild-­‐
type	   RNQ1	   (wtRNQ1)	   and	   the	   corresponding	   deletion	   (rnq1Δ)	   and	   analyzed	   for	   PrD-­‐GFP-­‐
















Supplemental	  Figure	  A1.4:	  Co-­‐purification	  of	  proteins	  with	  PrD-­‐GFP	  from	  cell	  lysates	  with	  Dot	  
aggregates.	  
	  Coomassie	   stain	   of	   eluate	   fractions	   from	   immuno-­‐precipitations	   with	   lysates	   from	   cells	  
expressing	  PrD-­‐GFP	  and	  displaying	  Dots	  ([PrD-­‐GFP+]-­‐lysates)	  or	  diffuse	  fluorescence	  ([prd-­‐gfp-­‐]-­‐
lysate)	  were	   incubated	  with	  no	  antibody	  (control,	   left	   lane)	  or	  antibodies	  against	  GFP	  (middle	  
and	  right	   lanes).	  Magnetic	  Dynal	  beads	  coated	  with	  protein	  A	  were	  used	  to	   isolate	  antibody–
protein	   complexes	   from	   the	   lysates.	   Stars	   indicate	   protein	   bands	   occurring	   specifically	  when	  
lysates	  from	  cells	  with	  PrD-­‐GFP	  in	  Dot	  aggregates	  were	  used.	  Size	  ranges	  of	  ∼10	  kDa	  steps	  were	  
cut	  out	  of	  the	  gel	  from	  eluates	  of	  cells	  with	  diffuse	  fluorescence	  (control)	  and	  Dot	  fluorescence	  





Supplemental	  Table	  A1.1:	  Table	  of	  proteins	  present	  only	  in	  protein	  bands	  isolated	  from	  Dot	  cell	  
lysates	  but	  not	  cell	  lysates	  with	  diffuse	  PrD-­‐GFP	  fluorescence.	  At	  least	  two	  different	  peptides	  of	  





Supplemental	  Figure	  A1.5:	  Characterization	  of	  PrD-­‐GFP	  in	  Ring-­‐	  or	  Dot	  aggregates	  by	  immuno-­‐
EM	  and	  determination	  of	  the	  dimensions	  in	  PrD-­‐GFP	  fibrils.	  
(A)	  Ultrathin	   sections	  of	   a	   cell	  with	  Dots	   (left)	   or	  Rings	   (right)	  were	  analyzed	  by	   immuno-­‐EM	  
with	  an	  antibody	  against	  GFP	  labeled	  with	  immunogold	  and	  confirmed	  that	  PrD-­‐GFP	  is	  present	  
in	  areas	  with	  accumulated	  fibrils.	  (B)	  Magnification	  of	  perpendicular	  section	  of	  a	  Ring	  aggregate	  
allows	  measuring	  the	  diameter	  of	  the	  inner	  core	  of	  the	  fibril	  (6–12	  nm),	  the	  entire	  fibril	  (25–30	  
nm),	   and	   the	   spacing	   between	   two	   fibrils	   (25–30	   nm).	   Identical	   measures	   were	   found	   for	  
bundles	  of	  fibrils	  from	  Dot	  aggregates.	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Supplemental	  Figure	  A1.6:	  Prion	  fibril	  accumulations	  at	  the	  IPOD	  are	  partially	  surrounded	  by	  
electron-­‐dense	  material	  typical	  for	  amorphously	  aggregated	  proteins.	  
A	  different	  cutout	  of	  the	  same	  DOT-­‐cell	  as	  shown	  in	  the	  electron	  micrograph	  in	  Fig.	  5A	  Lower	  
Left	  is	  compared	  with	  a	  magnification	  of	  Fig.	  4B,	  right	  column.	  The	  latter	  displays	  a	  fluorescence	  
microscopy	   image	   of	   cells	   expressing	   PrD-­‐YFP	   and	   Pdc1-­‐CFP	   after	   incubation	   with	   low	  
concentrations	  of	  menadione	  (0.1	  mM)	  for	  4	  h.	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Supplemental	   Figure	   A1.7:	   Expression	   of	   the	   dominant	   negative	   HSP104	   mutant	   K620T	  
induces	  the	  formation	  of	  PrD-­‐GFP	  Rings	  in	  the	  progeny	  of	  Dot-­‐containing	  cells.	  	  
A	  haploid	  strain	  with	  a	  deletion	  of	  PrD	  in	  the	  endogenous	  SUP35	  gene	  that	  expressed	  PrD-­‐GFP	  
under	   control	   of	   the	   GPD	   promoter	   and	   propagated	   the	   Dot	   state	   was	   transformed	   with	   a	  
plasmid	  coding	  for	  the	  dominant	  negative	  HSP104	  mutant	  HSP104-­‐K620T	  [Parsell	  DA,	  Sanchez	  
Y,	  Stitzel	  JD,	  Lindquist	  S	  (1991)	  Nature	  353:270–273]	  under	  control	  of	  a	  glucocorticoid	  inducible	  
promoter	  [Schirmer	  EC,	  Lindquist	  S	   (1998)	  Methods	  Enzymol	  290:430–444].	  Cells	  were	  placed	  
on	   an	   agarose	   pad	   on	   a	   microscope	   slide	   either	   lacking	   (A)	   or	   containing	   (B)	   10	   μM	  
deoxycorticosterone	   to	   induce	   expression	   of	   the	   HSP104	   mutant	   and	   allowed	   to	   divide	   for	  
several	  hours.	  The	  images	  represent	  a	  merge	  of	  several	  focal	  planes	  taken	  at	  the	  end	  (12	  h)	  of	  
time-­‐lapse	  microscopy	  experiments.	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Supplemental Figure A1.8: Similar levels of Hsp104 in cells with diffuse PrD-GFP 
fluorescence, PrD-GFP Rings or Dots. 
Different dilutions of cell lysates from cells displaying diffuse, Ring or Dot fluorescence were 
subjected to SDS/PAGE followed by Western blot analysis onto PVDF membranes. The PVDF 
membranes were stained with Ponceau-S (Upper) to control for loading and subsequently 
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Abstract	  
Our	   laboratory	   has	   used	   yeast	   to	   model	   the	   cellular	   defects	   caused	   by	   the	   human	  
proteins	  implicated	  in	  neurodegenerative	  diseases.	  Furthermore,	  we	  have	  studied	  the	  reliance	  
of	   fungal	  pathogens	  on	  the	  protein	  folding	  machinery	  to	  evolve	  drug	  resistance.	  Recently,	  we	  
have	  begun	  to	  apply	  the	  lessons	  we	  learned	  from	  these	  two	  research	  areas	  to	  the	  investigation	  
of	  the	  malaria	  pathogen	  Plasmodium	  falciparum.	  	  
The	   genome	   of	   P.	   falciparum	   is	   very	   AT-­‐rich	   and	   consequently	   encodes	   an	   unusual	  
amount	   of	   asparagine-­‐rich	   proteins,	   predicted	   to	   be	  non-­‐globular	   and	  of	   low	   complexity	   and	  
thus	   likely	   to	   impose	   unique	   demands	   on	   the	   protein	   folding	   machinery.	   Strikingly,	   P.	  
falciparum	  also	  shows	  a	  marked	  expansion	  of	  the	  heat	  shock	  protein	  40	  (Hsp40)	  family	  of	  co-­‐
chaperones.	  During	  its	  life	  cycle	  in	  its	  human	  host	  P.	  falciparum	  infects	  and	  remodels	  red	  blood	  
cells.	  We	  propose	   that	   during	   this	   process	   the	   parasite	   relies	   on	   a	   greatly	   expanded	   class	   of	  
Hsp40	  co-­‐chaperones.	  	  
We	  have	  developed	  assays	  to	  assess	  the	  function	  of	  Pf	  Hsp40s	  in	  yeast	  and	  we	  seek	  to	  
identify	  small	  molecules	  that	   inhibit	  the	  functions	  of	  those	  chaperones.	   In	  particular	  we	  focus	  
on	  a	  Pf	  Hsp40	  that	  has	  been	  shown	  to	  be	  crucial	  to	  parasite	  proliferation.	  Compounds	  inhibiting	  
the	  function	  of	  this	  Hsp40	  in	  yeast	  will	  be	  tested	  in	  established	  parasite	  survival	  and	  host	  cell	  
remodeling	  assays	  to	  elucidate	  the	  role	  of	  this	  Hsp40	  in	  the	  parasite	  life	  cycle.	  
	  
Specific	  Aims	  
The	   induction	   of	   heat	   shock	   proteins	   (Hsps)	   is	   one	   the	   most	   highly	   conserved	  
homeostatic	  mechanisms	  known	  and	  is	  observed	  in	  all	  organisms,	  from	  bacteria	  to	  man.	  These	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proteins	   have	   diverse	  molecular	   functions	   but	   all	   are	   related	   to	   solving	   problems	   in	   protein	  
folding.	  When	   pathogens	   enter	   their	   hosts	   the	   sudden	   change	   in	   temperature,	   and	   ensuing	  
fevers	  in	  the	  host,	  create	  a	  crisis	  in	  protein	  folding	  that	  causes	  an	  extreme	  dependence	  on	  Hsps.	  	  
Plasmodium	   falciparum	   causes	   the	   most	   severe	   form	   of	   human	   malaria	   and	   is	  
responsible	   for	   the	   majority	   of	   casualties.	   The	   genome	   of	   P.	   falciparum	   is	   very	   AT-­‐rich	   and	  
consequently	   encodes	   an	   unusual	   amount	   of	   asparagine-­‐rich	   proteins,	   predicted	   to	   be	   non-­‐
globular	   and	   of	   low	   complexity	   and	   thus	   likely	   to	   impose	   unique	   demands	   on	   the	   protein	  
folding	  machinery.	  Strikingly,	  P.	   falciparum	  also	  shows	  a	  marked	  expansion	  of	   the	  heat	  shock	  
protein	  40	  (Hsp40)	  family	  of	  co-­‐chaperones.	  During	  its	  life	  cycle	  in	  its	  human	  host	  Pf	  infects	  and	  
remodels	  red	  blood	  cells.	  We	  propose	  that	  during	  this	  process	  the	  parasite	  relies	  on	  the	  greatly	  
expanded	  class	  of	  Hsp40	  co-­‐chaperones	   to	  not	  only	   remodel	   the	   infected	   red	  blood	  cells	  but	  
also	  to	  cope	  with	  the	  misfolding	  of	  asparagine-­‐rich	  proteins.	  
We	   have	   developed	   assays	   to	   assess	   the	   function	   of	   Pf	   Hsp40s,	   using	   yeast	   as	   a	  
convenient	  discovery	  platform,	  and	  seek	  to	  identify	  small	  molecules	  that	  inhibit	  the	  functions	  of	  
these	  proteins.	  For	  the	  purpose	  of	  this	  grant	  we	  focus	  on	  the	  Pf	  Hsp40,	  PFA0660w,	  which	  has	  
been	  shown	  to	  be	  essential	   for	  parasite	  proliferation,	  but	  also	  provide	  preliminary	   results	   for	  
other	   Pf	   Hsp40s.	   The	   compounds	   suppressing	   PFA0660w	   function	   will	   be	   used	   as	   probes	   to	  
investigate	  the	  role	  of	  the	  Hsp40	  PFA0660w	  in	  parasite	  biology	  and	  to	  explore	  their	  potential	  as	  
therapeutic	  targets.	  
	  
Specific	  Aim	  1	  (Primary	  HTS	  assay):	  Identification	  of	  small	  molecules	  that	  inhibit	  the	  activity	  of	  
the	  Pf	  Hsp40	  PFA0660w	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Plasmodium	  Falciparum	   exports	   several	  Hsp40s	   to	   remodel	   its	   red	  blood	  host	   cell.	  Of	  
those	   the	   Hsp40	   PFA0660w	   (GeneID:	   813268)	   has	   been	   suggest	   to	   be	   required	   for	   parasite	  
survival.	   Expression	   of	   this	   Hsp40	   is	   very	   toxic	   in	   yeast,	   and	   this	   toxicity	   depends	   upon	   its	  
functional	   interaction	  with	   yeast	  Hsp70interaction.	   This	   toxicity	   provides	   us	  with	   an	   assay	   of	  
PFA0660w	   function	   that	   can	   be	   easily	   used	   to	   screen	   for	   inhibitors.	   In	   conjunction	  with	   the	  
Outreach	   Lab	   at	   the	   Broad	   Institute,	   a	   designated	   MLPCN	   center,	   we	   have	   adapted	   this	  
phenotypic	  assay	  for	  a	  384-­‐well	  based	  small	  molecule	  screen	  and	  have	  already	  completed	  initial	  
tests	   of	   assay	   robustness.	   We	   propose	   to	   screen	   the	   MLPCN	   small	   molecule	   collection	   for	  
specific	  inhibitors	  of	  Hsp40	  PFA0660w	  activity.	  
According	   to	   listings	   available	   on	   Pubchem	   no	   screens	   specifically	   targeting	   Pf	   Hsp40	  
function	  have	  been	  performed	  to	  date.	  The	  proposed	  screen	  would	  be	  carried	  out	  at	  the	  Broad	  
Institute	  MLPCN	  screening	  center.	  
	  
Specific	  Aim	  2	  (Secondary	  assay):	  Elimination	  of	  identified	  small	  molecules	  toxic	  to	  human	  cells	  
While	   yeast	   survival	   screens	   are	   particularly	   suited	   to	   the	   discovery	   of	   target-­‐specific	  
small	   molecules	   that	   are	   non-­‐cytotoxic,	   we	   will	   specifically	   eliminate	   compounds	   that	   are	  
inherently	   toxic	   to	   human	   cells.	   To	   do	   so,	   we	   will	   test	   the	   effect	   of	   the	   small	   molecules	  
identified	   under	   Aim	   1	   on	   the	   survival	   of	   non-­‐transformed	   human	   fibroblasts.	   Compound	  
cytotoxicity	  will	  be	  assessed	  using	  commercially	  available	  MTT	  cell	  proliferation	  and	  ToxiLight	  
assay	  kits.	  This	  kit	  provides	  a	  quantitative	  measurement	  of	  cytotoxicity	  based	  on	  the	  detection	  
of	  Adenylate	  Kinase	  released	  to	  the	  cell	  culture	  medium	  due	  to	  a	  loss	  in	  cell	  integrity.	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Specific	  Aim	  3	  (Secondary	  assay):	  Testing	  the	  efficacy	  of	  identified	  small	  molecules	  on	  parasites	  
in	  culture	  	  
To	  test	  the	  effect	  of	  identified	  Hsp40	  inhibitors	  on	  P.	  falciparum	  we	  will	  use	  a	  previously	  
established	  high-­‐throughput	  growth	  assay	  	  (BANIECKI,	  et	  al.	  2007).	  The	  assay	  takes	  advantage	  of	  
the	   fact	   that	   the	   parasite	   proliferates	   within	   DNA-­‐less	   red	   blood	   cells.	   Consequently	   the	  
fluorescent	  DNA	  staining	  dye	  DAPI	  can	  be	  used	  to	  measure	  DNA	  content	  and	  hence	  growth	  of	  
blood-­‐stage	  parasites.	  The	  assay	  is	  both	  simple	  and	  robust	  and	  has	  previously	  been	  used	  by	  the	  
Broad	  Institute	  screening	  platform.	  	  
	  
Specific	  Aim	  4	  (Tertiary	  assay):	  Mechanism	  determination	  using	  established	  in	  vitro	  chaperone	  
assays	  
Lastly,	  we	  will	  test	  the	  ability	  of	  the	  small	  molecules	  identified	  to	  interfere	  with	  Hsp40	  
function	   in	   in	  vitro	  chaperone	  assays.	  Specifically,	  we	  will	   test	   if	   the	  compounds	  can	   interfere	  
with	  the	  ability	  of	  Hsp40s	  to	  stimulate	  the	  ATPase	  activity	  of	  the	  human	  Hsp70	  and	  facilitate	  the	  
refolding	  of	  firefly	  luciferase	  in	  cooperation	  with	  the	  Hsp70.	  Both	  of	  these	  tests	  are	  hallmark	  in	  
vitro	   assays	   for	   co-­‐chaperone	   function	   and	   have	   been	   shown	   to	   be	   adaptable	   to	   testing	  
modulators	  of	  Hsp40	  function	  	  (FEWELL,	  et	  al.	  2004;	  LU,	  et	  al.	  1998).	  Using	  these	  assays	  we	  will	  
be	   able	   to	   easily	   determine	   the	   specificity	   of	   any	   compound	   capable	   of	   inhibiting	   Pf	  Hsp40	  
dependent	  ATPase	  stimulation	  or	  luciferase	  refolding	  by	  also	  testing	  its	  effect	  on	  human	  Hsp40	  





Malaria	   afflicts	   more	   than	   500	   million	   people	   annually	   (WHO	   2007).	   It	   is	   caused	   by	  
eukaryotic	   intracellular	  parasites	   that	   are	   spread	   from	  person	   to	  person	   through	   the	  bites	  of	  
infected	  mosquitoes.	  Of	  these	  parasites	  Plasmodium	  falciparum	  causes	  the	  most	  severe	  form	  of	  
human	  malaria	  and	  is	  responsible	  for	  the	  majority	  of	  casualties	  (RASTI,	  et	  al.	  2004).	  The	  genome	  
of	  P.	   falciparum	   is	  very	  AT-­‐rich	  and	  encodes	  an	  extremely	  unusual	  number	  of	  asparagine-­‐rich	  
proteins.	   These	   are	   predicted	   to	   be	   non-­‐globular	   and	   of	   low	   complexity	   and	   thus	   likely	   to	  
impose	  unique	  demands	  on	  the	  protein	  folding	  machinery	  (ARAVIND,	  et	  al.	  2003).	  Strikingly,	  P.	  
falciparum	  also	  shows	  a	  marked	  expansion	  of	  the	  heat	  shock	  protein	  40	  (Hsp40)	  family	  of	  co-­‐
chaperones	  (Figure	  A2.1)	  (BOTHA,	  et	  al.	  2007;	  PAVITHRA,	  et	  al.	  2007).	  Hsp40s	  are	  defined	  by	  the	  
presence	  of	  a	  J	  domain	  that	  can	  regulate	  the	  activity	  of	  Hsp70	  chaperones.	  Hsp70	  chaperones	  
facilitate	   the	   folding	   of	   nascent	   polypetide	   chains,	   as	   well	   as	   the	   disassembly	   of	   protein	  
structures	   and	   translocation	   of	   proteins	   across	   membranes	   (WALSH,	   et	   al.	   2004).	   Hsp40s	  
determine	   the	   activity	   of	   Hsp70s	   by	   stimulating	   Hsp70	   ATPase	   activity	   and	   hence	   stabilizing	  
their	   interaction	  with	  substrate	  proteins	  (QIU,	  et	  al.	  2006).	  We	  hypothesize	  that	  these	  Hsp40s	  
are	  crucial	  for	  P.	  falciparum	  pathobiology	  and	  propose	  to	  identify	  inhibitors	  of	  their	  molecular	  
functions.	  
Severe	  malaria	   occurs	   once	  P.	   falciparum	   infects	   human	   red	   blood	   cells	   and	   starts	   to	  
proliferate	  within	  them.	  The	  parasite	  remodels	  its	  host	  cell,	  especially	  the	  host	  cell	  membrane,	  
in	   order	   to	   avoid	   clearance	   in	   the	   spleen.	   To	   accomplish	   these	   modifications,	   the	   parasite	  
exports	   a	   wide	   range	   of	   proteins	   across	   its	   surrounding	   vacuolar	   membrane	   into	   the	  
erythrocyte.	   .	   The	   “exportome”	   consists	   of	   396	   proteins,	   which	   ultimately	   allow	   for	   the	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remodeling	  of	  the	  infected	  erythrocyte	  and	  thus	  its	  adherence	  to	  host	  endothelium	  (SARGEANT,	  
et	   al.	   2006).	   Cytoadherence	   of	   infected	   red	   blood	   cells	   is	   a	   crucial	   component	   of	   malaria	  
pathogenesis	  as	  it	  not	  only	  circumvents	  splenic	  clearance,	  a	  part	  of	  the	  host	  immune	  response,	  
but	  also	  leads	  to	  occlusion	  of	  the	  microvasculature	  in	  various	  tissues	  and	  organs	  (MILLER,	  et	  al.	  
2002;	  RASTI,	  et	  al.	  2004).	  
Among	  the	  proteins	  exported	  to	  modify	  the	  host	  cell	  is	  a	  special	  group	  of	  protein	  folding	  
assistants,	   known	   as	   the	   Hsp40	   co-­‐chaperones.	   Importantly,	   Hsp40	   co-­‐chaperones	   have	  
undergone	  a	  marked	  expansion	  in	  the	  P.	  falciparum	  genome	  (BOTHA,	  et	  al.	  2007;	  PAVITHRA,	  et	  al.	  
2007).	  Of	   the	  expanded	  number	  of	  Hsp40	  co-­‐chaperones,	  19,	  about	  half,	  are	  predicted	   to	  be	  
exported	   to	   the	  erythrocyte	   (BOTHA,	   et	   al.	   2007).	   Several	   of	   these	  exported	   chaperones	  have	  
very	  recently	  been	  shown	  to	  be	  essential	  for	  remodeling	  of	  the	  red	  blood	  cell	  and/or	  parasite	  
viability	  (MAIER,	  et	  al.	  2008).	  Hsp40s	  confer	  specificity	  to	  the	  refolding	  machinery	  by	  binding	  to	  
particular	   unfolded	   proteins	   and	   expedite	   their	   folding	   by	   stimulating	   the	   ATPase	   activity	   of	  
Hsp70	   chaperones.	   No	   members	   of	   the	   Hsp70	   family	   encoded	   by	   P.	   falciparum	   have	   been	  
shown	  to	  be	  exported;	  as	  such	  the	  exported	  Hsp40s	  have	  been	  suggested	  to	  interact	  with	  the	  
human	   host	   Hsp70	   (BOTHA,	   et	   al.	   2007;	   CHARPIAN,	   et	   al.	   2008;	   SARGEANT,	   et	   al.	   2006).	   The	   Pf	  
proteome	  also	  has	  a	  vastly	  increased	  frequency	  of	  proteins	  that	  show	  an	  extreme	  bias	  toward	  a	  
few	  amino	  acids,	  most	  notably	  asparagines	   (N),	  and	  are	  predicted	   to	   form	  non-­‐globular,	   low-­‐
complexity	   structures.	  The	  abundance	  of	   these	  proteins	  distinguishes	  Plasmodium	   from	  most	  
other	  eukaryotes	  (ARAVIND,	  et	  al.	  2003).	  We	  recently	  characterized	  a	  specific	  role	  for	  the	  yeast	  
Hsp40	  protein	   Sis1	   in	   the	   folding	  and	  detoxification	  of	   a	  N-­‐rich	  prion	  protein	   (DOUGLAS,	   et	   al.	  
2008).	  As	  such,	  we	  hypothesize	  that	  the	  extreme	  abundance	  of	  N-­‐rich	  proteins	  and	  the	  unusual	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expansion	   of	   Hsp40	   proteins	   encoded	   by	   the	   P.	   falciparum	   genome	   are	   related,	   with	   the	  
asparagine-­‐rich	  proteins	  requiring	  Hsp40s	  for	  their	  proper	  folding	  and	  function.	  	  
P.	   falciparum	   exports	   four	  Sis1-­‐homologs,	  Type	  2	  Hsp40	  chaperones,	   to	   the	   red	  blood	  
cell	   (BOTHA,	   et	   al.	   2007).	   Type	   2	   Hsp40	   chaperones	   are	   defined	   as	   containing	   the	   canonical	  
Hsp40	   J-­‐domain,	   GF	   region	   and	   C-­‐terminal	   domain.	   Of	   the	   four	   Sis1-­‐homologs,	   PFA0660w	  
(GeneID:	  813268)	  is	  the	  only	  one	  that	  appears	  to	  be	  essential	  for	  growth	  of	  the	  parasite	  in	  red	  
blood	  cells	  (MAIER,	  et	  al.	  2008).	  Several	  Type	  4	  Hsp40	  proteins,	  defined	  by	  the	  presence	  of	  a	  J-­‐
domain	   without	   a	   complete	   HPD	   motive,	   are	   also	   exported.	   Three	   of	   these,	   PF11_0034,	  
PF11_0509	  and	  PF10_0381,	  appear	  to	  be	  essential	  or	  required	  for	  the	  adhesion	  of	  infected	  red	  
blood	  cells	  to	  the	  endothelium.	  
We	  believe	  that	  targeting	  the	  critical	  interaction	  of	  Pf	  Hsp40s,	  and	  especially	  that	  of	  the	  
essential	  PFA0660w,	  with	  the	  chaperone	  machinery	  of	  the	  erythrocyte	  will	  provide	  an	  entirely	  




Expression	  of	  Pf	  Hsp40s	  in	  Saccharomyces	  cerevisiae	  
To	   identify	   inhibitors	   of	   Hsp40	   function	   we	   first	   designed	   phenotypic	   assays	   for	   P.	  
falciparum	  Hsp40	  function	  in	  Saccharomyces	  cerevisiae.	  Since	  Plasmodium	  Falciparum	  exhibits	  
a	  different	  codon	  bias	  than	  Saccharomyces	  cerevisiae,	  we	  recoded	  the	  four	  Type	  2	  Hsp40s	  and	  
the	   three	   Type	   4	   Hsp40s	   to	   facilitate	   their	   expression	   in	   yeast.	   Expression	   of	   the	   codon-­‐
optimized	   PFA0660w,	   via	   an	   inducible	   promoter,	   resulted	   in	   severe	   growth	   inhibition	   (Figure	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A2.2).	   Expression	   of	   PFE0055c	   and	   PF11_0034	   also	   resulted	   in	   moderate	   toxicity.	   Next,	   we	  
asked	   if	   toxicity	   of	   the	   two	   Type	   2	   Hsp40s,	   PFA0660w	   and	   PFE0055c,	   depended	   on	   their	  
functional	   interaction	  with	  yeast	  Hsp70.	  Hsp40s	  contain	  a	  J-­‐domain	  with	  a	  conserved	  triptych	  
HPD	  sequence	  motif	   that	   is	  essential	   for	   their	   stimulation	  of	   the	  ATPase	  domain	  of	  a	  partner	  
Hsp70	  (WALSH,	  et	  al.	  2004).	  We	  found	  that	  mutations	  of	  the	  HPD	  motives	   in	  the	  J-­‐domains	  of	  
PFA0660w	   and	   PFE0055c	   alleviated	   toxicity	   (Figure	   A2.3).	   We	   conclude	   that	   the	   toxicity	   of	  
PFA0660w	  and	  PFE0055c	  in	  yeast	  represents	  a	  readout	  of	  their	  chaperone	  function.	  	  
	   To	  further	  establish	  that	  the	  P.	  falciparum	  Type	  2	  Hsp40s	  could	  function	  as	  chaperones	  
in	   yeast	  we	   tested	   if	   they	   could	   complement	   the	   loss	   of	   the	   essential	   yeast	   Hsp40	   Sis1.	  We	  
utilized	  a	  strain	  deleted	  for	  Sis1	  whose	  growth	  was	  maintained	  by	  a	  counter-­‐selectable	  plasmid	  
carrying	   Sis1.	   We	   constitutively	   expressed	   the	   four	   P.	   falciparum	   Sis1	   homologs,	   selected	  
against	  the	  presence	  of	  the	  Sis1	  plasmid	  and	  assayed	  strain	  growth.	  Of	  the	  four	  Sis1	  homologs	  
only	   PFE0055c	   could	   complement	   for	   Sis1	   (Figure	   A2.4).	   As	   expected	   the	   HPD	   mutant	   of	  
PFE055c	   could	   not	   maintain	   growth.	   Consequently,	   PFE0055c	   can	   function	   as	   a	   Hsp40	   co-­‐
chaperone	  in	  yeast.	  	  	  
	  
Development	  of	  a	  PFA0660w	  growth	  assay	  
Screening	   for	   small	   molecule	   suppressors	   of	   toxicity	   eliminates	   compounds	   that	   are	  
toxic	  on	  their	  own.	  Since	  PFA0660w	  appears	  to	  be	  essential	  and	  induced	  a	  very	  robust	  toxicity	  
in	  yeast,	  we	  adapted	  the	  PFA0660w	  growth	  assay	  to	  a	  384-­‐well	  format	  to	  in	  order	  to	  screen	  for	  
inhibitors	   of	   PFA0660w	   function.	   Toxicity	   of	   PFA0660w	   expression	   in	   liquid	   media	   was	  
comparable	  to	  that	  seen	  on	  agar	  plates.	  Assay	  design	  and	  validation	  was	  carried	  out	  with	  the	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help	  of	  the	  Broad	  Institute’s	  Outreach	  Lab.	  In	  particular	  assay	  validation	  was	  carried	  out	  using	  
the	  Outreach	  Labs	  small	  molecule	  384-­‐well	  pilot	  screen	  plates:	  two	  plates	  of	  natural	  products,	  
two	   plates	   of	   biologically	   active	   compounds	   and	   one	   plate	   of	   commercially	   available	  
compounds.	  
Briefly,	   small	   molecules	   were	   pinned	   to	   384-­‐well	   clear	   bottom	   polystyrene	   plates	  
containing	  20µl	  of	  media,	  then	  20µl	  of	  media	  containing	  the	  PFA0660w	  harboring	  yeast	  strain	  
were	  overlaid;	  yielding	  40µl	  media	  per	  well	  with	  a	  final	  compound	  concentration	  of	  10µM.	  The	  
media	   used	   was	   standard	   synthetic	   yeast	  media	   containing	   galactose	   as	   a	   carbon	   source	   to	  
induce	   the	  expression	  of	  PFA0660w.	  After	   the	  addition	  of	   the	   yeast	   containing	  media,	   plates	  
were	  grown	  in	  a	  humidified	  chamber	  for	  three	  days	  at	  30	  °C.	  The	  cultures	  do	  not	  require	  mixing	  
during	  the	  3-­‐day	  incubation	  period.	  Cells	  were	  then	  resuspended	  by	  mild	  vortexing	  of	  the	  plates	  
and	  cell	  density	  was	  measured	  based	  on	  absorbance	  at	  600nm	  using	  a	  plate	  reader.	  	  
The	  assay	  was	  not	  affected	  by	  10µM	  DMSO	  and	  was	  used	  as	  a	  negative	  control.	  Two-­‐
percent	   glucose,	  which	   represses	   the	   expression	  of	   PFA0660w	   in	  our	   inducible	   yeast	   system,	  
was	   used	   as	   a	   positive	   control.	   The	   assay	   showed	   great	   between-­‐plate	   and	   day-­‐to-­‐day	  
robustness.	   The	   Z	   factor	   ranged	   between	   .766	   and	   .857	   for	   different	   pilot	   screen	   plates	  
screened	  on	  different	  days.	  	  
	  
Validation	  of	  the	  PFA0660w	  assay	  using	  a	  collection	  of	  putative	  anti-­‐malaria	  compounds	  
	   The	  screening	  platform	  at	  the	  Broad	  Institute	  has	  previously	  conducted	  a	  small	  molecule	  
screen	  for	  inhibitors	  of	  parasite	  proliferation	  in	  red	  blood	  cell	  culture.	  This	  screen	  was	  based	  on	  
a	   similar	   assay	   described	   under	   Aim	   3	   but	   did	   not	   encompass	   the	   large	   MLPCN	   compound	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collection	  that	  we	  propose	  to	  screen	  using	  our	  more	  directed	  and	  certainly	  cheaper	  yeast-­‐based	  
assay.	  To	  test	  whether	  our	  PFA0660w	  assay	  could	  result	  in	  the	  identification	  of	  compounds	  that	  
show	   activity	   against	   P.	   falciparum	   in	   culture	   we	   screened	   the	   collection	   of	   putative	   anti-­‐
malarials	  identified	  by	  the	  Broad.	  	  
This	  screen	  of	  460	  compounds	  resulted	  in	  13	  hits,	  of	  which	  10	  reproduced	  in	  individual	  
retests.	   The	   compounds	   suppressing	   PFA0660w	   toxicity	   did	   not	   affect	   our	   galactose-­‐based	  
expression	  system	  and	  did	  not	  suppress	  the	  growth	  defect	  caused	  by	  the	  expression	  of	  another	  
unrelated	   protein	   under	   identical	   assay	   conditions.	   In	   fact,	   three	   of	   these	   hits	   showed	   such	  
strong	  rescue	  of	  PFA0660w	  toxicity	   (average	  screen	  Z-­‐scores	  ranging	  from	  5.4	  to	  8.7)	  that	  we	  
will	  use	  them	  as	  positive	  controls	  in	  the	  future.	  	  
This	   specific	   validation	   screen	  proves	   that	   our	   yeast	   based	  PFA0660w	  growth	   assay	   is	  
capable	   of	   identifying	   small	   molecules	   with	   anti-­‐malarial	   activity.	   Yet	   following	   their	  
identification	  in	  the	  Broad	  screen	  this	  subset	  of	  compounds	  was	  not	  pursued	  as	  anti-­‐malarials,	  
as	   they	   either	   exhibited	   low	   IC50s	   or	  were	   toxic	   to	   human	   fibroblasts.	   As	   our	   screen	   of	   this	  
small	  collection	  resulted	  in	  several	  positives,	  we	  are	   likely	  to	   identify	  further	  compounds	  with	  
anti-­‐malaria	  activity	  by	   screening	  a	   larger	   collection	  of	   compounds,	   some	  of	  which	  may	  have	  
better	  IC50s	  than	  the	  compounds	  previously	  identified.	  	  
	  
Research	  Design	  and	  Methods	  
Specific	  Aim	  1	  (Primary	  HTS	  assay):	  Identification	  of	  small	  molecules	  that	  inhibit	  the	  activity	  of	  
the	  Pf	  Hsp40	  PFA0660w	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The	  yeast	  strain	  W303	  harboring	  a	  single	  copy	  vector	  with	  codon	  optimized	  PFA0660w	  
under	   the	  control	  of	   the	   inducible	  Gal1	  promoter	  will	  be	  pre-­‐grown	   in	  non-­‐inducing	  raffinose	  
media	  over	  night.	  Cultures	  will	  be	  diluted	  to	  an	  OD	  of	  0.2	  and	  grown	  for	  4	  hours	  to	  yield	  mid-­‐log	  
cultures	   ideal	   for	   reproducible	  galactose	   induction.	  Meanwhile,	  compound	  will	  be	  transferred	  
into	   20µl	   of	   yeast	   media	   in	   384-­‐well	   clear	   bottom	   polystyrene	   plates	   using	   a	   pinning	   robot	  
transferring	  100nl	  of	  compound	  per	  well.	  20µl	  per	  well	  of	  the	  mid-­‐log	  cultures	  of	  the	  PFA0660w	  
yeast	  strain	  will	  then	  be	  overlaid	  using	  a	  peristaltic	  pump	  driven	  plate	  filler.	  The	  plates	  do	  not	  
require	  mixing	  once	   the	   yeast	   cultures	  have	  been	  added.	   Plates	  will	   then	  be	   incubated	   for	   3	  
days	   at	   30	   °C	   in	   a	  humidified	   chamber	   to	  prevent	   evaporation	  of	   the	   liquid	  media.	  After	   the	  
incubation	  period	  the	  cells,	  which	  will	  have	  grown	  at	  the	  bottom	  of	  the	  plates,	  will	  be	  briefly	  re-­‐
suspended	   by	   vortexing	   the	   plates	   in	   a	   plate	   vortexer.	   Cell	   density	   in	   each	  well	  will	   then	   be	  
measured	  as	  OD	  600nm	  using	  a	  plate	  reader	  with	  an	  attached	  plate	  stacker.	  
Small	  molecules	  will	   be	   called	   as	   hits	   if	   their	   Z	   scores	   are	   higher	   than	   2.	   Hits	   will	   be	  
cherry	   picked	   and	   tested	   non-­‐specific	   effects	   in	   yeast	   growth	   assays	   such	   as	   suppression	   of	  
galactose	   induction.	   Briefly,	   a	   strain	   expressing	   a	   toxicity	   inducing	   protein	   unrelated	   to	  
PFA0660w	  will	   be	  used	   to	   test	   for	   unspecific	   effects	   of	   the	  hits	   on	   yeast	   growth	   assays.	   This	  
control	  assay	  is	  identical	  to	  the	  PFA0660w	  screen	  in	  setup	  and	  execution.	  	  
Yeast	   strains	   and	  media	   can	   easily	   be	   supplied	   to	   the	  MLPCN	   screening	   center.	   Their	  
cost	  is	  negligible	  compared	  to	  the	  baseline	  cost	  per	  well	  screened.	  
	  
Specific	  Aim	  2	  (Secondary	  assay):	  Elimination	  of	  identified	  small	  molecules	  toxic	  to	  human	  cells	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Identified	  hits	  cytotoxic	  to	  human	  cells	  but	  not	  to	  yeast	  cells	  may	  result	  in	  false	  positives	  
in	  the	  later	  malaria	  parasite	  assay.	  As	  such	  we	  will	  eliminate	  compounds	  that	  are	  toxic	  to	  non-­‐
transformed	   human	   fibroblasts.	   All	   small	   molecules	   identified	   under	   Aim	   1	   as	   specifically	  
suppressing	   the	   toxicity	   of	   PFA0660w	   expression	   will	   be	   tested	   unless	   they	   have	   been	  
previously	  annotated	  as	  being	  cytotoxic.	  
We	  will	   examine	   compound	   cytotoxicity	   using	   two	   commercially	   available	   assays:	   the	  
ATCC	  MTT	  cell	  proliferation	  assay	  and	  the	  Lonza	  ToxiLight	  BioAssay.	  The	  MTT	  assay	  measures	  
cell	   proliferation	   based	   on	   the	   ability	   of	   metabolically	   active	   cells	   to	   reduce	   the	   yellow	  
tetrazolium	   MTT.	   The	   ToxiLight	   assay	   provides	   a	   quantitative	   measurement	   of	   cytotoxicity	  
based	  on	  the	  detection	  of	  Adenylate	  Kinase	  released	  to	  the	  cell	  culture	  medium	  due	  to	  a	  loss	  in	  
cell	   integrity.	   Serial	   dilutions	   of	   the	   compounds,	   centered	   on	   the	   screening	   concentration	   of	  
10µM,	  will	  be	  added	  to	  primary	  human	  fibroblasts	  seeded	  in	  96-­‐well	  plates.	  After	  an	  incubation	  
of	  24	  hours	  the	  MTT	  and	  ToxiLight	  assays	  will	  be	  performed	  to	  measure	  cell	  proliferation	  and	  
viability.	  The	  amount	  of	  serial	  dilutions	  per	  compound	  will	  be	  determined	  based	  on	  the	  number	  
and	  availability	  of	  small	  molecules	  to	  be	  tested.	  	  
	  
Specific	  Aim	  3	  (Secondary	  assay):	  Testing	  the	  efficacy	  of	  identified	  small	  molecules	  on	  parasites	  
in	  culture	  	  
	   To	   determine	   if	   the	   identified	   suppressors	   of	   PFA0660w	   toxicity	   have	   anti-­‐malaria	  
activity,	  we	  will	  test	  their	  effects	  on	  the	  proliferation	  of	  blood-­‐stage	  P.	  falciparum.	  We	  will	  use	  a	  
previously	  established	  high-­‐throughput	  growth	  assay	  (BANIECKI,	  et	  al.	  2007)	  that	  has	  been	  in	  use	  
at	  the	  Broad	  Institute	  screening	  facility.	  This	  simple	  and	  robust	  assay	  uses	  the	  fluorescent	  DNA	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staining	   dye	   DAPI	   to	   measure	   DNA	   content	   and	   hence	   growth	   of	   blood-­‐stage	   parasites.	  
Compounds	  will	  be	  added	  to	  media	  containing	  96	  or	  384-­‐well	  plates,	  depending	  on	  the	  number	  
of	  hits	  to	  be	  tested.	  Synchronized	  ring-­‐stage	  parasite	  cultures	  will	  be	  added	  to	  plates	  with	  and	  
without	   the	   compounds.	   Following	   72	   h	   of	   incubation,	   DAPI	   will	   be	   added	   to	   detect	   and	  
quantify	  the	  amount	  of	  parasites	  present	  using	  a	  fluorescence	  plate	  reader.	  	  
	  
Specific	  Aim	  4	  (Tertiary	  assay):	  Mechanism	  determination	  using	  established	  in	  vitro	  chaperone	  
assays.	  
Finally,	  we	  will	  test	  the	  ability	  of	  the	  identified	  small	  molecules	  to	  directly	  interfere	  with	  
Hsp40	   function	  using	   in	   vitro	  chaperone	  assays.	  Activity	   of	  Hsp40s	   can	  be	  monitored	   in	   vitro	  
based	  on	  their	  ability	  to	  stimulate	  the	  ATPase	  activity	  of	  Hsp70	  chaperone	  and	  their	  ability	  to	  
facilitate	  the	  refolding	  of	  denatured	  luciferase.	  	  
We	  not	  only	  codon	  optimized	  PFA0660w	  for	  its	  expression	  in	  yeast,	  but	  also	  made	  sure	  
that	   it	  would	  be	   fit	   to	  be	  expressed	  and	  purified	   from	  E.	  Coli.	  Purified	  PFA0660w	  and	  human	  
Hsp70	  will	  be	   incubated	  with	  [32P]	  ATP	   in	  the	  presence	  or	  absence	  of	  the	  small	  molecules	  for	  
10min	   at	   30	   °C.	   ADP	   formation	   will	   be	   measured	   using	   thin	   layer	   chromatography	   on	  
polyethyleneimine	   cellulose	   plates(13).	   To	   measure	   luciferase	   refolding	   the	   chaperones	  
PFA0660w	   and	   human	   Hsp70	   will	   be	   incubated	   with	   chemically	   denatured	   luciferase	   in	   the	  
presence	  or	  absence	  of	  the	  compounds	  for	  30	  min	  at	  25	  °C.	  The	  refolding	  of	  luciferase	  can	  be	  
monitored	  using	  a	  standard	  luminometer.	  	  
Compounds	   capable	   of	   inhibiting	   chaperone	   activity	   in	   these	   assays	   will	   be	   further	  
tested	   to	   determine	   their	   specificity	   to	   PFA0660w.	   By	   repeating	   the	   assays	   using	   a	   human	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Hsp40	  co-­‐chaperone	  instead	  of	  PFA0660w	  we	  will	  be	  able	  to	  easily	  determine	  if	  any	  compounds	  
effect	  is	  specific	  to	  PFA0660w.	  
	  
Future	  Plan	  
Compounds	  that	  suppress	  PFA0660w	  toxicity	  in	  yeast	  and	  show	  activity	  against	  malaria	  
parasites	   in	   culture	  will	   be	  used	   to	  probe	   the	   role	  of	   the	  PFA0660w	  co-­‐chaperone	   in	   the	   life	  
cycle	   of	   the	   parasite.	   For	   example	   administration	   of	   the	   compounds	   to	   synchronized	   P.	  
falciparum	   cultures	   will	   allow	   us	   to	   determine	   at	   which	   stage	   of	   the	   parasite	   life	   cycle	  
PFA0660w	  is	  essential	  for	  parasite	  survival.	  Furthermore,	  we	  will	  use	  the	  identified	  compounds	  
to	  study	  how	  the	  exported	  PFA0660w	  affects	  the	  malarial	  and	  host	  proteome	  in	  red	  blood	  cells.	  
In	  particular	  we	  will	  examine	  effects	  on	  the	  rigidity	  of	  parasite-­‐infected	  red	  blood	  cells	  and	  their	  
adherence	  to	  endothelial	  surface	  proteins	  (MAIER,	  et	  al.	  2008).	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Figure	   A2.1:	   The	   Plasmodium	   falciparum	   genome	   has	   an	   increased	   abundance	   of	   Hsp40	  
chaperones.	  	  
Enrichment	   of	   Hsp40	   chaperones	   in	   P.	   falciparum	   in	   comparison	   to	   humans	   and	   other	  
Plasmodia	  species.	  Hsp40	  type	  is	  determined	  based	  on	  the	  Hsp40	  domains	  conserved.	  Adapted	  





Figure	  A2.2:	  Expression	  of	  codon-­‐optimized	  P.	  falciparum	  Hsp40s	  in	  yeast.	  	  
PFA0660w,	   PFB0090c,	   PFE0055c	   and	   PF11_0099	   are	   Type	   2	   Hsp40s.	   PF10_0381,	   PF11_0034	  
and	   PF11_0509	   are	   Type	   4	   Hsp40s.	   Proteins	   domains	   as	   determined	   by	   SMART	   are	   shown.	  
Expression	  of	  PFA0660w	  was	  very	  toxic,	  while	  expression	  of	  PFE0055c	  and	  PF11_0034	  was	  also	  







Figure	  A2.3:	  Toxicity	  of	  P.	  falciparum	  Hsp40s	  depends	  on	  chaperone	  function.	  
To	   determine	   if	   the	   toxicity	   of	   the	   Type	   2	  Hsp40s	   depended	   on	   their	   ability	   to	   interact	  with	  
Hsp70	  we	  introduced	  mutations	  in	  their	  HPD	  motives.	  The	  conserved	  HPD	  motive	  within	  the	  J-­‐
domain	   is	   required	   for	   the	  ability	  of	  Hsp40	  co-­‐chaperones	   to	  stimulate	   the	  ATPase	  activity	  of	  
Hsp70s.	   Mutations	   in	   the	   HPD	   motives	   of	   the	   Hsp40s	   PFA0660w	   and	   PFE0550c	   markedly	  
reduced	  their	   toxicity.	  This	   indicates	   that	   their	   toxicity	   is	  at	   least	  partially	  dependent	  on	  their	  




Figure	  A2.4:	  The	  P.	  falciparum	  Hsp40	  PFE055c	  can	  complement	  the	  loss	  of	  the	  essential	  yeast	  
Hsp40	  Sis1.	  
	  To	  determine	  if	  the	  recoded	  Type	  2	  Hsp40s	  could	  function	  as	  chaperones	  in	  yeast	  we	  tested	  if	  
they	  could	  complement	  the	  loss	  of	  the	  essential	  yeast	  Hsp40	  Sis1.	  After	  loss	  of	  Sis1	  only	  the	  
expression	  of	  PFE0055c	  could	  support	  a	  moderate	  level	  of	  growth.	  As	  expected,	  the	  non-­‐
functional	  HPD	  mutant	  of	  PFE0055c	  could	  not	  complement.	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Rnq1	  and	  asymmetric	  inheritance	  of	  damaged	  proteins	  
The	   IPOD	   (insoluble	   protein	   deposit)	   appears	   to	   play	   an	   important	   role	   in	   the	  
asymmetric	   inheritance	   of	   irreversible	   misfolded	   and	   damaged	   proteins	   as	   it	   is	  
preferentially	  retained	  in	  the	  aging	  mother	  cell	  (TYEDMERS,	  et	  al.	  2010).	  Rnq1	  amyloid	  is	  
one	  of	   the	   key	   species	   targeted	   to	   the	   IPOD	   (KAGANOVICH,	   et	   al.	   2008;	   TYEDMERS,	   et	   al.	  
2010)	  and	  can	   induce	   the	  amyloid	   formation	  of	  other	  proteins	   (DERKATCH,	  et	  al.	  2001).	  
Yet	  it	  remains	  unclear	  how	  the	  IPOD	  is	  formed	  or	  how	  misfolded	  proteins	  are	  specifically	  
targeted	   to	   it.	  As	   shown	  by	   the	  analysis	  of	  Rnq1	   toxicity	   suppressors	   containing	  prion	  
domains,	   the	   amyloid	   conversion	   of	   these	   proteins	  must	   either	   occur	   at	   the	   IPOD	   or	  
facilitate	  the	  targeting	  of	  these	  proteins	  to	  the	   IPOD.	  This	  raises	  the	  question	  whether	  
Rnq1	  plays	  a	  role	  in	  the	  asymmetric	  inheritance	  of	  protein	  damage.	  Rnq1	  could	  interact	  
with	  misfolded	  proteins	  thereby	  facilitating	  their	  amyloid	  formation	  and	  localization	  to	  
the	  IPOD.	  Intriguingly,	  once	  the	  amyloid	  conversion	  of	  a	  misfolded	  protein	  had	  occurred,	  
the	  self-­‐templating	  properties	  would	  turn	  capture	  of	  the	  remaining	  misfolded	  protein	  of	  
the	  same	  amino	  acid	  sequence	  into	  a	  self-­‐enabled	  process.	  	  
The	  fact	  that	  the	  Hsp104	  chaperone	   is	  required	  for	  the	  asymmetric	   inheritance	  
of	  damaged	  proteins	  supports	  the	  notion	  that	  amyloid	  formation	  may	  play	  an	  important	  
role	   in	   asymmetric	   inheritance	   (ERJAVEC,	   et	   al.	   2007).	   Hsp104	   is	   required	   for	   the	  
maintenance	   and	   inheritance	   of	   amyloid-­‐based	   yeast	   prions	   (CHERNOFF,	   et	   al.	   1995;	  
SHORTER,	   et	   al.	   2005)	   and	   has	   been	   shown	   to	   facilitate	   amyloid	   formation	   in	   vitro	  
(SHORTER,	  et	  al.	  2004).	  It	  has	  not	  been	  investigated	  whether	  Rnq1	  is	  needed	  for	  Hsp104’s	  
effect	  on	  asymmetric	  inheritance	  and	  longevity.	  In	  some	  regards	  it	  appears	  unlikely	  that	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Rnq1	  would	  be	  required.	  Hsp104	  overexpression	  can	  suppress	  the	  aging	  defect	  of	  a	  SIR2	  
mutant	  strain	  and	  Hsp104	  overexpression	  has	  not	  been	  shown	  to	   influence	  the	   in	  vivo	  
prion	  properties	  of	  Rnq1	  (ERJAVEC,	  et	  al.	  2007).	  Furthermore,	  I	  observed	  that	  Hsp104-­‐GFP	  
fusions	  in	  part	  localize	  to	  the	  IPOD	  even	  in	  cells	  that	  should	  be	  prion	  minus	  due	  to	  prior	  
inhibition	  of	  Hsp104	  (this	   is	  to	  some	  extent	  indicated	  in	  (KAGANOVICH,	  et	  al.	  2008)).	  The	  
latter	   itself	   seems	  worthy	  of	   additional	   investigation.	  Hsp104	   could	  potentially	   be	   the	  
“founding”	  component	  of	   the	   IPOD	  that,	   in	  a	  manner	  similar	   to	   the	  one	  described	   for	  
Rnq1	   above,	   captures	   misfolded	   proteins	   and	   triggers	   their	   self-­‐propagating	   ordered	  
amyloid	   assembly.	   Yet,	   given	   Rnq1’s	   ability	   to	   induce	   the	   amyloid	   formation	   of	   other	  
proteins,	  Rnq1	  could	  very	  well	  act	  in	  concert	  with	  Hsp104.	  	  
	   Hence,	  it	  would	  be	  interesting	  to	  investigate	  how	  Rnq1	  and	  its	  prion	  status	  affect	  
yeast	  longevity.	  As	  accumulation	  of	  damaged	  proteins	  during	  aging	  could	  induce	  [RNQ+]	  
formation	   it	   would	   be	   important	   to	   abrogate	   Rnq1’s	   prion	   forming	   ability	   for	   control	  
experiments.	  Unfortunately,	  simply	  using	  a	  complete	  deletion	  of	  RNQ1	  might	  give	  rise	  to	  
“side	   effects”.	   It	   has	   been	   shown	   that	   promoter	   of	   the	   neighboring	   and	   divergently	  
transcribed	  ORF	  BIK1	  extends	   into	  the	  RNQ1	  ORF	  and	  that	  deletion	  of	  RNQ1	  results	   in	  
the	  down-­‐regulation	  of	  BIK1	  expression	  (STRAWN,	  et	  al.	  2006).	  Hence,	  it	  would	  be	  best	  to	  
create	   either	   a	   targeted	   deletion	   of	   just	   the	   Rnq1	   prion	   domain	   or	   to	   introduce	   a	  
premature	  stop	  codon	  into	  the	  RNQ1	  ORF	  that	  prevents	  Rnq1	  prion	  domain	  translation.	  
Longevity	  of	  [RNQ+]	  and	  [rnq-­‐]	  strains	  could	  then	  be	  compared	  to	  that	  of	  a	  strain	  unable	  
to	   form	   Rnq1	   amyloid	   or	   any	   other	   type	   of	   Rnq1	   aggregate.	   If	   Rnq1’s	   ability	   to	   form	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amyloid	   is	   found	   to	   confer	   increased	   longevity,	   it	   could	   then	   be	   tested	   if	  moderately	  
expressing	  solely	  the	  prion	  domain	  of	  Rnq1	  had	  the	  same	  effect.	  
Chapter	   Three	   raises	   the	   question	   whether	   the	   core	   spindle	   pole	   body	   (SPB)	  
component	   Spc42	   assembly	   can	   serve	   as	   a	   sensor	   of	   protein	   damage	   that	   delays	   cell	  
cylce	  progression	  to	  ensure	  asymmetric	  inheritance.	  The	  effect	  of	  Rnq1	  overexpression	  
on	   Spc42	   localization	   and	   cell	   viability	   is	   very	   profound.	   Cells	   arrested	   due	   to	   Rnq1	  
toxicity	  may	   be	   able	   to	   reinitiate	  mitosis	   and	   rebud	   to	   some	   extend,	   but	   progeny	   of	  
these	  cells	  are	  likely	  to	  be	  aneuploid	  due	  to	  chromosome	  missegregation.	  Therefore,	  if	  
Spc42	  assembly	  serves	  as	  a	  sensor	  of	  protein	  damage,	  physiological	  effects	  ought	  to	  be	  
more	   subtle	   than	   those	   induced	  by	  Rnq1	  overexpression.	   But	   as	   the	  dosage	  of	   Spc42	  
appears	  to	  be	  tightly	  regulated	  (JASPERSEN,	  et	  al.	  2004),	  protein	  damage	  would	  only	  have	  
to	  alter	  Spc42	  assembly	  and	  localization	  slightly	  to	  delay	  spindle	  duplication.	  
I	   attempted	   to	   use	   a	   Spc42-­‐GFP	   fusion	   to	   monitor	   Spc42	   assembly,	   but	   this	  
approach	   did	   not	   allow	  me	   to	   detect	   small	   changes	   in	   the	   rate	   or	   amount	   of	   Spc42	  
assembly.	   I	   was	   able	   to	   observe	   that	   various	   proteotoxic	   conditions	   resulted	   in	   what	  
appeared	  to	  misoriented	  spindles	   (late	  stage	  dividing	  cells	   in	  which	  the	  SPBs	  were	  not	  
properly	   segregated	   to	   the	  mother	  and	  daughter	  cells),	  but	   I	   could	  not	   reliably	  detect	  
overt	  mislocalizations	  of	  Spc42.	  The	  amount	  of	  Spc42	  molecules	  per	  cell	  is	  relatively	  low,	  
making	   it	   difficult	   to	   detect	   Spc42-­‐GFP	   in	   anything	   but	   clear	   foci.	   As	   such	   a	   more	  
sensitive	   assay	   for	  measuring	   Spc42	   assembly	   or	   detecting	   its	   localization	   throughout	  
the	   cell	   is	   needed	   to	   further	   explore	   this	   question.	   FRET	   between	   Spc42	   and	   other	  
interacting	   SPB	   components,	   for	   instance	   Spc29,	   may	   provide	   a	   reliable	   readout	   of	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proper	  SPB	  assembly.	  Fluorescence	  correlation	  spectroscopy,	  which	  has	  been	  previously	  
used	  to	  monitor	  the	  dynamics	  of	  yeast	  prion	  protein	  oligomers	   in	  vivo	  (KAWAI-­‐NOMA,	  et	  
al.	   2006),	   could	   be	   used	   to	   measure	   the	   rate	   of	   movement	   of	   a	   Spc42-­‐GFP	   fusion	  
throughout	  the	  cell.	  
Another	   approach	   to	   examine	   how	   misfolded	   proteins	   can	   influence	   Spc42	  
assembly	  and	  localization	  would	  be	  to	  determine	  the	  molecular	  basis	  of	  the	  Rnq1::Spc42	  
interaction.	   Spc42	   is	   a	   highly	   phosporylated	   coiled-­‐coil	   protein	   and	   SPB	   assembly	  
appears	   to	   be	   governed	   largely	   by	   coiled-­‐coil	   interactions	   (DONALDSON,	   et	   al.	   1996;	  
ZIZLSPERGER,	  et	  al.	  2010).	  Intriguingly,	  a	  recent	  study	  investigated	  the	  role	  of	  coiled-­‐coils	  
in	   the	  aggregation	  and	  conformational	   switching	  of	  prion	  proteins	  and	  polyQ	  proteins	  
(FIUMARA,	   et	   al.	   2010).	   Decreasing	   or	   enhancing	   the	   propensity	   to	   form	   coiled-­‐coils	  
altered	  the	  extent	  of	  aggregation	  accordingly.	  A	  region	  within	  Rnq1’s	  prion	  domain	  was	  
predicted	   to	   form	   a	   coiled-­‐coil	   and	   furthermore	   proteins	   interacting	   with	   mutant	  
huntingtin	  were	  also	   shown	   to	  contain	   coiled	  coil	  domains	   (FIUMARA,	   et	  al.	   2010).	  This	  
suggests	  that	  the	  interaction	  between	  Rnq1	  and	  Spc42	  may	  be	  mediated	  by	  a	  transient	  
coiled-­‐coil	   formation	  within	  the	  prion	  domain	  of	  Rnq1	  as	   it	  undergoes	   its	   transition	  to	  
the	  amyloid	  state.	  	  	  
The	  Keating	  lab	  at	  MIT	  has	  analyzed	  the	  coiled-­‐coil	  interactions	  between	  various	  
SPB	  components	   (ZIZLSPERGER,	  et	  al.	  2010;	  ZIZLSPERGER,	  et	  al.	  2008).	  Their	   in	  vitro	  assays	  
could	  easily	  be	  extended	  to	  include	  the	  predicted	  coiled-­‐coils	  predicted	  within	  Rnq1	  and	  
other	   proteins	   prone	   to	   aggregate.	  We	  have	  previously	   shown	   that	   overexpression	  of	  
just	   the	   Rnq1	   prion	   domain	   itself	   is	   not	   toxic	   (DOUGLAS,	   et	   al.	   2008).	   As	   such	   the	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formation	  of	  the	  predicted	  coiled-­‐coil	  within	  the	  Rnq1	  prion	  domain	  may	  require	  certain	  
sequence	  contexts,	  but	   it	  should	  be	  possible	  to	  engineer	  a	  coiled-­‐coil	  starting	  with	  the	  
predicted	   amino	   acid	   sequence.	   These	   experiments	   would	   not	   only	   allow	   us	   to	  
determine	  which	   precise	   protein	   contacts	   determine	   the	  Rnq1::Spc42	   interaction,	   but	  
would	  answer	  how	  specific	   this	   type	  of	   interaction	   is.	  Does	  the	  Rnq1	  coiled-­‐coil	  mimic	  
coiled-­‐coils	  formed	  by	  other	  SPB	  components?	  Can	  other	  proteins	  prone	  to	  misfold	  and	  
aggregate	   form	   similar	   coiled-­‐coils?	   The	   results	   could	   then	   be	   used	   to	   design	   further	  
experiments	   aimed	   at	   investigating	   how	   and	   under	   which	   conditions	   coiled-­‐coil	  
interactions	  with	  misfolded	  proteins	  may	  impede	  SPB	  assembly.	  
	  
Yeast	  model	  of	  Abeta	  toxicity	  
	   The	   identification	   of	   genetic	  modifiers	   of	   Abeta	   toxicity	   using	   our	   yeast	  model	  
opens	   the	  door	   for	  a	  wide	   range	  of	   additional	   investigations.	   Since	  many	  of	   them	  are	  
already	  ongoing	  I	  will	  discuss	  them	  rather	  briefly.	  
	   First	  of	  all,	   it	  will	  be	   important	   to	  determine	   if	   screen	  hits	  besides	  PICALM	  can	  
suppress	   the	   toxicity	  of	  Abeta	  oligomers	  on	  primary	  cortical	  neurons.	  Subsequently,	   it	  
will	   be	   interesting	   to	   investigate	   how	   the	   various	   genetic	   suppressors	   function	   to	  
counteract	  toxic	  Abeta	  species.	  Jessica	  Goodmann,	  a	  postdoc	  in	  the	  lab,	  is	  characterizing	  
the	  oligomeric	   species	   formed	  by	  Abeta	  expressed	   in	  yeast.	   If	  any	  of	   these	  oligomeric	  
species	  are	  proteotoxic,	  we	  may	  find	  that	  our	  genetic	  suppressors	  alter	  the	  ratios	  of	  the	  
Abeta	   species	   formed.	   For	   the	   genes	   that	   can	   counteract	   Abeta	   oligomer	   toxicity	   in	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neuron	   cultures,	   one	   could	   test	   how	   they	   influence	   the	  binding	   and	   internalization	  of	  
labeled	  Abeta	  oligomers	  to	  and	  into	  neuronal	  cells.	  	  
	   We	  also	  have	  begun	  to	  collaborate	  with	  Li-­‐Heui	  Tsai’s	  group	  to	  test	  the	  genetic	  
suppressors	  of	  Abeta	  toxicity	  in	  mouse	  models	  of	  AD.	  We	  (in	  particular	  Shu	  Hamamichi	  
in	  collaboration	  with	  Damien	  Rei	  and	  Johannes	  Graeff	  of	  the	  Tsai	  lab)	  hope	  to	  test	  if	  the	  
suppressors	   can	   ameliorate	   the	   neuronal	   degeneration	   and	   behavioral	   phenotypes	  
observed	   in	  AD	  mouse	  models	   such	  as	  5xFAD	  mice.	   5xFAD	  mice	  exhibit	   intraneuronal	  
Abeta	   accumulation,	  which	  may	   be	   especially	   interesting	   from	   the	   perspective	   of	   our	  
yeast	  model,	  amyloid	  plaque	  formation,	  neurodegeneration,	  and	  memory	   loss	  (OAKLEY,	  
et	   al.	   2006).	   We	   will	   administer	   select	   genetic	   suppressors,	   beginning	   with	   PICALM,	  
using	  AVV	  vectors	  and	  will	  later	  score	  the	  extent	  of	  neuron	  loss	  and	  memory	  decline.	  	  
	   Furthermore,	  we	  hope	  to	  discern	  if	  rare	  mutations	  in	  the	  homologs	  of	  our	  alpha-­‐
synuclein	   and	   Abeta	   screen	   hits	   contribute	   to	   Alzheimer’s	   and	   Parkinson’s	   disease	  
(COOPER,	   et	   al.	   2006;	   YEGER-­‐LOTEM,	   et	   al.	   2009).	   Vikram	  Khurana	   and	   I	   have	   assembled	  
lists	   of	   hit	   homologs	   to	   be	   sequenced	   for	   Parkinson’s	   and	   Alzheimer’s	   disease,	  
respectively.	   This	   analysis	   will	   require	   intricate	   multi-­‐plexing	   of	   sequencing	   runs	   and	  
computational	   analyses	   to	   filter	   out	   false	   positives.	   Our	   effort	   is	   aided	   by	  Whitehead	  
fellow	  Yaniv	  Erlich.	  Yaniv	  is	  an	  expert	  on	  high-­‐throughput	  sequencing	  analysis	  aimed	  at	  
the	   identification	  of	   rare	   disease	   variants	   (EDVARDSON,	   et	   al.	   2010;	   ERLICH,	   et	   al.	   2009).	  
Vikram	  and	  Sue	  are	  currently	  procuring	  funding	  and	  clinical	  samples	  to	  be	  sequenced.	  
	   Finally,	  our	  yeast	  model	  may	  enable	  us	   to	  determine	  how	  clioquinol	  and	  other	  
metal	  chelators	  can	  detoxify	  Abeta	  in	  a	  cellular	  setting.	  It	  was	  found	  that	  yeast	  exposure	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to	  clioquinol	  induces	  a	  metal	  starvation	  response	  in	  yeast,	  but	  those	  experiments	  used	  
highly	   toxic	   concentrations	   of	   clioquinol	   (LI,	   et	   al.	   2010).	   Kent	   Matlack	   and	   I	   have	  
performed	   gene	   expression	   analysis	   to	   decipher	   the	   responses	   elicited	   by	  
concentrations	   of	   clioquinol	   capable	   of	   suppressing	   Abeta	   toxicity.	   Elena	  Nabieva	   has	  
begun	   to	   compare	   these	   results	   to	   the	   gene	   expression	   profile	   elicited	   by	   Abeta	  
expression.	   The	  hope	   is	   that	   these	  microarray	  data	  will	   pinpoint	  particular	   genes	   that	  
are	   required	   for	   the	   efficacy	   of	   clioquinol-­‐based	   suppression.	  We	  will	   then	   test	   if	   the	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